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 Abstract 
Background: Stratified medicine was defined as the use of biomarkers to select patients 
more likely to respond to a treatment or experience an adverse event. 
Aims: To investigate the hypothesis that there is a mismatch between the theoretical 
proposals and practice of predictive biomarker research, focusing on the clinical utility 
stage. 
Methods: Methodological research was identified in a systematic review of frameworks for 
staged evaluation of predictive biomarkers. Actual research supporting 50 real cases 
identified in European Medicines Agency licensing was analysed. A case study of recent 
research into ERCC1 in non-small cell lung cancer was undertaken. Existing discrepancies 
between the theory and practice were identified and possible reasons and consequences 
of these were discussed. 
Findings: A mismatch between theory and practice was identified. It appeared to be a 
result of both the practice not following some theoretical requirements, and the 
underdevelopment of methodology for certain situations. Areas of clinical research with 
insufficient relevant methodology were identified. 
Conclusions: The major research priorities identified in this thesis were development of a 
clear hierarchy of biomarker research designs and development of methodology related to 
the biomarker threshold. 
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In 1992 Barbara Bradfield was told her breast cancer has come back. It was aggressive, 
spread to her neck and lungs. Her disease was declared terminal. She agreed to 
participate in a phase I trial of a new drug, developed especially to treat her type of 
cancer. A year later, at the end of the trial, her scans showed no evidence of disease. 
Five years later there was still no evidence of recurrence2 and according to most recent 
sources, she remains cancer-free.3 The drug, trastuzumab, was amongst the first targeted 
cancer treatments developed and later became a standard treatment for patients with 
human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer.4 
Stories such as this often captivate the public and give hope for future developments of 
treatments well suited to every individual patient, but initial enthusiasm is often not 
supported by further research.  
What can be done to hear more of the success stories in the future and minimise the 
failures in the area which has become known as stratified medicine? With the aim of 
leading to better care for patients, this thesis will attempt to identify biomarker research 
that has been carried out to a good standard. It will also suggest improvements to the 
conduct of such research.  
  
4 
[page intentionally left blank] 
 
 
5 
In order to set the scene for this thesis, an understanding of some concepts around 
stratified medicine is required. These are briefly discussed below. 
1.1 FACTORS INFLUENCING DRUG EFFECTS 
It is sufficient to read a clinical trial report, even for a targeted drug such as trastuzumab, 
to realise that drugs do not always have the same effect in all patients: only some will 
benefit and there will usually be a group experiencing a serious adverse event.  
A wide spectrum of factors that can influence an individual’s response to treatment has 
been reported in the literature. These include: 
 Genetic factors, such as the presence and characteristics of therapeutic targets, 
drug-metabolising enzymes, drug transporters, or targets of adverse drug 
reactions,5-7 
 The setting in which the treatment is administered,5 
 Patient’s compliance with treatment,5 
 Environmental factors, such as diet, or concomitant medication5,6 
 Other factors – for example age, or circadian rhythm.5,6 
The scale of the variability of response to treatments may be appreciable. According to 
some authors, drugs may not have the desired effect in 30-40% of patients and treatments 
such as chemotherapy in some cases are only beneficial for 30% of patients.8,9 In addition, 
adverse effects associated with drug treatment can be a serious problem. A review of 
European studies that were published from 2000 onwards found that the percentage of all 
hospital admissions that was associated with adverse drug reactions ranged from 0.5% to 
12.8% (median 3.5%).10 
This clearly demonstrates the need for ways to predict which patients are most likely to 
benefit from a given treatment and in whom the treatment is likely to cause 
unacceptable harm.  
1.2 STRATIFIED MEDICINE AND BIOMARKERS 
A number of different terms have been used to describe the changes brought about by 
the use of new tools that help to provide patients with more individualised treatments. 
These include personalised, tailored, individualised, precision and stratified medicine. 
There are numerous definitions of these terms in the literature and often these are used 
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interchangeably. Some authors, however suggest more subtle distinctions and an 
example of these will be used to better explain the scope of this thesis.  
Figure 1.1 demonstrates a simple model with empirical and personalised medicine at 
opposite ends of a spectrum and stratified medicine in the middle. Empirical medicine 
may be defined as prescribing the same treatment to all patients with a particular 
condition without taking into account their individual characteristics (although in practice 
this extreme is uncommon). An example of such treatments may be provided by non-
steroidal anti-inflammatory drugs.9 At the other end of the spectrum, personalised 
medicine proposes patient treatment customised for each individual.11 This concept 
would describe treatments such as therapeutic cancer vaccines prepared using the 
patient’s own tumour tissue.12 
Somewhere between these two extremes lies stratified medicine where “a patient can be 
found to be similar to a cohort that has historically exhibited a differential therapeutic 
response using a biomarker that has been correlated to that differential response.”9  
 
Figure 1.1 Position of stratified medicine on the spectrum between empirical and personalised medicine and the 
focus of each term11 
A broad classification of such patient cohorts based on different levels of response has 
also been suggested,13 where patients are grouped into: 
1) Responders – those with a positive response to a drug, 
2) Super responders – a subgroup of responders with exceedingly good response to 
a treatment that is statistically distinguishable from the remaining responders; this 
group may not exist for all treatments, 
3) Nonresponders – for whom the drug does not have any effect, 
4) Negative responders – patients who suffer from unacceptable adverse effects. 
The use of a biomarker (or biological marker) is central to the concept of stratified 
medicine. One of the most widely cited definitions of a biomarker is that proposed by a US 
Empirical medicine:
population
Stratified medicine:
cohorts
Personalised medicine:
individual
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National Institute of Health workshop: “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.”14  
Although the term “biomarker” is often used in the context of stratified medicine, some 
authors suggest it would be more appropriate to talk about a “classifier”, which could be 
described as a mathematical function which translates single or multiple biomarker values 
into categories (for example likely or unlikely to respond to treatment) that may be used 
for decision-making.15,16 However, in practice the term “biomarker” appears to be used in 
preference to “classifier” and has arguably a broader scope. In addition, the term 
“classifier” is often used to indicate signatures based on, for example, multiple genes. Thus 
this thesis will follow the common nomenclature and use the term “biomarker”. 
Not every biomarker that can be measured will be directly relevant to stratified medicine. 
The most crucial here are predictive biomarkers, which have been variously defined. 
Some of the examples of these definitions are: 
 “a marker that predicts the differential efficacy (benefit) of a particular therapy 
based on marker status”17 
 “measured at baseline to identify patients who are likely or unlikely to benefit from 
a specific treatment”16 
 used to select patients for treatment based on the “estimation of probability of 
response to a particular agent”18 
 separating “a population with respect to the outcome of interest in response to a 
particular (targeted) treatment”19 
What all these definitions have in common is that the predictive biomarkers are used: 
1) for prediction of patient outcome (either in terms of efficacy or safety), and  
2) in the context of a particular treatment. 
These two points will be used throughout the thesis to identify relevant biomarker cases 
and methodologies. Further, predictive biomarkers are classed within the thesis based on 
their purpose as either predicting treatment efficacy or safety. 
The use of a predictive biomarker in the context of a particular treatment differentiates it 
from a prognostic one, which is “associated with a differential outcome regardless of the 
therapy given, even if choice of therapy is available”.17 Prognostic biomarkers, such as 
cancer stage may distinguish populations where different treatments are appropriate. 
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However these would not guide the choice of a particular treatment based on differential 
response to that treatment.17 
This distinction may prove more complex in certain cases. For example, HER2 expression in 
breast cancer (BC) was identified in the late 1980s as a prognostic biomarker: women 
whose tumours overexpressed HER2 have a more aggressive cancer resulting in shorter 
survival time.20 However, for treatment with trastuzumab this biomarker also has a 
predictive role. Therefore, since the introduction of this targeted treatment it is no longer 
possible to argue that HER2 expression “is associated with a differential outcome 
regardless of the therapy given.”17 
Another type of biomarker that needs to be mentioned here are diagnostic biomarkers. 
These are “used in people with signs or symptoms to aid assessing whether they have a 
condition.”21 An example of a diagnostic biomarker is the presence of a BCR/ABL fusion 
gene which needs to be confirmed to diagnose chronic myeloid leukaemia (CML).22 
Again, the distinction is not simple as over time with better understanding of biology, 
biomarkers once considered predictive may become part of a redefinition of the disease 
or its subtype, and thus a diagnostic biomarker.23 For example, a recent paper suggested 
dividing acute myeloid leukaemia into 11 genomic subgroups,24 one of which is based on 
a biomarker previously used as predictive of response to arsenic trioxide (t(15;17) 
translocation).25 
A final type of biomarker that requires mention are biomarkers used for dose selection. For 
example, levels of CYP2C9 enzyme could potentially be used for improved selection of a 
warfarin dose in anticoagulation therapy. These biomarkers can have a huge impact on 
treatment benefit, as inappropriate dose could limit the efficacy or result in serious 
adverse effects.7 However, these are considered outside of the scope of this thesis.  
There are other types of biomarkers, such as monitoring, screening, staging or 
predisposition biomarkers.26 These however will not be discussed here, as they are of little 
relevance to the scope of this thesis. 
To provide an indication of the growing use of some of the discussed concepts, a quick 
search of PubMed was carried out in March 2016, the results of which are shown in Figure 
1.2. It produced only 189 hits for “stratified medicine”. However “predictive biomarker” 
produced over 1.3 thousand hits and “personalised (or personalized) medicine” over 7.5 
thousand. The great popularity of the term “personalised medicine” most likely results from 
its use in a wide number of contexts, including what this thesis will call “stratified 
medicine”. 
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Carried out 17.03.2016. Prior to 1996 only hits for “personalised (or personalized) medicine” were obtained – one 
in 1990 and one in 1971. Data for 2016 not shown, as does not account for an entire year. 
Figure 1.2 Number of hits in PubMed for some terms related to stratified medicine 
1.3 BIOMARKER MEASUREMENT IN BIOLOGICAL SAMPLES 
Before discussing methodological issues around predictive biomarkers, a brief outline of 
biomarker measurement is necessary to provide the reader with an appreciation of the 
practical issues that need to be addressed when incorporating a biomarker into a clinical 
study. 
In terms of the biological characteristic that is measured, the most important types of 
biomarkers that have been used as predictive are generally molecular in nature and 
include:  
1) Chromosome-level – referring to the characteristics of entire chromosomes. There 
are a number of biomarkers of this type, one of the most relevant being reciprocal 
translocations. This term describes the exchange of molecular fragments between 
two different (non-homologous) chromosomes.27 One of the most recognised 
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examples is the Philadelphia chromosome – a shortened chromosome 22, resulting 
from an exchange of defined fragments between chromosome 9 and 22.28  
2) Gene level biomarkers – referring to the presence of certain genetic traits. Two 
types are important here:  
 Presence of a variant of a gene (allele) - such as that of the human 
leukocyte antigen, class I B (HLA-B*5701 allele) which predicts that patients 
are likely to show a hypersensitivity reaction to abacavir,29 
 Mutation within a gene - the permanent change in the nucleotide 
sequence, for example KRAS mutation which has been used to predict 
lack of response to epidermal growth factor receptor (EGFR) targeted 
drugs.18 
These are often considered constant. However, for tumours and viral genomes the 
mutation rate is high resulting in these biomarkers changing over time, often 
resulting in development of resistance to a previously effective treatment.30 
3) Gene expression level biomarkers – referring to the presence and amount of a 
given protein,18 such as HER2 or excision repair cross-complementation group 1 
(ERCC1) expression. One of the major challenges is that these biomarkers are by 
nature continuous. Yet, in order to be used for predicting patients’ response these 
often need to be dichotomised.31 Another important challenge is that gene 
expression can be measured directly at protein level or at messenger RNA level 
and these two approaches do not necessarily provide comparable results.32 Some 
of the issues around the different methods of measuring protein expression 
biomarkers will be investigated in more detail in Chapter 7, using ERCC1 as an 
example.  
Other biomarker types have also been investigated, although more rarely, such as 
functional magnetic resonance imaging as a potential predictor of response to 
antidepressant treatment in major depressive disorder.33  
The above biomarker types can be measured in a variety of biological specimens, which 
include: 
 Tumour tissue – in which the majority of biomarkers predictive of treatment 
efficacy in cancer, such as HER2 expression are measured, 
 Patients’ healthy tissue – this is particularly relevant to biomarkers predicting 
treatment safety and biomarkers identifying a subset of patients with an inherited 
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condition. An example of the first situation is the presence of HLA-B*5701 allele, 
which is used to predict adverse events associated with abacavir treatment.34-36 
An example of the second kind is the presence of the G551D mutation in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene in cystic fibrosis 
patients.37 
 Viral genome – generally biomarkers predicting efficacy of treatments for viral 
diseases, such as viral resistance biomarkers in human immunodeficiency virus 
(HIV) infection treatment. 
There is a variety of laboratory methods that have been developed to measure 
biomarkers, often with multiple assays available for the same purpose. To be used in a 
clinical setting, such laboratory methods need to be “fit-for-purpose”, which often requires 
demonstration of acceptable analytical parameters:  
 Precision (or reproducibility1) – where repeated measurements on the same 
sample made under the same laboratory conditions result in the same biomarker 
values,18 
 Accuracy – reflecting how close the biomarker measurement is to the true value.18 
These may often depend on a wide variety of factors other than the type of the 
laboratory assay used, such as the concentration of reagents or timing of laboratory 
procedures.1 In any case, establishment of the precision of a biomarker test may be 
relatively easy compared to accuracy, for which there may be no reference standard 
against which to compare the biomarker assay.18 
Apart from the analytical parameters, the biomarker measurement can be influenced by 
both pre- and post-analytical factors. Pre-analytical factors include for example the 
biological sample collection method, processing and storage.1 Post-analytical factors 
encompass issues around the reporting and provision of the laboratory data to the 
clinic.38  
Although a lot of attention has been given to the analytical factors, there are suggestions 
in the literature that the majority of errors in hospital laboratories may be due to pre- or 
post-analytical factors.39,40 Some of the pre-analytical issues will be investigated in 
Chapter 7, focusing on biological specimen collection and processing. 
Finally, factors such as biological rhythms and diet have also been cited in the literature as 
potentially influencing laboratory measurements.38 Although these may appear irrelevant 
to predictive biomarker measurement, there is at least one case (HER2 expression in BC) 
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where evidence suggests the biomarker values may fluctuate in women during the 
menstrual cycle.41 
1.4 PREDICTIVE BIOMARKER DEVELOPMENT 
A number of strategies have been suggested for taking a biomarker from discovery to the 
clinic. These aim to ensure control of the factors influencing biomarker measurement and 
use of only “fit-for-purpose” predictive biomarkers in clinical practice. A systematic review 
of these will be reported in Chapter 2 where different models proposed in the literature will 
be discussed. Figure 1.3 provides a simple overview of the biomarker development 
process and some of the major concepts are discussed below. 
 
Figure 1.3 Overview of predictive biomarker development process 
The initial discovery stage aims to identify biomarkers which may be used as predictive of 
treatment effect.18,42 There are two general approaches to this: 
 Knowledge-driven – based on known disease pathogenesis and/or 
pharmacological mechanism of action of a drug. This approach is limited by the 
extent of knowledge of disease biology and the validity of the assumptions 
made.43-45 
 Data-driven – using high-throughput techniques to identify one or more biomarkers 
that differ between cohorts (for example responders and non-responders). This 
approach may require large sample sizes and involves a high risk of producing 
false positive associations.43-45 
These two approaches may be combined and it has been suggested this may be the 
optimal strategy, particularly in the development of multi-marker classifiers.43-45  
establishment of  
clinical utility
clinical validation
analytical validation
discovery
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However, a very common situation is an opposite sequence of events, where discovery of 
treatments follows the identification of a particular molecular target. The presence of the 
drug target later becomes a predictive biomarker.46 An example of such a process is the 
development of trastuzumab to target HER2 on tumour cell surface,20 which will be 
described in Chapter 2. 
In either case of discovery sequence, it has been postulated the next step should be 
analytical validation of the biomarker(s). This stage investigates the analytical parameters 
of the laboratory assay such as precision and accuracy discussed above.18,47-49 It also 
aims to define the laboratory procedures for measurement of the biomarker, such as 
biological specimen processing times.44 The importance of this stage will be one of the 
problems addressed by Chapter 7. 
If the biomarker assay has demonstrated satisfactory analytical validity, the next stage 
involves clinical validation. This stage focuses on establishing a correlation between the 
biomarker values and the clinical outcome.18,43,49  
The final stage, evaluating clinical utility, provides information on whether the biomarker 
improves patient care. It usually requires availability of a laboratory assay with sufficiently 
short turn-around time to inform clinical decisions.50 Usually on completion of this stage a 
decision is made about the implementation of a predictive biomarker in clinical 
practice.47-49,51,52 This stage will be the focus of Chapters 3-6 and will also be important for 
Chapter 7. 
1.5 REGULATION IN EUROPE 
The majority of predictive biomarkers used in clinical practice fall under the class of in vitro 
diagnostics. These are regulated by the EU Directive, 98/79/EC on in vitro diagnostic 
medical devices, which is currently under revision.53 
According to the Directive to access the European market the manufacturer mainly 
requires to ensure the performance of the assays is relatively safe and that the assay 
performs (in terms of for example accuracy) as described in the technical 
documentation. In most cases this is assessed based on the documents provided by the 
manufacturer to a notified body. This includes a range of information, such as a 
description of the technology, description of the quality system, results of evaluation of 
assay performance and results of stability tests. Certain cases are listed in the Directive (for 
example HLA-B allele testing), where additional measures are required. These may involve 
either the notified body testing the assay performance or auditing the quality assurance 
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system.54 These measures correspond to establishing the analytical validity of a predictive 
biomarker described above in section 1.4.  
There is no formal process for further evaluation of predictive biomarkers to be used in 
clinical practice. However often drugs are licensed in populations that have been 
identified by a predictive biomarker. In a large number of cases this licensing is done by 
the European Medicines Agency (EMA), as in Europe a centralised drug evaluation by the 
EMA is required for drugs for treatment of a number of conditions, drugs obtained from 
biotechnology processes and all drugs used for rare conditions (orphan medicines). 
Companies can also apply for a centralised marketing authorisation of other drugs.55 
Although the EMA does not license biomarkers, it evaluates drugs in groups of patients 
which can be defined by predictive biomarkers (for example trastuzumab is licensed for 
use in HER2 overexpressing BC patients).56 Therefore reviewing EMA licensing decisions is 
likely to give a broad overview of the impact of predictive biomarkers on treatment 
selection since 1995 (when EMA was established57). 
The European system appears to be ensuring limited evidence standards for predictive 
biomarkers prior to their implementation in clinical practice, and this will be further 
investigated in Chapter 5 and 6. An alternative approach has been put into place in the 
USA, where the Food and Drug Administration (FDA) evaluates both the biomarker assay 
and the new drug. New biomarkers intended as predictive are evaluated in this context 
prior to the FDA considering the drug.58 
1.6 STUDY DESIGNS 
The main focus of this thesis is on studies which are undertaken in the context of the 
clinical utility stage. These provide information to enable a decision on the routine 
implementation of a predictive biomarker in clinical practice. Some of the designs more 
typically utilised for the prior stages of biomarker development, have also been used for 
such decision-making, as will be discussed in Chapter 5 and 6. These designs are briefly 
described below and illustrated using patient flow diagrams. For simplicity, in the 
diagrams, the treatment expected to be more beneficial in biomarker positive patients is 
labelled as “experimental treatment” and the treatment that comprises standard care or 
placebo as “control treatment”. For controlled studies a two-arm design is shown, 
although in practice multiple arms may be included in a such study. 
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1.6.1 RANDOMISED TRIALS WITH BIOMARKER INTEGRAL TO DESIGN 
This group of study designs is often considered in the theoretical literature as the most 
appropriate for evaluation of the clinical utility of a predictive biomarker.18 The different 
randomised designs proposed in the literature are outlined below. 
1.6.1.1 ENRICHMENT DESIGN 
As shown in Figure 1.4, in the enrichment (also known as targeted) design the biomarker is 
used to restrict entry into the trial. The experimental drug, expected to be beneficial only 
in biomarker positive patients, is compared to a control intervention.15,18,48,49,59-61  
Such a trial provides information on the best treatment for biomarker positive patients.60,61 
If the biomarker is truly predictive, implementation of such a design offers advantages in 
terms of a reduced sample size compared to a trial without entry restriction.15,60,61 
However, although only biomarker positive patients are treated, recruitment and 
biomarker evaluation needs to be undertaken in the entire population with the 
condition.60,61 
One of the major limitations of this design is that it does not demonstrate the utility of the 
biomarker. It may therefore result in denying beneficial treatment to some of the patients 
identified as biomarker negative.61 
As the treatment is not evaluated in the biomarker negative patients, a strong biological 
rationale is required for excluding this group.15,48,49,59 It should only be undertaken using an 
assay which reliably identifies the biomarker positive patients.60,62 
 
Figure 1.4 Patient flow in an enrichment design 
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1.6.1.2 STRATIFIED DESIGN 
In a stratified design the biomarker status is used as a stratification factor and patients are 
randomised to treatment within each biomarker defined stratum,59,62 as shown in Figure 
1.5. Usually patients are stratified into biomarker positive and negative groups, however in 
some cases a stratum defined by an unknown biomarker status may also be included.63 
The stratified design may be most appropriate when a biomarker has been developed, 
but uncertainty remains about the effect of the treatment in biomarker negative 
patients.49 
This study design can provide information on the benefit of the treatment in all patients 
and within each biomarker-defined subgroup.61 It can also allow an indirect evaluation of 
the biomarker-based treatment strategy.17,61 
 
Figure 1.5 Patient flow in a stratified design 
Some authors suggest that stratification is only important in smaller trials, where uneven 
patient distribution between subgroups may impact on the interpretation of the results.48,61 
A statistical test of interaction between the biomarker status and treatment effects is 
possibly the most suitable method of data analysis in this design, however recruitment of a 
large enough sample to ensure sufficient power may be problematic.17,48,49 
1.6.1.3 BIOMARKER STRATEGY DESIGN 
In the biomarker strategy design shown in Figure 1.6 patients are randomised to either 
treatment guided by the biomarker status or irrespective of it.15,17,59,61,62 Outcomes in both 
arms are compared and thus the predictive value of the biomarker is assessed.17 
Importantly, this design allows a direct evaluation of the consequences of implementing 
the predictive biomarker in clinical practice.1,61,62 One of the important problems is 
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selection of the treatment strategy for patients with an unknown biomarker status, due to, 
for example, assay failure. 61 
 
Figure 1.6 Patient flow in a biomarker strategy design 
A major drawback of this design is that the biomarker strategy arm may be superior even 
if the biomarker is not predictive, as long as the experimental treatment provides more 
benefit irrespective of the biomarker status.61 This has been, to some extent, addressed by 
the proposition of a modified biomarker-strategy design (shown in Figure 1.7). In such a 
study patients in the non-biomarker strategy arm are randomised to one of the two 
treatments, rather than receiving the control intervention only. If the biomarker status is 
measured in both arms, this allows the assessment of the clinical utility of the biomarker.17  
 
Figure 1.7 Patient flow in a biomarker strategy design with randomisation in control arm 
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An important advantage of the biomarker-strategy design is that it allows testing of 
complex strategies with multiple biomarkers and treatments.61 However, a major concern 
in particular for the modified version is that this design may require a huge sample size.15 
This is largely due to a proportion of patients in both study arms receiving the same 
treatment, thus diluting any effects.1 It has been suggested that a stratified design might 
be a more efficient option in most cases.61  
1.6.1.4 ADAPTIVE DESIGNS 
A number of adaptive designs have been proposed in the literature and a recent review 
of these is available.64 Some examples of such trials are discussed below. 
One of these designs has been referred to as adaptive patient design. It is proposed to be 
utilised in a situation when there is suspicion that a biomarker is predictive, however it is 
likely that the treatment may offer benefit to biomarker negative patients as well. One 
variant of this design is shown in Figure 1.8.  
 
Figure 1.8 Patient flow in an adaptive patient design with interim analysis in biomarker negative patients 
In the beginning patients are included irrespective of their biomarker status. An interim 
analysis is then undertaken in biomarker negative patients who are assumed less likely to 
benefit from the experimental treatment. Depending on the results of the analysis either 
patients irrespective of the biomarker status, or only biomarker positive are recruited for 
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the remaining part of the trial.48,64 Such a trial allows evaluation of the biomarker and 
maximisation of recruitment of patients who are more likely to benefit.62 However, this 
design requires evaluation of outcomes relatively soon after treatment initiation to enable 
the interim analysis. In the case when the biomarker is predictive, it also requires more 
patients to be recruited than an enrichment trial.48 
Another example of an adaptive design that has been suggested for evaluation of 
predictive biomarkers is an adaptive signature design.64 This design is proposed for 
situations when no predictive biomarker is available at the start of the trial. As shown in 
Figure 1.9, patients are included irrespective of the biomarker status in two stages and 
randomised to either experimental or control treatment. The data from the first stage are 
used to identify a biomarker (usually a multi-marker classifier). In stage II the biomarker 
status is prospectively evaluated in newly recruited patients and randomisation continues 
as in stage I. 
 
Figure 1.9 Patient flow in an adaptive signature design 
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2) comparison of the experimental and control treatment in the biomarker positive 
patients who were recruited in stage II. 
The overall significance level is split between the two analyses.65 
1.6.2 RANDOMISED TRIALS WITH BIOMARKER NOT INTEGRAL TO THE DESIGN 
1.6.2.1 PROSPECTIVE-RETROSPECTIVE DESIGN 
Although a prospective trial designed to evaluate the clinical utility of a predictive 
biomarker would be ideal, some authors argue that it may not always be feasible or 
ethical.1,15 A prospective-retrospective study can be undertaken if: 
 information emerges on a potential predictive biomarker for which there is an 
assay of acceptable analytical validity, and  
 archived biological specimens are available for the vast majority of patients from 
a completed randomised trial independent of the data which generated the 
biomarker hypothesis.  
A schematic representation of such a study is shown in Figure 1.10. In this case a protocol 
should be developed to test the biomarker hypothesis prior to any analysis of archived 
specimens. This should be then used to undertake a study utilising the available biological 
specimens and collected patient data.1,62 
 
Figure 1.10 Patient flow in a prospective-retrospective study 
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This study design can potentially address similar questions to a stratified design and, if well 
conducted, the results can be treated as coming from a prospective randomised trial.62 
However, problems exist regarding the possible bias which may be introduced by the 
missing or not analysable biological specimens. Another concern may be the difference 
in the tissue processing and storage procedures between the archived biological 
specimens and the biological samples that would be used to measure the biomarker 
status in the future patients in clinical practice. These discrepancies may potentially lead 
to results not being applicable in clinical practice.62 
1.6.2.2 SUBGROUP ANALYSES OF RANDOMISED TRIALS 
Subgroup analyses of data from randomised trials are not in any way specific to the area 
of stratified medicine. However they have a very important role, as by definition this field 
attempts to identify subsets of patients with differential treatment effects. In trials with such 
analyses patients are enrolled irrespective of their biomarker status. Three types of 
subgroup analysis may be undertaken that are encountered in this thesis: prospective, 
retrospective and cross-sectional.  
In the prospective type, a subgroup analysis based on the biomarker status is planned in 
the study protocol. The biomarker may be measured in the beginning of the trial or later 
on, using baseline biological specimens.66,67 Data may be analysed in a similar way to that 
coming from a stratified design and identical information can be obtained. However, 
such analyses may often be underpowered and subject to limitations associated with 
multiple testing.68-71 
In the retrospective (or post hoc) type a biomarker subgroup of interest is identified only 
after the conclusion of the trial. The biomarker status is then measured (using, for example, 
archival tumour samples) and a subgroup analysis is performed.67 Again, this analysis can 
provide similar information to a stratified design, however the probability of false positive 
findings is much higher.69,71 It has been suggested this analysis may be more suitable for 
earlier stages of biomarker development, rather than evaluation of clinical utility.62 
The concept of cross-sectional analysis emerged from examples of trials looking at viral 
resistance biomarkers in HIV infection.72,73 In such an analysis, on completion of a 
randomised trial, a subgroup of patients from one or from multiple treatment arms is 
identified based on their outcome - usually lack or loss of response to treatment. The 
biomarker (or a panel of biomarkers) is evaluated in this group of patients only. Such an 
analysis is comparable to a cross-sectional study and can only provide information on the 
prevalence of the biomarker in the patients with a particular outcome. In spite of their 
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obvious limitations, such analyses are undertaken due to the possibility of development of 
treatment resistance during a trial.74,75 Such resistance biomarkers are later used to 
choose treatments for new patients. 
1.6.3 NON-RANDOMISED STUDIES 
Non-randomised studies evaluating biomarkers are usually considered relevant to 
development stages prior to evaluation of clinical utility. This may be generally true, 
however for rare diseases and drugs demonstrating extraordinary benefit, such study 
designs may be used to make decisions on biomarker and drug use in clinical practice. 
These designs have not been described extensively in theoretical literature, however they 
will be encountered in Chapters 5-7. 
1.6.3.1 SINGLE ARM STUDY INCLUDING ONLY BIOMARKER POSITIVE PATIENTS 
Figure 1.11 shows the patient flow in a single arm study including only biomarker positive 
patients. All patients are given the experimental treatment and only activity of the drug in 
biomarker positive patients can be demonstrated.76 
 
Figure 1.11 Patient flow in a single arm study including only biomarker positive patients 
1.6.3.2 SINGLE ARM BIOMARKER-STRATEGY STUDY  
This study design was identified from ongoing studies, for example where ERCC1 
expression was used to select treatments for patients.77 As shown in Figure 1.12, the design 
includes patients irrespective of their biomarker status and allocates them to a biomarker- 
based treatment, corresponding to one arm of the biomarker strategy randomised 
controlled trial (RCT). Under the assumption that the biomarker is not prognostic, the 
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biomarker negative subgroup may provide some comparison for the biomarker positive 
patients.  
 
Figure 1.12 Patient flow in a single arm biomarker-based strategy study  
1.6.3.3 SINGLE ARM STUDY INCLUDING PATIENTS IRRESPECTIVE OF BIOMARKER STATUS 
In this design all patients are included irrespective of their biomarker status and all receive 
the same experimental treatment, as shown in Figure 1.13. The biomarker is measured in 
all of the included patients to identify a subgroup responding to the treatment.78 
 
Figure 1.13 Patient flow in a single arm study including patients irrespective of biomarker status 
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Umbrella and basket trials can offer minimisation of costs and increase in efficiency of 
conducting research into treatments with associated predictive biomarkers.  
1.6.4.1 UMBRELLA TRIAL 
Umbrella trials investigate multiple drugs associated with multiple predictive biomarkers. 
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characteristics.79 As shown in Figure 1.14, patients are assigned to the appropriate 
treatment based on their biomarker status.80,81 As multiple biomarkers can often be 
evaluated using the same platform, this approach can offer substantial efficiency gains. 
In addition, in clinical areas where targeted treatments may only be appropriate for a 
small proportion of patients, these trials offer large improvements in terms of recruitment. 
Umbrella trials may be both randomised, including a control group as in the case of 
FOCUS482 and non-randomised as in case of National Lung Matrix trial.83 
 
Figure 1.14 Patient flow in an umbrella trial 
1.6.4.2 BASKET TRIAL  
Basket trials investigate a single drug in a range of diseases (usually cancers).79,80 At least 
three variants of this design can be identified based on the inclusion criteria. In these 
studies patients are: 
1) included based on similar molecular characteristics,79,80 
2) positive for a range of biomarkers which are likely drug targets,81,84 
3) included irrespective of their biomarker status and a range of potential biomarkers 
is evaluated to discover predictive biomarkers.84 
Basket trials are often utilised as discovery tools to rapidly screen for response in different 
disease settings.85 Based on the results of such trials, cohorts which show the most 
promising results can be expanded.81 An example of such a trial is investigating 
vemurafenib in patients with a range of V600 mutation positive tumours.86 
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1.7 AIMS OF THE THESIS 
Poor study design and inadequate reporting of studies have been identified as a major 
obstacle to progress in the field of stratified medicine.18 There are a number of 
methodological papers postulating the most appropriate ways to develop predictive 
biomarkers and the best study designs to evaluate clinical utility. Anecdotal evidence 
suggested there might be a large discrepancy between the theory and practice of 
stratified medicine. This thesis investigates the hypothesis that there is a mismatch 
between the theoretical proposals and practice of predictive biomarker research, 
focusing on the final stage of biomarker evaluation prior to implementation in clinical 
practice. It will investigate the theory and actual research supporting 50 real cases. 
Existing discrepancies between the theory and practice will be identified. The possible 
reasons for such discrepancies and the resulting limitations of predictive biomarkers 
available in clinical practice will be explored. In addition, areas of clinical research with 
insufficient relevant methodology will be identified.  
Figure 1.15 provides an overview of the position of parts of this thesis (Chapters 2-7) 
relative to the theory and practice of stratified medicine. This structure was chosen to first 
introduce the biomarker development process in Chapter 2 and thus provide context for 
the identification of clinical research practice in Chapters 3-5. Chapter 6 will then 
compare the identified research practice to theoretical literature. Chapter 7 will return to 
the practical aspects and focus on issues related to the biomarker assay.  
Chapter 2 will expand the basic framework described in section 1.4 and introduced in 
Figure 1.15. It will try to answer the question of what frameworks have been proposed in 
the literature and whether there appears to be consensus - at least on some elements of 
such frameworks. Based on the findings of a systematic review the most appropriate 
strategies for development of “fit-for-purpose” predictive biomarkers will be identified. The 
aims, relevant research designs and criteria for entry into and completion of each stage 
of biomarker development will be discussed. As the clinical utility stage is the major focus 
of this thesis, Chapter 2 will identify not only what this stage should comprise, but also the 
necessary prerequisites. 
Chapter 3 will address the question on what predictive biomarkers have been included in 
EMA licensing. It will report on the identification of the dataset of real cases of predictive 
biomarkers which have been considered for marketing in the European Union. These 
predictive biomarkers come from both indications and contraindications of drugs 
considered by the EMA for licensing. Positive and negative recommendations are 
included and these will form the starting point for Chapters 4-6. The identified biomarker 
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cases will be characterised in terms of biomarker type, disease area and drug type. 
Licensing over time will also be considered to establish whether an expansion of stratified 
medicine is noticeable. 
 
 
Figure 1.15 Structure of the thesis 
EMA decisions will then be investigated further in Chapter 4, where an attempt will be 
made to find out what issues were important in decisions on licensing of a drug with a 
predictive biomarker in the indication. A text analysis of available documentation will 
explore these issues and the themes that emerge from the analysed documents will be 
described. Attention will also be given to the critical issues which resulted in the licensing 
refusal for a small number of drugs with an associated predictive biomarker.  
The themes identified in this Chapter 4, together with general methodological concerns 
will form the basis of criteria used in Chapter 5. This chapter will aim to investigate what 
level of evidence was sufficient to include a predictive biomarker in an indication by 
analysing the clinical trials that supported the EMA decisions. The study designs and 
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strength of evidence behind each recommendation will be considered. The evidence 
supporting drugs with a positive and negative licensing recommendation will be 
compared. Consideration will be given to the evidence standards emerging from the 
analysis that appear sufficient in practice to use a predictive biomarker in the clinic. 
After examining the studies supporting EMA decisions in Chapter 5, these will be 
compared in Chapter 6 to the methodology suggested in the literature. A 
methodological framework based on a systematic review describing study designs 
relevant to development and evaluation of clinical utility of predictive biomarkers has 
been published.78 The evidence collected in Chapter 5 will be used to assess the validity 
and limitations of the framework. Study designs used in practice, but not included in the 
methodology will be identified. The strength of the evidence supporting EMA decisions will 
further be evaluated. 
Chapter 7 will return to issues earlier in the predictive biomarker development process. It 
will try to answer what are the reasons and consequences of lack of standardisation in 
laboratory methods used for biomarker evaluation. It will investigate the impact of 
problems with analytical validity of a biomarker on trials undertaken for evaluation of 
clinical validity and utility. A case study of ERCC1 expression in non-small cell lung cancer 
(NSCLC) to predict response to cisplatin will be undertaken to address these issues. A 
survey of trials that were either ongoing or completed since 2007 will be reported. This will 
explore the variability in analytical and pre-analytical factors between trials and the 
motivation for the choice of particular biomarker assays. Consideration will be given to 
the impact of the identified variability on the usability of the trial results to inform clinical 
practice. 
Chapter 8 will provide a discussion of the main issues identified throughout this thesis and 
draw conclusions on the strengths and limitations of the research practice in the area of 
stratified medicine and the necessary future developments in trials methodology. 
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Abstract 
Background: A number of predictive biomarkers have changed clinical practice. 
However, there are also examples where potential predictive biomarkers failed at a late 
stage of development. Such cases of failure, together with the need to optimise the use 
of resources, suggest a structured approach to biomarker development is necessary. In 
contrast to drugs, no model for phased evaluation is in place for predictive biomarkers.  
Aims: To identify existing frameworks for staged evaluation of predictive biomarkers and 
the stages these propose. For each identified stage, explore the outcomes, relevant study 
designs and requirements for entry into and completion. To compare the frameworks. 
Methods: A systematic review of papers suggesting a framework for staged evaluation of 
predictive biomarkers was undertaken. These were identified through broad searches of 
MEDLINE, EMBASE and additional internet searches. Data were extracted on the 
characteristics of the frameworks and the stages they contained. Identified frameworks 
were compared and grouped based on the context in which the predictive biomarker 
was to be developed and the stages proposed. Information on each identified stage 
within each model was summarised and compared across models. 
Findings: 23 papers were identified that described a framework for staged evaluation of 
predictive biomarkers. These were grouped into four models: (I) general predictive 
biomarker development, (II) integrated into phased drug development, (III) development 
of a multi-marker classifier and (IV) development of marker predicting treatment safety. 
The most complete was model I (general), which comprised stages of: pre-discovery, 
discovery, analytical validation, clinical validation, clinical utility and implementation. The 
remaining models contained most of the same stages, however models II and III did not 
contain analytical validation and model IV clinical validation. The stages in models II-IV 
corresponding to those in model I were occasionally merged or subdivided. Different 
terminology was also used to describe similar concepts. Relevant study designs were 
described for all stages, however there seemed to be consensus mainly for the clinical 
utility stage, where RCTs designed to evaluate the biomarker were advocated (including 
enrichment, stratified and biomarker-strategy designs). The appropriate time to finalise the 
biomarker assay and select the threshold for continuous biomarkers was rarely mentioned. 
Where discussed, there was little agreement on these issues. 
Conclusions: The identified models suggest the need to consider the context in which the 
biomarker is developed. There was a large overlap between the four models, suggesting 
consensus on at least some of the research steps that may be necessary prior to 
predictive biomarker implementation into clinical practice.  
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2.1 BACKGROUND 
In drug development there is a widely accepted model, which identifies phases usually 
necessary for the authorisation of a drug therapy for use in clinical practice: drug 
discovery, pre-clinical research and phase I-III studies.87,88 There are exceptions where this 
sequence is not exactly followed. For example drugs for rare diseases may be 
implemented in clinical practice based on early phase trials or observational studies.89 
However, this model forms the basis of drug development programs which, for a particular 
reason, may introduce necessary modifications.89,90  
No such generally accepted model appears to be in place for staged evaluation of 
predictive biomarkers. Different organisations have proposed their own frameworks, such 
as the Food and Drug Administration (FDA) Drug-Diagnostic Co-Development Concept 
Paper.47 In addition, there have been numerous publications proposing models for staged 
evaluation. However, to date no consensus has been reached on the best way to 
develop predictive biomarkers. This may be a result of some of the complexities in the field 
of stratified medicine. One of the major issues is the possibility of discovery of predictive 
biomarkers at different times in relation to the drug with which they link. For example, 
some biomarkers may be discovered prior to the drug (in targeted treatments), while 
others will only emerge after the drug has been given market access.91 
A range of predictive biomarkers have been successfully implemented in clinical practice 
and these will be reviewed in Chapter 3. However, examples of failure at late stages of 
development, such as that of ERCC1 expression in NSCLC (investigated in Chapter 7), 
suggest the need for more structured approaches. As in the case of drug development, 
opportunity costs of research into potential predictive biomarkers need to be considered. 
It is therefore crucial, at each stage of the biomarker development process, to collect 
information allowing rational decision-making regarding whether and how to proceed 
further.92 Criteria are necessary that can be used for such decisions about entry into and 
completion of stages. It is particularly important to have a standardised approach to 
guide whether a potential predictive biomarker should enter a late phase trial.  
2.2 AIMS 
This systematic review aimed to investigate the path that should be followed in the 
development of a predictive biomarker to ensure that only biomarkers fit-for-purpose are 
used for treatment selection.  
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In particular, this encompassed identification of existing frameworks for staged evaluation 
of predictive biomarkers. For all identified frameworks the number and characteristics of 
the proposed stages were investigated. Within each stage information was sought on the 
aim of the stage, information to be collected, relevant study designs and requirements for 
entry into and completion. The process which led to the development of these 
frameworks was also investigated, as this was considered a potential indicator of the 
strength of these proposals.  
It was also of interest whether any criteria could be identified that would indicate that the 
biomarker development should be terminated. This would potentially take place when 
the biomarker is unlikely to complete a particular stage or result in a clinically meaningful 
tool.  
In addition, it was hypothesised that the models of staged evaluation may depend on the 
clinical context (for example development of a predictive biomarker alongside a 
treatment or at a later stage). 
To provide real-life context for the systematic review of frameworks proposed in the 
literature, a case study of the discovery and development of HER2 expression to predict 
response to trastuzumab in BC was undertaken. 
2.3 METHODS 
This section will first describe the systematic review, the main focus of this chapter. An 
outline of the methods relevant to the case study will be included at the end of this 
section.  
2.3.1 SYSTEMATIC REVIEW OF FRAMEWORKS FOR PHASED EVALUATION OF PREDICTIVE BIOMARKERS 
2.3.1.1 SEARCHES IN BIBLIOGRAPHIC DATABASES AND THE INTERNET 
Broad searches were undertaken in MEDLINE and EMBASE. These were supplemented by 
internet searches, which included websites of drug licensing agencies (EMA, FDA). The 
complete search strategies are reported in Appendix 3. These employed a combination 
of terms for:  
 the area of stratified medicine (such as “predictive biomarker” or 
“pharmacogenomics”), 
 staged evaluation (for example “hierarchical model”), and 
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 framework (for example “framework” or “guideline”).  
Both index and text terms were used. All identified references were imported into an 
EndNote X7 (Thomson Reuters) database.  
2.3.1.2 IDENTIFICATION OF INCLUDED FRAMEWORKS 
The titles and abstracts of all papers identified in the searches were screened for inclusion 
by one reviewer using the criteria reported in Box 2.1. 
Box 2.1 Inclusion criteria for the systematic review of frameworks for staged evaluation of predictive biomarkers 
 
Papers not published in English, although potentially relevant, were excluded due to 
financial and time constraints. It was anticipated that conference abstracts would 
contain insufficient detail to provide information useful for this chapter and were also 
excluded. 
Full texts of all papers potentially meeting inclusion criteria were obtained.  
A second reviewer independently checked a random sample of 15% titles and abstracts. 
In cases of disagreement, a full text was obtained for papers identified as potentially 
relevant by at least one reviewer. 
Two independent reviewers assessed the full texts for inclusion in the review using the 
same criteria as in the screening stage. All disagreements were resolved by discussion.  
Reference lists of all papers assessed in full text were screened to identify additional 
potentially relevant papers. If identified, these were added to the EndNote database and 
assessed for inclusion, first based on the title and abstract and then, if potentially relevant, 
a full text was obtained.  
Inclusion: papers or resources proposing a complete framework or part of a 
framework (more extensive than a single stage) for staged evaluation of predictive 
biomarkers from discovery to clinical implementation. 
Exclusion: papers or resources not meeting the inclusion criteria (for example clinical 
trials), not published in English and conference abstracts. 
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2.3.1.3 DATA EXTRACTION 
Data were extracted into an Excel 2010 (Microsoft) spreadsheet from each included 
framework. The data extraction items were focused on the stages and their content and 
are shown in Box 2.2. 
Box 2.2 Data extraction items for review of frameworks for staged evaluation of predictive biomarkers 
 
A data extraction table is provided in Appendix 4. 
2.3.1.4 DATA ANALYSIS 
Frameworks were compared to identify any shared approaches to staged evaluation. This 
was undertaken based on the situation to which they were applicable and the stages 
proposed. These items were used to construct models which best reflected the 
approaches proposed in multiple frameworks. 
For each constructed model, the identified stages were summarised. Descriptions of 
reported study designs relevant to each stage, outcomes of each stage, entry and 
completion criteria were included. Particular attention was also given to identification of 
the stage within the framework when a procedure for biomarker evaluation should be 
finalised, resulting in a standardisation of biomarker evaluation from that point forwards. 
 suggested stages of biomarker development, 
 description of these stages, 
 the aim of each stage, 
 the outcome of each stage – referring to the information or product (for 
example finalised assay) available as a result of a stage, 
 requirements for a biomarker to enter each stage, 
 requirements for biomarker to complete each stage, 
 criteria for biomarker development to be stopped at a given stage, 
 study designs relevant to each stage, 
 information regarding clinical context, 
 basis of the framework – defined as the information source or process on 
which the proposed framework was based, 
 country from which the framework originated. 
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The optimal time when a threshold for continuous biomarkers should be established was 
also investigated. 
The stages proposed in these models were compared and contrasted. This was 
undertaken to find whether there is consensus in the literature with regard to the most 
appropriate strategies for predictive biomarker development. 
2.3.2 CASE STUDY 
The case study on discovery and development of HER2 expression to predict response to 
trastuzumab was intended mainly to provide context and illustrate the process of 
predictive biomarker development. Internet searches were undertaken for review articles 
describing the development of HER2 expression to predict response to trastuzumab. The 
citations in these review papers were utilised to identify relevant primary studies. Websites 
of the FDA and EMA were also searched to identify relevant documentation. The research 
undertaken in the process of HER2 development was summarised in chronological order 
to best reflect the events that led to the introduction into clinical practice of both the 
biomarker and the drug. 
2.4 CASE STUDY OF HER2 EXPRESSION TO PREDICT RESPONSE TO TRASTUZUMAB IN 
BREAST CANCER 
In this case study attention will be given to the research into the biomarker and drug, as 
this is an example of drug-biomarker co-development. The majority of the research was 
conducted by or with the participation of scientists working for Genetech, the company 
which developed trastuzumab and marketed it in the USA.20,93 A more detailed 
description of this case study is available in Appendix 5. 
2.4.1 HER2 DISCOVERY AND CLINICAL SIGNIFICANCE 
In the mid-1980s a new protein involved in cancer was discovered. Due to its structural 
similarity to EGFR, it was thought to also be a growth factor receptor, although its ligand 
was unknown. This protein was therefore called “human EGF receptor 2”, or HER2 for 
short.94,95 
The first large-scale study exploring the clinical significance of HER2 was published in 1987. 
It analysed tumour tissue from 189 women with BC. The most important part of the study 
focused on 86 tumours from patients with node-positive disease. A strong correlation was 
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found between HER2 amplification (evaluated using Southern blotting) and the number of 
nodes involved. It also appeared to be a good prognostic factor of survival and time to 
relapse – second only to the number of nodes involved. Importantly, the vast majority of 
HER2 genes evaluated for amplification were not mutated.96 Subsequent attempts at 
replication of these findings in small studies led to mixed results.97  
A large retrospective study, including 526 patients with BC was undertaken by scientists 
involved in the original study of HER2 clinical significance. It found that in 345 node-
positive patients HER2 amplification (evaluated using Southern blotting) was an 
independent predictor of both relapse and overall survival (again, second only to the 
number of nodes involved). However, a clear association was not seen in patients with 
node-negative disease.98 This study also explored the relationship between HER2 gene 
amplification and expression at the level of RNA (evaluated using Northern blotting) and 
protein (evaluated using immunohistochemistry (IHC) and Western blotting). There was a 
strong correlation between the results of all four laboratory techniques. However, results 
obtained using Northern and Western blotting showed the weakest association with 
clinical outcomes.98 
The suggestion that increased expression of the HER2 proto-oncogene (non-mutated 
gene) may be sufficient to drive cancer was then confirmed in in vitro experiments.99  
2.4.2 DRUG DISCOVERY AND DEVELOPMENT 
In 1989 a number of mouse antibodies against HER2 were investigated in vitro. One of 
these, muMAb 4D5, led to the most extensive inhibition of tumour proliferation and 
showed high specificity for HER2. This antibody was selected by Genetech for further 
development.20  
In vivo proof of concept studies that followed showed satisfactory effects of the 
antibody.20 However, as muMAb 4D5 was a molecule of mouse origin, it was likely that 
using it in human patients would result in an immune reaction – production of human anti-
mouse antibodies. This was confirmed in a phase I trial including 12 patients with HER2 
overexpressing breast and ovarian tumours. It also showed that muMAb 4D5 was well 
tolerated and localised to tumour tissue.20 
To address the immune reaction, a series of humanised antibodies were prepared and 
investigated in vitro. Of these, huMAb 4D5-8 showed the highest affinity for HER2 and one 
of the best inhibitions of cell proliferation. It also appeared to have little effect on a cell 
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line from normal tissue, thus promising limited adverse events.100 HuMAb 4D5-8 later 
became known as trastuzumab, or Herceptin.97 
Animal research suggested trastuzumab may have synergistic interactions with certain 
chemotherapeutic drugs such as cisplatin, docetaxel and cyclophosphamide. It was also 
demonstrated to have an acceptable safety profile when administered over a long 
period to a range of animals including primates.97  
2.4.3 PHASE I TRIALS 
Three phase I trials were undertaken between June 1992 and March 1993. All of these 
trials included patients with refractory metastatic BC overexpressing HER2 (assay NR). One 
trial (Ho407g, n=16) investigated a single dose of trastuzumab and two trials a weekly 
dose schedule - either as monotherapy (Ho452g, n=17),101 or in combination with cisplatin 
(Ho453g, n=15).102  
Administration of trastuzumab was shown to be safe. A dose limiting toxicity was not 
reached.103 There was also no evidence of development of an anti-trastuzumab immune 
response. Encouragingly, four patients in the combination trial demonstrated objective 
response to treatment.20 
Based on these results, a dose schedule for phase II trials was established involving a 250 
mg loading dose followed by a 100 mg weekly dose.104 
2.4.4 PHASE II TRIALS 
Phase II trials recruited patients between March 1993 and September 1996 and evaluated 
trastuzumab as monotherapy(Baselga 1996,104 n=39 and Cobleigh 1999,105 n=222), or in 
combinations with cisplatin (Pegram 1998,106 n=39). Cobleigh 1999 introduced a new dose 
schedule based on body mass.105  
All trials were single-arm and evaluated the drug only in HER2 IHC positive patients. The 
assay utilised muMAb 4D5 across all three trials. However, in Cobleigh 1999 CB11* was also 
used.105 The threshold for considering patients as HER2 positive was also changed from 
≥25% of cells staining positive in the first trial104 to >10% cells staining either lightly (2+) or 
strongly (3+) in the subsequent two trials.105,106 
                                                                
* The reason why and how these antibodies were combined was NR 
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The percentage of patients who responded to monotherapy (either CR or PR) was 11%104 
and 15%.105 Nineteen percent of the patients responded to the combination of 
trastuzumab with cisplatin.106 The median time to loss of response ranged from 5.1 to 5.4 
months. In the combination trial the median overall survival was 13 months (range 0, >30 
months). The drug was also shown to be relatively safe.104-106 
2.4.5 DEVELOPMENT OF COMMERCIAL ASSAY (HERCEPTEST) 
In December 1996 Genetech started a partnership with a diagnostics company (DAKO) 
to develop a commercial HER2 expression assay - HercepTest.93,107 
In one study HercepTest was compared to the assay used in clinical trials (IHC, antibody 
NR) using 548 tumour specimens. Concordance between the two assays ≥75% was 
assumed acceptable. The results demonstrated a 79% (95% CI: 76, 82%) concordance. 
The HercepTest sensitivity was 0.79 (95%CI: 0.73, 0.83) and specificity 0.78 (95% CI: 0.73, 
0.83).108  
Another study used 168 breast tumours, which had previously been characterised using 
five different methods of HER2 evaluation. HercepTest was shown to have  85% 
concordance (95% CI: 78, 89%), a sensitivity of 0.6 (95% CI: 0.5, 0.7) and a specificity of 1 
(95% CI: 0.95, 1).108 
A number of reproducibility studies were also undertaken (for example lot-to-lot).108 
In 1998 HercepTest was approved by the FDA to aid assessment of eligibility for 
trastuzumab treatment.93,107 
2.4.6 PHASE III TRIAL 
A randomised phase III trial (H0648g, also included in datasets in Chapter 5 and 6) 
recruited 469 HER2 positive patients with progressive metastatic BC between June 1995 
and March 1997. Their biomarker status was determined using IHC (antibody NR), where 
2+ or 3+ staining in >10% of cells was classed as positive. The trial compared trastuzumab 
with chemotherapy (anthracycline, cyclophosphamide, or paclitaxel) to chemotherapy 
alone.109 
It demonstrated that the median time to progression for trastuzumab added to 
chemotherapy was 7.4 months and for chemotherapy alone 4.6 months (p<0.001). The 
combination of trastuzumab and paclitaxel appeared the most beneficial. Cardiac 
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dysfunction was observed in 51 patients treated with trastuzumab, although the 
mechanism was unclear.109 
2.4.7 MARKETING AUTHORISATION 
The FDA considered trastuzumab in a fast-track process and it was approved in 1998 in 
combination with paclitaxel for first-line treatment of HER2 positive metastatic BC patients 
and as monotherapy for second and third line therapy.93 
An application was submitted to the EMA in the beginning of 1999 and was approved in 
the middle of 2000 in a similar indication.110 
2.5 FINDINGS OF THE SYSTEMATIC REVIEW OF FRAMEWORKS FOR PHASED EVALUATION 
OF PREDICTIVE BIOMARKERS 
Having described the case of the development of HER2 expression for prediction of 
response to trastuzumab, this chapter will now focus on how such a process was 
described in the methodological literature. This case study will then be used in the 
Discussion to explore how well the theoretical proposals match this example of research 
practice. 
2.5.1 IDENTIFICATION OF INCLUDED PAPERS 
The review process is shown in Figure 2.1. MEDLINE and EMBASE searches resulted in a total 
of 26,624 records. An additional 63 records were identified in internet searches. All of these 
were imported into an EndNote database. After removal of duplicates, 16,268 references 
remained. Screening of reference lists of papers assessed in full text resulted in addition of 
four references to the database.  
All titles and abstracts were assessed for inclusion by one reviewer and 2700 were 
checked by a second reviewer. The second reviewer identified two potentially relevant 
references111,112 missed by the first reviewer. These two papers were obtained in full text 
and subsequently both were excluded. 
Due to the complexity in applying the inclusion criteria to the titles and abstracts, a full 
text was sought for 340 papers. The full text could not be obtained for 13 references, 
which are reported in Appendix 6. 296 papers were excluded based on the assessment of 
the full text. 277 of these did not describe a framework and 19 did not include predictive 
biomarkers in their scope. A list of excluded full texts together with reasons for exclusion is 
reported in Appendix 7. Data were extracted on the 23 complete frameworks. 
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Inclusion criteria were met by 31 papers. Of these, 23 described a complete framework 
and eight113-120 focused only on a fragment of such a framework. These, for example, 
described only the stages of analytical and clinical validation. Given the extent of 
information available from the papers describing a full framework and potential difficulty 
in matching the papers describing a fragment of a framework to any model, the eight 
papers reporting a fragment of a framework were not analysed. 
 
Figure 2.1 Flow chart for review of frameworks for staged evaluation of predictive biomarkers 
2.5.2 IDENTIFIED MODELS FOR STAGED DEVELOPMENT OF PREDICTIVE BIOMARKERS 
Identified frameworks were grouped into four models (shown in Box 2.3). 
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These models are discussed in more detail in sections 2.5.3 - 2.5.6 below. Model I is 
described in detail. Models II-IV are considered special cases of this model and are 
therefore only briefly summarised and a full description is available in Appendix 8. 
Box 2.3 Models identified from the review of frameworks for staged evaluation of predictive biomarkers 
 
2.5.3 MODEL I (GENERAL) 
2.5.3.1 IDENTIFIED FRAMEWORKS 
Eleven papers described frameworks matched to model I (general).18,43,44,47,121-127 The 
details of these papers are reported in Table 2.1. All of these were published in 2010 or 
later. They included four to seven stages and in some cases stages were also sub-divided 
into multiple sub-stages. Four of the frameworks focused on predictive biomarkers or 
companion diagnostics,18,47,121,125 while the remaining seven had a wider scope and 
described, for example, development of any biomarker. One of the papers focused on 
proteomic biomarkers.127 Where specified, the disease areas for which the frameworks 
were proposed were cancer,18,43,44,122 autism (suggesting this was generalisable to 
complex diseases in general)121 and neurological and neuropsychiatric disorders.124  
The authors came mainly from the USA and European countries. The grounds on which 
the framework was proposed were only provided in four papers: an FDA concept paper,47 
a process used by the Early Detection Research Network43 and considerations emerging 
from real-life examples.125,127  
The order of stages in the identified frameworks was generally in agreement with that 
proposed for model I, as shown in Table 2.2. All frameworks included the discovery and 
clinical utility stage. Four frameworks included a pre-discovery stage.47,121,125,127 Analytical 
Model I (general) described stages for development of predictive biomarkers 
that appeared to be applicable to any context, 
Model II (alongside phased drug development) tied the biomarker 
development to the phases of drug development, 
Model III (multi-marker classifier) described development of a multi-marker 
classifier and focused mainly on construction of a statistical model for the 
classifier, 
Model IV (safety biomarker) focused on biomarkers predicting safety of 
treatments already available in the clinic. 
 
44 
validation was not mentioned in two,121,124 clinical validation in four,121,122,124,127 and 
implementation in four.44,47,121,125 Ecker 2013121 and Kaur 2013124 differed most from the 
proposed model. On completion of the discovery stage these two frameworks proposed 
proceeding immediately into the utility stage. 
Table 2.1 Frameworks matched to model I 
NR – 
not 
reported 
 
Framework Stages 
(number) 
Scope Country/ 
region 
Basis  
Alymani 
201018 
4 (+6 sub-
stages) 
predictive biomarkers 
for solid tumours 
UK NR 
Ecker 
2013121 
6 (+ 2 sub-
stages) 
development of 
targeted treatment 
for autism (complex 
diseases) 
UK, 
Switzerland 
NR 
FDA 201547 4 (+ 4 sub-
stages) 
predictive in vitro 
biomarkers; dug-
diagnostic co-
development 
USA USA drug regulator concept 
paper; for discussion, not for 
implementation 
Goosens 
2015122 
4 any cancer 
biomarker 
USA, 
Switzerland 
NR 
Heckman-
Stoddard 
201243 
5 
any cancer 
biomarker USA 
based on Early Detection 
Research Network process to 
guide biomarker development 
for early detection 
Henry 
201244 
5 (+ 2 sub-
stages) 
any cancer 
biomarker 
USA NR 
Horvath 
2010123 
6 any biomarker Hungary, 
Australia 
NR 
Kaur 
2013124 
4 pharmacogenomics 
in neurological and 
neuropsychiatric 
diseases 
India NR 
Love 
2012125 
7 companion 
diagnostics; written 
from the perspective 
of drug/ diagnostic 
developing 
company 
USA consideration of biomarker 
cases 
Majkic 
2011126 
5 any biomarker Serbia NR 
Mischak 
2012127 
6 (+4 sub-
stages) 
any proteomic 
biomarker 
International considerations in a real-life 
example 
 Table 2.2 Labels and stage numbers in identified frameworks matched to model I 
Stage Alymani 
201018 
Ecker 2013121 FDA 200547 Goossens 
2015122 
Heckman-
Stoddard 
201243 
Henry 
201244 
Horvath 
2010123 
Kaur 2013124 Love 
2012125 
Majkic 
2011126 
Mischak 
2012127 
p
re
-d
is
c
o
v
e
ry
 
 
(1-5) 
(1) Human 
phenotypes 
(2) Human 
genotype(s) 
(3) Animal 
models 
(4) Cellular 
assays 
(5) Drug dev. 
and 
screening 
(1)  
Basic 
research 
 
     
(1)  
Defining 
unmet 
need 
 
(1) 
Initial disc. 
and 
validation 
d
is
c
o
v
e
ry
 
(1)  
Disc. 
(5) 
BM dev. 
(2)  
Prototype 
design or 
disc. 
(1) 
BM disc. 
(1) 
Preclinical 
exploratory 
studies 
(1-2) 
(1) Id. of a 
potential 
BM 
(2) Dev. of 
a 
candidate 
BM 
(1-2) 
(1) 
Association 
of disease 
with a new 
BM 
(2) Potential 
use of new 
BM in 
practice 
(1-2) 
(1) Id. of 
markers 
(2) 
Validation 
and 
interpretatio
n of data 
(pre-clinical 
mechanistic
) 
(2)  
BM 
discovery 
(1) 
Preclinical 
investigatio
n 
 
(1-2) 
(1) Initial 
disc. and 
validation 
(2) panel 
advice 
a
n
a
ly
ti
c
a
l 
v
a
li
d
a
ti
o
n
 
(2) 
BM 
validation 
(2.1) 
method 
dev. 
(2.2) pre-
study 
validation 
(2.3) in-
study 
validation 
 
(3)  
Preclinical 
dev. 
(3.1) 
Analytical 
validity 
(3.2) 
Preclinical 
pilot 
feasibility 
studies 
(2)  
BM assay 
dev. and 
analytical 
validation 
(2) 
Clinical 
assay dev. 
(3) 
Analytic 
validity 
(3.1) 
analytic 
validity 
(3.2) pre-
analytic 
validity 
(3) 
Analytic 
validity 
 
(3) 
Technical 
assay 
validation 
(2)  
BM validity 
assessment 
 
(3.1-3.2) 
(3.1) BM 
evaluation 
in 
appropriate 
samples 
(3.2) panel 
advice 
4
5
 
 Stage Alymani 
201018 
Ecker 2013121 FDA 200547 Goossens 
2015122 
Heckman-
Stoddard 
201243 
Henry 
201244 
Horvath 
2010123 
Kaur 2013124 Love 
2012125 
Majkic 
2011126 
Mischak 
2012127 
c
li
n
ic
a
l 
v
a
li
d
a
ti
o
n
 
(3)  
BM 
qualificatio
n 
(3.1) 
retrosp. 
study 
(3.2) prosp. 
study (BM 
evaluation 
as 
secondary 
objective) 
 
(4)  
Clinical 
dev. 
(4.1)Clinical 
validity 
 
(3) 
 Retrosp. 
longitudinal 
repository 
studies 
 
(4)  
Clinical 
validity 
(4)  
Clinical 
validity 
(efficacy) 
 
(4)  
Clinical 
validation 
(3-4) 
(3) retrosp. 
epidemiolo
gical 
studies 
(4) prosp. 
clinical 
studies 
 
c
li
n
ic
a
l 
u
ti
lit
y
 (3.3)  
Prosp. 
study (BM 
evaluation 
as primary 
objective) 
(6)  
Clinical trials 
(4.2)  
Clinical 
utility 
(3)  
Validation 
of clinical 
utility 
(4)  
Prosp. study 
(5)  
Clinical 
utility 
(5)  
Clinical 
utility 
(effectiven
ess) 
(3)  
Functional 
interpretatio
n 
(5)  
Clinical 
utility 
(5)  
Randomise
d clinical 
studies 
(4) 
(4.1) 
intervention 
trial 
(4.2) panel 
advice 
im
p
le
m
e
n
ta
ti
o
n
 
(4)  
Clinical 
implement
ation 
 
 
(4)  
Clinical 
implement
ation 
(5)  
Cancer 
control 
 
(6) 
Clinical 
impact 
(efficiency) 
(4)  
Clinical 
implementa
tion 
(6-7) 
(6) 
medical 
utility  
(7) 
commerci
al 
adoption 
 
(5-6) 
(5) 
implementa
tion in 
clinical 
practice 
(6) 
feedback 
mechanism 
BM – biomarker; dev. – development; disc. – discovery; id. – identification; prosp. – prospective; retrosp. – retrospective; 
 
4
6
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2.5.3.2 STUDY DESIGNS AND OUTCOMES OF EACH STAGE  
This section will summarise the identified study designs that were considered relevant to 
each stage by the frameworks matched to this model. It will also provide an overview of 
what were perceived as the desirable information and products to be obtained as a 
result of each stage (the outcomes). 
Pre-discovery 
As shown in Table 2.3 there were no study designs discussed in the identified frameworks 
for the pre-discovery stage.  
Where reported, the outcome of this stage was focused around identification of the 
clinical need and context for biomarker development.121,125,127 One paper defined this 
further as development of a Target Product Profile and criteria for success.125 One paper 
also required development of animal models and cellular assays as well as the drug.121 
Table 2.3 Model I: pre-discovery stage 
N/A – not applicable; NR – not reported 
Discovery 
The identified frameworks suggested a wide range of strategies for biomarker discovery, 
as shown in Table 2.4.  
Framework Study design Outcome 
Alymani 201018 N/A N/A 
Ecker 2013121 NR 
 Define a clinical need 
 Develop cellular assays and animal models of a 
pathologic feature 
 Drug development  
FDA 201547 NR NR 
Goosens 2015122 N/A N/A 
Heckman-Stoddard 
201243 
N/A N/A 
Henry 201244 N/A N/A 
Horvath 2010123 N/A N/A 
Kaur 2013124 N/A N/A 
Love 2012125 NR 
 prepare Target Product Profile  
 define criteria for success - in therapeutic terms and 
fulfilling Target Product Profile 
Majkic 2011126 N/A N/A 
Mischak 2012127 NR Define clinical need and context 
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Table 2.4 Model I: discovery stage 
NR – not reported 
Framework Study design Outcome 
Alymani 
201018 
can be optimised by combining: 
 clinical correlation studies: analysis of bio-
specimens from patients 
 investigation in multiple preclinical model 
systems (in vitro and in vivo). 
 ideally understanding of 
biology 
 correlation between 
biomarker and outcome may 
be sufficient 
Ecker 
2013121 
NR biomarker discovery 
FDA 201547 discovery NR 
meeting with regulator to discuss development  
NR 
Goosens 
2015122 
 “most optimal setting is prospective sample 
collection and follow-up based on a fully 
predefined protocol” (costly and lengthy)  
 “retrospective analysis of samples archived as 
part of previously completed prospective trials 
(prospective-retrospective design)” - shorter 
time 
 biobank in which biospecimens and complete 
clinical annotations are prospectively 
accumulated” (based on protocols for cohort 
or case-control studies) 
 In practice, biomarker discovery is often 
based on “samples of convenience” 
 Initial validation in a separate independent 
patient sample, but cross-validation possible 
 biomarker discovery  
 initial validation 
Heckman-
Stoddard 
201243 
 two possible (complementary) approaches: 
1) "knowledge-based" - only selected markers 
2) "unbiased" - large number of biomarkers 
 preclinical studies: "could include animal 
models, cell lines, or clinical samples" 
biomarker discovery 
Henry 
201244 
multiple approaches; discussed two: 
1) candidates  based on biology understanding  
2) "discovery" approach - using techniques such as 
high-throughput sequencing and mass 
spectroscopy to identify one or more biomarkers 
that differ between cohorts; need careful design to 
minimise false positives 
biomarker discovery 
Horvath 
2010123 
 "Case-control studies are often sufficient" 
 '"Decision analytic modelling could be a cost-
saving approach for assessing the potential 
clinical utility of the new biomarker in various 
practical scenarios. 
 biomarker discovery 
 assessment of potential 
clinical utility 
Kaur 
2013124 
"human population based lab research” 
(Candidate gene and genome wide approach) 
Cell-culture or animal model based approach 
 biomarker discovery 
 understanding of biology 
Love 
2012125 
NR  characterise information 
provided by the biomarker(s) 
 identify appropriate platform 
 identify body site for imaging 
or sample type 
Majkic 
2011126 
correlative laboratory studies  correlation of biomarker with 
biological phenomenon 
 improve assay: reliability and 
sensitivity; standardise  
Mischak 
2012127 
NR discovery studies 
advice from multidisciplinary panel 
 biomarker discovery and 
initial validation 
 panel guidance on sample 
collection and study design 
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Three papers postulated two general and not mutually exclusive approaches: 
knowledge-based and data-driven.43,44,124 Where reported, the appropriate study design 
involved at least one of the two types of studies: 
 pre-clinical: cell line and animal model research,18,43,124  
 clinical correlative studies: mainly using case-control and cohort 
methodology.18,44,122,123  
Two papers also discussed the need for initial validation of discovery,122,127 either using an 
independent sample or cross-validation.122 Another paper proposed conducting decision 
analytical modelling to evaluate the potential clinical utility.123 Two papers suggested 
obtaining advice on further research either from the regulator,47 or a multidisciplinary 
panel.127 
Apart from identification of a candidate biomarker it was also suggested this stage should 
ideally provide understanding of the biology linking the biomarker to the outcome.18,124 
Definition of the parameters of the biomarker assay was also discussed as an outcome of 
this stage.125,126 
Analytical validation 
The design of studies to evaluate analytical validity was rarely reported, as shown in Table 
2.5. One paper claimed there was no generally accepted standard.18 The designs 
reported in three papers generally involved comparing the results of the assay to a known 
reference standard using biological specimens from patients.18,47,122 Two papers also 
proposed feasibility or pilot studies to be conducted at this stage.18,47 
The outcomes of analytical validation included test accuracy (for example sensitivity, 
specificity),18,43,44,47,122,123 precision18,47,123 and reproducibility.18,44,125 Establishing the 
biomarker cut-off was suggested in two papers.43,47 One of these identified the possible 
necessity for a grey zone between biomarker positive and negative patients. Such a grey 
zone is a set of biomarker values for which a treatment decision would not be biomarker-
dependent due to uncertainties in biomarker evaluation and clinical outcome 
assessment.  
At this stage frameworks also proposed developing a platform for use in clinical 
practice,47,122 and assay standard operating procedures.18,43 It was also indicated that 
biological variability of the biomarker should be investigated,44,126 as well as factors 
related to biological sample handling.44 The need for identification of the target 
population was also discussed.47 
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Table 2.5 Model I: analytical validation 
N/A – not applicable; NR – not reported; ROC – receiver operator characteristic 
Framework Study design Outcome 
Alymani 
201018 
no accepted standard - guided by Good 
Clinical Laboratory Practice and other 
standards, may not always be applicable 
feasibility studies to assess reagent 
availability; 
uses "controls (from patient samples or 
suitable surrogates) that contain known 
concentrations of the biomarker " 
"test the assay on real patient samples (…) 
to confirm consistent performance" 
method development and preliminary 
validation 
 parameters including: “selectivity, 
sensitivity, different choice of controls, 
different analyte recovery methods, 
precision, accuracy and 
reproducibility"  
 " stability of the analyte in controls 
and patient samples" 
 produce an analytical report  
 "construct a standard operating 
procedure" 
 generate valid patient data 
 "identify any issues that may occur 
when analysing real patient samples" 
Ecker 
2013121 
NR NR 
FDA 201547 analytical studies: 
 “using an independent prospective 
clinical dataset, or by testing 
retrospectively banked specimens 
from the original studies” 
 “pilot studies to determine relevant 
populations to be studied to establish 
clinical test performance and target 
cut- off points in biological specimens” 
 assay performance including 
sensitivity, specificity, precision 
 validate the test platform 
 establish test cut-offs taking into 
account clinical and analytical 
factors (may include a grey zone) 
 identify the populations to be studied 
Goosens 
2015122 
Usually by analytic validity studies 
“assaying the same set of samples by both 
the assay used in the initial discovery and 
the clinical deployment platform to 
determine robustness and reproducibility of 
the measurements” 
 adapt biomarkers to a clinical 
platform 
 accuracy and reliability of the 
platform 
Heckman-
Stoddard 
201243 
NR  for binary assay - sensitivity and 
specificity 
 if cut-off not known - use ROC curve 
 biomarker status association with 
patient and disease characteristics  
Henry 
201244 
NR  standard operating procedures 
 sensitivity, specificity and robustness of 
assay;  
 reproducibility within and between 
laboratories 
Horvath 
2010123 
analytic validity studies (details NR)  “e.g. technical sensitivity, specificity, 
imprecision and trueness" 
 "quality control procedures" 
 analytical characteristics improved if 
needed 
Kaur 
2013124 
N/A N/A 
Love 
2012125 
NR assay reproducibility in relevant sample 
types 
Majkic 
2011126 
NR  ability to distinguish between different 
phenotypes/ outcomes;  
 reference values and individual 
variation 
Mischak 
2012127 
 recommended by panel 
 present results to panel 
NR 
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Clinical validation 
There was a variety of clinical validation study designs discussed, as shown in Table 2.6. 
Two papers suggested this stage should begin with a retrospective study (further details 
NR), followed by a prospective one.18,126 One of these papers further describes this 
prospective study as a clinical trial investigating the drug and including the biomarker 
hypothesis as a secondary objective.18 One paper suggested conducting only a 
retrospective study using stored samples (further details NR),43 another proposed a case-
control design44 and one a diagnostic accuracy study.123 One paper suggested this stage 
should be carried out in parallel with phase I and II drug trials.47 One framework 
postulated that, if positive, the results of the clinical validation study should be 
reproduced in an independent dataset.44 
The proposed outcomes of this stage included sensitivity and specificity for clinical end-
point prediction,18,47,123,125 positive predictive value (PPV), negative predictive value (NPV) 
and diagnostic likelihood ratios.47 One paper suggested that the threshold for a 
continuous biomarker or multi-marker classifier should be developed at this stage.43 Other 
outcomes included linearity of the biomarker,125 biological variability43 and correlation 
between biomarker and outcome.126 
Clinical utility 
Most of the papers suggest evaluation of clinical utility in an RCT.18,43,47,121-124,126 Different 
study designs were suggested depending on the situation, as detailed in Table 2.8. These 
are described in more detail in Chapter 1 and briefly these were: 
 biomarker-strategy with or without randomisation in the control arm,18 
 prospective subgroup analysis of an RCT,47 
 biomarker stratified,18,47 
 enrichment,47 
 prospective-retrospective.47,122  
It was also noted that a systematic review or meta-analysis of multiple trials may be 
used.123,124 One paper suggested that depending on circumstances case-control or 
cohort methodology can be used rather than an RCT.124 
 Table 2.6 Model I: clinical validation 
N/A – not applicable; NR – not reported; PPV – positive predictive value; NPV – negative predictive value
Framework Study design Outcome 
Alymani 201018 clinical studies; no formal guidelines 
 " start by retrospectively analysing material from prior well-controlled studies 
from which high quality sample material as well as clinical outcome (…) is 
available (…) collection of tissues should be prospectively determined" 
 as alternative materials from bio-banks – useful for discovery (less robust) 
 After retrospective studies, a “prospective clinical study for the biomarker (…) 
as an adjunct to a clinical trial of which the primary objective is to test the 
efficacy of a drug” sample collection should be prospective and follow 
“standard operating procedures and other clinical trial regulatory guidance" 
“ sensitivity and specificity for clinical end-point determination” 
Ecker 2013121 N/A N/A 
FDA 201547 In parallel with phase I and II studies: 
 “studying the test in relation to the intended clinical outcome in patient 
subgroups with and without the analyte of interest” 
  “based on information known from analytical studies and based on pilot 
studies or careful analysis to determine relevant populations (…) clinical test 
performance” and target cut-offs  
 should use the same “endpoints used to indicate the clinical utility” of 
biomarker and provide information on the clinical impact of a test result 
for dichotomous/ dichotomised outcomes:  
 clinical sensitivity and specificity 
 PPV and NPV in patient population similar to intended 
indication  
 additionally positive and negative diagnostic likelihood ratios 
may be investigated 
Goosens 2015122 N/A N/A 
Heckman-
Stoddard 201243 
"retrospective analysis using stored samples”  determine if biomarker predicts outcome 
 continuous biomarker: find threshold 
 multiple markers: compare, develop combinations, assess if 
sequential testing adds information 
 assess within-individual variability 
Henry 201244  often use of convenience samples;  
 patients representative of the clinical question;  
 cases and controls should be similar;  
 sample handling and processing should be similar and biomarker assessment 
blind to group 
 observation of apparent clinical validity "needs to be reproduced in a 
completely independent set of samples in order to confirm validity" 
 consider independent validation by completely independent researchers 
show that "biomarker reliably divides the overall population of 
interest into two distinct groups” (such as more or less likely to have 
an event) 
Horvath 2010123 "usually investigated in diagnostic accuracy studies in a representative spectrum 
of patients, in order to obtain the clinical sensitivity and specificity of the test" 
clinical  sensitivity and specificity of the test 
Kaur 2013124 N/A N/A 
Love 2012125 NR  appropriate reproducibility (precision and accuracy) 
 appropriate  sensitivity and specificity 
 linearity over the range of possible test results for intended use  
Majkic 2011126 retrospective epidemiological studies followed by prospective clinical studies correlation between biomarker levels and clinical outcomes 
Mischak 2012127 N/A N/A 
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In the majority of the papers the outcome of this stage was assessing clinical utility of the 
biomarker.18,43,47,122,123,125-127 Some also mentioned confirmation of biomarker 
performance43,122 and evaluation of biomarker variability in response to administered 
drugs.126 According to one paper, the outcome of this stage should be new indications 
and drugs on the market.124 
Implementation 
The implementation stage is shown in Table 2.7. It referred to activities that would normally 
follow marketing of the biomarker. At the point of implementation only three frameworks 
report further collection of data: through cohort studies or case reviews,43 health 
technology assessment and clinical guideline development,123 or an unspecified 
feedback mechanism.127  
The outcomes of this stage were focused on implementation of the biomarker in clinical 
practice which involved incorporation of regulation into clinical guidelines122 and 
reimbursement.122,125 According to some frameworks impact on spending123,127 and 
population health should also be evaluated.43 
Table 2.7 Model I: implementation 
N/A – not applicable; NR – not reported  
Framework Study design Outcome 
Alymani 
201018 
NR NR 
Ecker 2013121 N/A N/A 
FDA 201547 N/A N/A 
Goosens 
2015122 
NR Implementation in clinical practice: 
 regulatory approval,  
 commercialisation,  
 coverage by health insurance companies,  
 incorporation in clinical practice guidelines 
Heckman-
Stoddard 
201243 
"may include cohort designs or 
clinical case reviews” 
real-life impact of the biomarker on reducing 
the burden of disease in the population 
Henry 201244 N/A N/A 
Horvath 
2010123 
 health technology 
assessment  
 guideline recommendations 
investigate "ethical, legal, financial or social 
implications of testing" 
Kaur 2013124 NR improved therapeutic response 
Love 2012125 NR  establish if the test is used to make 
treatment decisions that improve patient 
outcome 
 establish if the test (and treatment) are an 
appropriately reimbursed standard of care 
Majkic 2011126 N/A N/A 
Mischak 
2012127 
"feedback mechanisms to 
evaluate cost-effectiveness, 
clinical adoption, problems in 
routine application, unanticipated 
collateral problems" 
 implement in practice (may be on a 
limited scale if data on hard endpoints not 
robust) 
 collect data on “cost-effectiveness, 
clinical adoption, problems in routine 
application, unanticipated collateral 
problems” 
 Table 2.8 Model I: clinical utility 
N/A – not applicable; NR – not reported; RCT – randomised controlled trial; PPV – positive predictive value; 
Framework Study design Outcome 
Alymani 201018 prospective study - primary objective: “evaluation of the predictive power of the biomarker"  
Three designs suggested: 
 biomarker-strategy (no randomisation in control arm) 
 biomarker-strategy (randomisation in control arm) "for example, if one treatment is better than 
the other in both biomarker-positive and biomarker-negative patient subgroups. It may also 
allow a retrospective assessment of an alternative classification”; relatively inefficient 
 stratified (more efficient, allows testing for interaction and of biomarker prognostic impact; no 
direct assessment of predictive impact of biomarker; cannot be used if more than one 
biomarker and more than two treatments or outcomes other than efficacy assessed) 
clinical utility 
Ecker 2013121 Clinical trial NR 
FDA 201547 As a phase III trial; possible designs: 
 “simple two-arm randomization comparing a treatment and a control (...) with the results from 
the diagnostic test (...) used as a prespecified stratification factor in the post-hoc statistical 
analysis” – would “ allow for identification of a treatment by diagnostic test result interaction [if] 
results of the testing will not be readily available at the clinical sites”  
 randomization within differing strata by diagnostic test result 
 enriched – “careful explanation and justification of the enrichment technique used (diagnostic 
test, demographic information, other)” needed 
 “in cases where the analyte is stable and where collection bias (including spectrum bias, 
verification bias, and sampling bias) can be carefully characterized and addressed, 
prospectively designed retrospective clinical utility studies” possible 
clinical utility 
Goosens 
2015122 
Ideally, (...) statistically well- powered prospective trials” if infeasible - prospective- retrospective 
design and/or biobank/biorepository samples could be used 
 clinical utility; 
 confirm performance 
Heckman-
Stoddard 201243 
Prospective trial  establish if biomarker predicts outcome;  
 PPV of the biomarker 
Henry 201244 NR  assay useful in clinical practice 
 includes benefit-to-harm ratio 
Horvath 2010123 RCT, a systematic review or meta-analysis of multiple RCTs most appropriate clinical utility 
Kaur 2013124  correlation of markers with multiple outcomes in large independent populations; depending on 
resources, ethical issues and outcomes assessed this could be case-control, cohort or RCT; 
 meta-analysis of such studies 
new indications and drugs on market 
Love 2012125 NR  biomarker provides actionable information 
in relevant context 
 improved treatment decisions 
Majkic 2011126 RCT  improved treatment 
 “influence of drugs on biomarker values” 
Mischak 2012127  intervention trial as recommended by panel 
 present to panel 
benefit of biomarker 
5
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2.5.3.3 CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
Criteria for a potential predictive biomarker to enter into and complete a particular 
development stage were provided in six papers.18,43,47,123,124,127 These are shown in Table 
2.9. 
None were discussed for pre-discovery.  
For discovery, one paper claimed there are no accepted standards for entry or 
completion.18  
To commence analytical validation, papers suggested a validation plan needs to be in 
place,18 modelling needs to confirm there is potential for the biomarker to show desired 
clinical utility,123 or a multidisciplinary panel decides the biomarker can enter this stage 
based on discovery data.127 One paper suggested there are no standards for completion 
of this stage18 and another proposed a panel recommendation as the criterion.127  
Entering into clinical validation appeared to be dependent on the existence of a suitable 
biomarker test based on the analytical validation.18,43,47 One paper suggested the cut-off 
needs to be selected.47 With regard to completing this stage, it was stated in one paper 
that there are no standards.18 
Progression to the clinical utility stage, where reported, appeared to require satisfactory 
analytical validity47,127 and in one case having completed biomarker discovery (however 
this paper suggested proceeding to clinical utility immediately after discovery).124 For 
completion one paper suggested that considerations are similar to any other clinical 
hypothesis and usually require data from two or more adequate trials, although this may 
depend on the situation.47 Another paper claimed this was “traditionally settled by 
debate, consensus and time”.18  
Implementation generally required demonstration of clinical utility18,124,127 No criteria for 
completion were discussed. 
 
 Table 2.9 Model I: entry (in) and completion (out) criteria for stages 
Stage Alymani 201018 Ecker 
2013121 
FDA 200547 Goossens 
2015122 
Heckman
Stoddard 
201243 
Henry 
201244 
Horvath 
2010123 
Kaur 2013124 Love 
2012125 
Majkic 
2011126 
Mischak 2012127 
p
re
-
d
is
c
o
v
e
ry
 N/A NR NR N/A N/A N/A N/A N/A NR N/A NR 
d
is
c
o
v
e
ry
 No standard  NR NR NR NR NR NR NR NR NR In: NR 
Out: satisfactory 
discovery and 
initial validation 
a
n
a
ly
ti
c
a
l 
v
a
li
d
a
ti
o
n
 In: validation 
plan 
Out: no 
standard 
N/A NR NR NR NR In: 
"modelling 
confirms 
potential 
clinical utility" 
Out: NR 
N/A NR NR In and out: panel 
recommendation  
c
li
n
ic
a
l 
v
a
li
d
a
ti
o
n
 
In: validation 
must be fit-for-
purpose 
validation (full 
not necessary) 
Out: no 
standard 
N/A In: test analytically 
characterised; 
cut-off selected 
Out: NR 
N/A Good 
clinical 
assay 
NR NR N/A NR NR N/A 
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In: NR 
Out: “settled by 
debate, 
consensus and 
time” 
NR In: test analytically 
characterised; 
cut-off selected 
Out: usually data 
from two or more 
adequate trials 
NR NR NR NR In: 
Completion 
of discovery 
Out: NR 
NR NR In and out: panel 
recommendation 
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m
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In: qualified 
biomarker 
(clinical validity 
and utility) 
Out: NR 
N/A N/A NR NR N/A NR In: 
Completion 
of clinical 
utility 
Out: NR 
NR N/A In: panel 
recommendation 
Out: NR 
N/A – not applicable; NR – not reported; 
5
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2.5.4 MODEL II (ALONGSIDE PHASED DRUG DEVELOPMENT) 
2.5.4.1 IDENTIFIED FRAMEWORKS 
Three papers were identified that were matched to model II (alongside phased drug 
development). Two of these focused on predictive128,129 and one on any -omics 
biomarkers.130 As shown in Table 2.10, all of these frameworks matched well to the stages 
in model II. The process which led to construction of these frameworks was NR. 
Table 2.10 Labels and stage numbers in identified frameworks matched to model II  
Stage Garcia 2011128 Hodgson 2009129 Lin 2009130 
Pre-clinical (1) 
Preclinical discovery and 
analytical assay validation 
(1) 
Pre-clinical 
(1-3) 
(1) Discovery 
(2) Internal validation 
(3) External validation 
phase I trial (2) 
Phase I trial clinical 
qualification 
(2) 
Phase 1 (biomarker 
validation) 
(4) 
clinical trial (phase I, II) 
phase II trial (3) 
Phase II trial clinical 
qualification 
(3) 
Phase 2 trial against 
comparator in biomarker 
+ve and -ve patients 
(4) 
Clinical trial (phase I, II) 
phase III trial (4) 
Phase III trial clinical 
qualification 
(4) 
Phase 3 Preparation for 
commercial launch 
(5) 
Large clinical trial (phase 
III) 
implementation 
 
 
(6) 
Continued surveillance 
 
2.5.4.2 STUDY DESIGNS AND OUTCOMES OF EACH STAGE 
Little detail was available in the identified papers on study designs appropriate for each 
stage and the outcomes of these stages. The main relevant points are summarised below. 
Pre-clinical 
The relevant designs for this stage were: literature reviews,129,130 pre-clinical models,129 
case-control studies and data-mining.130 One framework suggested that an initial 
discovery study should be replicated for external validation.130  
This stage should aim to identify the candidate biomarker,129,130 provide understanding of 
the biomarker biology and assess performance characteristics of the assay.130 
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Phase I trials 
No relevant study designs were described in the papers.  
The main outcomes were “clinical usefulness”128 and evaluability and prevalence of the 
biomarker.129 
Phase II trials 
The proposed designs for this stage were either stratified or, for prolonged stable disease, 
randomised discontinuation. However, if sufficient evidence is available from a phase I 
expansion cohort, a study may not be needed.128 According to one paper this should 
provide evidence on the usefulness of the biomarker in a clinical setting and 
reproducibility, validity and variability of the assay.128 Another paper suggested 
conducting a benefit/risk ratio in all patients and biomarker-defined subgroups would be 
the aim129 
Phase III trials 
This stage should involve randomised trials: 
 with biomarker-based inclusion criteria for biomarkers with high predictive value 
(most likely referring to an enrichment design), or  
 stratified for biomarkers with low predictive value.128 
As a result of such a trial, information on biomarker utility should be obtained.128,129 One 
paper also suggested the biomarker assay should be finalised at the end of this stage.129  
Implementation 
None of the papers provided details of the implementation stage. 
2.5.4.3 CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
Criteria for entry into three stages (pre-clinical, phase II and phase III trial) were available 
from two papers.128,129 Completion was only discussed in one paper for the phase II trial 
stage.128  
To enter the pre-clinical stage some understanding of the drug mechanism of action was 
required.128  
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For entry into a phase II trial, “data on biomarker evaluability and prevalence and 
estimate of effect size” was needed.129 To complete phase II, clinical validity of the 
biomarker should be demonstrated.128  
For entry into phase a III biomarker trial, clinical validity of the biomarker needed to be 
shown.128  
2.5.5 MODEL III (MULTI-MARKER CLASSIFIER) 
2.5.5.1 IDENTIFIED FRAMEWORKS 
There were seven papers13,45,50,52,131-133 that described frameworks matched to model III 
(multi-marker classifier). None of the frameworks was focused exclusively on predictive 
biomarkers.  
As shown in Table 2.11, the order of stages in the identified frameworks was generally in 
agreement with that proposed for model III with one exception (Ginsburg 2006132). Three 
papers reported the basis of the proposed framework and this was: literature searches,133 
a committee with members from a variety of backgrounds,50 and experience from an 
observational study.45 
2.5.5.2 STUDY DESIGNS AND OUTCOMES OF EACH STAGE  
Pre-discovery 
Study designs in this stage reflected the different sources of data to be used later for 
discovery. These were: cell-line experiments,131 genetic association studies132 and a pilot of 
a multicentre study.45  
The outcomes of this phase generally included formulation of the question to be 
addressed,45 data collection,50,131-133 a validated biomarker discovery platform132,133 and a 
protocol for a multicentre study.45 
Identification of candidate biomarkers 
The study designs suggested for this stage were mainly focused around different statistical 
techniques, such as two-sample t-tests,131 or a variety of pattern recognition techniques132. 
Two approaches were suggested that can be used on their own or in combination: non-
hypothesis driven and hypothesis driven discovery.45 It was also proposed that the findings 
should be replicated in a new study and biological plausibility studies carried out.132 
The only outcome of this stage discussed was obtaining a set of candidate biomarkers.  
 Table 2.11 Labels and stage numbers in identified frameworks matched to model III (multi-marker classifier) 
Stage Cho 2012131 Ginsburg 2006132 Ioannidis 2011133 IOM 201250 Matsui 201352 Shahzad 201245 Simon 200513 
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ry
 
(1-2) 
(1) Data collection 
(2) Quality control/ 
pre-processing 
(1-2) 
(1) Biomarker 
discovery 
(2) Clinical and 
biological data 
collection 
 
(1) 
(1) Analytical 
tools 
(1.1.1) 
(1) Discovery and 
Test Validation Stage 
(1.1)Discovery Phase 
(1.1.1) Step 1: Data 
Quality Control 
 (1.1-1.2) 
(1) phased approach 
(1.1) Clinical phenotype 
consensus definition 
(1.2) Establishment of 
study logistics 
(1.2.1) initial protocol 
(1.2.2) feasibility studies 
(1.2.3) pilot studies 
(1.2.4) problem 
identification 
(1.2.5) trouble shooting 
(1.2.6) protocol 
modification 
(1.2.7) individual training 
(1.2.8) new protocol 
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(3) 
(3) Identification of 
candidate biomarkers 
(1, 2.1)  
(1) Biomarker 
discovery 
(2.1) Biomarker 
validation 
(2) 
(2) Clinically 
oriented 
discovery 
(1.1.2) 
(1.1.2) Step 2: 
Computational 
Model Development 
and Cross-Validation 
(1.1) 
(1) Developing 
genomic signatures 
(1.1) gene 
screening 
(1.3) 
(1.3) Candidate gene 
discovery 
(1) 
(1) developing a 
genomic classifier 
p
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d
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ti
o
n
 m
o
d
e
l 
d
e
v
e
lo
p
m
e
n
t 
(4) 
(4) Construction of 
prediction model 
(3) 
(3) Predictive 
model 
development 
(2) 
(2) Clinically 
oriented 
discovery 
(1.1.2) 
(1.1.2) Step 2: 
Computational 
Model Development 
and Cross-Validation 
(1.2 - 2.1) 
(1.2) ranking and 
selection 
(2) prediction 
analysis 
(2.1) development 
of predictor 
(1.4-1.5.1) 
(1.4) Differential Gene 
List Validation/ 
Verification 
(1.5) Molecular Classifier 
Algorithm Development 
(1.5.1) identification of 
classifier genes and 
cutoff 
(1) 
(1) developing a 
genomic classifier 
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(4) 
Construction of 
prediction model 
 (3) 
Validation 
(1.1.2) 
Step 2: 
Computational 
Model Development 
and Cross-Validation 
(2.2) 
Clinical validation 
of predictors 
(1.5.2) 
Independent Testing of 
Selected Classifier Genes 
(2-3) 
(2) Internal 
validation of a 
classifier in 
developmental 
studies 
(3) Evaluating if 
classifier is 
superior to 
existing 
prognostic 
factors 
e
x
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(4) 
Construction of 
prediction model 
(5)  
Implementation 
(5.1) Development 
of diagnostic test 
(3) 
Validation 
(1.1.3 - 1.2) 
(1.1.3) Step 3: 
Confirmation on an 
Independent 
Dataset  
(1.1.4) Step 4: 
Release of Data, 
Code, and the Fully 
Specified 
Computational 
Procedures to the 
Scientific Community 
(1.2) Test Validation 
Phase 
(1.2.1) Analytical 
Validatiton 
(1.2.3) Clinical/ 
Biological Validation 
(1.2.4) 
implementation of 
the new test in the 
workflow and quality 
management system 
of the CLIA-certified 
laboratory 
(2.2) 
Clinical validation 
of predictors 
(1.6) 
External Classifier 
Validation/ Testing 
(4) 
Translation of 
platforms and 
demonstrating 
assay 
reproducibility 
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(5) 
Independent 
validation of 
prediction 
(4) 
Decision support 
tool development 
(4) 
Clinical 
application 
(2) 
Evaluation for 
Clinical Utility and 
Use Stage 
(3) 
Biomarker-Based 
Clinical Trials for 
Assessing Clinical 
Utility 
(2) 
Comparison against 
standard of care & 
personalized use 
(5) 
Independent 
validation of 
genomic classifier 
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p
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 (5) 
Implementation 
(5.2) Health 
professional and 
public education 
(5.3) Development 
of clinical 
guidelines 
(5.4) Regulatory 
oversight in 
laboratories 
(5.5) Cost-
effectiveness 
(5.6) Privacy 
(4-5) 
(4) Clinical 
application  
(5) Post-clinical 
appraisal 
   
 
 
6
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Prediction model development 
Again, a variety of statistical models were suggested including linear discriminant analysis 
and support vector machines.131  
Two major tasks within this stage were identified:  
1) selection of biomarkers to be included in the classifier (feature selection) and  
2) construction of the prediction model.13,50,52  
Internal validation 
Internal validation was often described as involving two main approaches: 
 Split-sample – where the available sample of patients is divided into a training set used 
for model development and a separate test set used for testing the performance of 
the classifier,13,45,50,52 
 Cross-validation – where statistical techniques using a single set of patients for both 
development and validation of the classifier are implemented.13,45,50,52,131,133 
The outcome of internal validation was assessment of the performance of the classifier in 
terms of measures of accuracy such as classification error rate,13,131 AUC ROC,131 
sensitivity, specificity, PPV and NPV.13 
External validation 
This stage was generally synonymous with conducting a new study using an independent 
sample of patients. Some of the frameworks suggest this should be a large-scale133 and/or 
multicentre study,50,131 involving a diverse population,133 relevant to the intended use of 
the test.50,52 
The outcomes of this stage generally involved showing the adequate performance of the 
classifier. In some papers this was defined in terms of test accuracy,45,52,132 precision45,132 
and reproducibility.13,45,132 Other outcomes included demonstrating the generalisability of 
the classifier,50,133 specifying the type of the analyte to be used,132 investigating the 
influence of specimen handling on classifier results,45 developing a prototype biomarker 
platform132 and standardisation of the classifier.13,50 Cost-effectiveness of the test was 
mentioned by one paper in this stage.132 
It was also suggested that data and computer code used for the classifier should be 
made available to the scientific community, or at least the regulators to provide 
independent verification of the results obtained.50  
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Clinical utility 
The clinical utility stage generally required carrying out an RCT. The proposed designs, 
depending on the situation, were:  
 enrichment,  
 biomarker-strategy,  
 prospective subgroup analysis of an RCT, and 
 prospective-retrospective.13,50,52  
The possibility of undertaking an observational study was also suggested.133 It was also 
mentioned that if the event rate is very low, a single-arm trial including only biomarker 
positive patients may be appropriate.13  
This stage should lead to establishing the clinical utility13,50,52,131,133 and a fully developed, 
standardised classifier.131,133 It should also provide information on the feasibility of using the 
classifier in clinical practice.52  
Implementation 
This stage was to investigate cost-effectiveness of the biomarker.132,133 Issues such as 
education, policy and regulation of the test should be considered.132 Conducting an 
audit of the actual use in practice and cost-utility of the biomarker was also discussed.133  
2.5.5.3 CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
Criteria for entry into at least some of the first six stages were reported in five of the six 
papers.13,45,50,52,131,133 One paper reported criteria for completion of one stage (external 
validation).50  
Prior to pre-discovery, the phenotype of interest should be defined (for example the 
outcome to be predicted)45. It was also suggested that consideration should be given to 
whether it is possible to develop a classifier to address a given problem.50 
For entry into the discovery stage it was proposed that data of adequate quality 50 or 
adequately normalised131 should be available. Study infrastructure and logistics needed 
to be established.45 
For entry into prediction model construction the requirements provided were a 
manageable number of candidate genes131 and data of sufficient quality.50  
To initiate internal validation, a predictive model needed to be completed.50,52  
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For external validation, a complete model50,52 and satisfactory results from internal 
validation were required.13,50 Completion of internal validation needed full definition of 
the multi-marker classifier.50 
Before entry into the clinical utility stage, completion of discovery and validation of the 
model was required.50,133 According to one paper, at this point the classifier needs to be 
“locked-down”.50 
2.5.6 MODEL IV (SAFETY) 
2.5.6.1 IDENTIFIED FRAMEWORKS 
Two papers were identified that described a framework that matched model IV (safety). 
Both of these focused on a situation when drugs are already on the market when new 
biomarkers predictive of safety are identified. They were based on the experience and 
practice of organisations that aim to discover and develop safety biomarkers.51,134 
As shown in Table 2.12, the frameworks agreed relatively well with the proposed model, 
however neither of the two papers matched exactly the stages proposed.  
Table 2.12 Labels and stage numbers in identified frameworks matched to model IV  
 
Loo 201051 Matheis 2011134 
surveillance (1) 
Active surveillance, patient recruitment and 
collection of data and biomaterial 
(NR as stage, but setting up a 
dedicated biobank discussed) 
discovery (2) 
Identification of gene variants and replication 
of findings 
 
(1) 
Candidate biomarker identification 
pre-clinical (3) 
Pharmacokinetic and functional validation 
(NR as stage, but referred to as pre-
requisite to stage 2) 
analytical 
validation 
 
(2) 
Exploratory phase 
clinical utility (4) 
Prospective clinical studies to evaluate 
diagnostic utility 
(3) 
Confirmatory phase 
implementation (5) 
Determination of the cost-effectiveness of 
diagnostic testing 
(4) 
Submit for regulatory approval 
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2.5.6.2 STUDY DESIGNS AND OUTCOMES OF EACH STAGE  
The study designs and outcomes relevant to each stage were described in little detail in 
the identified frameworks. 
Surveillance  
For this stage recruitment of patients with adverse events and matched controls51 or 
establishment of a dedicated biobank134 was to be undertaken.  
None of the papers discussed the outcomes relevant to surveillance. 
Discovery 
One paper suggested the discovery stage should be based on a case-control study 
utilising a candidate gene approach supplemented by genome wide association studies 
(GWAS). The findings should then be replicated in a new study in a different population.51 
The other paper advocated the use of a literature review, databases and a biobank.134  
None of the papers discussed the outcomes of this stage. 
Pre-clinical 
Pre-clinical investigation was to be based on in vitro and animal model studies.51  
None of the papers discussed the outcomes of this stage. 
Analytical validation 
This stage was to involve a small study in healthy subjects and patients comparing the 
biomarker test under investigation to the reference standard.134  
The suggested outcomes to be assessed were the performance of the assay (including 
sensitivity, specificity, PPV, NPV, or ROC AUC), biological variability of the biomarker and 
stability of the analyte after sampling.134 
Clinical utility 
Studies addressing clinical utility of the biomarker differed between the two frameworks. 
These were:  
 a prospective clinical trial aiming to establish the utility of the predictive biomarker 
in preventing adverse events,51 
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 a study in a large patient population (“proof of performance”) aiming to establish 
biomarker performance and threshold. 134 
Implementation  
There was no information on the study designs or outcomes of the implementation stage. 
2.5.6.3 CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
These criteria were described only in Matheis 2011 for two stages.134 
Entry into the analytical validation stage was to be based on pre-clinical and clinical 
evidence supporting the biomarker. The validation protocol should also be discussed with 
the regulatory agencies. Completion of this stage was to be based on “assay 
acceptance criteria” defined prior to undertaking the validation.  
For biomarker utility, only entry criteria were described. These were the presentation of the 
results of analytical validation to regulatory agencies. 
2.6 COMPARISON OF MODELS 
2.6.1 IDENTIFIED STAGES IN CONTEXT OF MODEL I 
A general comparison of the stages included in different models based on their aims is 
provided in Figure 2.2. This was based on a comparison with model I, as it appeared to 
describe the most complete pathway. The similarities and differences between models, 
relative to stages of model I, are discussed below.  
Pre-discovery 
A pre-discovery stage was identified in model I, III and IV (where it was called 
“surveillance”). In model II it appeared to be merged with discovery as pre-clinical 
research. This generally included activities such as collection of data,132 ensuring the data 
are of sufficient quality,50,131,133 and formulation of the question to be addressed within the 
discovery stage.45,121,125  
 
 MODEL I (GENERAL) 
 
MODEL II (ALONGSIDE DRUG DEVELOPMENT) 
 
MODEL III(MULI-MARKER CLASSIFIER) 
 
MODEL IV (SAFETY) 
 
cb – candidate biomarkers; pm – prediction model; iv – internal validation; colours used to indicate stages with similar aims 
Figure 2.2 Stages of biomarker development addressing similar objectives in models I-IV 
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Discovery 
This stage was present in all models. As mentioned above, in model II it was merged with 
pre-discovery activities. In model III three stages were mapped to the discovery stage in 
model I: identification of candidate biomarkers, development of the predictive classifier 
and internal validation of the predictive classifier.  
A wide variety of discovery designs was identified and these included utilisation of one or 
more of: 
 pre-clinical models (in vitro and in vivo),18,43,124,128 
 correlative and/or case-control studies using biological specimens and data from 
patients,18,43,51,122-124,126,130,132,134 
 literature reviews.45,128,130,134 
Model III was somewhat different in terms of research designs, as it focused on the 
utilisation of statistical techniques for discovery, without providing much detail on the 
study methodology.52,131-133 
Some papers proposed two complementary approaches: 
1) Knowledge-driven – where identification of a new biomarkers is based on 
knowledge of disease biology and drug mechanism of action,43-45,51,124 
2) Data-driven – where biomarkers are identified based on the association between 
the biomarker value and outcome, for example in GWAS.43-45,51,124 
It was suggested that at this stage the understanding of the biological function of the 
biomarker would be ideal,18,124,126,130 however as this is not always possible correlation to a 
clinical outcome could be sufficient.18 
Two papers suggested that prior to discovery, consideration should be given to the 
feasibility of developing a biomarker to address a given question.50,130 The proposed 
criteria were based on cost-effectiveness130 and required assay parameters such as 
sensitivity or specificity.50 
Analytical validation 
Analytical validation was only included in model I and IV. However, some frameworks 
within the other two models included some forms of analytical validation at a different 
stage - for example during pre-discovery133 and external validation50 in model III.  
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The details of relevant study designs were rarely reported. These generally appeared to 
be comparing the biomarker assay to a reference standard and using either specimens 
from patients, or positive and negative controls,122 in a manner similar to concordance 
studies for HercepTest described in section 2.4.5. 
It was usually considered that this stage is when the analytical parameters of an assay 
should be established.18,43,44,47,121-123 Finalising standard operating procedures was also 
discussed.18,44  
Clinical validation 
Stages corresponding to clinical validation in model I have been included in model II 
(phase I trial and phase II trial) and III (external validation). The aim was often to show the 
biomarker predicts a clinical outcome in a new dataset, independent of that used for 
discovery.18,43-45,47,52,125,126,132 The relevant study designs varied depending on the model 
and the individual frameworks within the model. These included: 
 retrospective correlative studies using archived specimens,18,43,126 
 prospective studies where the biomarker does not form part of the primary 
hypothesis,18,126 
 RCT with biomarker-based primary hypothesis,128 
 analysis of samples from bio-banks.18  
Model III papers generally referred to studies using an independent set of samples for 
external validation, however the design was not described in detail.13,45,50,52,131-133 
Clinical utility 
All models contained a clinical utility stage. The majority of the frameworks agreed that 
the best study design for assessment of clinical utility of a predictive biomarker would be a 
large prospective study, preferably an RCT. The exact methodology would depend on 
the situation, for example the feasibility of conducting such a trial. The strength of the 
evidence supporting the use of the biomarker should also be taken into account when 
designing such a trial. The most commonly discussed RCT designs correspond to those 
outlined in Chapter 1: 
 biomarker-strategy (with or without randomisation in the control arm),13,18,50,52 
 stratified,18,47,50,128 
 enrichment,13,47,50,52,128 
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 prospective subgroup analysis of an RCT,13,47,50,52 
 prospective-retrospective analysis of an RCT.13,47,50,122  
It was also noted that a systematic review or meta-analysis of multiple trials may be 
used.123,124 It was proposed that in some circumstances, for example when ethical 
considerations preclude an RCT, case-control or cohort methodology may be 
acceptable.124,133 One paper suggested that a single-arm trial including only biomarker 
positive patients may be acceptable in cases where there is a low event rate.13 
Implementation 
This stage was included in all four models and focused on the steps necessary for the 
biomarker to become part of standard clinical practice. These included health 
technology assessment and implementation of biomarkers in clinical guidelines.122,123,132,133 
Some frameworks also mentioned audit of the use of the biomarker in actual clinical 
practice.127,133 
2.6.2 BIOMARKER THRESHOLD AND FINAL ASSAY 
The point at which the biomarker threshold and the final assay should be specified was 
rarely provided. Where discussed, it was proposed that the biomarker threshold should be 
defined as a result of:  
 analytical validation (model I),47  
 clinical validation (model I),43 or  
 clinical utility studies(model IV).134  
Nine papers provided recommendations on when the final form of the assay or classifier 
should be specified: 
 after analytical validation (model I),47 
 after a phase III trial (model II),129 
 after external validation (model III),13,50,131-133 
 on completion of the clinical utility stage (model III).131,133 
Finalising the assay at the end of the analytical validation was also indirectly suggested in 
papers proposing that by then, the analytical parameters of an assay should be 
established18,43,44,47,121-123 and standard operating procedures finalised.18,44  
72 
2.7 DISCUSSION 
This chapter reports the first systematic review of frameworks proposed in the literature for 
phased evaluation of predictive biomarkers. A similar approach has previously been 
utilised in a review of frameworks for phased evaluation of diagnostic tests.135  
Broad literature searches were undertaken and inclusion decisions were made by two 
independent reviewers. This ensured that the possibility of missing relevant papers was 
minimised. Some papers which may potentially be considered relevant, such as the 
Cancer Research UK roadmap, were excluded, as insufficient detail was available to 
identify whether these in fact proposed a staged biomarker development process.136  
Data extraction and synthesis was carried out by one reviewer only. This involved a 
number of subjective judgements, as for example on the aim and classification of 
biomarker development stages. It is possible that if undertaken by another reviewer, the 
classification would differ to some extent. 
Twenty three papers were included in the synthesis. Of these, only nine reported being 
based on real-life experience or work of a multi-disciplinary group.43,45,47,50,51,125,127,133,134 The 
remaining twelve did not report any basis for the proposed process.  
All identified frameworks were mapped to four models which emerged from the literature 
review. The identified models differed with respect to their purpose and context. Model I 
provided the most general framework for phased evaluation of predictive biomarkers, 
without specifying the type of the biomarker or the stage of the drug life-cycle. Model II 
focuses on development of a predictive biomarker integrated into the standard drug 
development programme. Model IV focused on the development of biomarkers 
predictive of treatment safety, identified after the drug has been made available in 
clinical practice. Model III was distinguished by the fact that it aimed to describe 
development of a multi-marker classifier. Also its main focus was on the statistical 
techniques involved. For this reason, it also appeared to differ most from the remaining 
three models – both in terms of the stages proposed and in the language used. 
The clinical area for which the frameworks were proposed was identified in 10 cases. In 
most cases it was cancer.13,18,43,44,122,128,129 The other diseases were: autism,121 
cardiovascular,130 and neurological and neuropsychological.124 This aspect did not seem 
to influence the type of the proposed framework. 
As shown in Figure 2.2, it was possible to identify general similarities in sequence and aims 
of stages across the different models. These comparisons were using model I as a starting 
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point, as it arguably assumed the broadest perspective. Model I included the stages 
summarised in Table 2.13. 
Table 2.13 Summary of stages in model I 
Stage Description 
Pre-discovery focusing mainly on question formulation and data collection 
Discovery aiming at the identification of biomarkers for further development; ideally two 
approaches should be combined here: knowledge-driven and data-driven 
Analytical 
validation 
aiming to establish the  accuracy of the biomarker assay 
Clinical validation Investigating the correlation between the biomarker and the outcome 
Clinical utility evaluating the benefit of the use of the biomarker in clinical practice 
Implementation focusing on measures which may ensure uptake of the biomarker in clinical practice 
 
The study designs proposed for each stage varied between different models and papers. 
In some cases, such as analytical validation, there was little information on the most 
appropriate research methodology. The most detail was reported for the clinical utility 
stage, where different RCTs with the biomarker integral to their design were generally 
considered ideal. However it was acknowledged in a number of frameworks that this may 
not always be feasible.  
There also seemed to be little mention or agreement on the time when the assay should 
be finalised and - for continuous biomarkers –the threshold established. This ranged from 
completion of the analytical validation stage47 to completion of clinical utility.131,133,134 
An interesting point was raised with regard to the biological plausibility of the biomarker 
being predictive. A number of frameworks argued that a good understanding of the role 
of the biomarker in the disease and drug mechanism should be achieved.18,124,126,130 
However, one of the papers acknowledged this may not always be possible and 
correlation of the biomarker value with a clinical outcome could be sufficient.18 
It was also of interest for this review to identify criteria for entry into and completion of 
stages, also referred to in the literature as "decision gates".92 This was very rarely discussed 
beyond claiming that satisfactory results of the current or previous stage should be 
obtained (for completion and entry criteria respectively).  
One paper stressed the importance of involving a multidisciplinary panel at each stage 
when a decision on further research is to be made.127 Other papers postulated 
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involvement of regulatory bodies in such decisions.47,50,134 This appears to be a rational 
approach, as addressing biomarker development from one perspective may lead to 
substantial omissions. This was, for example observed in the frameworks matched to 
model III, which appeared to be focusing on the statistical analysis of classifiers and 
neglected issues associated with the laboratory procedures. 
Criteria for termination of the biomarker development programme were generally not 
discussed. However, two papers noted that prior to undertaking any research, the 
feasibility of development of a biomarker useful in addressing a given clinical problem 
should be considered.50,130 
Section 2.4 described the development of HER2 expression and trastuzumab. This was, in 
fact, an example of a drug developed to target a particular biomarker. Based on the 
available literature, the sequence of stages here involved: 
 biomarker discovery, 
 drug discovery (based on biomarker), 
 drug pre-clinical development, 
 drug early clinical development (phase I and II), 
 parallel biomarker analytical validation and phase III trial (using a different assay 
to that later implemented in clinical practice), 
 implementation. 
This scenario appears closest to model II, however there are some important differences. 
In particular, the phase III trial utilised a different assay to evaluate patents’ HER2 status to 
that which was later implemented in clinical practice. It appears that the use of a 
different assay in the phase III trial might be a serious limitation, particularly that it 
demonstrated a concordance with the assay later used in practice of only 79%. Although 
this discrepancy could be a result of using a relatively old case study, there are still a 
number of situations when multiple assays are available to evaluate the same biomarker. 
It is not always clear whether their results are comparable, as in the case of multiple PD-L1 
assays in lung cancer.137 These issues will be addressed in more detail in Chapter 7.  
Finally, the proposed models are all based on the assumption that a phased system is 
advantageous. However, there is some disagreement in the literature and more flexible 
approaches have been suggested. For example, the Pharmaceutical Research and 
Manufacturers of America proposal suggests investigating whether biomarkers meet 
evidence standards for a given application, rather than adhering to particular stages.138 
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These flexible approaches can offer an alternative to a staged system. Even if such a 
point of view is taken, the existing frameworks may still be useful as a source of evidence 
standards to address particular issues. 
2.8 CONCLUSIONS 
To summarise the findings of the systematic review four models for predictive biomarker 
development were constructed based on the identified frameworks. The most complete, 
in terms of the aims, was model I (general), which included the following stages: 
1) Pre-discovery 
2) Discovery 
3) Analytical validation 
4) Clinical validation 
5) Clinical Utility 
6) Implementation 
There were some broad similarities between the different models, however they did not 
always include the same stages. There was a large variety of study designs suggested for 
each stage, especially outside of evaluation of clinical utility. Very little information was 
available on the entry and completion criteria for each stage. The time for “locking” the 
final assay was rarely commented on. Where reported, it was completion of analytical 
validation, prior to or after the clinical utility stage. Similarly, defining the biomarker 
threshold was rarely discussed and where included, there was little agreement on when it 
should take place. Some papers suggested it should be established on completion of the 
analytical validation or the clinical utility stage. The clinical area which the frameworks 
were addressing did not seem to influence their content. 
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Abstract 
Aims: To investigate how many and what predictive biomarkers are currently included in 
European Medicines Agency licensing of drugs. 
Background: Stratified medicine is often heralded as the future of clinical practice. A key 
part of stratified medicine is the use of predictive biomarkers, which identify patient 
subgroups most likely to benefit or least likely to experience harm from an intervention. 
However the impact of stratified medicine on treatment practice is unknown. 
Methods: Indications and contraindications of all drugs considered by the EMA and 
published on their website were screened to identify predictive biomarkers. For all 
included Biomarker-Indication-Drug (B-I-D) combinations data were collected and 
summarised on the type of the biomarker, whether it selected a subgroup of patients 
based on efficacy or safety, therapeutic area, marketing status, date of licensing 
decision, date of inclusion of the biomarker in the indication or contraindication, and on 
orphan designation. 
Findings: 49 B-I-D combinations were identified over 18 years. These included 37 
biomarkers and 41 different drugs. All identified biomarkers were molecular. Six drugs 
(relating to 10 B-I-D combinations) had an orphan designation at the time of licensing. The 
identified B-I-D combinations were mainly used in cancer and HIV treatment, but also in 
hepatitis C and three other indications (cystic fibrosis, hyperlipoproteinemia type I, and 
methemoglobinemia). In 45 B-I-D combinations biomarkers were used as predictive of 
drug efficacy and in four of drug safety. It appeared that there was an increase in the 
number of B-I-D combinations introduced each year, however the numbers were too 
small to identify any definite trends. 
Conclusions: Given the large body of literature documenting research into potential 
predictive biomarkers and extensive investment into stratified medicine, relatively few 
predictive biomarkers were included in licensing. These were also limited to a small 
number of clinical areas (mainly cancer and HIV). This might suggest a need for 
improvement in methods of translation from laboratory findings to clinical practice. 
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3.1 BACKGROUND 
3.1.1 ROLE OF STRATIFIED MEDICINE 
Drugs are rarely effective in all patients and may be associated with serious adverse 
events.8 The challenge of stratified medicine is to identify predictive biomarkers that 
identify patient subgroups (or strata) with a differential therapeutic response to a linked 
intervention, allowing more appropriate and effective use of interventions to maximise 
patient benefit and minimise the occurrence of serious adverse events.9,139 Predictive 
biomarkers are defined particular to a treatment for a condition, where biomarker values 
are associated with differential efficacy or safety profile of that treatment.16-19 The use of 
predictive biomarkers promises a more appropriate choice of treatment and it can also 
help to rationalise funding decisions, avoiding costs of futile treatment and of adverse 
events. However, the additional cost of measuring the marker has to be taken into 
account. Examples of successful use of predictive biomarkers include BC treatment with 
drugs such as tamoxifen, where it is prescribed to women who are oestrogen receptor 
positive,140 or trastuzumab, which is only given to patients with HER2 overexpression in their 
tumour.20  
Chapter 2 reviewed the potentially long and complex process of developing predictive 
biomarkers and there is a large body of literature documenting research into these.141,142 
Millions of pounds have been invested into stratified medicine, both in industry and 
through programs from funding bodies such as the Medical Research Council143 and 
Cancer Research UK.144 However, it has been hypothesised that stratified medicine has 
not been implemented in practice as much as expected. This chapter provides evidence 
of the impact of stratified medicine research to date and, if less than expected, this will 
highlight the need to review the underlying reasons and address the problems. 
3.1.2 CHOICE OF DATA SOURCE  
As mentioned in Chapter 1, in Europe a centralised drug evaluation by the EMA is 
required for a large number of drug types, including those with an orphan designation, 
granted to drugs intended for the treatment of a life-threatening or chronically 
debilitating condition which is either affecting no more than 5 in 10,000 people in the EU 
or when the revenue is unlikely to cover the investment in drug development.145 
Companies can also apply for a centralised marketing authorisation of other drugs.55 
Although the EMA does not license biomarkers, it evaluates drugs in groups of patients 
which can be defined by predictive biomarkers (for example trastuzumab is licensed for 
use in HER2 overexpressing BC patients, as described in the case study in Chapter 2).56 
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Therefore reviewing EMA licensing decisions is likely to give a broad overview of the 
impact of predictive biomarkers on treatment selection since 1995, when the EMA was 
established57. 
3.2 AIMS 
This systematic review aimed to find out how many and what predictive biomarkers were 
included in the indications and contraindications considered by the EMA. The disease 
areas where predictive biomarkers have been used and whether there was any trend 
over time suggesting an increase in the use of predictive biomarkers were also 
investigated. 
3.3 METHODS 
3.3.1 UNIT OF ANALYSIS 
A Biomarker-Indication-Drug (B-I-D) combination was defined as the unit of analysis, 
relating to the use of a predictive biomarker with a particular drug (defined here as the 
active substance rather than the trade name) for a particular condition or disease.16-19 This 
was done to separate cases such as for example 
 HER2 expression used to predict response to trastuzumab in BC, and  
 HER2 expression used to predict response to trastuzumab in stomach cancer. 
Safety biomarkers can be used in more than one disease area to predict the same 
adverse event. Therefore these indications were grouped into one B-I-D combination, as 
long as the adverse events predicted were the same. 
3.3.2 DATABASE OF DRUGS IN EMA LICENSING 
A database of all drugs identified in EMA licensing was created in Microsoft Excel 2010, 
which included the drug name, licensing status, indication and contraindication. The 
indications and contraindications of all drugs listed on the EMA website in either European 
Public Assessment Reports or Pending Decisions146,147 (accessed on the 17th of January 
2013) were included in the database.  
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3.3.3 SELECTION OF B-I-D COMBINATIONS 
Selection of relevant B-I-D combinations was carried out in two stages, using the criteria 
shown in Box 3.1.  
In the first stage all database entries were screened by two independent reviewers to 
identify those potentially including a predictive biomarker in the indication or 
contraindication. If an entry was identified by at least one of the reviewers as potentially 
relevant, it was included in the second stage of screening.  
Box 3.1 Inclusion and exclusion criteria for identification of B-I-D combinations containing predictive biomarkers 
 
In the second stage, a list of potential B-I-D combinations was created in MS Excel based 
on the entries identified in the first stage. The list of potential B-I-D combinations was 
assessed by two independent reviewers using the inclusion/exclusion criteria shown in Box 
3.1. This stage utilised, as necessary:  
 information in the Summary of Product Characteristics (which sets out the 
information on the drug obtained in the assessment process and summarises its 
properties and clinical use together with the clinical trial evidence that was 
considered by the EMA148),  
To be included the biomarker had to: 
1) be used in the indication and/or contraindication of the drug, 
2) be associated with a particular treatment, 
3) identify a subgroup of patients with a particular disease eligible for treatment with 
the drug. 
 
Excluded biomarkers were: 
1) associated with a non-therapeutic substance (for example vaccines), 
2) not used as predictive, including: 
 used for diagnosis, screening or forming part of the disease definition (already 
established for defining a disease) or established disease subtype, 
 prognostic only (associated with outcome regardless of treatment and not 
predictive of treatment response1) 
 associated with another treatment (for example the biomarker was not 
associated with the differential efficacy or toxicity of the drug of interest, but 
another drug given in combination with the drug of interest). 
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 the Scientific Discussion (which discusses the properties and clinical evidence in 
more detail), 
 ICD10 classification,149  
 targeted internet searches and  
 expert advice.  
Any disagreements between reviewers applying inclusion criteria were resolved by 
discussion. 
3.3.4 DATA EXTRACTION 
For the included B-I-D combinations data were collected using the information available 
on the EMA website into an Excel spreadsheet on items shown in Box 3.2. 
Box 3.2 Data extraction items for the review of predictive biomarkers in EMA licensing 
 
To provide a context for the review, data were also collected on the total number of 
drugs licensed each year with and without an orphan designation.  
3.3.5 DATA ANALYSIS 
The majority of the data were summarised narratively. The numbers of B-I-D combinations 
considered each year were summarised using bar graphs. The time from the initial 
licensing of the drug to inclusion of the predictive biomarker was plotted. When drugs 
were discussed, this referred to the active substance, unless explicitly stated that the 
brand names were considered (as in Figure 3.3). 
 type of the biomarker used as predictive,  
 whether it selected a subgroup of patients based on efficacy or safety,  
 therapeutic area,  
 marketing status,  
 date of licensing decision,  
 date of inclusion of the biomarker in the indication or contraindication,  
 presence of an orphan designation 
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3.4 FINDINGS 
As shown in Figure 3.1, 883 entries in the database of EMA licensing were screened, 
corresponding to an 18-year period (1995-2012). After the first stage of screening 203 
potentially relevant B-I-D combinations were identified from 100 entries, as some 
indications and contraindications contained multiple potentially relevant biomarkers.  
 
Figure 3.1 Flow diagram for the systematic review of predictive biomarkers in EMA licensing 
In the second stage of screening 154 of these were excluded because the potential B-I-D 
combinations included a non-therapeutic substance (such as contrasting agent) in seven 
cases, or the biomarker was not predictive in 147 cases. Details of excluded potential B-I-D 
combinations are reported in Appendix 9. Forty nine B-I-D combinations were identified, 
including 37 biomarkers and 41 different drugs.  
883 entries in the EMA licensing 
database
(1995 - January 2013)
100 entries potentially 
included one or more 
predictive biomarkers
203 potential B-I-D 
combinations
49 included B-I-D 
combinations 
(37 biomarkers, 41 
drugs)
154 excluded:
7 non-therapeutic substances
147 not predictive: 
- 10 associated with another treatment
- 8 metabolic / drug interaction
- 5 monitoring biomarkers
- 4 mentioned, not used to identify a subgroup
- 92 diagnostic / disease defining: 33 identified 
in ICD 10 codes, 48 diagnostic, 11 define disese
- 24 identify established disease subtype
- 3 prognostic
783 did not potentially 
include a predictive 
biomarker
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Most of the identified drugs were authorised, with the exception of: 
 gemtuzumab ozogamicin (Mylotarg) – refused; 
 zoledronic acid (Zometa) – pending (with negative recommendation); 
 imatinib (Glivec) in one of the five identified indications (aggressive systemic 
mastocytosis) - withdrawn prior to refusal; 
 amprnavir (Agenerase) – withdrawn; 
 nelfinavir (Viracept) – withdrawn; 
3.4.1 B-I-D COMBINATIONS OVER TIME 
The number of new B-I-D combinations considered by the EMA each year is shown in 
Figure 3.2. It increased overall from zero or one per year in the late 1990s, to a maximum 
of 7 in 2011 and 2012. This was however not a steady increase, as this number showed 
fluctuation between 2000 and 2006, a decrease between 2006 and 2010, followed by an 
increase in the number in 2011 and 2012.  
 
Figure 3.2 Number of new B-I-D combinations considered each year by disease area (includes biomarkers 
added after the drug was initially licensed) 
When drug brands (including generic drugs) are considered, a predictive biomarker was 
included in the indication or contraindication when the drug was first licensed in 35 cases. 
For one drug (Xeloda, with capecitabine as the active substance) the date of inclusion of 
the biomarker was unclear from the documentation. For the remaining drugs the time 
from the initial licensing decisions to the inclusion of a predictive biomarker ranged from 
zero (initial decision included predictive biomarker) to ten years, as shown in Figure 3.3. 
 
 
 
Drug brand names were used, as these correspond to individual licensing decisions; filled circles indicate a generic drug; Cap – capecitabine; MC – metylthionium chloride 
Figure 3.3 Time from initial licensing of a drug to inclusion of a predictive biomarker in the indication or contraindication 
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Data for 2012 include 4 generic drugs (all with capecitabine as the active substance) 
Figure 3.4 New drugs authorised each year with and without a predictive biomarker in the indication or 
contraindication (excludes biomarkers added after the drug was initially authorised) 
The proportion of new drug brands (including generic drugs) that already contain a 
predictive biomarker in the indication of contraindication was considered at the time of 
the first licensing decision. This increased over time and was close to 10% in 2003, 2004, 
2005, 2011 and 2012 (shown in Figure 3.4). 
3.4.2 DRUGS WITH AN ORPHAN DESIGNATION 
As shown in Figure 3.5, six drugs associated with a predictive biomarker had an orphan 
designation at the time of licensing, however for two it was removed at the end of the 
marketing exclusivity period.150 One of the six drugs (imatinib) was associated with five 
different predictive biomarkers in five different indications. Therefore, in total there were 10 
B-I-D combinations including a drug with an orphan designation and this constituted 20% 
of all the identified B-I-D combinations. 
3.4.3 IDENTIFIED B-I-D COMBINATIONS 
The identified B-I-D combinations all contained molecular predictive biomarkers. Only four 
biomarkers were used to predict adverse events (reported in Table 3.1), while 33 were 
used to predict treatment efficacy (reported in Table 3.2).  
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Includes drugs where orphan designation was later removed 
Figure 3.5 New orphan drugs authorised each year with and without a predictive biomarker in the indication or 
contraindication (excludes biomarkers added after the drug was initially authorised) 
Most of the indications were for treatment of cancer (29 B-I-D combinations) and viral 
diseases, mainly HIV (17 B-I-D combinations). The remaining biomarkers were used to 
stratify metabolic and blood disorders (cystic fibrosis, hyperlipoproteinemia type I, and 
methemoglobinemia).  
Table 3.1 Biomarkers predictive of adverse events identified in the review of EMA licensing 
Biomarker Indication Drug 
DPD deficiency Colorectal Neoplasms 
Colonic Neoplasms 
Stomach Neoplasms 
Breast Neoplasms 
Capecitabine (Xeloda and generic 
drugs: Capecitabine Accord; 
Capecitabine Krka; Capecitabine 
Medac; Capecitabine Teva) 
DPD deficiency Stomach Neoplasms tegafur / gimeracil / oteracil (Teysuno) 
HLA-B*5701 allele HIV Infections Abacavir (Kivexa; Trizivir; Ziagen)* 
NADPH reductase 
deficiency 
Methemoglobinemia Methylthioninium chloride 
(Methylthioninium chloride Proveblue) 
* HLA-B*5701 allele is predictive of hypersensitivity to abacavir, which is present in three three drugs: Kivexa 
(abacavir / lamivudine); Trizivir (abacavir / lamivudine / zidovudine); Ziagen (abacavir) 
3.5 DISCUSSION 
Stratified medicine is promoted as key to the future of medicine, and is currently one of 
the most active areas of clinical research. This review likely provided the first indication of 
the number and nature of predictive biomarkers included in licensing in Europe based on 
the drug indications and contraindications on the EMA website. Forty nine B-I-D 
combinations were identified. All identified biomarkers were molecular. The identified B-I-D 
combinations were mainly used in cancer and HIV treatment, with only five used in other 
disease areas.  
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Table 3.2 Biomarkers predictive of efficacy identified in the review of EMA licensing 
Biomarker Indication Drug 
ALK gene rearrangement Carcinoma, Non-Small-Cell Lung Crizotinib (Xalkori) 
BRAF V600 mutation Melanoma Vemurafenib (Zelboraf) 
CCR5 tropism HIV Infections Maraviroc (Celsentri) 
CD-33 expression*  Leukemia, Myeloid, Acute gemtuzumab ozogamicin (Mylotarg)‡ 
EGFR expression Colorectal Neoplasms Cetuximab (Erbitux) 
EGFR expression Carcinoma, Non-Small-Cell Lung Erlotinib (Tarceva) 
EGFR mutation Carcinoma, Non-Small-Cell Lung Erlotinib (Tarceva) 
EGFR mutation Carcinoma, Non-Small-Cell Lung Gefitinib (Iressa) 
EpCAM expression CancerAscites Catumaxomab (Removab) 
FIP1L1-PDGFR 
rearrangement 
Hypereosinophilic Syndrome Imatinib (Glivec)# 
G551D mutation in CFTR 
gene 
Cystic Fibrosis Ivacaftor (Kalydeco)‡ 
genotype 1 HCV Hepatitis C, Chronic Boceprevir (Victrelis) 
genotype 1 HCV Hepatitis C Telaprevir (Incivo) 
HER2 expression Breast Neoplasms Lapatinib (Tyverb) 
HER2 expression Breast Neoplasms Trastuzumab (Herceptin) 
HER2 expression Stomach Neoplasms Trastuzumab (Herceptin) 
HER2 expression Breast Neoplasms Everolimus (Afinitor) 
HER2 expression ** Breast Neoplasms pertuzumab (Perjeta) 
Hormone dependency Prostatic Neoplasms Degarelix (Firmagon) 
Hormone receptor 
expression** 
Breast Neoplasms zoledronic acid (Zometa) 
Hormone receptor 
expression 
Breast Neoplasms Everolimus (Afinitor) 
Kit (CD 117) expression Gastrointestinal Stromal Tumors Imatinib (Glivec)# 
Kit (D816V) mutation*** Aggressive Systemic 
Mastocytosis 
Imatinib (Glivec)# 
KRAS mutation Colorectal Neoplasms Cetuximab (Erbitux) 
KRAS mutation Colorectal Neoplasms Panitumumab (Vectibix) 
LPL protein detectable Hyperlipoproteinemia Type I alipogene tiparvovec (Glybera)‡ 
oestrogen receptor 
expression 
Breast Neoplasms Fulvestrant (Faslodex) 
oestrogen receptor 
expression 
Breast Neoplasms Toremifene (Fareston) 
PDGFR gene 
rearrangements 
Myelodysplastic-
Myeloproliferative Diseases 
Imatinib (Glivec)# 
Philadelphia chromosome Precursor Cell Lymphoblastic 
Leukemia-Lymphoma 
Dasatinib (Sprycel)‡ 
Philadelphia chromosome Precursor Cell Lymphoblastic 
Leukemia-Lymphoma 
Imatinib (Glivec)# 
t(15;17) translocation Leukemia, Promyelocytic, Acute arsenic trioxide (Trisenox)# 
viral resistance mutations*** HIV Infections Amprenavir (Agenerase) 
viral resistance mutations HIV Infections atazanavir sulphate (Reyataz) 
viral resistance mutations HIV Infections Darunavir (Prezista) 
viral resistance mutations HIV Infections efavirenz / emtricitabine / tenofovir 
disoproxil (Atripla) 
viral resistance mutations HIV Infections Emtricitabine (Emtriva) 
viral resistance mutations HIV Infections emtricitabine /rilpivirine /tenofovir 
disoproxil (Eviplera) 
viral resistance mutations HIV Infections Enfuvirtide (Fuzeon) 
viral resistance mutations HIV Infections fosamprenavir calcium (Telzir) 
viral resistance mutations HIV Infections lopinavir / ritonavir (Kaletra) 
viral resistance mutations*** HIV Infections Nelfinavir (Viracept) 
viral resistance mutations HIV Infections rilpivirine hydrochloride (Edurant) 
viral resistance mutations HIV Infections tenofovir disoproxil fumarate (Viread) 
viral resistance mutations HIV Infections Tipranavir (Aptivus) 
* refused, **pending, ***withdrawn,‡ drug designated an orphan medicine, # orphan designation has been 
removed at the end of exclusivity period 
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It is likely that the 49 identified B-I-D combinations from the EMA database do not 
represent a complete list of the predictive biomarkers used in practice as some B-I-D 
combinations could have been considered by national regulatory agencies, particularly 
for drugs considered before EMA was established in 1995. In addition, EMA licensing is not 
compulsory for some disease areas, such as mental health. However, a number of drugs 
with indications in depression of schizophrenia have been considered by the EMA. 
Therefore although this approach may not provide a complete list of all predictive 
biomarkers used in Europe, relatively few are likely to have been omitted, particularly from 
recent years.57  
The fact that some of the identified B-I-D combinations included biomarkers introduced to 
an indication of an already licensed drug suggests that at least to some extent 
stratification occurring after the initial licensing of a drug was captured. However, the 
actual extent to which this takes place in clinical practice is difficult to evaluate. 
Furthermore, as mentioned in Chapter 1, in Europe there is no formal process for licensing 
predictive biomarkers for clinical use beyond the requirements of the in vitro diagnostic 
Directive.54 Therefore a number of such biomarkers may be used in practice without 
inclusion in drug licensing.  
Several types of biomarkers were excluded. These included biomarkers used for dose 
adjustments as they do not directly predict efficacy or adverse events (although 
inappropriate dose selection could limit the treatment efficacy or cause adverse events).7 
This review also excluded prognostic biomarkers. In practice these can be used for 
treatment selection (as for example Oncotype DX151), however this is based on the 
assessment of need for treatment rather than probability of patients responding to a 
particular therapy.1 Only biomarkers associated with drug treatments were investigated. 
Other biomarkers may be used in practice with non-drug treatments (for example 
radiotherapy152).  
The definition of a predictive biomarker can be difficult to apply, as over time predictive 
biomarkers may become part of a new definition of the disease or its subtype23 and 
therefore be classed as diagnostic. In this evaluation diagnostic biomarkers (for example 
these included factor IX deficiency, or genetic testing for familial lipoprotein lipase 
deficiency) were excluded, as well as biomarkers used to identify an established subtype 
of a disease (mainly ST segment elevation and non-ST segment elevation myocardial 
infarction).  
The spectrum of diseases where predictive biomarkers have been successfully developed 
is relatively narrow. This suggests a possible need for more research in other clinical areas. 
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The vast majority of the B-I-D combinations were associated with treatment efficacy and 
only four with safety. As adverse events associated with some treatments could be serious, 
the possibility to screen out patients at high risk prior to commencing treatment would be 
beneficial.  
A relatively large proportion of the drugs with an associated predictive biomarker 
identified in this review had an orphan designation. This seems surprising, as convincing 
evidence to support the use of a drug in a subgroup of patients with a rare condition 
might be difficult to obtain, due to the small numbers of patients available to test the 
hypotheses. 
It is difficult to provide accurate estimates of the extent of research into potential 
predictive biomarkers, however it has been suggested in 2011 that the number of 
publications on different biomarkers (not only predictive) was in the area of 15,000.141 
Another paper published in 2009, which reviewed genetic markers evaluated as potential 
predictors of response to treatment, found that 541 different genes were investigated as 
potential predictive biomarkers in 1,668 papers.142 It can be reasonably expected that this 
number largely increased since these papers were published. This review shows that few 
predictive biomarkers have been included in licensing relative to this large body of 
literature documenting numerous potential predictive biomarkers. Therefore, in spite of 
the substantial investment in research, the promise of stratified medicine is probably not 
yet being realised to a large extent. The reasons for this might include poor translation of 
findings of laboratory studies into clinical context (the frameworks for which were 
discussed in Chapter 2), or the failure to identify effective predictive biomarkers and 
treatments. Even though it is becoming easier and cheaper to gather huge sets of 
genomic data, its interpretation is challenging, which can potentially hinder translational 
research. Recognising this, initiatives have been undertaken both in the USA (National 
Institutes of Health and the Food and Drug Administration) and UK (Medical Research 
Council) to promote the translation of basic research into clinical practice.143 Also the 
availability of datasets such as the Cancer Cell Line Encyclopaedia and a similar UK 
initiative might contribute to the faster progress of stratified medicine.153,154 The relatively 
small number of predictive biomarkers identified in licensing might also indicate the need 
for more sound methodological standards for biomarker discovery and development.155 
The evidence supporting these 49 B-I-D combinations will be considered in Chapter 5 and 
Chapter 6 to find out what evidence standards seem to be sufficient in practice. However 
first, Chapter 4 will explore the issues considered by the EMA when evaluating the 
evidence supporting the identified B-I-D combinations. 
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3.6 CONCLUSIONS 
This chapter likely provides the first indication of the number and nature of predictive 
biomarkers included in licensing in Europe using systematic review methodology. Given 
the large body of literature documenting research into potential predictive biomarkers 
and extensive investment into stratified medicine, relatively few predictive biomarkers 
were included in licensing. These were also limited to a small number of clinical areas. 
Forty nine B-I-D combinations were identified over 16 years, which included 37 biomarkers 
and 41 different drugs. There appeared to be an increase in the number of B-I-D 
combinations introduced each year, however the numbers were too small to attempt the 
identification of any trend. All identified biomarkers were molecular. The clinical areas 
were mostly limited to cancer and HIV treatment. The other indications were hepatitis C, 
cystic fibrosis, hyperlipoproteinemia type I, and methemoglobinemia. Of the identified 49 
B-I-D combinations, ten included a drug with an orphan designation. 
The relatively low number of identified predictive biomarkers could potentially indicate 
the need for improvement in methods of translation from laboratory findings to clinical 
practice. 
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Abstract 
Background: The review of drugs considered by the EMA with a predictive biomarker in 
the indication or contraindication described in Chapter 3 identified 49 B-I-D combinations. 
This chapter focuses on the rationale provided by the EMA for their recommendations 
and the issues that seemed to be considered important when considering indications and 
contraindications containing predictive biomarkers. 
Aim: To explore the rationale provided by the EMA to support the inclusion of predictive 
biomarkers in drug indications and contraindications; to identify criteria used and 
compare these to an initial a priori framework. 
Methods: A framework analysis of Scientific Discussions and Assessment Reports obtained 
from the EMA website was undertaken. Seven initial criteria were used as a starting point 
and as new criteria emerged from the data, they were added to the framework. For 
each recommendation it was noted which criteria were mentioned and whether they 
were met. 
Findings: The analysis identified 41 different criteria and these were grouped into 13 
themes. The themes that were most frequently commented on were: population, study 
design, clinical efficacy evidence, toxicity, context, pre-efficacy evidence supporting the 
drug. An analysis of critical issues in negative recommendations highlighted the 
importance of clinical efficacy, but also identified a number of other crucial themes such 
as population and study design. A case study highlighted the importance of the context 
in interpretation of study results. 
Discussion: A comprehensive text analysis was undertaken that identified the issues 
discussed in EMA documentation relevant to B-I-D combinations. Although it was possible 
to identify certain criteria that were used more frequently or that appeared critical in 
negative recommendations, it was difficult to identify any clear patterns indicating the 
necessary or sufficient criteria. Also how the same criteria were applied to different B-I-D 
combinations seemed to be very dependent on the context in which the B-I-D 
combination was considered. The findings of this text analysis need to be considered as 
exploratory due to some limitations. The text analysis was undertaken by one reviewer 
only and therefore it is possible that some issues were missed. It is also likely that these 
results are influenced by selective reporting in EMA documents of the issues discussed.  
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4.1 BACKGROUND 
The review of drugs considered by the EMA with a predictive biomarker in the indication 
or contraindication described in Chapter 3 identified 49 B-I-D combinations. The next 
stage of research was planned to investigate the evidence supporting EMA 
recommendations for these B-I-D combinations. For this purpose a set of seven criteria was 
proposed (as described below in section 4.3.3).  
Prior to applying these criteria an exploratory text analysis reported in this chapter was 
carried out to identify the issues considered important by the EMA while issuing 
recommendations for these drugs. This was undertaken to possibly modify the list of criteria 
considered relevant, should important new issues be identified. The criteria used by the 
EMA were also of interest, as these would imply at least some of the issues important for 
implementation of predictive biomarkers in clinical practice. In particular of interest were 
criteria for inclusion of predictive biomarkers in indications and contraindications which 
could be considered: 
 necessary conditions - if the condition was not met, the indication containing the 
predictive biomarker would be rejected.156 
 sufficient conditions - if the entire set of such conditions was met, the indication 
containing the predictive biomarker would be accepted.156 
The Scientific Discussions and Assessment Reports were analysed as these documents 
provided a record of the discussions that lead to issuing recommendations. Within these 
documents the focus was on the discussion sections, as these provided judgments, rather 
than only summarising the evidence available. This was undertaken using a framework 
analysis using the proposed seven criteria as a starting point.  
4.2 AIMS 
This framework analysis aimed to explore the rationale underpinning the EMA 
recommendations on inclusion of predictive biomarkers in drug indications and 
contraindications. It also undertook to compare these criteria with seven proposed in an 
initial framework. In particular, the questions shown in Box 4.1were addressed.  
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Box 4.1 Questions addressed by text analysis of EMA documents 
 
4.3 METHODS 
4.3.1 DATA SOURCE 
Scientific Discussions and Assessment Reports were obtained from the EMA website for all 
B-I-D combinations identified in the review described in Chapter 3. These documents were 
chosen, as they aim to report on the evidence and discussions underpinning EMA 
recommendations on drug licensing.  
After a drug is granted marketing authorisation, the EMA publishes the Committee for 
Human Medicinal Products (CHMP) report as the European Public Assessment Report 
(EPAR), which includes “the reasons for its opinion in favour of granting authorisation, after 
deletion of any information of a commercially confidential nature”. For negative decisions 
the EMA also publishes such information together with reasons for the refusal.157 
The EPARs do not have clearly identified authors, although the rapporteurs responsible for 
an evaluation of a particular drug can be identified. These documents follow a standard 
layout, defined by a template.158 An EPAR contains either a Scientific Discussion or an 
Assessment Report and these documents outline the evidence and reasoning behind the 
recommendations issued by the EMA.  
The length of the Scientific Discussions or Assessment Reports varies substantially between 
different EPARs and for the included B-I-D combinations it was between five159 and 147 
pages.160 The structure of these documents is generally similar, as it follows a template, as 
shown in Box 4.2. 
1) What criteria have been used by the EMA to support their decisions?  
2) What is the relationship between the criteria used by the EMA and the 
criteria proposed in the initial framework, as described in section 4.3.3 
below? 
3) Are there any criteria which can be considered necessary conditions for a 
predictive biomarker to be included in an indication? 
4) Is there a set (or sets) of criteria which can be considered sufficient 
conditions for a predictive biomarker to be included in an indication?  
5) Is there any variation in the criteria used depending on the clinical area, 
biomarker type (efficacy or safety) or presence or absence of an orphan 
designation? 
101 
 
Box 4.2 Standard sections included in EMA documents 
 
In some of the documents certain sections were not present. For example, when the 
document discussed an extension of a therapeutic indication of an already marketed 
drug, the introduction or the chemical, pharmaceutical and biological aspects were 
often omitted.  
For the purpose of this analysis, the introduction and the last three sections were of 
primary interest, as the focus was the identification of criteria applied to clinical-level 
data. Therefore, information was sought mainly in these sections. 
4.3.2 FRAMEWORK ANALYSIS 
Framework analysis of EMA documents was conducted by one reviewer. This approach to 
text analysis was taken, as it offered a structured process to data collection and 
analysis.161 It also permitted the use of an initial framework as a starting point and 
comparison of data obtained in the review to that framework.161,162 This approach not 
only allowed the identification of the criteria used by the EMA, but also exploration of how 
these related to the criteria considered important prior to undertaking this analysis.  
The initial a priori framework was constructed based on background information and 
team discussion.161,162 Data collection from identified documents was undertaken 
1. Introduction – providing background information about the disease, available 
treatment options, the new drug and its possible position in the treatment 
pathway. 
2. Chemical, pharmaceutical and biological aspects – including information on 
issues such as drug manufacturing, chemical composition and stability. 
3. Toxico-pharmacological aspects - including information on pharmacokinetics, 
pharmacodynamics and toxicology, usually based on preclinical studies. 
4. Clinical aspects – providing information on the investigation of the drug in 
humans, including information from a range of studies, with the level of evidence 
depending on the particular drug in question; usually includes a discussion of 
clinical efficacy. 
5. Clinical safety – providing details of the investigation of safety in all patients that 
have been exposed to the drug; usually includes a discussion of clinical safety. 
6. Overall conclusion and benefit-risk assessment. 
 
102 
 
following an iterative approach. In each iteration a sample of five B-I-D combinations 
(four for the last iteration, due to the total number of B-I-D combinations identified) was 
compared with the proposed framework and the information on whether the proposed 
criteria were discussed and met was recorded. If new criteria were identified from a 
document, the framework was expanded to incorporate these.  
4.3.3 INITIAL FRAMEWORK 
The initial framework was constructed from criteria considered important in assessing the 
methodology and strength of evidence supporting inclusion of a biomarker in a drug 
indication. An initial overview of the evidence underlying B-I-D combinations was utilised 
to support the selection of the criteria, before the reports were read in full detail. The initial 
framework comprised the criteria shown in Box 4.3. 
Box 4.3 Initial criteria 
 
4.3.4 IDENTIFICATION OF SAMPLES FOR ITERATIONS 
Each iteration comprised five B-I-D combinations selected to provide a maximum 
variation sample163 - to provide a range of B-I-D combinations in terms of disease areas 
considered, type of the biomarker (efficacy or safety), orphan status and the final EMA 
decision. The aim of this structure of the analysis was to increase the chance of identifying 
new criteria as early as possible in the process. This ensured that as new criteria emerged, 
these were included in the current and following iterations and thus the possibility of 
missing criteria was minimised. This was particularly important as the analysis was 
1) The population in studies was in accordance with the population identified by 
the drug indication. 
2) The design of the studies supporting the inclusion of the biomarker in the 
indication was appropriate. 
3) The primary outcome assessed in the supporting studies was appropriate. 
4) The sample size in studies was sufficiently large. 
5) The biomarker status was available for a sufficiently large proportion of patients 
in the studies. 
6) The patients with available biomarker status were representative of the whole 
trial population. 
7) There was sufficient evidence supporting the biomarker based on the results for 
the primary outcome.  
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performed by one reviewer only. The sample for the first iteration was selected so that the 
five documents described drugs belonging to all of the below categories: 
 a cancer treatment, 
 an HIV treatment, and 
 a treatment for a disease other than cancer or HIV, 
 an efficacy biomarker, 
 a safety biomarker, 
 a drug with an orphan designation, 
 a drug without an orphan designation, 
 an authorised drug, 
 a rejected drug. 
The following samples were identified using the same criteria as the first iteration, unless no 
more B-I-D combinations in a given category were left. In that case they were substituted 
by B-I-D combinations meeting other criteria from the list above. 
4.3.5 DATA COLLECTION 
All texts were compared with the initial framework. For each criterion it was recorded 
whether it was mentioned and considered by the EMA to be met. A criterion was 
considered as mentioned if it was present in any discussion section of the document. 
Statements made elsewhere in the document were only included if they were expressed 
as a normative statement (providing a judgement of facts). Factual (or positive) 
statements outside of a discussion section were not considered relevant. The difference is 
demonstrated in the example of two possible statements on the same issue: 
Factual statement: The number of patients included in all studies was 455. 
(excluded) 
Normative statement: The number of patients included in all studies was 455 and 
was considered sufficient. (included) 
A quote from the original document to support this was also recorded. De novo criteria 
were added to the initial framework and from that point it was recorded whether any 
were mentioned and/or met in the subsequent B-I-D combinations. All information was 
recorded in an Excel spreadsheet.  
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4.3.6 DATA SUMMARY 
The identified criteria were grouped into themes based on their subject. The criteria and 
themes were discussed in the context of the initial framework (outlined in section 4.3.3). 
The frequency of the use of each criterion and theme in positive and negative 
recommendations was summarised. Variations in criteria used were explored based on 
factors outlined in aim 5: 
 clinical area,  
 biomarker type (efficacy or safety), 
 presence or absence of an orphan designation. 
An attempt was made to identify criteria that may be considered necessary and 
sufficient for marketing authorisation of a drug with a predictive biomarker in the 
indication or contraindication. This was undertaken taking into account the constraints of 
a relatively small sample of available EPARs. To identify the necessary conditions for 
marketing authorisation criteria and themes were considered that were: 
 not met by at least one negative recommendation and  
 at least partially met, unclear or not mentioned for all positive recommendations.  
For the set of sufficient conditions for marketing authorisation, it was attempted to identify 
the minimum set of criteria and themes met in positive recommendations. 
4.3.7 PILOTING 
The first iteration of the framework analysis was used to pilot the data collection process. 
In case of difficulties in carrying out the planned analysis, modification would be made. 
However, as there were no issues in undertaking the pilot iteration, the text analysis was 
carried out without modifications. 
4.4 FINDINGS 
4.4.1 EMA RECOMMENDATIONS IDENTIFIED 
Details of the selection of cases for text analysis are presented in the flow diagram in 
Figure 4.1. A Scientific Discussion or an Assessment Report was obtained for 48 B-I-D 
combinations. For two B-I-D combinations the relevant Scientific Discussion or Assessment 
Report was not available (HLA-B*5701 allele in treatment of HIV infection with abacavir 
and D816V mutation in c-Kit in treatment of systemic mastocytosis with imatinib). An 
additional B-I-D combination was also identified from the analysis of the documents 
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available on the EMA website§ (EGFR expression in treatment of NSCLC with cetuximab). 
In addition a single B-I-D combination provided two recommendation cases, as the EMA 
first issued a negative recommendation and later revised it to a positive one (LPL protein 
expression in treatment of hyperlipoproteinemia type I with alipogene tiparvovec). This 
meant there were 49 cases for the analysis. 
 
Figure 4.1 Flow diagram for identification of cases for framework analysis of EMA recommendations 
4.4.2 IDENTIFIED CRITERIA 
In total, 41 different criteria were identified, including the seven originally proposed and 
these are listed in Box 4.4 and Box 4.5. Where possible, the criteria identified were grouped 
                                                                
§ This B-I-D combination (cetuximab for treatment of EGFR expressing NSCLC) was only identified on 
downloading all Scientific Discussion documents from the EMA website. The relevant indication was 
not mentioned on the EMA website, but one of the downloaded documents contained a discussion 
of the negative recommendation 
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into common themes. These criteria were identified during different iterations from 45 
positive and four negative recommendations.  
4.4.3 THEMES BASED ON THE ORIGINAL CRITERIA  
As well as collecting information on the use of the original seven criteria, new criteria that 
appeared to fall within the same theme were added to the list (as shown in Box 4.4). The 
themes were generally based on the original criteria with the exception of the theme 
relating to results for the primary outcome. The themes are described below, however 
detailed descriptions of the criteria falling within each theme are not included, but are 
provided in Box 4.4 and their use reported in section 4.4.5. 
4.4.3.1 THEME 1: POPULATION  
This theme included one criterion – whether the population in the studies supporting the B-
I-D indication was in accordance with the indication. The population characteristics were 
usually mentioned, however normative statements were not always provided. An 
example of where this criterion was not met is: 
“the pivotal trials with gemtuzumab included an ill-defined population, which 
in many cases could have been exposed to intensive re-induction 
chemotherapy. This population does not correspond to the claimed 
indication. Because the studies and claimed populations are different, it is 
impossible to extrapolate the results observed to the claimed indication.”164 
(CD-33 expression – AML - gemtuzumab ozogamicin) 
4.4.3.2 THEME 2: STUDY DESIGN 
This theme focused on the appropriateness of the study design. It comprised four criteria, 
as shown in Box 4.4, encompassing different features of study design. In cases when the 
design was judged as appropriate, a brief statement was usually provided, such as: 
“The design and duration of studies is in line with regulatory requirements”165 
(G551D mutation - cystic fibrosis – ivacaftor) 
When the design was considered inadequate, more detail was usually given: 
“according to CHMP guidelines, this full application should have been based 
on data generated by randomised controlled clinical trials rather than by 
open-label, non-comparative studies”164 
(CD-33 expression – AML - gemtuzumab ozogamicin) 
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Box 4.4 Themes based on the original criteria including newly identified items falling within the same theme 
 
* original a priori criteria 
Theme 1: Population – population in studies was in accordance with the population identified by 
the drug indication* 
Theme 2: Study design  
2.1. design of the studies supporting the inclusion of the biomarker in the indication was 
appropriate* 
2.2. amendments to trials were acceptable 
2.3. imbalances between groups in trials were acceptable or no imbalances were present 
2.4. level of possible bias was acceptable 
2.5. statistical approach to data analysis was adequate 
Theme 3: Primary outcome - primary outcome assessed in the studies was appropriate* 
Theme 4: Sample size - sample size in studies was sufficiently large* 
Theme 5: Proportion of patients with biomarker status available - biomarker status was available 
for a large enough proportion of patients in the studies* 
Theme 6: Subgroup with available biomarker representative - patients with available biomarker 
status were representative of the whole trial population* 
Theme 7: Clinical efficacy evidence 
7.1. sufficient evidence supporting conclusions based on the results for the primary outcome  
7.1.a. irrespective of biomarker 
7.1.b. supporting the biomarker (including enrichment design)* 
7.2. sufficient evidence supporting conclusions based on the results for the secondary outcomes 
7.2.a. irrespective of biomarker 
7.2.b. supporting the biomarker (including enrichment design) 
7.3. sufficient evidence supporting conclusions based on the results for any outcomes 
7.3.a. irrespective of biomarker 
7.3.b. supporting the biomarker (including enrichment design) 
7.4. sufficient evidence to conclude clinical benefit  
7.4.a. in all patients, irrespective of the biomarker status 
7.4.b. in the biomarker-defined group of patients (including enrichment design) 
7.5. consistency of results across subgroups (other than defined by the biomarker) 
7.6. sufficiently long-term data provided 
7.7. results reproduced in more than one study 
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4.4.3.3 THEME 3: PRIMARY OUTCOME 
This theme comprised one criterion, which reflected whether the primary outcome used in 
studies supporting the B-I-D combination was appropriate.  
Again positive judgements were usually in the form of a brief statement, while negative 
opinions on the primary outcome provided more detail, as for example: 
“due to the short survival expectancy in this group of patients, OS [overall 
survival]  would have been a more adequate primary endpoint”166  
(HER2 expression - Breast Neoplasms – lapatinib) 
4.4.3.4 THEME 4: SAMPLE SIZE 
This theme comprised one criterion – whether the sample size in included studies was 
adequate. It appeared that the information on the sample size was mainly provided as 
part of a descriptive summary of studies, rather than a criterion for judgement on the 
strength of supporting evidence, as in the following example: 
“A total of 356 patients with EGFR-expressing metastatic colorectal cancer 
(…) received the combination treatment of cetuximab with irinotecan.”167 
(EGFR expression - colorectal neoplasms – cetuximab) 
4.4.3.5 THEME 5: PROPORTION OF PATIENTS WITH BIOMARKER STATUS AVAILABLE  
This theme comprised one criterion – whether the proportion of patients form studies 
supporting the B-I-D combinations with an available biomarker status was sufficiently 
large. Such information was discussed in few cases, for example:  
“The SAG [Scientific Advisory Group] expressed concerns about the results 
submitted, in particular about the large amount of missing data with respect 
to EGFR mutation status which should have been controlled by design and 
conduct of the clinical studies. In this respect, the clinical studies presented 
were considered to be inadequate...” 168 
(EGFR mutation – NSCLC – gefitinib) 
4.4.3.6 THEME 6: SUBGROUP WITH AVAILABLE BIOMARKER REPRESENTATIVE 
This theme again comprised only one criterion – whether patients in the studies supporting 
the B-I-D combinations with an available biomarker status were representative of all the 
patients in these studies.  
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This criterion was mentioned in only one of the 49 analysed documents, where it was 
considered not met: 
“[Referring to last line setting] In the KRAS evaluable population, there is an 
imbalance with respect to ECOG PS favouring the experimental arm. (…) 
[Referring to second line setting] There is an imbalance with respect to age 
favouring the experimental arm in the KRAS evaluable population. Comparing 
FAS [full analysis set] with KRAS, it is noticed that ECOG PS tended to be poorer 
in the KRAS population”169 
(KRAS mutation - colorectal neoplasms – cetuximab) 
4.4.3.7 THEME 7: CLINICAL EFFICACY EVIDENCE 
Initially this theme included the strength of evidence supporting the biomarker (or drug – 
for enrichment designs) based on results for the primary outcome. However, analysis of 
EMA documents showed that the decisions were based on a wider range of outcomes 
and also took into account efficacy evidence irrespective of the biomarker status. This 
theme was expanded to include criteria evaluating whether there was sufficient 
evidence to conclude that the drug provided clinical benefit, which involved a 
judgement of the importance and relevance of the efficacy findings from studies. Other 
criteria considered within this theme are reported in Box 4.4. 
4.4.4 NEW THEMES IDENTIFIED 
Twenty criteria were identified that did not fall within the themes constructed based on 
the initial seven criteria. These were grouped into six themes, as shown in Box 4.5. 
4.4.4.1 THEME 8: TOXICITY 
This theme comprised one criterion – whether the drug toxicity was considered 
acceptable. This was usually commented on in the context of treatment efficacy, as for 
example: 
“In conclusion, in the particular context of the proposed indication, Trisenox 
presented an acceptable safety profile, even if some particular concerns 
remained in the monitoring some adverse events...”170  
(t(15;17) translocation and/or PML/RAR-α gene – APL- arsenic trioxide) 
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Box 4.5 New criteria and themes identified in the text analysis of EMA documents 
 
4.4.4.2 THEME 9: CONTEXT 
This theme focused on the wider context in which the drug was considered and included 
criteria such as availability of the treatments, how novel the drug was, whether the 
Theme 8: Toxicity – drug toxicity was acceptable 
Theme 9: Context 
9.1. drug offers more acceptable route/ mode of delivery 
9.2. no cross resistance with other available treatments observed 
9.3. sufficient evidence available to support the B-I-D combination compared to other available 
treatment options 
9.4. drug addressed an unmet clinical need 
9.5. biomarker prognostic of poor outcome for standard care 
9.6. novel mechanism of drug action/ new active substance 
Theme 10: Biomarker test 
10.1. availability of biomarker test on the market or clear guidelines for test 
10.2. biomarker test is accurate 
10.3. information on how the biomarker was assessed in studies was sufficient 
10.4. correlation between continuous biomarker level and treatment effect 
Theme 11: External evidence 
11.1. supporting evidence from drugs with similar mechanism of action 
11.2. evidence from previous studies (for example when indication is being broadened) 
11.3. conclusions supported by published meta-analysis or other literature sources 
Theme 12: Pre-efficacy evidence supporting the biomarker 
12.1. evidence from pre-clinical studies to support biomarker 
12.2. evidence from mechanism of action to support biomarker 
Theme 13: Pre-efficacy evidence supporting the drug 
13.1. quality of the product acceptable 
13.2. preclinical studies provide sufficient information 
13.3. sufficient evidence available to support selected dose and/or duration of treatment 
13.4. ADME/ pharmacokinetics characterised sufficiently 
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biomarker used to identify patients for treatment with the drug was also prognostic of a 
poor outcome for standard care (details provided in Box 4.5).  
The wording was usually relatively brief, as for example: 
“crizotinib has successfully addressed a high unmet medical need for a 
relatively rare NSCLC subtype”171  
(ALK gene rearrangement – NSCLC – crizotinib) 
4.4.4.3 THEME 10: BIOMARKER TEST 
This theme comprised four criteria focusing on the performance of the biomarker test 
used in studies supporting the B-I-D combinations and the availability of a biomarker test 
for use in clinical practice. For example, the use of such a criterion was identified in a case 
where the EMA document appeared critical of the available biomarker tests: 
“It is also acknowledged that EGFR status may be subject to measurement 
error (false-positive and false-negative results, nonvalidated methods, arbitrary 
cut-off values for defining positive patients, etc.)”172 
(EGFR expression – NSCLC – erlotinib) 
4.4.4.4 THEME 11: EXTERNAL EVIDENCE  
This theme focused on evidence outside of the B-I-D combination that could potentially 
provide some additional information to support the decision. This could involve evidence 
from drugs with a similar mechanism of action, studies of the same drug used in a different 
indication or published literature. 
An example of evidence from drugs with similar mechanism is shown below: 
“Even though publications are generated in a different indication, the general 
scientific knowledge of AAV [adeno-associated virus] vectors has increased in 
particular with regard to long term expression of protein and knowledge 
related to long term safety of AAV vector therapies. These data should also be 
taken into consideration for Glybera using a broader approach.”160  
(LPL protein expression - hyperlipoproteinemia type I - alipogene tiparvovec) 
4.4.4.5 THEME 12: PRE-EFFICACY EVIDENCE SUPPORTING THE BIOMARKER 
This theme included two criteria, which judged whether the predictive biomarker was 
supported by pre-clinical studies and the proposed mechanism of drug action. For 
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example, in vitro studies were considered to support the association of particular virus 
mutations with resistance to a drug: 
“HIV-1 resistance, as observed in vitro and in HIV-1 infected patients to 
emtricitabine develops as the result of changes at codon 184 causing the 
methionine to be changed to a valine of the HIV reverse transcriptase.”173  
(viral resistance – HIV – emtricitabine) 
4.4.4.6 THEME 13: PRE-EFFICACY EVIDENCE SUPPORTING THE DRUG 
This theme comprised four criteria which judged whether evidence from preclinical, 
pharmacodynamics and pharmacokinetic studies was sufficient. The criteria were often 
discussed in detail, however brief normative statements were also provided, as for 
example: 
“The pharmacokinetics profile of emtricitabine was well defined”173  
(viral resistance – HIV – emtricitabine) 
It also included acceptable quality of the drug, which was usually commented on in a 
brief statement, such as: 
“The quality of this product is considered to be acceptable when used in 
accordance with the conditions defined in the SPC”174 
(DPD deficiency - colorectal, colonic, stomach and breast neoplasms – capecitabine) 
4.4.5 USE OF CRITERIA 
The use of different criteria within each B-I-D combination is shown in Table 4.1, while the 
frequency of use of different criteria is shown in Figure 4.2 for B-I-D combinations with 
positive recommendations and Figure 4.3 for those given negative recommendations. 
4.4.5.1 THEME 1: POPULATION  
At least some of the population characteristics were usually reported (in 31 of 49 
recommendations). These were usually either judged as at least partly representative of 
the population in the drug indication, or only reported without provision of a normative 
statement. In two negative recommendations the study population was judged as not in 
accordance with the drug indication.  
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Figure 4.2 Number of criteria mentioned in EMA documents supporting positive recommendations 
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4.4.5.2 THEME 2: STUDY DESIGN 
The appropriateness of the study design (criterion 2.1) was commented on in 34 of 49 
documents. It was judged as appropriate in 11 recommendations and partly adequate in 
six. When the design was judged as partly appropriate, various issues were discussed (such 
as randomisation, blinding, choice of comparator, or stratification factors) and only some 
of these were considered appropriate. The study design was considered inadequate in six 
recommendations, in four of which it did not preclude the drug from being authorised. In 
ten cases it was not clear whether the design was judged as appropriate.  
The remaining criteria within this theme were commented on infrequently (in three to nine 
recommendations) and they were mostly met. Clearly some of these were not applicable 
to all contexts – for example not all trials are amended to an extent that requires 
commenting on.  
4.4.5.3 THEME 3: PRIMARY OUTCOME 
The primary outcome was mentioned in 20 of the 49 cases. It was judged as appropriate 
in 11, partly appropriate in one, inappropriate in three and it was not clear in three cases.  
When it was partly met, this was due to either only some of the studies supporting the B-I-D 
combination being judged as having an appropriate primary outcome, or there were 
some reservations regarding the appropriateness of the outcome. 
The primary outcome was judged inappropriate either because an outcome was of 
limited clinical relevance, or because a more appropriate outcome (overall survival) 
could have been measured. 
4.4.5.4 THEME 4: SAMPLE SIZE 
The sample size was mentioned in 17of 49 recommendations, however a judgement on 
whether it was sufficient was only provided in two (in both judged as adequate). 
 
4.4.5.5 THEME 5: PROPORTION OF PATIENTS WITH BIOMARKER STATUS AVAILABLE  
This criterion was mentioned in four of 49 recommendations and it was not met in one and 
unclear in three. This infrequent use of this criterion is partly due to nineteen of the 
recommendations in the framework analysis being based on studies including only 
biomarker positive patients. Therefore the biomarker status was available by definition for 
all of the included patients. In the remaining cases the proportion of patients with an 
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available biomarker status did not seem to be an important concern. In the case when it 
was judged as too small, it did not preclude licensing of the drug in an indication defined 
by the biomarker.  
4.4.5.6 THEME 6: SUBGROUP WITH AVAILABLE BIOMARKER REPRESENTATIVE 
This criterion was mentioned in only one of the 49 analysed documents, where it was 
considered not met, however this did not preclude drug licensing. Again, one of the 
reasons for this criterion not being often mentioned may be frequent utilisation of studies 
including only biomarker positive patients.  
4.4.5.7 THEME 7: CLINICAL EFFICACY EVIDENCE 
In most recommendations (45 of 49) the results were discussed for  
 both primary (criteria 7.1 a and b) and secondary (criteria 7.2 a and b)outcome, 
and/or  
 any outcome - without consideration whether it was primary or secondary (criteria 
7.3 a and b).  
In three cases the evidence discussed was based on the primary outcome only. In one 
case the results were discussed for the secondary outcome (to support the biomarker) 
and for any outcome (to support the drug in all patients, irrespective of biomarker status). 
In 13 cases the discussion of efficacy results did not include any data relevant to the 
biomarker in question.  
Generally, the evidence in terms of efficacy results seemed to be mainly considered 
either sufficient or partly sufficient. There were some exceptions, where either all discussed 
results were considered unsatisfactory (two cases of negative recommendations), or only 
the evidence reported for secondary outcomes was insufficient, with satisfactory 
evidence for primary outcomes (two cases, both authorised). 
Apart from the judgment on the strength of evidence, there was usually (in 37 of 49 
recommendations) some comment on the clinical relevance of the benefit provided by 
the drug (in all patients and/or those identified by the biomarker, criteria 7.4 a and b)). In 
most cases the criterion of clinically relevant benefit was considered met or partially met. 
In five cases it was not met (three of these were rejections).  
In 25 of the 49 recommendations it was also considered whether the results varied for 
different subgroups of the population other than defined by the biomarker status, for 
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example age (criterion 7.5). Consistency of results was met in nine cases (one of which 
was rejected) and partially met in 10. The results were considered inconsistent across 
subgroups in four cases (including one negative recommendation). In two cases the 
results for different subgroups were discussed, but no conclusions on their consistency 
were drawn. 
In 26 of the 49 recommendations it was also discussed whether sufficiently long term 
follow-up data were available (criterion 7.6), or whether further follow-up would be 
required. In one case this criterion was partly met, as sufficiently long-term follow-up data 
were available only for a subgroup of the population identified by the indication. In the 
remaining cases the follow-up was not considered sufficiently long-term. However in most 
of these the follow-up data were requested as a post-marketing measure. 
For one negative recommendation the positive results of one study were not replicated in 
another study (criterion 7.7) and this was commented on as a substantial limitation to the 
credibility of these results.  
4.4.5.8 THEME 8: TOXICITY 
Toxicity was considered in 48 of the 49 recommendations. In 31 recommendations it was 
considered acceptable (including two rejections), in ten it was considered partially 
acceptable and in seven it was unclear whether it was acceptable (including two 
rejections). 
4.4.5.9 THEME 9: CONTEXT 
At least one criterion included in this theme was mentioned in 40 of the 49 included 
recommendations.  
Within this theme the most frequently mentioned criteria were:  
9.2 no cross-resistance with other available treatments observed (mentioned in 14 of 
49 recommendations, at least partially met in nine and not met in five),  
9.3 sufficient evidence available to support the B-I-D combination compared to other 
relevant treatment options (mentioned in 15 of the 49 recommendations, at least 
partially met in 11 and not met in four),  
9.4 drug addressed an unmet clinical need (mentioned in 27 of 49 recommendations, 
at least partially met in 24, not met in two and unclear in one). 
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The remaining criteria were mentioned less often and were usually met, apparently 
providing further support to a positive recommendation. 
4.4.5.10 THEME 10: BIOMARKER TEST 
Interestingly, criteria relevant to the biomarker test theme were not mentioned very often 
– only in ten of the 49 recommendations. The one most frequently mentioned (ten of the 
49 identified recommendations) was the availability in Europe of the biomarker test or 
clear guidelines on how to perform it (criterion 10.1). In four recommendations for 
authorised drugs the accuracy of the biomarker test was discussed (criterion 10.2). The 
remaining two criteria within the biomarker test theme (10.3 and 10.4) were mentioned 
only in one and two documents respectively. 
4.4.5.11 THEME 11: EXTERNAL EVIDENCE  
External evidence was mentioned in seven of the 49 recommendations and for all of 
these the criteria were at least partially met. In four cases evidence from drugs with a 
similar mechanism of action was discussed (criterion 11.1). Evidence from previous studies 
for example in a different indication (criterion 11.2) and from published literature (criterion 
11.3) were mentioned in three cases each. 
4.4.5.12 THEME 12: PRE-EFFICACY EVIDENCE SUPPORTING THE BIOMARKER 
In 17 of the 49 recommendations evidence from studies undertaken prior to efficacy trials 
was used to support the biomarker. The most frequently cited criterion within this theme 
(14 recommendations, 12 at least partially met, 1 not met, 1 unclear) was the evidence 
from the mechanism of drug action (criterion 12.2). Also evidence from pre-clinical studies 
(criterion 12.1) was taken into consideration in six recommendations where it was at least 
partially met. 
4.4.5.13 THEME 13: PRE-EFFICACY EVIDENCE SUPPORTING THE DRUG 
Evidence from lower level studies undertaken prior to efficacy trials was mentioned 
frequently (33 of 49 recommendations) and whether it was considered appeared to be 
mainly an artefact of the report structure, rather than any particular concerns.  
Acceptable quality of the drug (criterion 13.1) was mentioned in 21 recommendations 
and was at least partly met in all of these. Sufficiency of information from preclinical 
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studies (criterion 13.2) was commented on in 21 recommendations (at least partly met in 
19, not met in one and unclear in one). Evidence to support selected dose and/or 
duration of treatment (criterion 13.3) was commented on in 19 recommendations (at least 
partly met in 13, not met in four and unclear in two). Criterion of sufficiently characterised 
drug pharmacokinetics (criterion 13.4) was commented on in 17 recommendations (at 
least partly met in 13, not met in two and unclear in two). 
4.4.6 NECESSARY CONDITIONS 
The potential necessary criteria for authorisation of a drug with a biomarker in the 
indication or contraindication were identified as those not met by at least one of the 
negative recommendations, but at least partially met, unclear or not discussed for all 
positive recommendations. As there were only four negative recommendations with a 
Scientific Discussion or Assessment Report document available, these conclusions are 
limited. The identified necessary criteria were: 
 Theme 1: Population – population in studies was in accordance with the population 
identified by the drug indication - this was not met in two refusal 
recommendations.164,210 
 Theme 7: Clinical efficacy evidence 
o 7.1.a. sufficient evidence supporting conclusions based on the results for the 
primary outcome irrespective of biomarker - this was not met in one refusal 
recommendation.164  
o 7.1.b. sufficient evidence supporting conclusions based on the results for the 
primary outcome supporting the biomarker (including enrichment design) - this 
was not met in one refusal recommendation.164 
o 7.7. Results reproduced in more than one study - this was not met in one refusal 
recommendation.160  
 Theme 12: Pre-efficacy evidence supporting biomarker 
o 12.2. evidence from mechanism of action to support biomarker - this was not 
met in one refusal recommendation.209  
For all of these criteria there were no positive recommendations where these were not 
met. 
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4.4.7 SUFFICIENT CONDITIONS 
Based on the data collected it is difficult to identify sufficient criteria for authorisation. It 
appears that the majority of the criteria identified from the analysed documents were 
largely a result of selective reporting of issues important within the context of a given B-I-D. 
Therefore it did not seem possible to identify a set of sufficient criteria.  
Some of the criteria appeared to be important in the majority of the analysed 
documents. In the majority of the positive recommendations at least one criterion from 
these themes was completely or partly met: 
 Theme 7: Clinical efficacy evidence, 
 Theme 8: Toxicity – toxicity acceptable, 
 An at least one criterion from these themes: 
o Theme 9: Context, 
o Theme 10: Biomarker test, 
o Theme 11: External evidence, 
o Theme 12: Pre-efficacy evidence supporting the biomarker, 
o Theme 13: Pre-efficacy evidence supporting the drug, 
There was one EMA document where there was no information on any of these criteria.210 
There was also one refusal case where all of the above conditions were met.211 
This set of criteria is therefore not complete and it does not allow to completely distinguish 
between the positive and negative recommendations.  
4.4.8 VARIATION DEPENDING ON CLINICAL AREA 
Twenty nine of the 49 identified cases discussed cancer treatments – the most frequent in 
this dataset were breast, NSCLC and colorectal cancers. Sixteen recommendations 
discussed treatments for viral diseases: 14 HIV-1 (including 13 “viral resistance” biomarkers 
and one other) and two genotype 1 HCV treatments. Four recommendations were 
classed as blood/metabolic disease areas and included only orphan drugs.  
Cancer was the only clinical area where each individual criterion was mentioned at least 
once and, as it was the disease area with the largest number of recommendations 
included in this analysis; it substantially shaped the dataset as a whole. For the majority of 
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the identified criteria there were few differences between clinical areas. The criteria 
where the main differences occurred were:  
 Theme 3: the primary outcome was discussed less frequently for viral diseases 
(19%) than for the other clinical areas (55%). 
 Criteria 7.1.-7.3: study results were more commonly discussed with separation into 
primary and secondary outcomes for cancer and blood/metabolic diseases (66% 
and 75% respectively) than for viral diseases (31%), where they were usually 
discussed together for all outcomes.  
 Criterion 7.4: clinical benefit in the biomarker-defined subgroup was mentioned 
more frequently for blood/metabolic diseases (75%) than the remaining disease 
areas (56%). 
 Criterion 9.1: acceptable mode of delivery was referred to most frequently in viral 
diseases (31%), only mentioned in two of 29 cancer recommendations (7%) and 
not mentioned for blood/metabolic diseases. 
 Criterion 9.2: cross-resistance with other available treatments was more commonly 
discussed in viral diseases (75%), in only two cancer recommendations (7%) and 
none of the  blood/metabolic diseases. This is possibly due to inclusion in the 
dataset of only chronic viral diseases, often requiring a change in the treatment 
regimen due to arising resistance. Similar reasoning could however be applied to 
cancer, where multiple lines of therapy are also common. 
 Criterion 12.2: evidence from mechanism of action was used most frequently to 
support the biomarker in cancer (45%), one blood/metabolic (25%) and no viral 
disease recommendations.  
4.4.9 VARIATION DEPENDING ON THE TYPE OF THE BIOMARKER 
There were only three recommendations where the biomarker was predictive of 
treatment safety and in the remaining 46 recommendations biomarkers were predictive 
of treatment efficacy. A comparison of criteria used in recommendations for efficacy 
biomarkers with the three toxicity cases did not show any clear differences.  
4.4.10 VARIATION DEPENDING ON PRESENCE OF AN ORPHAN DESIGNATION 
In ten of the 49 recommendations the drug had an orphan designation. This included 
eight positive and two negative recommendations.  
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For most of the identified criteria there were no obvious differences in how frequently 
different criteria were mentioned or met. The criteria where the main differences occurred 
were: 
 Theme 2: in drugs with orphan designation there was no discussion of the statistical 
approach to data analysis, however it was only mentioned in three non-orphan 
cases (8%). 
 Theme 3: the primary outcome was discussed more frequently for orphan (60%) 
than for non-orphan drug recommendations (36%). 
 Theme 4: the sample size was discussed more frequently for orphan (80%) than for 
non-orphan(26%) drug recommendations. However for both of these drug types it 
was usually only mentioned, without providing any normative statements. 
 Criterion 7.6: sufficiently long term follow-up was mentioned more frequently for 
orphan drugs (80%) than non-orphan drugs (41%) and for both groups it was rarely 
met. 
 Criterion 9.2: cross-resistance was discussed less frequently for orphan drugs (20%) 
than for non-orphan (31%).  
 Criterion 9.3: comparison with other available treatments was discussed less 
frequently for orphan drugs (10%) than for non-orphan (36%). 
 Criterion 9.4: addressing an unmet clinical need was mentioned in most of the 
orphan drug recommendations (80%) and less frequently for non-orphan drugs 
(41%). 
 Theme 10: with one exception165 (criterion 10.1), issues related to the biomarker test 
were not discussed for orphan drugs. These were however relatively rarely 
discussed for the non-orphan drugs as well (23%). 
4.4.11 CRITICAL ISSUES IN B-I-DS WITH NEGATIVE RECOMMENDATIONS 
There were four negative recommendations. Based on the available documents it was 
attempted to identify issues which appeared to be critical for the negative 
recommendations. The main issues that were identified are reported below for each of 
the four recommendations together with the relevant themes. 
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4.4.11.1 GEMTUZUMAB OZOGAMICIN FOR TREATMENT OF CD33-POSITIVE AML 
Critical issues: 
Theme 1: population in the studies not in accordance with indication 
Theme 2: inappropriate study design 
Theme 7: limited information on efficacy 
The indication considered for this drug was treatment of adult patients with first relapse 
AML who are not candidates for other intensive re-induction chemotherapy. The main 
points raised in the Assessment Report are described below.164  
It was stated in the EMA document that at least some of the patients included in the 
studies were actually eligible for other cytotoxic regimens. This was confirmed by 
supportive studies where some of the patients were treated with high-dose chemotherapy 
and allogenic hematopoietic stem cell transplantation after treatment with gemtuzumab. 
It was also raised that a randomised trial would have been both possible and more 
appropriate, however this did not seem to be the most important concern. 
As it was considered that the population in the studies was not representative of the 
“theoretical situation where no other treatment option is available”, informal comparisons 
were undertaken with other available treatments for patients in first relapse. Based on 
these it was concluded that gemtuzumab results in only a modest rate of complete 
remission: 13% of patients in the studies compared to 20-70% for other available 
treatments based on published literature. It was also noted that there is little information 
on the duration of the response and other clinically relevant outcomes such as overall 
survival. 
4.4.11.2 CETUXIMAB FOR TREATMENT OF EGFR EXPRESSING NSCLC 
Critical issues: 
Theme 2: concerns about post-hoc data analysis 
Theme 7: limited benefit inconsistent across different outcomes 
Criterion 12.2: trial data inconsistent with drug mechanism of action 
The indication under consideration was first line treatment of EGFR-expressing NSCLC in 
combination with platinum-based chemotherapy.209 
The drug was initially rejected as the overall survival benefit it provided was considered 
“modest” (HR=0.88, 95%CI: 0.795-0.969, p=0.01 based on a pooled analysis of trials, about 
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one month improvement in median OS). These results were also not supported by 
convincing effects on PFS. Such benefit was considered insufficient to outweigh the safety 
concerns. This was however not a unanimous decision, and some members of the CHMP 
had a divergent position, for example: 
“The lack of convincing supportive data in terms of PFS was considered not to 
be critical because the overall pattern was generally consistent with OS in 
terms of a favourable treatment effect. 
There is an unmet medical need particularly in patients with tumors of non-
adenocarcinoma histology.”209 
It was also discussed that there appeared to be no effect of KRAS mutation status on 
treatment efficacy, and therefore EGFR signalling was possibly not related to treatment 
activity (two out of four studies included only patients with EGFR expressing tumours). This 
issue however appeared to be of lesser importance. 
The applicant requested the opinion to be re-examined for a population of patients 
under 65 years of age. It was observed that in the older patients there were more deaths 
early after initiation of treatment, which had a large impact on the efficacy and safety 
profile. The selection of patients based on age was justified by claiming that older patients 
were more frail and suffered from more comorbidities than younger ones.  
In this group of patients the point estimate of OS was slightly better (HR= 0.85; 95% CI: 0.72-
0.99; p=0.043, median OS benefit of about 1.5 months). However the conclusions of the 
CHMP did not change. The OS effect was still considered “modest” and not supported by 
PFS data.  
Additionally, concerns were expressed about the post-hoc analysis of data. It was pointed 
out that this was prone to bias and multiplicity problems. Also the safety profile for patients 
<65 years was similar to that for all patients in terms of percentage of patients 
experiencing serious adverse events. Therefore, a negative opinion was confirmed, 
although a minority of the CHMP again disagreed. 
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4.4.11.3 ZOLEDRONIC ACID FOR TREATMENT OF HORMONE RECEPTOR POSITIVE BREAST CANCER 
Critical issues: 
Theme 1: background therapy not representative of current practice 
Criterion 7.7: results not replicated (data from one trial only) 
Zoledronic acid (belonging to a class of drugs known as bisphosphonates) was 
considered as a treatment for hormone receptor positive early BC in premenopausal 
women. Zoledronic acid was already used to prevent bone resorption (break-down) in 
cancers involving the bone and thus to avoid skeletal events. This new application was 
withdrawn by the applicant after a negative opinion issued by the CHMP.210  
One of the major concerns was that the background therapy was considered 
unrepresentative of current European practice, as it did not include adjuvant 
chemotherapy. Another important concern seemed to be that the anti-tumour activity of 
zoledronic acid was to some extent surprising: 
“The direct anti-tumor activity of zoledronic acid appears very promising, but it 
also represents, at least conceptually, a new property of this potent 
bisphophonate.”210  
Therefore, in spite of very “promising results” of the trial that was submitted in support of 
the indication (disease free survival compared to endocrine therapy alone HR=0.66; 95% 
CI: 0.48, 0.90), the CHMP considered the fact that the results were not replicated to be of 
utmost importance (theme 7): 
“So far, the adjuvant benefit of zoledronic acid has only been demonstrated 
in one, single trial which remains one of the major concerns.”210  
4.4.11.4 ALIPOGENE TIPARVOVEC FOR LPL PROTEIN POSITIVE LIPOPROTEIN LIPASE DEFICIENCY 
Critical issues: 
Criterion 7.4: data on clinically relevant outcome not considered robust  
Criterion 7.7: insufficient evidence of long term benefit 
This drug is discussed in more detail in the case study in section 4.4.12 and therefore the 
critical issues for this decision are only briefly outlined here.  
The CHMP rejected this application due to two main reasons: 
127 
 
 Data on pancreatitis attacks (clinical outcome) were not considered robust and it 
was not unlikely that the observed improvement in this outcome was due to 
factors other than the treatment investigated. 
 Insufficient evidence of long term benefit of treatment in terms of surrogate 
outcomes was available.160  
4.4.12 CASE STUDY: DETECTABLE LEVELS OF LPL PROTEIN IN TREATMENT OF LPL DEFICIENCY WITH 
ALIPOGENE TIPARVOVEC 
This B-I-D combination was selected for the case study, as it was given a positive 
recommendation after an initial negative one. Therefore this case study could potentially 
provide some insight into what criteria were important for the EMA when considering 
drugs with predictive biomarkers in the indication or contraindication. This B-I-D 
combination is considered in more detail to allow a better understanding of the rationale 
underpinning EMA recommendations. 
4.4.12.1 BACKGROUND INFORMATION ON LPL DEFICIENCY AND ALIPOGENE TIPARVOVEC 
LPL deficiency is a rare recessive disease with prevalence of the disease judged as one to 
two people per million in the EU.160 It is diagnosed in adults, but symptoms can appear in 
children and include severe abdominal pain, colicky pains and pancreatitis. The 
complications of the disease include acute pancreatitis which may be life threatening 
and also lead to a chronic pancreatic insufficiency.212 
People with this disease do not produce a functional LPL enzyme.213 LPL is mainly found in 
skeletal and heart muscle, as well as fat tissue.212 It is involved in clearance from the body 
of triglyceride-rich chylomicrons, which are normally produced after a meal and deliver 
triglycerides to different parts of the body. The lack of functional LPL results in high levels of 
fasting chylomicrons and high plasma triglyceride concentration.213 Chylomicrons are in 
turn thought to be responsible for the clinical symptoms. When the drug was considered 
by the EMA there was no treatment available and management of LPL deficiency was 
mainly through extremely low-fat diet.212 
Alipogene tiparvovec (trade name Glybera) is a gene therapy drug comprising a non-
integrating adeno-associated viral vector which is used to deliver functional copies of the 
LPL gene to cells.160 The treatment is given on a single occasion as a number of 
intramuscular injections at different sites. It requires 12 weeks of immunosuppression 
following the injection.160 The treatment cannot be repeated, as all patients treated with 
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alipogene tiparvovec developed a high and persistent immune response to the drug, 
precluding retreatment.160,213,214 
4.4.12.2 NEGATIVE RECOMMENDATIONS 
Alipogene tiparvovec has been granted an orphan designation in 2004 and the 
application for marketing authorisation was first submitted in December 2009 in an 
indication that did not contain the biomarker: 
“Glybera is indicated for the long term correction of lipoprotein lipase 
deficiency, to control or abolish symptoms and prevent complications in adult 
patients clinically diagnosed with lipoprotein lipase deficiency (LPLD).”160  
This application was given a negative recommendation by the EMA in June 2011 due to 
insufficient evidence supporting clinical benefit, however as this indication did not contain 
a predictive biomarker, it will not be considered in detail here.  
In July 2011 the EMA was asked by the applicant to re-examine their decision. Additional 
information and effectiveness and safety analyses were also provided. 
The drug was first re-examined by Committee for Advanced Therapies (CAT), which 
concluded that the benefit of the drug 
“is sufficiently demonstrated in selected patients as defined by the restricted 
indication in patients diagnosed with LPL deficiency and suffering from at least 
one pancreatitis episode despite dietary fat restrictions. The indication is 
restricted to patients with detectable levels of LPL protein”160  
Although this is not explicitly stated in the documentation provided, it appears that it was 
CAT that limited the indication to patients with a history of pancreatitis episodes and 
introduced the biomarker. The CHMP disagreed with this opinion with one of the main 
reasons being insufficient evidence of long term benefit. It was also stated that the data 
on pancreatitis attacks (clinical outcome) cannot be considered robust and the 
observed change in pancreatitis rates may be due to factors other than the investigated 
treatment. Again, the drug was given a negative recommendation. There were however 
divergent positions (information on their content was not available). Details of the criteria 
considered in this recommendation are reported in Table 4.2. 
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4.4.12.3 POSITIVE RECOMMENDATION 
Following the refusal, the European Commission asked for a re-examination of the CHMP 
recommendation. The Applicant was asked whether they supported an indication 
“restricted to patients with detectable levels of LPL protein”.160  
As the applicant agreed, they were asked to provide an overview summarising data for 
this patient group. Detailed, individual patient data on 12 patients relevant to this 
indication were provided. Based on these it was concluded by both CAT and CHMP that, 
considering the “totality of evidence” the previously identified issues were resolved. In 
particular the issues below were discussed. 
The CHMP noted that the efficacy data based on pancreatitis events alone were 
insufficient to support the conclusions due to its limitations. However they noted that when 
equal-length of pre- and post- treatment periods are considered for each patient, less 
events occurred post-treatment. This data were also considered to be supported by 
weight gain in three patients that was not associated with pancreatitis or abdominal pain. 
This was considered consistent with diet violation not causing disease symptoms. It was 
also observed that there was a reduction in hospital admissions and intensive care unit 
stays post-treatment. Further evidence supporting the positive opinion was based on 
laboratory measures: observations in seven patients of LPL mass, LPL activity and LPL 
enzyme function, as well as vector DNA expression (unclear in how many patients this was 
measured).  
In making its recommendation, 
“The CHMP (…) took into consideration the extreme rarity of the condition and 
the high degree of unmet medical need, particularly in patients with severe or 
recurrent pancreatitis events”160  
and considered the “totality of evidence”. It was concluded that each individual 
component of the data on its own was subject to limitations and should not be 
considered in isolation. As a result it was concluded that based on: 
“- the persistence of LPL activity in patients who had had biopsies (8 biopsies 
performed in 7 patients; one patient had two biopsies, the first at 18 weeks 
and the second at 52 weeks),  
- the evidence of an effect on lipids, in particular the post prandial CM, (in 5/5 
patients at 14 weeks and 3/3 patients at 52 weeks),  
- the evidence presented on the reduction in the rate of pancreatitis”160  
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the positive effect of alipogene tiparvovec was confirmed in this group of patients. The 
concerns raised in the rejection recommendation were considered resolved (by majority 
of CHMP members). There was also a minority divergent opinion noted, which mainly 
concluded that:  
“the grounds for refusal initially voted have not been satisfactorily resolved 
and there are still uncertainties on the robustness and the relevance of the 
clinical results submitted”160  
Details of the criteria considered in this recommendation are reported in Table 4.2. 
4.4.12.4 DIFFERENCE BETWEEN THE POSITIVE AND NEGATIVE RECOMMENDATION 
It does not appear that there was a large change in the quantity or quality of data 
available between the negative and positive recommendations. It seems however that 
there was a change in the interpretation of the data, particularly for the results of 
included studies. In the positive recommendation the “totality of evidence” approach 
was emphasised, possibly implying that a positive trend across different outcomes to 
some extent compensates for the study limitations. It was also highlighted that this 
treatment is the first drug available for this patient population. 
4.5 DISCUSSiON 
The framework analysis of 49 EMA recommendations resulted in identification of 41 
criteria, which were grouped into 13 themes. These criteria were discussed in the analysed 
documents with varying frequency. The most frequently mentioned themes were: 
 Theme 1: Population 
 Theme 2: Study design 
 Theme 7: Clinical efficacy evidence 
 Theme 8: Toxicity 
 Theme 9: Context 
 Theme 13: Pre-efficacy evidence supporting the drug 
This analysis found that although there are some criteria which were considered more 
frequently than others in the context of EMA licensing recommendations, it is very difficult 
to identify any that can be considered sufficient or necessary.  
 
 
Table 4.2 Criteria considered in recommendations for LPL protein in treatment of LPL deficiency with alipogene tiparvovec (only themes and criteria where information was 
reported are included) 
Theme and/or criterion Negative recommendation Positive recommendation 
1. Population 
 
Reported, but no normative statement 
2. Study design 
2.2. amendments to 
trials acceptable 
 
The primary efficacy outcome was changed from plasma triglyceride levels to postprandial chylomicrons (pp-CM) as a surrogate efficacy 
marker – the CHMP agreed this was acceptable  
2.4. Level of possible 
bias acceptable 
 
“Considering the combination of the rarity of the indication as well as 
the fact that this is an autosomal recessive disorder with different levels 
of genetic penetration, a high consistency in the results is challenging 
to achieve. A lack of full consistency is acknowledged as a limitation 
of the data, but this does not rule out a favourable effect of Glybera.” 
3. Primary outcome pp-CM was considered acceptable 
4. Sample size 
 
“Acknowledging the limited dataset in the sub group of 12 patients 
with severe or multiple pancreatitis attacks, the CHMP discussed the 
pancreatitis results on the basis of individual patient data” 
7.1.a. Sufficient 
evidence supporting 
conclusions based 
on the results for the 
primary outcome 
irrespective of 
biomarker  
“there is currently insufficient data on pp-CMs to demonstrate the 
efficacy of Glybera based on only 3 patients at 52 weeks (of the 27 
patients enrolled in the clinical trial programme), even taking into 
account the extreme rarity of the disease” 
“Looking at the totality of the available evidence for efficacy, the 
CHMP considered (...) the evidence of an effect on lipids, in particular 
the post prandial CM, (in 5/5 patients at 14 weeks and 3/3 patients at 
52 weeks), (...) and concluded by majority, that there was sufficient 
evidence to confirm a positive effect on Glybera in this sub group of 
severe patients with a high degree of unmet medical need” 
7.2.a. Sufficient 
evidence supporting 
conclusions based 
on the results for the 
secondary outcomes 
irrespective of 
biomarker 
 
“Looking at the totality of the available evidence for efficacy, the 
CHMP considered 
- the persistence of LPL activity in patients who had had biopsies (8 
biopsies performed in 7 patients; one patient had two biopsies, the first 
at 18 weeks and the second at 52 weeks),(...)  
- the evidence presented on the reduction in the rate of pancreatitis 
and concluded by majority, that there was sufficient evidence to 
confirm a positive effect on Glybera in this sub group of severe 
patients with a high degree of unmet medical need.” 
7.4.a. Sufficient 
evidence to 
conclude clinical 
benefit irrespective of 
biomarker 
The main issues were: 
 lack of robust data on pp-CM  
 retrospective analysis of pancreatitis data did not provide 
evidence of efficacy in terms of a clinically meaningful reduction 
in pancreatitis 
 follow-up data on pancreatitis were insufficient (relatively short 
duration of post-treatment follow-up and large variability in 
historical annual pancreatitis rates)  
It was considered that: 
 effect of the treatment on pp-CM is biologically significant, even 
though it was tested on a small number of patients; pp-CM “data 
at 52 weeks (n=3 pts) suggest the presence of a metabolically 
relevant amount of LPL activity” 
 “The evidence generated for the reduction of pancreatitis events 
and severity of attacks, although hampered by statistical 
1
3
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 it could not  be excluded that the observed decrease of 
pancreatitis risk is due to other factors (lifestyle and diet changes) 
 there was no evidence of a relationship between pancreatitis 
events and reduction in hospital admissions and ICU stays  
limitations, suggested that Glybera leads to a clinically relevant 
reduction of pancreatitis risk.” 
 “This is also supported by the reduction in hospital admissions and 
ICU stay”  
 “The evidence generated by the overall efficacy data, 
acknowledging the limitations, is considered to be sufficiently 
robust” 
7.6. Sufficiently long 
term data provided 
Insufficient follow-up to conclude persistence of LPL activity and 
impact on annual rates of pancreatitis (which have very high year to 
year variability) 
Acknowledged that the follow-up was relatively short  
8. Toxicity acceptable The main risk was considered to be that the treatment requires 12 weeks of immunosuppression which was considered acceptable 
9.4. Drug addressed an 
unmet clinical need 
 
The group of patients for whom the treatment is intended was 
described as “sub group of severe patients with a high degree of 
unmet medical need” 
9.6. Novel mechanism 
of action/ new active 
substance  
alipogene tiparvovec was qualified a new active substance 
11.1. Supporting 
evidence from drugs 
with similar mechanism   
Data on other gene therapies using the same virus as the vector 
(mode of gene delivery) were used to support long term safety. 
11.3. Conclusions 
supported by 
published meta-
analysis or other 
literature sources  
“Residual baseline level of LPL is also important due to potential 
immunogenicity/tolerance and there should be further follow-up in this 
respect since it has been published that antibodies can in some 
instances neutralize LPL” 
12.1. Evidence from 
mechanism of action to 
support biomarker  
“In order to prevent an immune response against the transgene 
protein, treatment is restricted to patients with detectable levels of LPL 
protein” 
1
3
2
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Interestingly, as these were all recommendations that included a predictive biomarker, 
there was relatively little attention given to any issues associated with the biomarker test 
(theme 10). Criteria within this theme were commented on only in ten of the 49 analysed 
recommendations. 
An analysis of critical issues in negative recommendations identified a number of criteria 
which seemed to be important in these cases. These were often criteria within theme 7: 
clinical efficacy evidence. In these cases, for various reasons, the evidence supporting 
the drug efficacy was considered insufficient. Other critical issues included, for example, 
criteria from theme 1: population and theme 2: study design.  
In one case a B-I-D combination was first given a negative recommendation and after 
EMA reconsidered the evidence, drug authorisation was recommended. This was 
analysed in more detail in a case study. This suggested that to a large extent it was not 
new evidence that influenced the change in the recommendation, but a different 
perspective adopted by the EMA, with more weight given to the context (lack of any 
alternative treatment and rarity of the condition) and a “totality of evidence” approach.  
The context (theme 9) was considered very frequently (40 of 49 recommendations) and it 
seemed to influence interpretation of evidence on efficacy (theme 7) and toxicity (theme 
8). 
The initial seven criteria formed the basis for construction of the first seven themes. Of 
these, some appeared important both due to being frequently referred to in EMA 
documents and forming the basis of negative recommendations. However, some of these 
initial criteria did not seem to be of high importance (particularly theme 5: proportion of 
patients with biomarker status available and theme 6: subgroup with available biomarker 
status representative).  
There are a number of limitations to these findings, as the framework analysis was carried 
out by one person. There is therefore a possibility that some criteria were missed. The 
classification of criteria proposed here is to a very large extent subjective and a different 
person conducting the framework analysis may identify different criteria and themes.  
It is also likely that the identified criteria are to a large extent a result of selective reporting 
by the EMA. It has been suggested that documents should be considered in the context 
of authorship, their purpose and intended readers.215,216 These documents were written 
only to a very small degree as a record of discussions and may not reflect all the issues 
that were considered important. However these were the only available documents on 
these issues. A further identification of important issues could have been undertaken by 
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interviews with members of CHMP, however this was considered outside of the scope of 
this exploratory analysis. 
4.6 CONCLUSIONS 
Forty one criteria grouped into 13 themes have been identified in the framework analysis 
of 49 EMA recommendations for B-I-D combinations containing predictive biomarkers. It 
was not possible to identify sufficient or necessary criteria with any degree of certainty. 
It also appears that the way criteria were applied (as highlighted by a case study of 
alipogene tiparvovec) was largely context-dependent. 
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Abstract 
Background: Chapter 4 investigated the rationale for EMA recommendations for drugs 
with a predictive biomarker in the indication or contraindication that were identified in 
Chapter 3. All the 41 identified criteria used by the EMA were considered for use in this 
chapter. The focus of the current chapter is on the evidence base supporting the inclusion 
of a particular predictive biomarker in drug indications and contraindications. 
Aim: To analyse the evidence supporting EMA recommendations including a predictive 
biomarker reported in the EMA documentation and thus to identify evidence standards in 
positive licensing recommendations and contrast them with the evidence supporting the 
B-I-D combinations where licensing was refused. 
Methods: The criteria used to evaluate the evidence were: (1) population in accordance 
with the population identified by the drug indication, (2) design of the biomarker 
evaluation, (3) the type of primary outcome, (4) sample size (of patients with an available 
biomarker status) in studies; (5) findings - evidence supporting the biomarker based on the 
results for the primary outcome. These criteria were used to construct radial plots. In 
addition, the replication of findings of a single study and the consistency of the biomarker 
assay within a B-I-D combination were investigated. 
Findings:  Based on this analysis it seems that for biomarkers predicting treatment safety 
the evidence requirements were minimal, as in three of the four B-I-D combinations the 
biomarker predicting adverse events was based on the understanding of the drug action 
and/or metabolism. Evidence standards were not clear for biomarkers predicting 
treatment efficacy. In two cases of negative recommendations for non-orphan drugs, it 
appears that the promising results of a single study have not been replicated in another 
study. However, this was also the case for some of the B-I-D combinations which received 
a positive recommendation. For drugs with an orphan designation there was also little, if 
any, clear difference between the evidence base supporting the positive and negative 
recommendations.  
The analysis also identified poor reporting as an important issue limiting the evaluation of 
the studies and implementation of their findings.  
Conclusions: No clear evidence standards were identified in this analysis. These findings 
possibly highlight the importance of the context in which the B-I-D combinations were 
assessed. However, more consistent evidence standards may be needed to ensure 
optimal patient treatment. 
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5.1 BACKGROUND 
Chapter 4 based on EMA documentation analysed the rationale for EMA 
recommendations for drugs with a predictive biomarker in the indication or 
contraindication. It attempted to identify criteria used by the EMA to support these 
recommendations. This resulted in the identification of 41 different criteria grouped into 13 
themes. Some of these criteria were important from the perspective of drug licensing 
decisions in general (for example satisfactory quality of the product), but not specific to 
predictive biomarker evaluation.  
It was considered that licensing decisions result in the use of a particular predictive 
biomarker in clinical practice, as mentioned in Chapter 1 and Chapter 3. It was therefore 
expected that the analysis of this evidence base would provide an indication of the 
evidence standard sufficient to establish clinical practice that includes the use of a 
predictive biomarker to select patients for treatment with a given drug. This would 
correspond to the clinical utility stage discussed in detail in Chapter 1 and Chapter 2. The 
studies of interest were often grouped into main and supportive in the EMA 
documentation, with the main studies providing evidence most relevant to a particular 
indication. 
5.2 AIMS 
The aim of this chapter was to review the evidence that supported recommendations 
including a predictive biomarker reported in the EMA documentation. This was 
undertaken to identify evidence standards supporting positive licensing 
recommendations and contrast these with the evidence supporting the B-I-D 
combinations where licensing was refused. This was considered within different groups of 
B-I-D combinations: 
 where the biomarker predicted treatment efficacy and the drug did not have an 
orphan designation, 
 where the biomarker predicted treatment efficacy and the drug had an orphan 
designation, 
 where the biomarker predicted treatment safety. 
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5.3 METHODS 
5.3.1 DATA SOURCES 
Data were collected for studies for which it was reported in the EMA documentation that 
these evaluated the biomarker forming part of the B-I-D combination for use in clinical 
practice. 
Scientific Discussions and Assessment Reports were the main source of information on 
studies supporting B-I-D combinations. These were described in more detail in Chapter 4. 
For the majority of B-I-D combinations containing biomarkers predicting efficacy the 
relevant data were contained in the Clinical Efficacy section of the Scientific Discussion or 
Assessment Report. In some cases, for example where the biomarker was added at a later 
stage, other relevant document sections were also used as a data source. For example 
for LPL protein expression use in hyperlipoproteinemia type I to predict response to 
alipogene tiparvovec the original assessment (and therefore the Clinical Efficacy section) 
did not contain the biomarker. The relevant information was therefore only found in the 
re-assessment section of the document.  
For biomarkers predicting adverse events, information on the biomarker was not reported 
(NR) within one section. Therefore data were collected from any section of the report 
where these were mentioned. In one case the study was only reported for each drug 
containing the active substance in a separate document (Procedural steps taken and 
scientific information after the authorisation).217-219 
For each relevant study identified within the EMA documentation additional searches 
were undertaken for any published papers and online information (such as trial summaries 
available on manufacturer’s website). These additional searches were used to 
supplement information on trial design, biomarker assay used and biological sample 
collection. However, as the EMA often used data from ongoing trials, study results were 
only collected from the EMA documentation. 
5.3.2 SELECTION OF CRITERIA FOR EVALUATION OF THE EVIDENCE BASE 
5.3.2.1 THEMES CONSIDERED 
In Chapter 4, which explored the rationale for EMA recommendations, the identified 
criteria were grouped into 13 themes. These were all considered for use in this analysis.  
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5.3.2.2 SELECTION OF CRITERIA FOR ANALYSIS OF EVIDENCE SUPPORTING EMA RECOMMENDATIONS 
Criteria within each theme were considered, taking into account the following issues: 
 frequency of use of these criteria in EMA documents, 
 identification as a critical issue in negative recommendations, 
 methodological rationale, 
 their relevance to the final stage of predictive biomarker evaluation prior to 
implementation in clinical practice (corresponding to clinical utility stage), 
 feasibility of evaluation of these criteria. 
Where possible, multiple criteria and themes were merged into one. The selection of 
criteria for use in this chapter is discussed below. The final criteria are shown in Box 5.1. 
THEME 1: POPULATION  
This theme was relatively frequently mentioned within the EMA discussions. It was also one 
of the critical issues in negative recommendations. The similarity between the population 
within studies and the target population (identified by the drug indication) appears to be 
of high importance for both the general licensing decisions and the predictive biomarker 
question. It also appeared important from the methodological perspective, as 
exemplified by its common use in methodological quality tools and publications220-224 
Therefore this criterion was selected to be used in this chapter. However, as only evidence 
supporting the predictive biomarker was of interest, consideration was narrowed down to 
study participants with an available biomarker status.  
THEME 2: STUDY DESIGN  
Study design was also frequently mentioned by the EMA, although it was not always 
considered in the context of biomarker evaluation. Within this theme there were five 
different criteria, however some of these seemed to be applicable only to certain cases 
(such as acceptability of protocol amendments). Other criteria, even though they might 
be of high importance (for example whether the level of bias in studies was acceptable), 
might be difficult to measure and to a certain extent overlap with the study design 
criterion. Therefore the initial criterion of whether the study design was appropriate to 
evaluate the clinical utility of a predictive biomarker was used. This was again supported 
by methodological tools and literature.17,220-223,225 
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THEME 3: PRIMARY OUTCOME  
Appropriate choice of the primary outcome was mentioned relatively frequently in the 
EMA discussions and even though it is not only biomarker specific, it is an important 
criterion when considering the strength of evidence supporting a change in clinical 
practice.220-223,226 It was therefore used in this chapter. It was however acknowledged that 
it might be difficult to assess how appropriate an outcome may be without detailed 
knowledge of each of the identified disease areas. As obtaining expert advice for all B-I-D 
combinations was not feasible, this criterion was focused on the type of the primary 
outcome. This was determined based on the level of objectivity in outcome measurement 
and its clinical relevance. 
THEME 4: SAMPLE SIZE  
The sample size was mentioned relatively frequently in the EMA discussions, although often 
there was no judgement on whether it was sufficient. This is an important criterion, as a 
larger sample size will increase the certainty in the findings of a study.223,227 Initially this 
criterion was to consider all patients included in a study and be complemented by the 
proportion of patients with an available biomarker status (Theme 5, discussed below). 
However, it appeared these two criteria could be merged into one – the total number of 
patients with available biomarker status. The possibility that the patients with an available 
biomarker status may not be representative of the target patients would be captured by 
the population criterion. 
Therefore, the sample size criterion has been modified to only include patients with 
available biomarker status. 
THEME 5: PROPORTION OF PATIENTS WITH BIOMARKER STATUS AVAILABLE 
This criterion was rarely mentioned in EMA discussions and did not appear as one of the 
critical issues. The relevance of this criterion to the review was discussed above and it was 
partly incorporated into sample size.  
THEME 6: SUBGROUP WITH AVAILABLE BIOMARKER REPRESENTATIVE 
This criterion was mentioned only in one of the documents analysed in Chapter 4. This 
criterion was however considered important and was therefore incorporated into the 
population criterion, as described above.  
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THEME 7: CLINICAL EFFICACY EVIDENCE 
Some form of evidence supporting the clinical efficacy has been mentioned in all of the 
analysed documents. It was also one of the main critical issues in negative 
recommendations. The results of the study with respect to the biomarker were selected as 
these were considered crucial for establishing whether it is predictive. It would be ideal to 
consider all the outcomes measured within each study, however, within a realistic time 
frame, such approach would not be feasible for all the identified B-I-D combinations. 
Therefore the results considered will be limited to the primary outcome, as this is the 
outcome for which the most important evidence could be expected.223 
This however raised the issue of how to address the B-I-D combinations where the 
biomarker is predictive of drug toxicity. Arguably, from the point of view of evaluating the 
biomarker, the best case would have been evaluation in trials with drug safety as the 
primary outcome. However it was likely that this was not the case, as there may have 
been ethical and logistic limitations to such research. Therefore, for safety biomarkers the 
approach was more flexible. 
In such cases the initial criterion was therefore modified to include the relevant safety 
results and therefore has been renamed to “Findings”. 
There were two additional criteria identified within this theme that were potentially 
relevant. The first one – whether sufficiently long-term data were available was not 
feasible to measure objectively and therefore was not included as a criterion here. The 
second one – whether the results were reproduced in more than one study will not be 
addressed directly, however it will be illustrated by the number of studies supporting each 
B-I-D combination and the results of these studies.  
THEME 8: TOXICITY  
Although the criterion of acceptable drug toxicity was of high importance, it was not 
considered relevant to the strength of evidence supporting biomarkers predictive of 
treatment efficacy. For biomarkers predictive of treatment toxicity, the safety results have 
been incorporated into the criterion of findings. Therefore this theme will not be explicitly 
considered in this analysis.  
THEME 9: CONTEXT 
This theme was mentioned by the EMA in most cases. It was also considered the reason 
for recommendation change in the case study described in Chapter 4. Clearly different 
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evidence may be considered sufficient in a case where the new drug is the only 
treatment, as compared to disease areas where multiple options are available. However 
in practice it might be extremely difficult to measure the context objectively, especially 
for all the B-I-D combinations identified. Therefore, even though it is an important issue in 
appraisal of the evidence, the context will not be considered within this analysis. 
THEME 10: BIOMARKER ASSAY 
Issues related to the biomarker assay were not discussed frequently. The choice of the 
biomarker assay is important, as different laboratory procedures may not give 
comparable results (as will be discussed in the example of ERCC1 measurement in 
Chapter 7).Analytical validity of the biomarker evaluation procedures was generally not 
commented on. It would also be difficult to use for this analysis, as identifying relevant 
research could be problematic. 
However, the consistency of laboratory procedures used across different studies is also 
important and it will be identified in the summary. 
THEME 11: EXTERNAL EVIDENCE 
The external evidence (such as from drugs with similar mechanism) has only been rarely 
mentioned and it generally did not contribute to the main data supporting the 
recommendations. Its impact on the strength of the evidence base may also be marginal 
and questionable. It will therefore not be used in this chapter.  
THEME 12: PRE-EFFICACY EVIDENCE SUPPORTING THE BIOMARKER 
Lower level evidence (such as from the drug development programme) supporting the 
biomarker was only rarely mentioned and is not directly relevant to this chapter, which 
focuses on the evaluation of a biomarker for use in clinical practice (clinical utility). 
Therefore this theme will not be used in this chapter.  
THEME 13: PRE-EFFICACY EVIDENCE SUPPORTING THE DRUG 
Similarly to theme 12, as this is lower level evidence not directly relevant to clinical utility, it 
will not be used in this chapter.   
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5.3.3 FINAL CRITERIA  
The final criteria that were used for the evaluation of the evidence base reported in EMA 
documents are summarised below in Box 5.1.  
Box 5.1 Criteria that were used for evaluation of evidence base reported in EMA recommendations 
 
5.3.4 DATA EXTRACTION 
Data were collected by one reviewer from the EMA documentation and identified trial 
reports on the items shown in Box 5.2. 
The majority of these items were not included in the list of criteria selected for data 
analysis, however these were considered important to aid the interpretation of the study. 
Data were recorded in a MS Access database. 
5.3.5 DATA ANALYSIS 
5.3.5.1 SUMMARY OF STUDY NUMBERS AND PATIENT NUMBERS 
Data on the numbers of studies supporting each B-I-D combination were presented in a 
stacked bar chart and summarised as the median and range. The same approach was 
used for data on the numbers of patients supporting each B-I-D combination. The 
numbers of studies with a different rank (as described in section 5.3.5.2 below) were 
reported in tables and presented as percentages. 
1. Population – population with the biomarker status available in studies was in accordance with 
the population identified by the drug indication 
2. Study design - design of the studies supporting the inclusion of the biomarker in the indication 
was appropriate  
3. Primary outcome – the type of primary outcome assessed in the studies  
4. Sample size - sample size (of patients with an available biomarker status) in studies was 
sufficiently large 
5. Findings - evidence supporting the biomarker based on the results for the primary outcome 
(including enrichment design); for safety biomarkers secondary outcomes were considered if 
primary outcomes were irrelevant 
 Results were replicated in other studies 
 Biomarker evaluation procedure used was consistent across studies 
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Box 5.2 Data extraction items for the analysis of evidence supporting EMA recommendations 
 
5.3.5.2 ASSIGNMENT OF RANKS FOR DIFFERENT CRITERIA 
To facilitate construction of radial plots, for each study within a B-I-D combination the first 
five criteria (as outlined in Box 5.1) were assessed. These were scored mainly on ordinal 
scales (with the exception of patient number, which was measured on a continuous 
scale), and therefore the differences between individual ranks do not provide 
quantitative information. These were then plotted for each study, as described below in 
section 5.3.5.3. The further two criteria (whether results were replicated and the 
consistency of the biomarker assay used) were addressed by the number and 
appearance of the plots. 
The assignment of ranks for each criterion was carried out as described below.  
1. Population – this criterion was assessed as shown in Table 5.1. The highest rank was given 
to studies where the included patients were representative of all patients identified by the 
drug indication. It was lower when the study patients were either a subset or a wider 
 study name, 
 characteristics of included patients, 
 study EMA status (main, supportive or unclear), 
 study phase, 
 study design, 
 blinding, 
 power calculation (presence of and method), 
 primary outcome (and way of its measurement), 
 follow-up duration, 
 total number of patients and numbers of patients in different study arms, 
 treatment in each arm, 
 design of biomarker evaluation, 
 biomarker assessment and sample type, 
 results 
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group (where the relevant patient population could not be analysed separately). Finally, 
when the study population was different or NR, the lowest rank was given. 
Table 5.1 Ranks for the similarity between the study population and the indication 
Rank 
Study data cover the 
indication exactly 
Study data cover wider group and 
impossible to separate out relevant 
patients or covers subgroup of patients in 
the indication 
Study data on 
population different to 
indication/ NR 
1 0.5 0 
 
2. Design of biomarker evaluation – this criterion was assessed as shown in Table 5.2. The 
highest ranks were given to studies designed to evaluate the clinical utility of a predictive 
biomarker. Studies providing limited information on how well a biomarker predicts patient 
response were given progressively lower ranks. The lowest rank was given to cases when 
the study design was not relevant to the predictive biomarker or NR. The study designs 
used here are described in Chapter 1, with the exception of:  
 Non-RCT biomarker study: any non-randomised study where the biomarker 
evaluation is part of the study design, 
 Case reports and case series: observational studies with a small number of patients 
included; the biomarker status is measured, however evaluation of the biomarker 
was NR as part of the design. 
Table 5.2 Ranks for the study design 
Rank 
Stratified/ 
biomarker 
strategy 
RCT 
enrichmen
t 
RCT subgroup 
(prospective) 
RCT subgroup 
(retrospective
) 
RCT subgroup 
(cross-sectional); 
non-RCT biomarker 
study 
Not 
relevant
/ NR 
1 0.8 0.6 0.4 0.2 0 
 
3. Primary outcome – for this criterion objectively measured clinically relevant outcomes 
(such as survival and disease cure) were given the highest rank. These were followed by 
other clinically relevant outcomes and surrogate outcomes. The lowest rank was given to 
studies which did not define or report a primary outcome. The details of assigning a rank 
to a study are shown in Table 5.3. 
Table 5.3 Ranks for the primary outcome 
Rank 
Objectively measured 
clinically relevant 
outcomes (eg. overall 
survival, disease cure) 
Other clinically relevant 
outcomes (eg. PFS, TTP, 
QOL) 
Surrogate outcomes (eg. 
tumour response, HIV RNA 
level) None/ NR 
1 0.7 0.4 0 
148 
 
4. Sample size (with available biomarker status) is assessed on a scale from 0 (which 
would correspond to no patients in the study) to 1 (1000 or more patients in the study). An 
individual score is obtained by dividing the number of patients by 1000 for patient 
numbers up to 1000 and assigning a score of 1 for any number above 1000. Although this 
is a relatively arbitrary cut-off, it was selected as the majority of studies were smaller and 
therefore it provided discrimination between these. It was also chosen in preference to 
study power, as the power is heavily dependent on the assumptions about the biomarker 
and treatment effects. In addition, power was considered irrelevant for studies where the 
biomarker hypothesis was not primary and for observational studies. 
5. Findings – for this criterion, ranks were assigned as shown in Table 5.4. For hypothesis-
testing studies these were based on the p-value to indicate the level of uncertainty in the 
results: 
 For studies comparing biomarker strategy with standard care – for the comparison 
between the study arms, 
 For enrichment design – for the comparison between the study arms, 
 For stratified design and subgroup analyses – for the biomarker by treatment 
interaction test 
For studies where no hypothesis was tested, the rank was based on drug activity: 
 Studies with at least 6 patients showing activity in ≥50% patients are given a rank of 
0.4, 
 Studies with at least 6 patients showing activity in <50%, but ≥30% patients are 
given a rank of 0.2, 
 Studies with up to 5 patients are given a rank of 0.2 if there is activity in the majority 
of patients. 
Table 5.4 Ranks for the strength of the findings supporting the biomarker 
Rank 
P ≤0.01 
favors 
biomarke
r positive/ 
treatmen
t 
(enrichm
ent) 
(0.01, 
0.05) 
favors 
biomarke
r positive/ 
treatmen
t 
(enrichm
ent) 
0.05, 0.2] 
favors 
biomarker 
positive/ 
treatment 
(enrichment) 
No hypothesis 
tested and 
≥50% activity 
(n>5) 
No hypothesis 
tested and 
≥30% activity 
(n>5), activity 
in majority 
(n≤5) 
NR, no 
hypothesis 
and activity in 
<30% (n>5), 
no activity in 
majority (n≤5) 
1 0.8 0.6 0.4 0.2 0 
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The process of assigning ranks is illustrated below in Table 5.5, which shows the example of 
a study supporting the use of zoledronic acid in hormone receptor positive BC. 
Table 5.5 Example of rank assignment - supportive study (Z-FAST) for hormone receptor positive breast cancer 
treatment with zoledronic acid 
Criterion Rank Reason 
1. Population 0 The study included postmenopausal women with early stage 
BC, while the proposed indication was for premenopausal 
women with early BC 
2. Design of 
biomarker 
evaluation 
0.8 Enrichment RCT including only women with hormone receptor 
positive early BC 
3. Primary outcome 0.4 The primary outcome was bone mineral density, which was 
considered a surrogate outcome 
4. Sample size 0.602 There were 602 patients with an available biomarker status in 
the study 
5. Findings 1 At the end of the trial the difference in bone mineral density 
between treatment and control was significant (p<0.0001) and 
favored treatment with zoledronic acid 
 
5.3.5.3 SUMMARY PLOTS 
Ranks given for individual items were plotted on a radial plot – one for each study. The 
explanation of the labels used in the plots is provided in Figure 5.1. Within each B-I-D 
combination, studies using the same procedure for biomarker evaluation are all plotted 
using the same colour. However, the same colour used in different B-I-D combinations 
does not indicate identical or similar tests. The only exception is grey, which indicates that 
biomarker evaluation was undertaken, but the assay used was NR. 
 
P     population 
D    design 
O    outcome 
S     sample size 
F     findings 
Figure 5.1 Radial plot labels 
An area of the polygon was also considered as a quantitative summary across the 
different criteria. It was however not utilised due to the following reasons: 
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 The scales for all dimensions (except sample size) are ordinal and the sizes of 
intervals between any two ranks are meaningless. Calculating an area of the 
polygon would, for example suggest that a randomised enrichment study is 0.2 less 
than a biomarker stratified RCT. 
 The dimensions illustrated in the plots are not comparable.  
 The areas are dependent on the order in which different dimensions are drawn. 
An example is shown in Figure 5.2, where non-zero ranks were assigned to only two 
dimensions. When these two dimensions are neighbouring, there is a non-zero 
area, however when they are separated by another dimension (where the rank is 
zero), the area becomes zero. 
 
Figure 5.2 Example where area is influenced by position of different dimensions on a radial plot 
5.4 FINDINGS 
Based on the EMA documents 159 studies were included (reported in Appendix 12). Some 
studies were used more than once to support different B-I-D combinations: 
 Non-overlapping subgroups of patients from Heinrich 2008 were used to support 
two B-I-D combinations – one with a positive recommendation194 and one with a 
negative one200 
 Data from the same patients in BOLERO-2 and Baselga 2009 were used to support 
two licensed B-I-D combinations that included the same drug and indication, but 
a different biomarker.228 
The median number of studies per B-I-D combination was 2.5 (range zero to 19). The data 
for efficacy biomarkers included in B-I-D combinations without an orphan designation are 
presented in Figure 5.3 and in Figure 5.5 for B-I-D combinations with an orphan 
designation.  
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For B-I-D combinations where there was no orphan designation the total number of 
studies ranged from one to six. The number of main studies was:  
 one for 17,  
 two for 11 and  
 three for five B-I-D combinations.  
The number of supportive studies varied from one to five, as shown in Figure 5.3. In three 
cases the status of the studies (as main or supportive) was NR.  
The total number of studies for B-I-D combinations containing orphan drugs ranged from 
zero to 19. For these B-I-D combinations the number of main studies was: 
 one in two cases, 
 two in three cases, and 
 three in one case. 
The number of supportive studies varied from one to 13. For four B-I-D combinations the 
study status as main or supportive was NR and for one B-I-D combination there were no 
studies. 
For biomarkers predicting safety (four B-I-D combinations) there was only one study 
undertaken to support one B-I-D combination. In the remaining three cases the biomarker 
was based on the understanding of the drug metabolism.  
For all studies supporting each B-I-D combination radial plots were constructed and these 
are reported in Appendix 13  
Application of the seven criteria to the EMA dataset is discussed below and then the 
evidence supporting groups of B-I-D combinations is discussed. 
5.4.1 APPLICATION OF CRITERIA 
5.4.1.1 POPULATION 
As shown in Table 5.6, the population in studies was mostly either in agreement with, or 
covered a subgroup or wider group than the drug indication. In some cases where the 
study population was a subgroup of that identified by the indication, different studies 
supporting one B-I-D combination collectively covered the entire indication. 
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Table 5.6 Number of studies evaluating the predictive biomarker in different study populations relative to the 
indication 
B-I-D combinations 
Population in 
agreement with 
indication 
Subgroup or 
wider group Different or NR Total 
all 55 (35%) 92 (57%) 14 (9%) 161 
efficacy non-
orphan  
50 (49%) 40 (39%) 12 (12%) 102 
efficacy orphan  4 (7%) 52 (90%) 2 (3%) 58 
safety  1 (100%) 0 0 1 
 
The situation when the study participants were only a subgroup of the patients identified 
by the indication was more common in B-I-D combinations including a drug with an 
orphan designation. Only three studies of the 58 supporting orphan drugs included a 
patient group representative of the entire indication. This may be due to a large number 
of these studies being case reports or case series. 
There were also some cases where the studies did not include a patient group in 
agreement with the drug indication, for example: 
 one supportive study for two B-I-D combinations (Baselga 2009) – the indication 
was for previously treated progressive or recurrent BC, while the study included 
only patients with an untreated primary tumour,228 
 three supportive studies for a refused B-I-D combination, in which case the 
indication was the treatment of BC in premenopausal women, while the studies 
included postmenopausal women.211 
5.4.1.2 SAMPLE SIZE 
The median number of patients included in all studies supporting B-I-D combinations was 
88 (range 1 to 1956) and for main studies the median was 274 (range 6 to 1803). Further 
details of median patient numbers in identified studies for different study types and types 
of biomarkers are reported in Table 5.7. As expected, the numbers were much smaller for 
B-I-D combinations containing a drug with an orphan designation than for those without 
an orphan designation. Figure 5.4 shows patient numbers supporting each efficacy B-I-D 
combination without an orphan designation and data for B-I-D combinations including a 
drug with an orphan designation are presented in Figure 5.6. For safety biomarkers there 
was only one study which included 1956 patients. 
 
 
 
Figure 5.3 Number of studies supporting non – orphan B-I-D combinations with a biomarker predicting treatment efficacy 
 
 
*number of patients NR for one main study; ** number of patients NR for two main studies; *** number of patients NR for one supportive study; **** number of patients NR for two supportive studies;  
Figure 5.4 Number of patients in studies supporting non – orphan B-I-D combinations with a biomarker predicting treatment efficacy 
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Table 5.7 Median (range) number of patients within study types supporting B-I-D combinations 
B-I-D combinations main studies supportive studies all studies* 
all 274 (6, 1803) 61.5 (1, 1065) 88 (1, 1956) 
efficacy non-
orphan  
364 (22, 1803) 151 (11, 1065) 233 (11, 1803) 
efficacy orphan  52 (6, 167) 1 (1, 192) 7 (1, 694) 
safety  0 0 1956** 
*also include studies with an unclear status; ** there was only one study with unclear status; studies where patient 
numbers were NR were not included in the calculation;  
medians for all studies of given type supporting a B-I-D combination; if there were no studies of a given type, the 
B-I-D combination was not included in the combination 
 
 
*One known study and at least one other study 
Figure 5.5 Number of studies supporting orphan B-I-D combinations with a biomarker predicting treatment 
efficacy 
5.4.1.3 STUDY DESIGN 
The identified study designs are summarised in Table 5.8. There was only one biomarker 
strategy design study. The design with the highest frequency in this dataset was 
enrichment (28%). This was followed by non-RCT studies (27%), which mostly included 
single-arm studies either including only patients who were biomarker positive, or 
irrespective of biomarker status. 25% of the identified studies evaluated the biomarker in a 
subgroup analysis of an RCT: 5% in a prospective, 10% in a retrospective and 10% in a 
cross-sectional one. There was a large number of case series and case studies (17%). 
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There was also one literature review and three studies where the design of the biomarker 
evaluation could not be identified.  
 
Figure 5.6 Number of patients in studies supporting orphan B-I-D combinations with a biomarker predicting 
treatment efficacy 
Table 5.8 Number of studies evaluating the predictive biomarker in each design patients within study types 
supporting B-I-D combinations 
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* includes one literature review and three studies where the design of biomarker evaluation was unclear 
For drugs without an orphan designation where the biomarker was predictive of efficacy 
the most frequent study design was enrichment (38%). Subgroup analyses of RCTs 
comprised 40% of all studies in this group, with retrospective and cross-sectional being the 
most common. Non-RCT studies comprised 19% of all studies. 
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For drugs with an orphan designation case studies and case series comprised 48% of all 
studies. The remaining designs were non-RCT studies (41%) and enrichment trials (10%).  
For the biomarkers predicting safety there was only one biomarker strategy trial identified. 
This trial was a variant where the biomarker positive patients (more likely to experience an 
adverse event) were excluded from the biomarker strategy arm after randomisation.29  
5.4.1.4 PRIMARY OUTCOME 
As shown in Table 5.9, the primary outcome was a surrogate in 45% of studies. It was NR or 
not defined in 30% of studies, often reflecting the observational character of these studies. 
Objective clinically relevant outcomes were assessed in 7% of studies and other clinically 
relevant in 17% of studies. 
Table 5.9 Number of studies using different types of primary outcome within study types supporting B-I-D 
combinations 
B-I-D combinations 
objective 
clinically 
relevant 
other 
clinically 
relevant surrogate NR/ none Total 
all 11 (7%) 28 (17%) 73 (45%) 49 (30%) 161 
efficacy non-
orphan  
9 (9%) 26 (25%) 60 (59%) 7 (7%) 102 
efficacy orphan  2 (3%) 1 (2%) 13 (22%) 42 (72%) 58 
safety  0 1 (100%) 0 0 1 
 
As expected, the study outcome was generally dependent on the indication.  
A primary outcome was available for 95 out of the 102 studies that supported B-I-D 
combinations with a non-orphan drug and a biomarker predicting efficacy. 55 of the 95 
studies were carried out in a cancer indication and these assessed: 
 overall survival in nine studies, 
 progression free survival in 26 studies, 
 tumour response in 22 studies. 
There were 38 studies with an available primary outcome supporting authorised B-I-D 
combinations for HCV and HIV drugs. In this group all studies measured a primary 
outcome related to levels of the virus in blood. Although this outcome possibly does not 
reflect the disease mortality or morbidity, it would be difficult to measure a more relevant 
outcome within a population of patients suffering from a chronic condition. 
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For B-I-D combinations including drugs with an orphan designation data on a primary 
outcome were available for 16 of the 58 studies. 13 of these were undertaken in cancer 
and these measured:  
 overall survival in two studies,  
 progression free survival in one studies, 
 tumour response in 10 studies. 
In three studies investigating a drug for cystic fibrosis, the primary outcome was volume 
exhaled during the first second of a forced expiratory manoeuver (FEV1). Measurement of 
this surrogate outcome may again be at least partly due to the chronic character of the 
disease. 
In one case of a study supporting a B-I-D combination with a biomarker predicting 
treatment safety, the occurrence of a hypersensitivity reaction (measured by patch test) 
was the primary outcome. 
The variation in the primary outcomes assessed partially reflects the inclusion of phase III 
studies and those of earlier phases. It may also be associated with the difficulties in 
measuring more robust outcomes, such as overall survival in cases where the drug 
treatment may be followed by another therapy. 
5.4.1.5 FINDINGS 
The strength of findings is shown in Table 5.10. 50 (26%) of the studies provided evidence 
supporting the biomarker hypothesis and of these: 
 39 (19% of all 161 studies) had highly significant results (p ≤ 0.01), 
 8 (5% of all 161 studies) had significant 0.01, 0.05]), 
 3 (2% of all 161 studies) indicated a trend in support of the biomarker hypothesis (p 
0.05, 0.2]). 
In 55 studies evidence of drug activity in biomarker positive patients was shown and it was 
considered: 
 strong in 27 (17% of all 161 studies), and 
 weak in 28 (17% of all 161 studies). 
In 56 studies (35%) it was considered the results did not provide sufficient support to the 
biomarker hypothesis, treatment activity in biomarker positive patients, or were NR. 
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Table 5.10 Findings of studies evaluating the predictive biomarker in each design patients within study types 
supporting B-I-D combinations 
B-I-D 
combinations 
Hypothesis tested No hypothesis; activity 
NR, p>0.2, 
activity 
<30% 
(n>5) 
<50% 
(n≤5) Total 
highly 
significant 
P ≤0.01 
significant 
0.01, 
0.05) 
trend 
0.05, 
0.2)  
strong 
≥50% 
(n>5) 
weak 
≥30% 
(n>5) 
≥50% (n≤5) 
all  39 (19%) 8 (5%) 3 (2%) 27 (17%) 28 (17%) 56 (35%) 161 
efficacy non-
orphan  
33 (32%) 8 (8%) 2 (2%) 12 (12%) 3 (3%) 44 (43%) 102 
efficacy 
orphan  
5 (9%) 0 1 (2%) 15 (26%) 25 (43%) 12 (21%) 58 
safety 1 (100%) 0 0 0 0 0 1 
 
For B-I-D combinations with a non-orphan drug and a biomarker predicting efficacy of the 
102 studies:  
 32% had highly significant results of a hypothesis test (p≤0.01), 
 8% had significant results of a hypothesis test ( 0.01, 0.05]), 
 2% indicated a positive trend based on of a hypothesis test  (0.01, 0.05]), 
 12% showed strong evidence of activity, 
 3% showed weak evidence of activity, and 
 43% did not provide evidence in support of the biomarker.  
For B-I-D combinations with an orphan drug few of the 58 studies provided evidence 
based on a hypothesis test – 9% had highly significant results (p ≤ 0.01) and 2% showed a 
trend supporting the biomarker 0.01, 0.05]). The majority of the studies provided 
evidence of drug activity in biomarker positive patients: 26% strong and 43% weak. In 21% 
the results did not provide evidence in support of the biomarker.  
There was one study investigating a safety biomarker and it provided highly significant 
results (p ≤ 0.01).  
5.4.1.6 REPLICATION OF RESULTS 
There were five cases of B-I-D combinations where only a single study was reported that 
evaluated the biomarker (shown in Appendix 13). All of these were for efficacy 
biomarkers in non-orphan B-I-D combinations. All of these were also authorised.  
There may however be additional cases where, although multiple studies were included, 
these were, for example, not conducted in similar patient populations. 
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5.4.1.7 CONSISTENCY OF THE BIOMARKER ASSAY USED 
Only one type of biomarker assay was used in all studies supporting a B-I-D combination in 
15 cases. In five of these the B-I-D combination was supported by a single study. In the 
evidence supporting eight B-I-D combinations at least two different types of biomarker 
assay were used. For the remaining cases it was not possible to tell, as the biomarker assay 
was NR for some or all of the studies supporting a B-I-D combination. There were no 
noticeable differences between the types of biomarker, orphan and non-orphan drugs 
and authorised and refused B-I-D combinations. 
When the biomarker was quantitative (for example EGFR expression), the threshold was 
often NR. No study reported the rationale for the choice of the threshold. 
5.4.2 EVIDENCE SUPPORTING B-I-D COMBINATIONS INCLUDING BIOMARKERS PREDICTING EFFICACY 
WITHOUT AN ORPHAN DESIGNATION 
There were 102 studies supporting 36 B-I-D combinations where the biomarker was 
predicting treatment efficacy and the drug did not have an orphan designation. Of 
these, 95 studies were identified in the documents for 34 authorised B-I-D combinations 
and seven for two refused ones. These are shown in Figure 5.7 and discussed in more 
detail below. 
5.4.2.1 AUTHORISED DRUGS 
The enrichment design was the most common in this dataset. The number of patients 
included in these trials varied from 165 to 1099. There were also a number of subgroup 
analyses: prospective (sample size ranging from 57 to 437), retrospective (sample size 
ranging from 71 to 844) and cross-sectional (sample size ranging from 11 to 187). There 
were also a number of non-randomised (usually single-arm) studies with the number of 
patients with an available biomarker status ranging from 13 to 400.  
The identified evidence is discussed below based on the best study design (according to 
the ranking introduced in Table 5.2) identified for each B-I-D combination. 
ENRICHMENT DESIGN 
The enrichment design was used in 18 of the 34 B-I-D combinations and in 16 of these it 
was part of the group of main studies. In the two cases where it was not a main study: 
 
 
 
 
*EGFR(M)NE – a pooled analysis was not included here, as it includes some of the patients reported in individual studies; ** data not available on patient numbers for studies: 
VRHAm – one study of unclear design; VRHAt – two studies of unclear design; VRHF – one cross-sectional subgroup RCT analysis; VRHTe – one prospective subgroup analysis; 
VRHTr – two cross-sectional subgroup RCT analyses; *** only data pooled across multiple studies was available: ERBT – across 3 studies; VRHD – three studies (including one non-
RCT); VRHEn – two studies; VRHNel – two studies 
Figure 5.7 Numbers of patients supporting non – orphan B-I-D combinations with a biomarker predicting treatment efficacy by study design 
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 the status of studies (as main or supportive) was NR (HER2 expression – BC - 
trastuzumab),102 
 the main study was a single arm study that was supported by an ongoing 
enrichment trial and another single arm study (ALK mutation – NSCLC - 
crizotinib).171  
Examples of an enrichment design visualised using radial plots is shown in Figure 5.8.  
 
Figure 5.8 Examples of an enrichment design supporting B-I-D combinations 
Where the best study had an enrichment design (18 B-I-D combinations) it was usually 
undertaken in a population representative of that in the indication (11 cases) or at least 
part of the population (6 cases). The population characteristics were NR in one case. The 
primary outcome was PFS in eight, OS in two and a surrogate outcome in eight cases. In 
16 of the B-I-D combinations where an enrichment RCT was the best design the results 
were highly significant (p ≤ 0.01) and these were also supported by other studies: 
 at least one more enrichment trial (sometimes with less significant findings) and/or 
single arm study102,167,175-177,182,185,186,228-230 in 12 cases,  
 at least one single-arm study 
 one enrichment trial, two prospective subgroup analyses, two single arm studies 
and a literature review180 in one case,  
 a retrospective RCT subgroup analysis and two single arm studies231 in one case,  
 a retrospective RCT subgroup analysis228 in one case, 
 in one case there were four enrichment RCTs and two cross-sectional RCT 
subgroup analyses.208 
 no additional trials in two cases.187,190 
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The additional studies often showed weaker evidence in support of the predictive 
biomarker or treatment use in the biomarker positive patients. 
For two B-I-D combinations the results of the enrichment trial they were not significant (p > 
0.2). These were supported by either single-arm studies (which also showed no evidence 
of activity)167 or an enrichment trial (with non-significant results) and single-arm studies, 
some of which showed activity in biomarker positives.183 
PROSPECTIVE SUBGROUP ANALYSIS 
For three B-I-D combinations the best study design was a prospective subgroup analysis 
and in all of these it was identified as one of the main studies. An example of this design 
visualised using radial plots is shown in Figure 5.9. The population in these studies was 
representative of at least a subgroup of that identified by the drug indication. In two 
cases the findings of the subgroup analysis were significant for overall survival(p ≥ 
0.05)179,181 and in one these were NR for a surrogate primary outcome.207 In all three B-I-D 
combinations there were additional studies included and these were: a single arm 
study,179 a retrospective subgroup analysis,181 and a cross-sectional subgroup analysis.207 
 
Figure 5.9 Example of a prospective subgroup analysis used to support a B-I-D combination 
RETROSPECTIVE SUBGROUP ANALYSIS 
In six B-I-D combinations cases a retrospective subgroup analysis (example of visualisation 
provided in Figure 5.10) was the best study design. In five of these it was labelled as a 
main study and in one the study status was not clear.169 For four of these B-I-D 
combinations the population in the subgroup analysis was representative of that in the 
drug indication,159,192,232,233 for one it was a subgroup169 and in one it was not clearly 
reported.205 
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Figure 5.10 Example of a retrospective subgroup analysis used as a main study to support a B-I-D combination 
In three cases there was a single retrospective subgroup analysis supporting the B-I-D 
combination. It one case each the for the subgroup analyses the findings were: highly 
significant (p≤0.01) for PFS,192 NR for PFS,159 neither the outcome, nor the findings were 
reported.205 
In the remaining three B-I-D combinations in addition to a retrospective subgroup analysis 
supporting the biomarker, there were other studies: another retrospective subgroup 
analysis,169 two cross-sectional subgroup analyses203 and two studies of unreported 
design.198  
CROSS-SECTIONAL SUBGROUP ANALYSIS 
A cross-sectional subgroup analysis was the best design in six B-I-D combinations (an 
example is shown in Figure 5.11), all of which included viral resistance mutations used to 
predict lack of treatment efficacy in HIV. In most cases there were only studies of this 
design included: a single one in three199,234,235 and two in in two cases.204,236 In one case 
there was a study of unreported design in addition to the cross-sectional analysis.197 
These analyses generally provided evidence on only a subgroup of the relevant 
population, as they included only patients who did not respond to, or lost response to the 
treatment. They usually showed high prevalence of the resistance mutations in non-
responders (often above 50%). 
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Figure 5.11 Example of a cross-sectional subgroup analysis used as a main study to support a B-I-D combination 
SINGLE-ARM  
There were no cases in this dataset where a single-arm study (example shown in Figure 
5.12) was the best study design supporting a B-I-D combination. In only one case it was 
the only main study.171  
 
Figure 5.12 Example of a single-arm study used as a main study to support a B-I-D combination 
5.4.2.2 REFUSED DRUGS 
There were two cases where the B-I-D combination was given a negative 
recommendation. In both cases there was one main enrichment trial with significant210 or 
highly significant findings209 (as shown in Figure 5.13). These results were however not 
replicated in another study. In one case there were three additional enrichment studies 
that showed efficacy, however these were conducted in a different population 
(postmenopausal rather than premenopausal women).210 In the other case there was 
another enrichment study and a single arm study, which did not show significant efficacy 
and substantial activity respectively.209 
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Figure 5.13 Examples of main studies supporting refused B-I-D combinations without an orphan designation 
5.4.3 EVIDENCE SUPPORTING B-I-D COMBINATIONS INCLUDING BIOMARKERS PREDICTING EFFICACY 
WITH AN ORPHAN DESIGNATION 
There were 58 studies supporting 10 B-I-D combinations where the biomarker was 
predicting treatment efficacy and the drug had an orphan designation. Of these, 53 
studies were identified in the documents for 8 authorised B-I-D combinations and five for 
two refused ones. These are shown in Figure 5.14 and discussed in more detail below. 
5.4.3.1 AUTHORISED DRUGS 
In this part of the dataset again the best study design was an enrichment trial (with 
sample size ranging from 55 to 694). However lower-level evidence was more frequently 
used and this included mainly non-RCT studies (sample size ranging from 5 to 353), case 
reports and case series. 
ENRICHMENT 
In three cases the best study design supporting the B-I-D combination was an enrichment 
design. In one case two such trials were labelled as main studies and in the remaining two 
cases the status as main or supportive was not indicated. All of these included patients 
who were representative of a subgroup or a wider group compared to the population 
identified by the indication.  
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Figure 5.14 Numbers of patients supporting orphan B-I-D combinations with a biomarker predicting treatment 
efficacy by study design 
In all three cases an enrichment trial provided strong evidence in support of the efficacy 
of the drug in biomarker positive patients (p≤0.01), as illustrated in Figure 5.15. The primary 
outcomes measured were overall survival191 or a surrogate outcome.165,196 These were 
supported by:  
 another enrichment study with less significant findings,191  
 another enrichment study with less significant findings and a single arm study,165  
 single arm studies.196 
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Figure 5.15 Examples of enrichment RCTs 
NON-RANDOMISED STUDIES 
In four cases the best design was a non-randomised study (mainly single-arm) with the 
biomarker forming part of the design (examples are shown in Figure 5.16). In three of these 
at least one non-randomised study was labelled as main and in one its status as main or 
supportive was not. Where reported, the primary outcome was tumour response.  
The number of non-randomised studies supporting a B-I-D combination varied from one to 
five. In three cases at least one showed drug activity in >50%170,184,194 and in one in >30% of 
patients.195  
For two B-I-D combinations only non-randomised studies were found.170,195 In the remaining 
two cases these were supported by either 13194 or 14184 case reports and series. 
 
Figure 5.16 Non-randomised studies 
CASE REPORTS AND SERIES 
Case reports and series (examples shown in Figure 5.17), usually showing activity, were 
used to support more robust study designs, however these were never used on their own. 
These were often judged to be only partly representative of the patients identified by the 
drug indication.  
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Figure 5.17 Examples of case series and reports used to support B-I-D combinations with an orphan designation 
MECHANISM OF DRUG ACTION 
In one case (LPL deficiency) the biomarker was based on the mechanism of drug action 
only and no studies investigating the biomarker were reported.214 
5.4.3.2 REFUSED DRUGS 
There were two B-I-D combinations with a negative recommendation. In both cases the 
best study design was a non-randomised study (an example shown below in Figure 5.18). 
These generally included a subset of patients identified by the proposed drug indication. 
All the non-randomised studies measured tumour response as their primary outcome and 
did not demonstrate large drug activity (<30% in all of these). In one case there was a 
single non-randomised study and data from 30 patients from other, unspecified studies.200 
In the other case three non-randomised studies were reported.164 
 
Figure 5.18 Radial plot characteristic of refused B-I-D combinations with an orphan designation 
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5.4.4 EVIDENCE SUPPORTING B-I-D COMBINATIONS INCLUDING BIOMARKERS PREDICTING DRUG 
SAFETY 
There were four B-I-D combinations where the biomarker was predictive of treatment 
toxicity (all received a positive recommendation). For three of these there were no studies 
provided that evaluated the biomarker and the inclusion of the biomarker in the B-I-D 
combination was based on the mechanism of drug action.174,178,193 In one case there was 
one study reported (it was not clear whether it was a main study)34-36 – the PREDICT-1 trial, 
which evaluated HLAB*5701 in a biomarker-strategy design.29 The patients in this trial were 
representative of those identified by the indication. The primary outcome was occurrence 
of a hypersensitivity reaction and a highly significant result was shown (p≤0.01). The radial 
plot for this trial is shown below in Figure 5.19. 
 
Figure 5.19 Radial plot for the PREDICT-1 trial 
5.5 DISCUSSION 
This chapter investigated the evidence supporting the inclusion of predictive biomarkers in 
the indication or contraindication of drugs considered by the EMA. 159 studies were 
analysed in an attempt to identify standards of evidence sufficient for inclusion of a 
predictive biomarker in a drug licence. Radial plots were used to summarise the criteria 
selected for this chapter.  
The findings of this chapter did not provide a clear picture of the evidence standard 
required in practice by the EMA. There were cases where similar levels of evidence 
supported B-I-D combinations with a positive and negative recommendation. This 
suggests the evidence may be considered within a given context, rather than required to 
meet a certain standard. This was also identified as an important factor in Chapter 4. 
There were however a number of issues that were identified within the evidence base.  
The common use of enrichment design can be potentially problematic. Although it 
provides information on the efficacy of the drug within a patient population identified by 
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the biomarker, it does not evaluate the biomarker itself. Even if significant efficacy is 
shown, it is possible a wider population of patients could benefit. This was shown in the 
example of vemurafenib, which was originally developed to target melanoma positive for 
the BRAF V600E mutation. In the course of clinical research it emerged that the assay used 
to evaluate this biomarker and include patients into trials was classifying patients with 
other V600 mutations as positive. As these patients clearly benefited from treatment with 
vemurafenib, they were also included in the final indication.176 
In two cases the biomarker predicted lack of efficacy (KRAS mutation) and was identified 
after an initial marketing authorisation. This biomarker was investigated only in 
retrospective subgroup analyses, some of which included only a relatively small subgroup 
of patients from the original study (for example 33% in the CO.17237,238 and 23% in the 
EPIC169,239 study). Although due to the relatively late stage of the drug cycle when this 
biomarker was identified, it was potentially difficult to investigate it in a more robust 
design. And in spite of the limitations in the evidence base, it appears to have become 
important in clinical practice. 
A cross-sectional subgroup analysis was only observed in HIV studies. In this design at the 
end of the trial plasma HIV RNA samples from patients who had no or lost response to the 
treatment were evaluated for presence of viral mutations. This approach appears to be 
largely justified, as viral resistance mutations may be undetectable at baseline or develop 
later in response to the treatment.74,75 A retrospective subgroup analysis at the end of the 
trial may also not be possible, as in patients responding to treatment the amount of the 
HIV virus in their blood falls below the level of detection.240 However, as the studies cannot 
use controls (samples from patients who responded to the treatment), there is a danger 
that this may result in a large number of chance findings. 
For orphan drugs, as expected, the population studied was smaller than for non-orphan 
drugs. It was however clear that in some cases patient numbers were relatively large and 
single-arm studies included up to 353 patients. It appears that in such cases a randomised 
trial would have been feasible and would have provided more robust data. 
There were also four B-I-D combinations where the inclusion of the biomarker in the 
indication (one B-I-D combination with an efficacy biomarker) or contraindication (three 
B-I-D combinations with a safety biomarker) was based on the understanding of the 
mechanism of drug action or drug metabolism. Although clinical trials of biomarkers 
predicting adverse events can be challenging, the PREDICT-1 trial29 demonstrates that it is 
possible in at least some cases.  
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All HIV studies were assigned a low score for the outcome assessed, which generally was 
based on plasma HIV RNA levels at a certain time point. However, as HIV is a chronic 
condition and on development of resistance to one treatment regimen a new one is 
initiated, it would be very difficult (if not impossible) to measure an outcome more directly 
related to morbidity or mortality. The same may also apply to certain cancer settings, 
where the treatment is not curative and a further line of therapy is given after 
development of tumour resistance.  
This review attempted to explore the standards of evidence supporting EMA 
recommendations, however it was on occasion limited by the lack of reporting of 
important data in the EMA documentation. An attempt was made to identify published 
papers and other information sources (such as trial reports published on the drug 
manufacturer’s website) that would supplement the information provided within EMA 
documents. This was however not always possible as there were no additional sources 
found or based on the very limited information provided by the EMA the trial could not be 
unambiguously identified.  
Poor reporting was especially important with regard to the information on the biomarker 
assay. Within the EMA documentation there was usually not enough detail about the 
biomarker assay used and sample collection. This information was more frequently 
reported in published papers, however important details were often still missing.  
The analysis was also limited by the fact that data collection and analysis was carried out 
by one reviewer only.  
5.6 CONCLUSIONS 
For biomarkers predicting treatment efficacy the evidence standards were not clear. In 
two cases of negative recommendations for non-orphan drugs, it appears that the 
promising results of a single study have not been replicated in another study. This however 
was also the case for some of the B-I-D combinations which received a positive 
recommendation. For drugs with an orphan designation there was little, if any, clear 
difference between the evidence base supporting the positive and negative 
recommendations.  
Based on this chapter it appears that for biomarkers predicting treatment safety the study 
evidence requirements are minimal, as in three of the four B-I-D combinations the 
biomarker predicting safety was based on the understanding of the drug action and/or 
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metabolism. However, interestingly, this group also included the only biomarker strategy 
design within the entire dataset. 
The analysis identified poor reporting, especially of information related to the biomarker 
assay and biological sample collection, as an important issue limiting the evaluation of 
the studies and implementation of their findings.  
These findings possibly highlight the importance of the context in which the B-I-D 
combinations were assessed. However, there is also need for more consistent 
methodological and evidence standards to ensure optimal patient treatment. 
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Abstract 
Background: To ensure that biomarkers used in clinical practice are truly predictive, 
appropriate study designs need to be used. Chapter 5 investigated what evidence 
supported licensing of biomarker-indication-drug combinations in practice. 
Aims: The main aim of this chapter was to assess the validity and any limitations of the 
framework proposed in Tajik 201378 for study designs for evaluation of predictive 
biomarkers by application of study data from Chapter 5. Based on the discrepancies 
between the framework and the existing data, the framework was to be modified. 
Methods: The systematic review that provided a framework for study designs for stratified 
medicine (Tajik 201378) was critically appraised. The framework proposed in this review 
was applied to the data from Chapter 5.  Based on the comparison, the framework was 
modified. 
Findings: The framework in Tajik 201378 was modified based on the dataset identified in 
Chapter 5 to include seven major study designs (case report, case series, single-arm, 
enrichment, randomise-all and biomarker-strategy), four of which were further subdivided 
into subclasses of design. Six additional questions that could be addressed by studies were 
also identified. Of the 152 studies that had sufficient data to identify their design, 86 
matched those proposed in Tajik 2013.78  For published papers authors’ conclusions 
seemed to be mainly addressing questions possible to answer based on the study design, 
although there were a number of studies where conclusions beyond these appeared to 
be made.  The study labels did not often reflect the biomarker aspect of the study. 
Conclusions: The framework in Tajik 201378 needed to be modified to better reflect the 
study designs found in practice. This suggests there might be a substantial discrepancy 
between what designs are proposed and evaluated in the methodological literature and 
those identified in the dataset supporting EMA recommendations. There may be a need 
to apply more robust methodology to studies carried out in practice, as well as develop 
the methodology for certain cases, for example investigation of HIV resistance mutations. 
There is also a need for more transparent labelling of biomarker-based studies.  
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6.1 BACKGROUND 
The use of predictive biomarkers can offer substantial improvement to patient care, by 
identifying patients more likely to benefit from a particular treatment.9,241 There have been 
some advancements in the field, however biomarker research has also seen many 
failures.242 To ensure that biomarkers used in clinical practice truly offer patient benefit, 
appropriate study designs need to be used for their evaluation prior to implementation in 
clinical practice.21,49  
Chapter 5 investigated what evidence supported licensing of biomarker-indication-drug 
(B-I-D) combinations in practice. Study design labels were given based on a subjective 
selection of published papers and theoretical concerns in one case (introducing the 
name “cross-sectional subgroup analysis” of an RCT). However it was still not known how 
this compared to the entirety of the methodological literature on evaluation of predictive 
biomarkers.  
A systematic review of trials methodology for stratified medicine was identified (Tajik 
201378). This review proposed a framework which matched different study designs to the 
questions that can be answered within these. This framework was therefore used to 
compare the methodological literature with the research practice identified in Chapter 5. 
6.2 AIMS 
The aim of this chapter was to assess the validity and any limitations of the framework 
proposed in Tajik 201378 for study designs for evaluation of predictive biomarkers by 
application to study data from Chapter 5. This was undertaken to explore how the 
methodological literature matched the studies carried out in practice. Based on any 
discrepancies, the framework was to be modified to better reflect methodology used in 
practice. It was considered how the authors’ conclusions matched the questions that the 
design of their study could potentially address. It was also investigated how each design 
was described in study publications.  
6.3 METHODS 
The identified systematic review (Tajik 201378) was critically appraised using criteria based 
on the AMSTAR tool243 that were adapted to a methodological review context (reported 
in section 6.4.1). Some limitations to the methodology were identified. It was however 
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considered that the framework proposed by this review may be relatively complete with 
regards to study designs proposed in the theoretical literature.  
Therefore the framework proposed by Tajik 201378 was applied to the evidence collected 
in the review of evidence supporting EMA recommendations (Chapter 5). 
6.3.1 APPLYING THE FRAMEWORK IN TAJIK 201378 TO THE EMA DATASET 
The Tajik 201378 systematic review proposed a framework identifying the questions that 
can be addressed by each identified study design (reproduced below in Table 6.2). This 
framework was applied to the evidence supporting EMA recommendations identified in 
Chapter 5.  
6.3.1.1 STUDY DESIGNS AND QUESTIONS ADDRESSED 
For each study identified in Chapter 5 the design was: 
 assigned according to the framework in Table 6.2 if the design matched the 
proposed categories, 
 based on Chapter 5 if the design did not fall under any of the proposed 
categories. 
In addition,  for the category of “randomise-all” study designs a further description was 
retained (for example “prospective subgroup analysis”), as based on the findings of 
Chapter 5 there was variation within this category with possible impact on the information 
provided by different subtypes of this study design. Therefore it was considered that this 
category of study design might need refining.  
Study designs that did not match the framework in Tajik 201378 were added to the 
framework and questions answered by these designs were considered. This was partially 
based on consideration of study authors’ conclusions (explained in more detail in section 
6.3.1.2 below) and partially on theoretical concerns. 
For each study the questions addressed by the design were recorded. This was also 
summarised for each B-I-D combination and questions addressed by the main studies 
were highlighted.  
Where relevant, the biomarker type, drug orphan status and classification of studies by 
the EMA as main (forming the major part of the evidence supporting a drug indication) or 
supportive were noted. 
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6.3.1.2 CONCLUSION AND STUDY LABEL REPORTING IN IDENTIFIED PUBLICATIONS 
Where there were publications available matched to the identified study, the conclusions 
from the most recent relevant publication were extracted. It was then attempted to class 
these conclusions as commenting on questions 1-8 in Table 6.2 using the criteria in Table 
6.1. 
Table 6.1 Criteria used to class conclusions from identified publications 
Question Criteria 
1-3 For each population (respectively: biomarker positive, biomarker negative 
and overall) words such as “effectiveness” or “efficacy” were used in the 
conclusions or the clinical effects were stated and no attempt was made to 
label the results as, for example, exploratory or suggestive. 
4-5 For each population (respectively: biomarker positive, biomarker negative 
and overall) words such as “effectiveness” or “efficacy” were used in the 
conclusions or the clinical effects were stated and no attempt was made to 
label the results as, for example, exploratory or suggestive. 
6 Biomarker effects were compared between experimental and control study 
group, an interaction test was mentioned, or conclusions on whether the 
biomarker was predictive were made. 
7-8 Biomarker-based strategy was commented on compared to different 
treatments (control and experimental respectively) within the overall patient 
population. 
 
If there were conclusions relevant to the predictive biomarker, that were not described in 
questions 1-8, these were considered for addition to the list of questions addressed by the 
different designs. If the question list was expanded, the new question was given a label 
(A1, A2 and so on) and it was considered whether any of the study designs addressed this 
question. The criteria for classifying study conclusions as addressing any of the new 
questions (A1, A2 and so on) were defined. 
If available, the study design label reported in the matched publication was recorded 
and compared to that proposed by Tajik 201378 or, if there was none, Chapter 5. 
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Table 6.2 List of effects that can be assessed and questions that can be answered by the trials of each design 
category. Reproduced from the Tajik 201378 systematic review 
Questions trial can answer 
Single
-arm* Enrichment 
Randomise
-all** 
Biomarker-strategy 
With 
biomarker 
measurem
ent in the 
control arm 
Without 
biomarker 
measurem
ent in the 
control arm 
With 
treatment 
randomisatio
n in the 
control arm 
Treatment effects       
Q1. How does the 
experimental treatment 
compare with the control 
treatment in biomarker-
positives? 
     indirect  
Q2. How does the 
experimental treatment 
compare with the control 
treatment in biomarker-
negatives? 
      
Q3. How does the 
experimental treatment 
compare with the control 
treatment in overall study 
population? 
      
Biomarker effects       
Q4. Is the biomarker status 
associated with the 
outcome in the standard of 
care group? (Is the 
biomarker prognostic?) 
     indirect  
Q5. Is the biomarker status 
associated with the 
outcome in the 
experimental treatment 
group? 
      
Biomarker by treatment 
effect 
      
Q6. Is the biomarker status 
associated with a benefit 
of experimental treatment? 
(Is the biomarker is 
predictive?) 
      
Strategy effects       
Q7. How does the 
biomarker-based treatment 
strategy compare with the 
control treatment in the 
overall study population? 
   indirect    
Q8. How does the 
biomarker-based treatment 
strategy compare with the 
experimental treatment in 
the overall study 
population? 
   indirect    
* this includes biomarker positive and negative patients and the label will be modified in the following tables to 
reflect this; ** this would include the stratified design, prospective-retrospective framework and all types of 
subgroup analysis described in Chapter 1 
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6.4 FINDINGS 
6.4.1 CRITICAL APPRAISAL OF TAJIK 201378 SYSTEMATIC REVIEW USING THE AMSTAR TOOL 
The detailed critical appraisal of this review is reported in Appendix 14.  
There were some issues in this systematic review, suggesting it could have potentially 
missed some of the existing trial designs. There were also some doubts to whether the 
proposed framework truly reflects the information that can be obtained from each trial 
design. It was however considered that the proposed framework might be sufficiently 
complete to be used within this thesis for the comparison of the most commonly discussed 
study methodologies with studies carried out in practice. 
6.4.2 IDENTIFIED STUDY DESIGNS 
The collected data for all studies and matched publications are reported in Appendix 15. 
In total there were 159 studies in the dataset, however the design with respect to 
biomarker evaluation could be identified for 152 of these. The design of 86 studies 
matched the categories in the framework proposed in Tajik 201378. These studies were: 
 seven single-arm studies including biomarker positive and negative patients, 
 41 enrichment studies, 
 37 randomise-all studies, 
 one biomarker-strategy study with biomarker measurement in the control arm (this 
was however modified to exclude biomarker negative patients from the biomarker 
strategy arm) 
There were no biomarker-strategy trials without biomarker measurement in the control arm 
or with randomisation in the control arm. 
There were 66 primary studies for which the design did not match the framework 
proposed by Tajik 201378. These were: 
 21 case reports - detailed reports on individual patient(s) management; defined 
here as including five patients or less, 
 five case series - small observational study without a clear design; defined here as 
including more than 5 patients,  
 35 single arm studies including only biomarker positive patients – similar to the 
single arm study in Tajik 201378 with narrower inclusion criteria, 
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 one single arm study including only biomarker negative patients  – similar to the 
single arm study in Tajik 201378 with narrower inclusion criteria, 
 three non-randomised comparative studies including both biomarker positive and 
negative patients – studies that included patients of any biomarker status that 
were allocated to different treatments based on clinical considerations and 
therefore did not provide a robust comparison between different treatment 
options, 
 one enrichment study including biomarker negative patients only - similar to the 
enrichment study in Tajik 201378, however only biomarker negative patients (not 
expected to respond to treatment) were included. 
The identified study designs are summarised in Figure 6.1. 
 
Figure 6.1 Study designs in EMA dataset according to the expanded framework proposed in Tajik 201378  
Further, based on the questions that could be potentially answered by different designs 
and the strength of evidence the following sub-types of randomise-all study design were 
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 11 prospective subgroup analyses – the subgroup analysis based on the biomarker 
was planned in the study protocol and the biomarker was measured in the 
beginning of the trial, 
 11 retrospective subgroup analyses - after the conclusion of the trial a biomarker 
subgroup of interest was identified, the biomarker status was tested (using, for 
example, archival tumour samples) and a subgroup analysis was performed, 
 15 cross-sectional subgroup analyses - after the conclusion of the trial a subgroup 
of patients (either from one treatment arm only or from multiple treatment arms) 
was identified based on outcome (for example lack of response to treatment) and 
the biomarker (or a panel of biomarkers) was assessed in this group – the final 
information provided was the prevalence of the biomarker in the subgroup of 
patients. 
The cross-sectional subgroup analysis was identified only in studies investigating viral 
resistance mutations to predict lack of response to drugs for treatment of HIV infection, as 
discussed in Chapter 5. This disease setting may present a challenging situation, where a 
more robust trial design may be difficult to achieve. The virus with the resistance mutations 
may be either present at baseline in quantities below the limit of detection for the 
currently available tests, or develop later in response to the treatment.74,75 A retrospective 
subgroup analysis at the end of the trial may however not be possible, as in patients 
responding to treatment the amount of the HIV virus in their blood falls below the level of 
detection and therefore no mutations can be detected.240 This information may still be 
however useful for prediction of response to the treatment in future patients, as using the 
drug in the clinic may lead to the spread of the resistant virus in the patient 
population.244,245 
6.4.3 ADDITIONAL QUESTIONS IDENTIFIED 
As a result of expanding the list of study designs and analysis of the conclusions in 
identified papers, six additional questions were added (shown in Box 6.1). 
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Box 6.1 Additional questions identified in the analysis 
 
Where relevant, these new questions (A1-A6) were mapped onto the original study 
designs (reported in Tajik 201378) and those identified in this chapter.  
6.4.4 NEW PROPOSED FRAMEWORK 
Based on the newly identified designs and questions an expanded framework was 
proposed (shown in Table 6.3). The new questions (A1-A6) were grouped with the original 
questions (Q1-Q8) according to themes these addressed. 
For RCT study designs where treatment effects compared to a control group could be 
investigated, activity was considered irrelevant, as higher level evidence on efficacy was 
available. 
A list of all the questions included in the expanded framework is provided in Box 6.2. 
6.4.5 QUESTIONS ADDRESSED BY STUDIES IN THE ENTIRE DATASET 
For 156 of the 159 studies in the dataset sufficient information was available on the design 
to allow evaluation of which questions were addressed within this design based on the 
proposed framework. These included 99 studies supporting drugs without an orphan 
indication (53 main studies and 46 supportive and unclear studies) and 57 studies 
supporting drugs with an orphan indication (9 main studies and 48 supportive and unclear 
studies). The high number of supportive and unclear studies in the orphan category was 
mainly due to a large proportion of these being case reports. 
A1. Does the experimental treatment show activity in biomarker-positives? 
A2. Does the experimental treatment show activity in biomarker-negatives? 
A3. Does the experimental treatment show activity in biomarker-unknowns? 
A4. Does the experimental treatment show activity in overall study population? 
A5. How does the experimental treatment compare with the control treatment in 
biomarker-unknowns? 
A6. What is the prevalence of patients with a different biomarker status in patients 
not responding to treatment? 
 
 185 
 
Table 6.3 Expanded framework 
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Q1             i  
Q2               
A5               
Q3               
Q4             i  
Q5               
Q6               
Q7         i i     
Q8         i i     
A6               
w - weak evidence; i - indirect evidence; crossed out area indicates that for RCT study designs 
activity was considered irrelevant, as higher level evidence on efficacy was available 
 
When all 156 studies with known design were considered (details shown in Figure 6.2), the 
most frequently addressed questions were A1 and Q1 (respectively activity and 
effectiveness of the investigated drug in biomarker positive patients), both of which were 
addressed by over 60 of the 156 studies. However, effectiveness was addressed more 
frequently by main studies (69% of all studies addressing Q1 were classed as main), while 
activity was mainly within the scope of supportive and unclear studies (88% of studies 
addressing A1 were classed as supportive or unclear). Question A6 (biomarker prevalence 
in non-responders) was addressed by 38 studies, 25 (66%) of which were classed as main. 
                                                                
‡ Exact question depends on the type of patient(s) included in the case report 
§ Exact question depends on the type of patients included in the case series 
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Between 20 and 30 studies addressed questions Q2-Q8 and between 52% and 64% of 
these were classed as main. Question A2 (activity in biomarker negative) was addressed 
by 12 studies, all supportive or unclear. Question A3 (activity in biomarker unknown) was 
addressed by one and A4 (activity in all patients) by five supportive or unclear studies. 
Question A5 (effectiveness in biomarker unknown) was addressed by three main and one 
supportive study. 
Box 6.2 Questions included in the expanded framework  
Treatment activity 
A1. Does the experimental treatment show activity in biomarker-positives? 
A2. Does the experimental treatment show activity in biomarker-negatives? 
A3. Does the experimental treatment show activity in biomarker-unknowns? 
A4. Does the experimental treatment show activity in overall study population? 
Treatment effects 
Q1. How does the experimental treatment compare with the control treatment in 
biomarker-positives?78 
Q2. How does the experimental treatment compare with the control treatment in 
biomarker-negatives?78 
A5. How does the experimental treatment compare with the control treatment in 
biomarker-unknowns? 
Q3. How does the experimental treatment compare with the control treatment in overall 
study population?78 
Biomarker effects 
Q4. Is the biomarker status associated with the outcome in the standard of care group? (Is 
the biomarker prognostic?)78 
Q5. Is the biomarker status associated with the outcome in the experimental treatment 
group?78 
Biomarker by treatment effect 
Q6. Is the biomarker status associated with a benefit of experimental treatment? (Is the 
biomarker is predictive?)78 
Strategy effects 
Q7. How does the biomarker-based treatment strategy compare with the control 
treatment in the overall study population?78 
Q8. How does the biomarker-based treatment strategy compare with the experimental 
treatment in the overall study population?78 
Biomarker prevalence 
A6. What is the prevalence of patients with a different biomarker status in patients not 
responding to treatment? 
Italics indicate question form the original Tajik 201378 framework 
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Figure 6.2 Questions addressed in all studies 
When the 99 studies supporting drugs without an orphan designation were considered 
(shown in Figure 6.3), the most frequently addressed question was Q1 – drug effectiveness 
in biomarker positive patients (57 studies, 40 (70%) of which were classed as main). 
Question A6 (biomarker prevalence in non-responders) was addressed in 38 studies, 25 
(66%) of which were main studies. There were 22 or 23 studies that addressed each of the 
questions Q2-Q8 (61% and 66% of these were classed as main). Activity in biomarker 
positive patients (A1) was addressed by 17 studies, only one of which was classed as 
main. Question A5 (effectiveness in biomarker unknown) was addressed by 3 main and 
one supportive or unclear study. Question A4 (activity in all patients) was addressed by 
one supportive or unclear study. Question A5 (effectiveness in biomarker unknown) was 
addressed by three main and one supportive or unclear study. Question A3 (activity in 
biomarker unknown) was not addressed by any of the studies in this dataset. 
 
Figure 6.3 Questions addressed in studies supporting drugs without an orphan indication 
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When the 57 studies supporting drugs with an orphan designation were considered 
(shown in Figure 6.4), the most frequently addressed question was A1 (activity in 
biomarker positive patients) – in 50 studies (14% of which were classed as main). This was 
largely due to the fact that a high proportion of these studies (42% of 50 studies reporting 
on A1) were case reports. Question A2 (activity in biomarker negative) was addressed by 
11 studies, all supportive or unclear. Again, five of these 11 studies were case reports. A 
maximum of six studies addressed questions A3 (one supportive or unclear study), A4 (four 
supportive or unclear studies), Q1 (two main and two supportive or unclear studies), Q4 
(three supportive or unclear studies) and Q5 (one main and five supportive or unclear 
studies). A number of questions were not addressed at all for B-I-D combinations with an 
orphan drug: Q2, Q3, Q6-Q8, A5 and A6. 
 
Figure 6.4 Questions addressed in studies supporting drugs with an orphan indication 
6.4.6 QUESTIONS ADDRESSED WITHIN B-I-D COMBINATIONS 
Of the 50 B-I-D combinations in the EMA review (discussed in Chapter 5), sufficient 
information on the design of supporting studies to identify what questions were addressed 
was available for 49. For one B-I-D combination the study design with respect to the 
biomarker was unclear. Detailed information on the questions addressed within each B-I-D 
combination is reported in Appendix 15. 
6.4.6.1 QUESTION TYPES ADDRESSED 
Figure 6.5 presents the number of B-I-D combinations out of a total of 49 for which 
different types of questions, described in Box 6.2 were addressed by the supporting study 
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designs. In this analysis it was assumed that if there was information on treatment effects, 
treatment activity became irrelevant and was not included in the diagram. The exact 
questions addressed in B-I-D combinations are however reported in Figure 6.6 and Figure 
6.7 below.  
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For categories where questions on treatment effects were addressed data on treatment activity are not 
considered. 
Figure 6.5 Number of B-I-D combinations where different question categories were addressed by the supporting 
studies 
In four cases there were no studies supporting the B-I-D combination and therefore none 
of the questions within the framework were addressed. For four B-I-D combinations only 
treatment activity was addressed and in 17 treatment effects. Three B-I-D combinations 
were supported by studies addressing only treatment activity and biomarker effects. In 13 
cases all question types were addressed. In five cases the available research could only 
provide information on biomarker prevalence in patients not responding to treatment. The 
remaining three B-I-D combinations had information potentially available on a mixture of 
categories, one each on: 
 treatment effects and biomarker prevalence in non-responders, 
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 all items apart from biomarker prevalence in non-responders, and 
 biomarker prevalence in non-responders only. 
6.4.6.2 QUESTIONS ADDRESSED 
The exact combinations of questions addressed by the available evidence supporting 35 
non-orphan B-I-D combinations with biomarkers predicting treatment efficacy are shown 
in Figure 6.6. For 13 of those the evidence available could only provide information on 
treatment activity or effects in biomarker positive patients. In one case the supporting 
studies could provide evidence on the treatment effects in biomarker positive and 
negative patients. For 14 B-I-D combinations information was available on all original 
questions proposed in Tajik 201378 (Q1-Q8), however not all of these provided information 
on the treatment effects in patients with an unknown biomarker status (A5), biomarker 
prevalence in patents who did not respond to treatment (A6) and the questions related 
to treatment activity (A1-A4). In five cases only biomarker prevalence in patents who did 
not respond to treatment was addressed (A6). One B-I-D combination was supported by 
studies addressing treatment effects in biomarker positive patients (Q1) and biomarker 
prevalence in patents who did not respond to treatment (A6).  
A1 A2 A3 A4 Q1 Q2 A5 Q3 Q4 Q5 Q6 Q7 Q8 A6            
                                           
                                                
                                        
                                        
                                                
                                        
                                         
                                        
                                             
                                                  
              0 
     5    10 
              Number of B-I-D combinations 
Figure 6.6 Number of non-orphan B-I-D combinations with biomarkers predicting treatment efficacy where 
different questions were addressed by the supporting studies 
Questions addressed by studies supporting ten orphan B-I-D combinations with biomarkers 
predicting treatment efficacy are shown in Figure 6.7. In one case there were no studies 
supporting the B-I-D combination. Only treatment activity in biomarker positives (A1) was 
addressed in four and treatment activity (A1) end effects (Q1) in biomarker positives in 
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two cases. The remaining three B-I-D combinations were supported by evidence 
addressing a mixture of questions on treatment activity (A1, A2, A4) and biomarker effects 
(Q4 and Q5). 
                     
A1 A2 A3 A4 Q1 Q2 A5 Q3 Q4 Q5 Q6 Q7 Q8 A6        
none         
                                       
                                     
                                    
                                    
                                         
              0     5  
              Number of B-I-D combinations 
Figure 6.7 Number of orphan B-I-D combinations with biomarkers predicting treatment efficacy where different 
questions were addressed by the supporting studies 
There were four B-I-D combinations where the biomarker was predictive of treatment 
safety, however study evidence was available only for one. This included one study which 
provided evidence on the effects of the biomarker strategy compared to the 
experimental treatment in the overall study population (Q8). 
6.4.7 AUTHORS’ CONCLUSIONS COMPARED TO PROPOSED FRAMEWORK 
Author’s conclusions were available for 110 studies. These were summarised according to 
which questions they discussed (details shown in Appendix 15). Where studies included 
only biomarker positive (or negative) patients the conclusions talked about treatment 
activity or efficacy without mentioning the biomarker, it was assumed that these 
conclusions referred to patients with the relevant biomarker status. The questions 
addressed by authors’ conclusions compared to those in the proposed framework are 
summarised in Table 6.4.  
For the questions not included in Tajik 201378 (A1-A6) and therefore not described in 
section 6.3.1.2  the following definitions were used:  
 Activity (A1-A4) was considered to be commented on in the conclusions of a paper if 
these used the word “activity”, or talked about the drug inhibiting a target. Activity 
was also assumed if the results were described as suggestive of efficacy or 
effectiveness and response to treatment was mentioned without indicating clinical 
relevance of the treatment. 
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 A5 was applied similarly to Q1-Q3, only it referred to patients with an unknown 
biomarker status. 
 A6 was considered to be commented on if authors mentioned the prevalence of the 
biomarker positive in patients who did not respond to treatment.  
Authors of about 30% of the non-randomised studies provided conclusions beyond 
activity and these included efficacy of the treatment compared to standard practice. 
One single arm study including only biomarker positive patients also provided conclusions 
on the association between the biomarker status and treatment outcome. 246 This is partly 
possible in the case of a continuous biomarker, where only patients with a value above a 
certain threshold are included, but the actual biomarker values are used for analysis. In 
this case, however, the biomarker used was not continuous (EGFR mutation). 
Randomised enrichment trials generally only reported conclusion on the efficacy of the 
treatment within the biomarker-defined subgroup of patients. In one case an enrichment 
trial including only biomarker positive patients provided conclusions on the association 
between the biomarker status and treatment outcome.247 This is probably due to the 
continuous nature of the biomarker (HER2 expression). In addition, four enrichment studies 
(all investigating HIV treatments) commented on the prevalence of the biomarker in 
patients failing the treatment. This was due to the fact that the studies included only 
patients who at the start of the study were not identified as carriers of virus with treatment 
resistance mutations, however they could have developed these mutations at the end of 
the study (as discussed in section 6.4.2 for cross-sectional subgroup analyses).  
The randomise-all (prospective and retrospective) studies essentially made conclusions in 
agreement with the framework proposed. The only exceptions were four prospective 
subgroup analyses where patients with an unknown biomarker status were included as a 
separate subgroup and, appropriately, conclusions were made about these.  
Of the five cross-sectional subgroup analyses only one commented on the biomarker 
prevalence in patients failing treatment. The remaining four made conclusions about the 
biomarker being associated with the outcome in the treatment and/or control group.  
Questions A3, A4 and Q8 were not commented on by any of the study authors. 
 
  
 
Table 6.4 Questions addressed in identified papers mapped onto the proposed framework 
 
Shaded areas indicate questions that can be addressed by each trial design according to the proposed framework; crossed out area indicates that for 
RCT study designs where activity was considered irrelevant, as higher level evidence on efficacy was available
                                                                
** Exact question depends on the type of patients included in the case report (biomarker positive, negative, or unknown) 
†† Exact question depends on the type of patients included in the case series (biomarker positive, negative, or unknown) 
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6.4.8 LABELS REPORTED IN PUBLISHED PAPERS 
The labels for study designs used in papers matched to included studies are reported in 
Table 6.5 grouped by biomarker study design.  
No reference to the biomarker was made in the study design label for the majority of the 
identified designs: case reports, case series, single-arm, enrichment and biomarker-
strategy studies. The label usually described the study referring to characteristics such as 
presence or absence of control group, randomisation, or blinding. In these cases the 
biomarker information was usually described as part of the inclusion criteria and/or 
patient characteristics for a particular study. 
For non-RCT comparative studies one of three labels available made a reference to the 
biomarker by referring to the study as molecular characterisation.248  
Randomise-all studies were also usually described without referring to the fact that 
patients of any biomarker status were included. The only exception was labelled as an 
“open-label trial that enrolled patients regardless of EGFR expression”.249 
The subgroup analysis labels sometimes contained information on the fact that these 
were investigating biomarkers. Of the seven identified unique labels for prospective 
subgroup analyses two referred to biomarkers: “predefined candidate biomarkers”250 and 
“virologic genotyping substudy”.251 Of the three identified unique labels for retrospective 
subgroup analyses one referred to biomarkers (“biomarker analysis”175,252). All four 
identified unique labels for cross-sectional subgroups referred to biomarkers and these 
were: “retrospective genotypic and phenotypic analyses,”253 ” genotypic and 
phenotypic resistance analyses,”254 “genotypic analysis”255 and “resistance analysis”.256 
The only identified study label matching the framework in Tajik 201378 was “single-arm 
study”. The remaining labels (“enrichment”, “randomise-all” and “biomarker-strategy”) 
were not used. From the extended framework the labels “case report” and “case series” 
were used.  
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Table 6.5 Study labels used in published papers 
Study design Labels in papers 
Case report  case 
 case report 
Case series  case series  
 cohort of patients 
Single-arm (positive 
and negative) 
 prospective study 
 single-arm/ open-label exploratory study 
 randomized trial‡‡ 
 open-label, randomized study§§ 
Single-arm positive 
only 
 study (often single-arm) often further described as one or more of the 
following: dose-escalating/ dose-escalation, expanded, Gehan two-stage 
design, noncomparative, open , open-label, pilot, prospective, Simon two-
stage 
 clinical trial or prospective clinical trial 
 open-label, nonrandomized trial 
 
Single-arm negative 
only 
study 
Non-RCT comparative  molecular characterisation 
 study 
 study on retrospective cases 
Enrichment (positive)  randomised trial or study often further described as one or more of the 
following: clinical, double-blind, placebo-controlled, open-label, pilot, two-
arm, double-dummy, parallel-group, controlled, two-by-two factorial, 
prospective  
 trial with further descriptors: clinical, active-controlled, non-inferiority 
Enrichment (negative) randomised, placebo-controlled, double-blind trial 
Randomise-all 
(prospective) 
 randomised trial or study often further described as one or more of the 
following: clinical, double-blind, open-label, parallel-group, placebo-
controlled, postmarketing, three-arm comparison 
 clinical trial or just trial 
prospective subgroup analyses were described as: 
 correlative studies 
 exploratory analyses in patient subgroups 
 planned subgroup analyses 
 pre-planned analyses according to predefined candidate biomarkers 
 preplanned, blinded, subset analysis 
 preplanned subgroup analyses 
 virologic genotyping substudy 
Randomise-all 
(retrospective) 
 randomised trial or study with further descriptors: double-blind, open-label , 
placebo-controlled 
 open-label  trial that enrolled patients regardless of EGFR expression 
 placebo-controlled study 
retrospective subgroup analyses were described as: 
 biomarker analysis 
 correlative analysis 
 retrospective subgroup analysis 
 
Randomise-all (cross-
sectional) 
 randomised trial or study with further descriptors: 2-arm, dose-ranging, 
double-blind, equivalence, noninferiority, open-label, prospective 
 clinical trial  
cross-sectional subgroup analyses were described as: 
 genotypic analysis 
 genotypic and phenotypic resistance analyses 
 resistance analysis 
 retrospective genotypic and phenotypic analyses 
Biomarker-strategy double-blind, prospective, randomised study 
Reported study labels are in italics  
                                                                
‡‡ RCT compared two arms with different doses of the drug under investigation 
§§ RCT compared two arms with different doses of the drug under investigation 
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6.5 DISCUSSION 
The framework in Tajik 201378 contained six trial designs that could provide information on 
one or more of eight questions. It was modified based on the dataset identified in 
Chapter 5 to include seven major study designs, four of which were further subdivided into 
subclasses of design. In particular lower-level designs were added (case reports and 
series, other types of single-arm studies and non-RCT comparative studies). Six additional 
questions that could be addressed by studies were also identified.  
The framework proposed in Tajik 201378 turned out to be too narrow compared to the 
study designs identified in the dataset from the EMA review. As a result, it needed 
expanding to add study designs and questions that were addressed by studies. It also 
appeared to emphasise some study designs (three types of biomarker-strategy design), 
which seem to have very little application in practice, possibly due to practical reasons 
and low efficiency.13 
It appears that some designs may be relatively common in practice without a large body 
of methodological literature underpinning these. This might be due to the fact that the 
choice of the study design may be driven, in addition to being able to obtain robust data, 
by factors such as practical or ethical considerations.257 This was possibly the reason for 
the frequent use of study designs including only biomarker positive patients and of cross-
sectional subgroup analyses. The cross-sectional subgroup analysis, although currently 
limited to HIV treatments, might in the future become more important in other clinical 
areas, such as cancer due to the better understanding of tumour heterogeneity and 
evolution.258 
For some study designs the questions these could potentially address were, to some 
extent, situation-dependent. For example, for continuous biomarker studies including only 
patients who are biomarker positive can contribute information on the correlation 
between the biomarker and outcome. Even though only patients with a biomarker value 
above a certain threshold are included, within the study there is still a distribution of 
different biomarker values and these can be correlated with patient outcomes. 
Frequently in publications study labels did not refer to the biomarker aspect of the design. 
The relatively widespread terms used in methodological literature (“enrichment”, 
“randomise-all” and “biomarker-strategy”)78 were not encountered in this dataset. 
Biomarkers often seemed to be reported as an inclusion criterion only and not considered 
a major component of the study design. To some extent, subgroup analyses were an 
exception, as the labels for these frequently mentioned biomarkers. This might suggest the 
need for better labelling of studies.  
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The questions addressed by studies supporting B-I-D combinations were considered. For 
only 14 of 49 B-I-D combinations supporting studies provided information on whether the 
biomarker was predictive and the benefit of implementing a biomarker-based strategy. 
The remaining studies mainly investigated activity or effectiveness within biomarker-
defined patient groups. Some studies investigated the correlation between the biomarker 
status and study outcome, or the biomarker prevalence in patients not responding to 
treatment. This could potentially reflect a strong biological basis for evaluating the 
treatment in biomarker positive patients and a robust biomarker test. However, it could 
also suggest a need for improvement in the study methodology. 
It is not certain whether other published systematic reviews suggesting different 
frameworks were available, as systematic searches were not undertaken. Another 
systematic review of trials methodology for evaluation of predictive biomarkers was 
published as a conference abstract.259 The data provided in the abstract were however 
not sufficient to utilise within this chapter and personal communication with the first author 
suggested the work on non-adaptive trial designs would not be published in the near 
future.260 
The limitations in the methodology of the Tajik 201378 review may potentially impact on the 
results of this chapter. However, as methodological literature is concerned, these 
limitations may be less serious than in the case of systematic reviews evaluating clinical 
effects of interventions. There are very little, if any, consequences of missing some 
methodological papers if the information contained in them was obtained from other 
publications. 261 It has been in fact argued that attempting to identify all relevant papers 
may be redundant and represent highly inefficient use of time and resources.262 
The EMA dataset itself may be a limited representation of research practice. It is more 
likely to include studies where at the design stage the evidence supporting the biomarker 
is much stronger and therefore some designs might not be seen. For example, the 
stratified design was not encountered in this dataset to evaluate any of the biomarkers, 
however this design has been used in multiple cases in practice. For example the trials 
evaluating erlotinib in NSCLC were stratified by EGFR gene copy number (MARVEL),61 or 
EGFR mutation type (OPTIMAL).263  
Another limitation of this work is that searches for the studies in the EMA dataset went up 
to the beginning of 2013. There may be some newer studies with a different design. One 
person collected the data and analysed it. This may be particularly important in 
summarising the conclusions of study authors’, as these may have more than one 
interpretation. 
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However this piece of work was based on a relatively large sample of studies (n=159) and 
was carried out in a systematic way, therefore it may provide a relatively robust 
comparison of at least some research practice against the Tajik 201378 framework. 
6.6 CONCLUSIONS 
The framework proposed in Tajik 201378 needed expanding to encompass all study 
designs identified in the dataset from the EMA review. This suggests there might be a 
discrepancy between what designs are proposed and evaluated in the methodological 
literature and carried out in practice. There may be a need to further develop and gain 
better understanding of the limitations of methodology for certain cases, such as 
investigation of HIV resistance mutations. 
It was also clear that for the majority of B-I-D combinations there was no evidence to 
address the question of whether the biomarker was truly predictive, or whether the 
implementation of the biomarker in clinical practice would result in patient benefit. This 
could potentially suggest that either in most cases there is a strong biological rationale not 
to evaluate the biomarker, or there is a need for improvement in the methodology of 
studies being conducted.  
For published papers authors’ conclusions seemed to be mainly addressing questions 
possible to answer based on the study design, although there were a number of studies 
where conclusions beyond these appeared to be made.  
The study labels did not often reflect the biomarker aspect of the study. This suggests there 
is a need to improve the labelling of biomarker studies in practice. 
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Abstract 
Background: Implementation of findings of predictive biomarker research in clinical 
practice, requires sufficient information on the appropriate procedures of biomarker 
evaluation. Ideally, the procedures used should be consistent across different studies, to 
facilitate combining their results and provide a useful tool for implementation in clinical 
practice applications. 
Aim: The aim of this chapter is to provide a case study of how a particular predictive 
biomarker, ERCC1, was assessed in recent research and what motivated the choice of 
laboratory procedures. Thus this case study aims to identify general lessons that can be 
learned for the wider context of predictive biomarker research. 
Methods: Searches were carried out in three databases of ongoing trials on 26.03.2013. 
Details of ERCC1 assessment and study design were obtained from records in these 
databases. In addition, questionnaires were sent to all identified studies asking for detailed 
information on ERCC1 evaluation procedures and the rationale for their choice. 
Findings: Thirty three studies of ERCC1 in platinum-based chemotherapy of non-small-cell 
lung cancer were identified that were either ongoing or completed or terminated after 
1st January 2007. Information was received in response to the questionnaires for 16 studies. 
The procedures for ERCC1 evaluation varied substantially and, where reported, (20 
studies) included reverse transcriptase quantitative polymerase chain reaction (nine 
studies), immunohistochemistry (five studies) and other methods (six studies). In five of the 
identified studies ERCC1 evaluation was initially planned, but not undertaken. Even when 
different studies used the same assay, there was still variation in the details of the 
laboratory techniques and scoring systems used.  
Conclusions: Large variation was found across studies in the procedures used for ERCC1 
evaluation. This could potentially limit the comparability of results between different 
studies. To enable evidence-based clinical practice, there needs to be a generally 
accepted standard biomarker test as well as standardised laboratory protocol to be 
followed, especially in late phase studies. A consensus on and validation of the 
procedures to evaluate a predictive biomarker may be required in the early phase of 
research to achieve this. If multiple procedures for evaluation are to be used, research 
needs to demonstrate that these result in comparable classification of patients into 
biomarker positive and negative 
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7.1 BACKGROUND 
Chapter 2 reviewed the different frameworks for development of predictive biomarkers. 
One of the elements of some of these was analytical validation of the biomarker. This 
involved establishment of acceptable accuracy and replicability of the procedures used 
to evaluate these biomarkers. It also seems important that standardised procedures are 
used to enable combining the results of multiple studies and implementation of their 
findings in clinical practice. There are however reasons to believe that in practice there is 
little consistency in the procedures used. As shown in Chapter 5, there is often substantial 
variability in the procedures used for evaluation of an individual biomarker within B-I-D 
(Biomarker-Indication-Drug) combinations. Also, a review of published papers 
investigating the use of excision repair cross-complementation group 1 (ERCC1) to predict 
response to platinum-based chemotherapy in lung cancer found that there was large 
variability in the assays used.264 This review was published in 2011, thus including relatively 
early ERCC1 evaluations. There is a possibility that the more recent research practice has 
become more harmonised.  
This chapter therefore set out to investigate the reports of consistency of methods for 
evaluation of ERCC1 as a biomarker predictive of response to platinum-based 
chemotherapy in ongoing or recently completed studies in NSCLC patients. It also 
attempted to explore the rationale that motivated the choice of assays. This particular 
case was chosen in preference to any of the B-I-D combinations identified in Chapter 3, 
as ERCC1 was still being investigated as a potential predictive biomarker, while the B-I-D 
combinations contained biomarkers that have already been considered ready for 
implementation in clinical practice. Therefore, ERCC1 was more likely to illustrate the more 
recent research practice. This chapter sets out to provide a case study, from which lessons 
can be learned that may apply to a wider context of predictive biomarker research. 
To enable a detailed discussion of the results of this case study, the background to the 
investigation of ERCC1 as a biomarker predictive of response to platinum-based 
chemotherapy will be outlined. Some of the more important procedures for ERCC1 
evaluation will also be introduced below. 
7.1.1 TREATMENT OF NON-SMALL-CELL LUNG CANCER 
Lung cancer is one of the leading causes of cancer death globally.264-266 Cancer 
registration data from England shows 34 848 new lung cancer cases diagnosed in 2011.267 
The majority of patients have NSCLC histology.266,268 The prognosis of lung cancer patients 
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is generally poor,264,268 with a five year survival of about 5% for patients with advanced 
NSCLC and about 15% for all patients irrespective of stage.266 In spite of development of 
new, targeted treatments, platinum-based chemotherapy remains part of standard care 
in NSCLC.264,268-270 
The effectiveness of platinum-based chemotherapy is however limited,265,271 with 
resistance to treatment resulting in little or no patient benefit and potentially unnecessary 
toxicity.272 Identification of biomarkers predictive of resistance (or lack of efficacy) to 
platinum-based chemotherapy could potentially result in avoiding unnecessary treatment 
and lead to significant improvement in patient care, as well as better allocation of 
healthcare resources. 
7.1.2 PLATINUM-BASED CHEMOTHERAPY: MECHANISM OF ACTION AND RESISTANCE 
Understanding the mechanism of action of platinum-based agents was an important step 
towards identification of potential biomarkers predictive of lack of treatment efficacy. 
Although it is still a subject of research, there is certainty that DNA is the primary target of 
platinum-based chemotherapy.273 The main effects of this type of chemotherapy on cells 
involve preventing cell replication, interruption of cell function, and, most importantly, cell 
death (apoptosis).  
This discussion will focus on cisplatin, as the mechanism of action of cisplatin is probably 
the most extensively studied and it is, to some extent, representative of the other 
platinum-containing agents.  
As shown in Figure 7.1, after administration, cisplatin is taken up into cells, where it is 
converted into an active form. The activated molecule then binds strongly to DNA, but 
can also bind to other molecules within the cell (such as RNA and some proteins). On 
binding to DNA, cisplatin can create adducts, which lead to the effects outlined above. 
Formation of adducts is followed by activation of complex pathways (both pro-survival 
and pro-apoptosis),273 which may vary for different platinum-containing agents.272 
Resistance to platinum-containing therapy has been observed in a high proportion of 
patients. As illustrated in Figure 7.1, there is a wide range of proposed mechanisms of 
resistance and it has been suggested that it may involve several mechanisms at the same 
time. The major mechanisms of resistance involve: 
 reduction in cisplatin uptake and/or increase in efflux from the cell,272,273 
 increase in cisplatin inactivation, mainly by presence of proteins which react with 
activated cisplatin and stop it from binding to DNA,272,273 
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 various mechanisms involved in repair of damaged DNA and preventing 
apoptosis.272,273  
The first two mechanisms can be, to some degree, overcome by the use of other 
platinum-containing agents (such as carboplatin). Enhanced repair, however, generally 
results in resistance to other platinum-containing drugs as well.273 
The nucleotide excision repair (NER) pathway has been suggested as one of the major 
routes of platinum adduct repair. Increase in expression of NER genes has been 
correlated with resistance to cisplatin and other platinum-containing drugs.272,273 The 
ERCC1 enzyme in particular has a role in removing cisplatin adducts.266 
 
Figure 7.1 Major mechanisms of action of cisplatin chemotherapy and related resistance mechanisms 
7.1.3 INVESTIGATION OF ERCC1 EXPRESSION IN IALT BIO AND 2011 RE-ANALYSIS 
This biological rationale, as well as evidence from in vitro and small retrospective studies, 
pointed to ERCC1 expression as a biomarker predictive of response to platinum-based 
chemotherapy in NSCLC. This was investigated in IALT Bio, a retrospective analysis of 
patients enrolled in the IALT RCT, which included 1867 patients and compared adjuvant 
cisplatin to observation only.265 Paraffin-embedded tumour tissue samples from 783 
patients were analysed, which constituted 42% of all patients included in the original IALT 
RCT.265,274 The biomarker evaluation was undertaken by IHC using the 8F1 antibody 
(Neomarkers, Fremont, California, USA).265 
IALT Bio results indicated that patients whose tumours had low levels of ERCC1 expression 
were benefiting from cisplatin chemotherapy both in terms of overall survival (adjusted 
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HR=0.65, 95% CI: 0.50, 0.86) and disease free survival (HR=0.65, 95% CI: 0.50, 0.85) 
compared to observation only control group. At the same time, for patients with high 
tumour ERCC1 expression levels there seemed to be a non-significant trend suggesting 
shorter overall survival with cisplatin treatment compared to control (HR=1.04, 95% CI: 0.84, 
1.55). The test of interaction indicated a predictive effect of ERCC1 expression both for 
overall survival (p=0.009) and disease free survival (p=0.008).265 The results of this study 
have largely increased interest in ERCC1 as a biomarker predictive of response to 
platinum-based chemotherapy.  
A new retrospective analysis was undertaken in 2011 and published in 2013. It included 
samples from IALT Bio and two other studies. For this analysis tumour tissue samples were 
available for only 589 patients from the IALT RCT – about 32% of patients from the original 
trial. The same antibody and laboratory procedures were used, however a substantial 
inconsistency was observed. For patients with their biomarker status evaluated both in IALT 
Bio and the 2011 re-analysis: 
 34% of patients initially classed as ERCC1 negative, were classed as positive in 
2011, 
 2% of patients initially classed as ERCC1 positive, were classed as negative in 2011, 
 classification was consistent for 64% of patients.271 
Based on the 2011 evaluation, ERCC1 no longer appeared predictive of overall survival 
(HR=0.81, 95% CI: 0.50, 1.31 for ERCC1 negative and HR=0.96, 95% CI: 0.74, 1.25 for ERCC1 
positive). Furthermore, combined data from all three studies showed a trend suggesting 
patients classed as ERCC1 positive were more likely to benefit from cisplatin 
chemotherapy, although the interaction test was not significant (p=0.23).271 
The authors of the 2011 re-analysis undertook additional laboratory work investigating the 
role of ERCC1, which resulted in identification of different forms of the ERCC1 protein 
(isoforms), with potentially only one of them having a role in cisplatin resistance. They 
concluded that: 
“Currently available antibodies do not have adequate discrimination for 
therapeutic decision making regarding cisplatin-containing treatment in 
patients with NSCLC, which requires the specific detection of the unique 
functional isoform of ERCC1 — ERCC1-202”.271 
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7.1.4 METHODS USED FOR ERCC1 EVALUATION 
The two main methods that have been used for ERCC1 evaluation are IHC and reverse 
transcriptase quantitative polymerase chain reaction (RTqPCR).264,275 These are described 
in more detail in Appendix 16. For both assays the results will not only be influenced by the 
choice and performance of the assay, but also by pre- and post-analytical factors which 
have been introduced in Chapter 1.276 
7.1.5 AIMS 
The aims of this chapter are: 
1) to identify the procedures for evaluation of ERCC1 as a biomarker predictive of 
response to platinum-based chemotherapy in NSCLC in studies that were ongoing, 
or completed or terminated on 1 January 2007 or later, 
2) to investigate the details of the laboratory procedures employed in studies, and 
explore the rationale that motivated the choice of a specific procedure. 
7.2 METHODS 
As shown in Box 7.1, the systematic review was undertaken to address the first aim: to 
investigate the procedures for ERCC1 evaluation used in studies of platinum-based 
chemotherapy in NSCLC patients that were ongoing and recently completed or 
terminated (after 1st January 2007). ERCC1 was of interest as a predictive biomarker and 
not prognostic. In practice this was however difficult to ascertain, therefore it was 
assumed that studies investigating platinum-containing chemotherapy and measuring 
ERCC1 are likely to be using this biomarker as predictive. There was no limitation in terms 
of study design or outcomes assessed. 
The second aim involved investigating the details of laboratory procedures and rationale 
for the choice of the methods for ERCC1 evaluation in the identified studies. This was 
addressed by the questionnaire. 
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Box 7.1 Definition of the question addressed by the systematic review 
 
7.2.1 SEARCHES IN ONGOING TRIALS DATABASES 
Searches were undertaken on 26.03.2013. in the ClinicalTrials.gov, WHO and Controlled-
Trials database. Search terms used are reported in Table 7.1 below. The full search 
strategies can be found in Appendix 17. 
Table 7.1 Search terms used in ongoing trials databases to identify studies potentially using ERCC1 as predictive 
of platinum based therapy 
Clinical area Biomarker Treatment* 
Lung 
NSCLC 
ERCC1  
ERCC-1  
ERCC 
excision AND repair  
customized  
individualized  
tailored  
personalized  
biomarker  
pharmacogenomic  
pharmacogenetic 
cisplatin  
carboplatin 
platinum  
platin  
chemotherapy 
Terms in each column were combined using the “OR” operator; columns were then combined using the “AND” operator; 
*ClinicalTrials.gov only 
 
Results of the searches (study number, title and link to the full record) were entered into an 
Excel spreadsheet. Duplicates identified based on the study number were removed after 
comparison of entries in different databases to ensure no unique studies were removed.  
Population: patients with non-small cell lung cancer 
Intervention: platinum-containing chemotherapy 
Comparator: any, including none 
Outcome: any 
Biomarker: Excision Repair Cross-Complementation Group 1 (ERCC1) expression 
Study: any ongoing study or completed/ terminated after 1st January 2007 
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7.2.2 IDENTIFICATION OF RELEVANT STUDIES 
Studies meeting the criteria reported in Box 7.1 were included. 
The application of the inclusion criteria proceeded in two stages. In the first stage of 
screening study titles were screened for inclusion by two independent reviewers. Any 
study that was judged by at least one reviewer as potentially meeting the inclusion criteria 
(above) or unclear was included in the second stage of screening. Only studies clearly 
not meeting the inclusion criteria were excluded at this stage. The full records of all studies 
included after the first stage were downloaded from the databases of ongoing trials. 
In the second stage the full records of studies identified in the first stage were considered 
for inclusion by two independent reviewers. Studies were included if they met all inclusion 
criteria. An exception was made for studies only specifying the intervention as 
chemotherapy or systemic therapy, where all the remaining criteria were met. These were 
also included to avoid potential omissions of relevant studies.  
Disagreements between the two reviewers regarding inclusion decisions were resolved by 
discussion and in two cases by seeking further information on the studies in internet 
searches. The reasons for all exclusions at this stage were recorded. 
7.2.3 DATA EXTRACTION 
Data were extracted by one reviewer into an Excel spreadsheet from records obtained 
from databases of ongoing trials that were downloaded on 12.04.2013. Information was 
collected on the items shown in Box 7.2.  
7.2.4 QUESTIONNAIRE 
A questionnaire was prepared in collaboration with clinical and pathology experts. It 
included questions related to details of laboratory methods for ERCC1 evaluation. The full 
questionnaire can be found in Appendix 18. 
The questionnaires were sent by email to contacts for each included study, as indicated 
in the relevant entry in a database of clinical trials. Where there was no individual 
identified (in the case of two studies), contact with the sponsor or the corresponding 
author (for a published trial) was attempted. The questionnaire was sent on 5 August 2013. 
Where no reply was received, a reminder was sent on 28 January 2014. 
Information received was extracted into the Excel spreadsheet for all items included in the 
questionnaire.  
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Box 7.2 Data extraction items for review of trials evaluating ERCC1 
 
7.2.5 SEARCHES FOR PUBLISHED PAPERS 
Additional searches using Google and Google Scholar were undertaken for published 
papers for studies where a reply was not received and which were not ongoing. The terms 
used included, but were not limited to: trial number, trial acronym and trial title. These 
searches were undertaken during the week commencing 11 August 2014. 
7.2.6 DATA ANALYSIS 
The data obtained were summarised narratively. For all included studies the summaries 
were based on the best information available. Where available, information from 
 Trial ID and acronym 
 Study phase 
 Study status (ongoing, completed, terminated or withdrawn) 
 Study title 
 Study start date and planned end date 
 Interventions investigated in the study 
 Role of platinum-containing chemotherapy 
 Design (with respect to ERCC1) 
 Planned sample size 
 NSCLC stage 
 Methods of obtaining tumour tissue samples (also investigated in the 
questionnaire) 
 Methods of ERCC1 assessment (also investigated in the questionnaire) 
 Primary outcome 
 Study location 
 Study sponsor 
 Study contact details for the purpose of sending the questionnaire 
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questionnaires was used and in the remaining cases data extracted from databases of 
ongoing trials were utilised. Data on the study design with respect to the biomarker were 
analysed by study phase, as it was hypothesised that the design should vary depending 
on the phase, with designs aiming at finding a correlation between the biomarker and 
response to treatment occurring mainly in earlier phases. For the purpose of analysis 
seamless study designs were grouped according to the earlier phase component (for 
example a phase I/II was grouped with phase I studies). 
The type of biomarker assay used was also analysed by phase, as again the highest 
variation in the choice of assays for ERCC1 evaluation was expected to be seen in early 
phase trials, where the biomarker was still in development. It was expected that the 
laboratory methods would become more standardised in later phase studies. In addition, 
data on the assays used were analysed by year of study initiation to investigate whether 
there is any trend suggesting that the choice of an assay may be dictated by 
technological developments. For each individual method where information was 
available from questionnaires, the details of the laboratory procedures were compared. 
Data on the rationale for the choice of an assay were compiled from the replies received.  
7.3 FINDINGS 
The numbers of studies identified in each stage of the review as well as the number of 
replies received are shown in Figure 7.2.  
The searches identified 921 records across the three databases. After removing 
duplicates, 730 studies remained. Thirty three studies met the inclusion criteria.  
A questionnaire was sent to a contact for each of the 33 included studies. A completed 
questionnaire was returned by eight respondents. In further eight cases an email was 
received, which included, for example, published papers or conference abstracts, as well 
as information that even though reported in the database of ongoing trials, ERCC1 
assessment was not undertaken. 
The searches for published papers did not result in identification of any publications. 
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Figure 7.2 Flow diagram outlining the results of searches in ongoing trials databases, review of studies and replies 
received for the questionnaire 
7.3.1 INCLUDED STUDIES 
Of the identified 33 studies 18 were ongoing, eight completed, two terminated early and 
one withdrawn prior to enrolment. The status of four studies was unknown. There were 14 
phase II, five phase III and two phase I studies. There was also one each: phase 0, phase 
I/II, phase II/III and phase IV study. The study phase was NR for eight studies. Nine studies 
ClinicalTrials.gov  -
317 records
WHO - 303  records
921 study titles
730 study titles 
screened
330 studies potentially 
relevant
33 studies included -
questionnaires sent
17 no reply 
received
16 replies received
- 8 questionnaires
- 8 email only
exclusions:
285 no ERCC1 assessment
5 not NSCLC patients
4 duplicate entries with different numbers  
in different databases
2 no platinum-based chemotherapy
1 completed prior to 2007
400 studies not 
considered relevant
191 duplicates 
removed
Controlled-Trials  -
301 records
Id
e
n
ti
fi
ca
ti
o
n
 
Sc
re
e
n
in
g 
El
ig
ib
ili
ty
 
In
cl
u
d
e
d
 
 213 
 
were conducted in Asia, eight in Europe, 13 in North America and one study included 
locations in both Europe and North America. For two studies the location was NR.  
As shown in Figure 7.3, six studies planned to include up to 50 patients, nine between 51 
and 100, 14 between 101 and 500, two between 501 and 1000 and two more than 1000 
patients.  
 
Figure 7.3 Planned numbers of patients in included studies 
In 18 of the included studies the intervention was reported as containing cisplatin, in nine 
carboplatin, in three a platinum-containing agent and in three it was unclear.  
As shown in Figure 7.4, eighteen studies investigated correlation between ERCC1 status 
and patient outcome, without this biomarker being integral to the trial design. Fourteen 
used ERCC1 on its own, or in combination with other biomarkers to determine the 
treatment strategy (either in an RCT or single-arm trial). One RCT was stratified by ERCC1 
status. 
A correlative non-randomised design for ERCC1 investigation was most frequently used in 
early phase studies (phase 0, I and II). A relatively large proportion of phase II studies 
reported testing a strategy that was based on ERCC1 and in some cases also included 
other biomarkers. Phase III trials included one correlative RCT, one RCT stratified by ERCC1 
and three RCTs using ERCC1 to select the treatment strategy. The phase IV study was 
biomarker-based strategy RCT.  
Detailed characteristics of the included studies are reported in Table 7.3.  
7.3.2 ERCC1 EVALUATION BASED ON BEST AVAILABLE INFORMATION 
This section presents details of procedures for ERCC1 evaluation based on combined 
information from the survey and records in ongoing trials databases, which are reported in 
Figure 7.5.  
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Figure 7.4 Planned trial sample size and design with respect to ERCC1 by trial phase in identified studies 
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Table 7.2 Characteristics of included studies ordered by the study phase 
Trial ID 
Trial 
status Reply received 
Start - 
end 
year 
Type and role of 
chemotherapy; 
NSCLC stage Design 
Sample 
size ERCC1 assessment method* 
Phase 0 
NCT01261299277 Ongoing No 2010 
- 
2013 
Carboplatin; 
palliative 
Stage IV 
single-arm correlative 80 quantitative RT-PCR  
Phase I (including phase I/II) 
NCT01059552278 Ongoing No 2009 
- 
2013 
Cisplatin; unclear 
Stage IIIa/IIIb 
single-arm correlative 22 NR 
NCT01416961279 Withdraw
n 
No 2011 
- 
2011 
Cisplatin; unclear 
Stage IIIa/IIIb 
single-arm correlative 0 NR 
NCT01386385280 Ongoing No 2011 
- 
2016 
Carboplatin; only 
treatment 
Stage III 
RCT, correlative 132 NR 
Phase II (including phase II/III) 
EUCTR2011-
005267-24-IT 
(CONTEST)281 
Ongoing Yes 
(questionnaire) 
2012 
- 
2014 
Cisplatin; 
neoadjuvant 
Stage IIIa 
Randomised biomarker - 
strategy design (using 
ERCC1, RRM1, EGFR, TS) 
168 RTqPCR; ERCC1 RNA level as ratio of 
ERCC1 gene transcripts to β-actin 
reference gene transcripts; cut-off 
1.7 
NCT00775385 
(TASTE)282 
Ongoing Yes (email + 
conference 
presentation) 
2009 
- 
2014 
Cisplatin; 
adjuvant  
Stage II/IIIa 
Randomised biomarker - 
strategy design (using 
ERCC1 and EGFR) 
165 IHC; details NR 
NCT00792701 
(S0720)77 
Ongoing No 2008 
- 
2016 
Cisplatin; 
adjuvant 
Stage Ia/Ib  
single-arm biomarker 
strategy (using ERCC1 
and RRM1) 
55  immunofluorescence-based 
automated quantitative analysis; 
additional available samples using 
RT-PCR and RTqPCR, polymorphism, 
ERCC1 expression at protein level; 
tissue microarray analysis of genes 
associated with DNA synthesis, 
damage repair, and drug efficacy 
NCT01003964283 Ongoing No 2009 
- 
2013 
Cisplatin; unclear 
Stage IIIb/IV 
RCT correlative 284 NR 
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Trial ID 
Trial 
status Reply received 
Start - 
end 
year 
Type and role of 
chemotherapy; 
NSCLC stage Design 
Sample 
size ERCC1 assessment method* 
NCT01194453284 Ongoing Yes 
(questionnaire) 
2009 
- 
2012 
Cisplatin; first-line 
Stage IIIb/IV 
RCT correlative 300 RTqPCR; median value as threshold 
(value NR) 
NCT01356368285 Ongoing No 2010 
- 
2013 
Cisplatin; first line 
Stage IIIb/IV 
single-arm biomarker 
strategy (using ERCC1, β-
Tubulin and RRM1) 
35 NR 
NCT01731626286 Ongoing Yes (email) 2013 Cisplatin;p 
neoadjuvant and 
adjuvant 
Stage Ib to IIIb 
single-arm correlative 52 Not undertaken 
NCT00705549287 Terminat
ed 
Yes 
(questionnaire) 
2008 
- 
2011 
Cisplatin; unclear 
Stage IIIb/IV 
single-arm biomarker 
strategy (using ERCC1, 
BRCA1 and RRM1) 
88 RTqPCR with threshold based on the 
a chart analysis in >800 samples 
NCT00191308288 Complet
ed 
Yes (email + 
conference 
abstract) 
2005 
- 
2010 
Cisplatin; 
neoadjuvant 
Stage Ib to IIIa 
single-arm, correlative 30 not conducted due to insufficient 
tumor samples and ”lack of scientific 
value” 
NCT00582634289 Complet
ed 
No 2004 
- 
2007 
Cisplatin; 
adjuvant 
Stage Ib to IIIa  
single-arm correlative 4 NR 
NCT01781988 
(PTINCLC)290 
Ongoing Yes 
(questionnaire) 
2009 
- 
2013 
Carboplatin; NR 
NR 
Randomised biomarker-
strategy design based 
on ERCC1, RRM1, TS and 
β-Tubulin 
200 IHC using ZSGB-Bio in China 
antibody; H-score >1 classed as 
ERCC1 high 
NCT01648517291 Ongoing No 2012 
- 
2015 
Carboplatin; 
unclear 
Stage IIIb/IV 
Randomised biomarker-
strategy design based 
on ERCC1 and RRM1 
162 mRNA expression 
NCT00736814292 Unknown No 2008 
- NR 
Carboplatin; only 
treatment 
Stage IIIb/IV 
Randomised biomarker-
strategy design based 
on ERCC1 and RRM1 
117 RT-PCR 
NCT00729612293 Unknown Yes (email) 2008 
- 
2010 
Carboplatin; NR 
Stage IIIb/IV or 
recurrent 
single-arm correlative 63 Not undertaken 
NCT00215930 
(MADe IT)294 
Complet
ed 
Yes (email + 
publications) 
2004 
- 
2009 
Carboplatin; only 
treatment  
Stage IIIb/IV 
single-arm biomarker 
strategy (using ERCC1 
and RRM1) 
53 RTqPCR using ABI prism 7700; Perkin-
Elmer, Foster City, CA; threshold: 
ERCC1 expression above/ below 8.7 
2
1
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Trial ID 
Trial 
status Reply received 
Start - 
end 
year 
Type and role of 
chemotherapy; 
NSCLC stage Design 
Sample 
size ERCC1 assessment method* 
Phase III 
EUCTR2007-
007639-17-GB 
(ET)295 
Ongoing Yes 
(questionnaire) 
2008 
- 
2014 
Cisplatin; only 
treatment 
Stage IIIb/IV 
Randomised stratified 
(by ERCC1) 
1272 IHC using Neomarkers (ThermoFisher) 
clone 8F1 antibody; threshold: Quick 
Score 6 and over 
EUCTR2008-
001764-36-IT 
(ITACA)296 
Ongoing Yes (email + 
conference 
poster) 
2008 
- NR 
Cisplatin; 
adjuvant  
Stage II/IIIa 
Randomised biomarker - 
strategy design (using 
ERCC1 and TS) 
700 RTqPCR using 7900 ABIPRISM; values 
dichotomized on median value using 
ΔΔCT method (value NR) 
NCT00113386297 Terminat
ed 
Yes (email) 2005 
- 
2009 
Cisplatin; 
neoadjuvant 
Stage IIIa 
RCT correlative 19 Terminated early due to poor 
accrual 
NCT00174629 
(GILT 
Docetaxel)298 
Complet
ed 
Yes 
(questionnaire) 
2001 
- 
2007 
Cisplatin; only 
treatment 
Stage IIIb/IV 
Randomised biomarker - 
strategy design (using 
ERCC1) 
449 RTqPCR; threshold: median using 
ΔΔCT method (value 3.42) 
EUCTR2008-
000617-30-DE 
(MADeIT)299 
Ongoing No 2008 
- 
2015 
Carboplatin; only 
treatment 
Stage IIIb/IV 
Randomised biomarker-
strategy design based 
on ERCC1 and RRM1 
267 ERCC1 expression at protein level 
Phase IV 
ChiCTR-TRC-
11001327300 
Ongoing 
 
No 2010 
- 
2013 
Cisplatin; NR 
Stage IIIb/IV 
Randomised biomarker - 
strategy design, (unclear 
if ERCC1 used) 
210 NR 
Phase NR 
NCT01294280 
(LACE-BIO)301 
Ongoing  Yes 
(questionnaire) 
2008 
- 
2013 
Cisplatin; 
adjuvant 
Early stage  
analysis of samples from 
completed trials 
1606 IHC using Ab-2, clone 8F1 
(Neomarkers) with H-score >1 classed 
positive 
NCT00900172302 Unknown No 2008 
- 
2009 
Carboplatin; 
unclear 
Stage IIIb/IV 
RCT, correlative 180 Polymorphisms in ERCC-1(…) are 
assessed using Taqman assays. 
NCT00797238303 Unknown No 2007 
- 
2010 
platinum-based; 
neoadjuvant 
Stage III 
single-arm correlative 100 NR 
NCT00222404 
(Pharmacogeno
scan)304 
Complet
ed 
Yes 
(questionnaire) 
2005 
- 
2010 
platinum-based; 
unclear 
Any stage 
single-arm correlative 556 IHC; antibody and threshold NR 
2
1
7
 
  
 
Trial ID 
Trial 
status Reply received 
Start - 
end 
year 
Type and role of 
chemotherapy; 
NSCLC stage Design 
Sample 
size ERCC1 assessment method* 
NCT01141686305 Complet
ed 
No 2009 
- 
2009 
platinum-based; 
unclear 
Stage NR 
single-arm correlative 90 FISH and IHC 
NCT01574300 
(CASTLE)306 
Ongoing No 2010 
- 
2017 
Unclear; unclear 
Stage IV 
single-arm correlative 250 NR 
NCT00422500307  Complet
ed 
Yes (email) 2003 
- 
2010 
Unclear; unclear 
Stage III to IV 
single-arm correlative 204 Not undertaken  
NCT00442520308  Complet
ed 
No 2006 
- 
2008 
Unclear; unclear 
Stage NR 
single-arm correlative 70 NR (SNPs in ERCC1 gene) 
* information in italics is based on the returned questionnaires and emails received 
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Surgical resection, biopsy or cytology includes one study where cut sections on slides were also used 
Figure 7.5 ERCC1 evaluation in identified studies 
The procedures for evaluation of ERCC1 varied across studies, with RTqPCR used in nine 
studies and IHC in five. In two studies use of multiple methods was reported: 
 immunofluorescence-based automated quantitative analysis for in situ expression 
and (if additional samples available): RT-PCR, RTqPCR, polymorphism analysis and 
ERCC1 assessment in identified studies based on ongoing trials databases and returned information
tumour sample assay
20 15 10 5 phase 5 10 15 20
number of studies number of studies
NR
0
I
II
III
IV
ERCC1 assessment in identified studies based on returned information
tumour sample assay
10 8 6 4 2  phase 2 4 6 8 10
number of studies number of studies
NR
0
I
II
III
IV
RTqPCR IHC
gene expression NER polymorphism
multiple methods NR
not undertaken
biopsy
(FF)PE tumour tissue
surgical resection
surgical resection or biopsy
surgical resection, biopsy or cytology
NR
not undertaken
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tissue microarray analysis of genes associated with DNA synthesis, damage repair, 
and drug efficacy 
 fluorescence in situ hybridization (FISH) and IHC 
In one study NER polymorphism was measured. In two studies gene expression was 
measured, but further details were NR. In five studies (where questionnaires were 
returned), although initially planned, there was no ERCC1 evaluation undertaken. There 
was no information on the procedures used in nine studies.  
The type of specimen used also varied across studies: 
 three studies used surgical resection only, 
 five studies used biopsy, 
 cytology on its own was not used, 
 three studies used surgical resection or biopsy,  
 one study used surgical resection, biopsy, or cytology, 
 one study used the combination of all three techniques together with cut sections 
on slides, 
 two studies reported use of paraffin embedded specimens (of these one used 
formalin and one did not report the fixative), 
 the type of specimen was NR in 13 cases, and 
 in five studies ERCC1 evaluation was not undertaken. 
There seemed to be no clear pattern indicating less variation in the procedures used in 
later phase trials. 
It was also hypothesised that although there was no clear trend depending on the study 
phase, there might be some consistency in preferences for different methods depending 
on the time of the initiation of the study. This was however not confirmed by the available 
evidence (Figure 7.6). 
7.3.3 ERCC1 EVALUATION BASED ON INFORMATION RECEIVED IN REPLIES TO QUESTIONNAIRES 
Information was received for 16 studies. Nine of these were phase II, four phase III and for 
three the phase was not known. For five studies the person contacted informed that 
although previously planned, ERCC1 evaluation was not undertaken due to issues such as 
early termination of study, unavailability of sufficient samples to be tested, or funding. 
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Figure 7.6 Assays for evaluation of ERCC1 expression in identified studies by date of study initiation 
7.3.3.1 OBJECTIVE AND TIME OF ERCC1 EVALUATION 
The objective of ERCC1 evaluation was correlative in three studies, assignment of 
treatment strategy in seven and patient stratification in one (details are shown in Figure 
7.4). The studies where the planned ERCC1 evaluation was not undertaken were all 
correlative (one phase III RCT, three phase II single-arm studies and one single-arm study 
where the phase was NR).  
Of the eleven studies that carried out ERCC1 evaluation, it was done prospectively (prior 
to patients receiving treatment) in all eight studies which used the biomarker to identify 
the treatment strategy or stratify randomisation. Three studies used ERCC1 in a correlative 
analysis and all of these evaluated the biomarker retrospectively and blind to patient 
outcome. 
7.3.3.2 ERCC1 EVALUATION PROCEDURES 
Nine of the replies reported on the site where evaluation of ERCC1 was carried out. It was 
done in a central laboratory in seven studies and in an individual hospital in two. In studies 
assessing ERCC1 prospectively the time needed for results to be returned to the treating 
physician varied between a minimum of one to two days (assessment carried out in 
individual hospital, rather than central laboratory) to 14 days.  
The details of methods used are reported in Figure 7.5.  Where replies to the questionnaire 
were received, there was large variation in procedures for evaluation of ERCC1. RTqPCR 
was used in six and IHC in five studies. The type of specimen used also varied across 
studies: 
0
2
4
6
8
10
n
u
m
b
e
r 
o
f 
st
u
d
ie
s 
u
si
n
g
 a
n
 
a
ss
a
y
year of study initiation 
RTqPCR
IHC
ERCC1 gene expression
NER gene polymorphism
multiple methods
NR
 222 
 
 three studies used surgical resection only, 
 one study used biopsy only, 
 cytology on its own was not used, 
 three studies used surgical resection or biopsy,  
 one study used surgical resection, biopsy, or cytology, 
 one study used the combination of all three techniques together with cut sections 
on slides, 
 two studies did not report it. 
In the five studies where more than one technique to obtain the specimen was used, 
biopsy was used for the majority of samples. In four of these studies biopsy was the 
method of obtaining 60 to 90% of tumour samples, and for one study details on the 
frequency of use of different techniques were NR. 
In the five studies where ERCC1 was evaluated with IHC, the monoclonal 8F1 antibody 
was used in three studies (in 1:300 dilution in two and NR in one study), the ZSGB-Bio, China 
in one (in 1:50 dilution) and it was NR in one study. Ancillary methods were reported for 
two of these studies and did not appear similar.  
For obtaining an expression score four studies used the H-score and one study used the 
Allred Quick Score. The thresholds for classifying patients as positive were Allred Quick 
Score 6 and above, and for the H-score a value of 1 was chosen as the threshold in two 
studies and the median value in one study (analysis undertaken retrospectively).  
The percentage of patients classed as positive by IHC was 0.78 in one study, 0.6 in two 
studies, 0.25 in one study and NR in one study. 
In the six studies which used RTqPCR it appears that each study used a different set of 
primers, although this could not be established with certainty due to poor reporting. β-
actin on its own was used as the reference gene in four studies. In one study β-actin was 
used together with phosphoglycerate kinase (PGK) and in one study 18SrRNA was used. 
Three studies used the median as the threshold value, two selected a particular value and 
in one the threshold was not clearly reported.  Details of RTqPCR procedures used are 
reported in Table 7.3. Only two studies reported the method used to calculate the 
quantity of ERCC1 RNA and it was the ΔΔCT method. 
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The percentage of patients classed as ERCC1 positive was reported for two studies using 
RTqPCR and was 0.6 and 0.64. In one study it was reported that as it is an ongoing 
prospective study, the percentage is unknown. 
7.3.4 RATIONALE FOR CHOICE OF ERCC1 EVALUATION PROCEDURES 
The rationale for the choice of the procedure varied across studies, as shown in  
Table 7.4. The reasons provided were: experience of the laboratory, published literature, 
previous research experience (for example pilot study), a belief that the method of 
choice was superior or the limitations imposed by the type of tumour samples available. 
For one study it was declared that:  
“no rationale for the present time : the AB are not isoforms specific!! only one 
iosoforms is functional in DNA repair and no antibody recognises it 
specifically”. 
 
Table 7.3 Details of RTqPCR used in studies where information was returned 
study primers 
reference 
gene(s) threshold chosen 
EUCTR2008-001764-36-
IT  
(ITACA) 
exons-spanning β-actin 
median using ΔΔCT 
method (value NR) 
EUCTR2011-005267-24-
IT  
(CONTEST) 
don’t know (carried out by 
external laboratory) 
β-actin 
ratio of ERCC1 to 
reference gene 
transcripts: 0.14 (low), 13.4 
(high), Cut-off: 1.7 
NCT00174629  
(GILT Docetaxel) 
designed according to their Ref 
Seq  in 
https://www.ncbi.nlm.nih.gov/sites
/entrez?db/gene 
β-actin 
median using ΔΔCT 
method (value 3.4) 
NCT00705549 
“primers have been previously 
described in details (Papadaki et 
al BR J Ca)” – paper could not be 
identified 
β-actin and PGK 
unclear (“the cut-off was 
based on the a chart 
analysis in >800 samples”)  
NCT01194453 
primers spanning exons 7-9 of the 
ENST00000300853 ERCC1 
transcript: 
5’TCGTCTCCCGGGTGACTG 
3’and5’TTCTCTTGATGCGGCGATG
AG 3 
β-actin median (value NR) 
NCT00215930  
(MADe IT) 
intron-spanning primers  
housekeeping 
gene 18SrRNA 
above/ below 8.7 
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Table 7.4 Rationale for the choice of method of ERCC1 assessment in studies for which information was provided 
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EUCTR2007-007639-17-GB  
(ET) 
       
EUCTR2008-001764-36-IT  
(ITACA) 
       
EUCTR2011-005267-24-IT  
(CONTEST) 
       
NCT00174629  
(GILT Docetaxel) 
       
NCT00705549        
NCT00775385   
(TASTE) 
       
NCT01194453        
NCT01294280  
(LACE-BIO) 
       
NCT01781988  
(PTINCLC) 
       
NCT00215930  
(MADE IT) 
       
NCT00222404  
(Pharmacogenoscan) 
       
 
7.4 DISCUSSION 
There were 33 studies that met our inclusion criteria, ranging from phase 0 to phase IV. 
Fifteen of the studies used ERCC1 as an integral part of their design: either to allocate 
treatment or to stratify patients.  
The aim was to investigate whether the laboratory methods used for ERCC1 assessment 
have become more standardised since a meta-analysis published in 2011 found large 
variation.264 The findings suggest that there is still large variation in both the laboratory 
procedures and the tumour specimens used for ERCC1 evaluation. As indicated in section 
7.1, this could potentially suggest that results of trials using different methods may not be 
comparable, even though they appear to be evaluating the same biomarker. 
In fact, some small studies have suggested that classifying patients as ERCC1 positive and 
negative based on either RTqPCR or IHC can lead to relatively large discrepancies.275,309 
For example, one study investigating samples from 91 patients found that there was a 
statistically significant correlation between the ERCC1 mRNA and protein expression 
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levels. However when thresholds for classification of patients as positive and negative 
were used, 33% of tumours ERCC1 negative by RTqPCR were IHC positive and 32% IHC-
negative tumours were classed as ERCC1 positive using RTqPCR.310 These findings possibly 
suggest that both techniques cannot be used interchangeably.  
In this review even when the same assay was used the details of the laboratory 
procedures often varied. This could largely influence the comparability of results between 
different studies.  
Three out of five studies using IHC used the 8F1 antibody (Nomarkers). The use of the same 
antibody is crucial, as different antibodies bind to different epitopes and can therefore 
have different sensitivities and specificities.311,312 In two of the three studies using the 8F1 
antibody, the dilution was reported and it was the same. Consistency is again important, 
as antibody dilution can influence results and has been shown to influence the proportion 
of cells classed as positive for other biomarkers (HER2 and p53 expression).311 
There was also a large variation in the techniques used for RTqPCR, especially in terms of 
the primers used, which can have a substantial impact on the results obtained using this 
method.313 Five of the six studies used β-actin as the reference standard (in one case 
together with another gene). The choice of a reference standard can be challenging 
and several publications have suggested that levels of β-actin expression can vary and 
may not be a good reference standard.314,315 The thresholds chosen in individual studies 
also varied and, interestingly, three studies chose the median value obtained within the 
study. This seems to imply an assumption that half of the patients in these studies are 
resistant to platinum-based chemotherapy due to ERCC1 overexpression, however there 
seems to be no obvious reason for this assumption. 
An important factor involved in comparison of different RTqPCR experiments is the yield of 
the reverse transcriptase reaction which copies RNA into cDNA, which can largely 
influence the results.316 No information however was collected on this issue. There are 
numerous methods for calculation of the amount of the target RNA. Only two studies 
reported the method used and it was the ΔΔCT method. The threshold for classifying 
patients as positive did not show much variation, which is an encouraging finding, as for 
relatively consistent experimental procedures this would facilitate comparison of results 
from different laboratories.312 
Apart from the different tests used, the methods of tumour sample collection also varied 
between studies. A small study using IHC for ERCC1 assessment suggested that there 
might be a discrepancy in classifying patients’ ERCC1 expression levels depending on 
whether tumour tissue was obtained using biopsy or surgical resection.317 Another study 
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found discrepant results depending on whether a tumour sample was obtained (using a 
range of methods) from the primary tumour or a metastatic site.318 
Where reported, the proportion of patients classed as ERCC1 positive ranged from 0.25 to 
0.78. This would further suggest that the procedures and criteria used in different studies 
for classifying ERCC1 expression levels do not produce comparable results. It is however 
also possible that this variation is, for example, largely due to chance or ERCC1 is 
expressed at different levels in different NSCLC stages. 
When undertaking this review and questionnaire it was hypothesised that the highest 
variation in the choice of assays for ERCC1 assessment should be seen in early phase trials 
and higher levels of standardisation were expected for later phases. This was however not 
observed. There was relatively large variation in the methods chosen for ERCC1 
evaluation in phase II and III trials. There was also no evidence of a trend suggesting 
certain methods of ERCC1 evaluation became more popular at a particular time (for 
example due to publication of research suggesting one method could be superior). 
With regards to the rationale for the choice of a particular method, it was often motivated 
by experience of either the laboratory or the researchers involved, although for three 
studies published literature was also referred to.  
As recent research suggests there may be no ERCC1 assay capable of identifying a 
subgroup of patients more likely to benefit from platinum-based chemotherapy.271 This 
raises the issue of potentially unnecessarily enrolling patients in trials where ERCC1 is, or 
was integral to the trial design. This potentially resulted in suboptimal treatment of these 
patients and a suboptimal allocation of resources. 
This systematic review is based on a relatively small sample of studies and detailed 
information (obtained from the questionnaire) was limited to only 16 of these. The 
objective here was however not quantitative in nature, but to provide an example of 
large discrepancies in evaluation of a potential predictive biomarker. There is no reason 
to believe that this example is not representative of at least some stratified medicine 
research. A potentially similar situation was recently identified in programmed-death 
ligand 1 (PD-L1) testing in NSCLC, where multiple IHC assays using different antibodies are 
under development for four different drugs and there is still uncertainty with regards to 
how well these assays predict patient response.137 
From the perspective of reviewing evidence and implementing biomarkers in clinical 
practice, it would be ideal if there was one valid laboratory procedure used for biomarker 
evaluation in all studies. However, in practice this is unlikely to happen as the technology 
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in this field is rapidly developing. New laboratory procedures are being developed, which 
can potentially be cheaper, faster and more accurate. It is therefore not surprising that 
these are implemented in studies, although this review did not identify an effect of 
dissemination of new technologies on the choice of the laboratory procedures. This 
presents a challenge for implementing the findings of studies using different procedures in 
clinical practice, especially since, as some research on ERCC1 suggests, the results 
obtained using different procedures may not be comparable. Therefore there is a need 
for more research to ensure that procedures used to evaluate the same predictive 
biomarker actually stratify patients into comparable cohorts. 
7.5 CONCLUSIONS 
This example of ERCC1 evaluation in NSCLC highlights the need for a more structured 
approach to development and analytical validation of biomarkers prior to their use in 
clinical trials. Although on a superficial level it may appear that studies are using the same 
assay (for example IHC), variation in important details of the laboratory procedures may 
result in lack of comparability between results of different trials. If a test is to be used in 
clinical studies, especially later phase, ideally its accuracy should already be established. 
There also needs to be consensus on a standardised validated biomarker evaluation 
protocol to be followed in clinical trials, which would ensure there is a definitive procedure 
to be used in future clinical practice.  
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8.1 MAIN FINDINGS 
This thesis investigated the hypothesis that there is a mismatch between the theoretical 
proposals and practice of stratified medicine research, focusing on the clinical utility 
stage of predictive biomarker development.  
The theoretical approaches were ascertained by undertaking a systematic review of 
frameworks for staged evaluation of predictive biomarkers (Chapter 2) and by using a 
published systematic review of trials methodology relevant to clinical utility (Tajik 201378).  
The practice of stratified medicine research was identified in a systematic review of 
predictive biomarkers in EMA licensing followed by an analysis of the supporting evidence 
(Chapter 3-5). The methodology was then compared to practice in Chapter 6.  
Chapter 7 investigated the practice of stratified medicine research by focusing on the 
research designs and the aspects of trials related to the choice of laboratory procedures 
for biomarker evaluation. It undertook this through a case study of ERCC1 as predictive of 
response to platinum-based chemotherapy in NSCLC in studies that were ongoing or 
completed since 2007. 
8.1.1 WHAT ARE THE STRATEGIES FOR PREDICTIVE BIOMARKER DEVELOPMENT? 
Chapter 2 reviewed frameworks for staged evaluation of predictive biomarkers proposed 
in the literature. This was undertaken to find the most appropriate strategies that could 
lead to fit-for-purpose predictive biomarkers.  
The systematic review identified 23 papers describing complete frameworks. This thesis 
proposed four models based on the stages identified and the situation to which these 
were applicable. The general model (model I) offered the most comprehensive 
approach, suggesting the following stages: 
1) pre-discovery, 
2) discovery, 
3) analytical validation, 
4) clinical validation, 
5) clinical utility, 
6) implementation. 
The remaining three models may be considered to provide special cases of the general 
model. These focused on: biomarker development alongside phased drug development 
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(model II), development of multi-marker classifier (model III) and development of a safety 
biomarker when the drug is already on the market (model IV). Model III differed 
substantially from the remaining three, as it focused primarily on statistical issues. 
Study designs appropriate for each stage often varied both between the four models and 
the individual frameworks within these. For some stages, such as analytical validation, 
there was little information on the most appropriate research methodology.  
The clinical utility stage was reported in most detail and for this stage there was most 
agreement between frameworks. RCTs were generally considered the best choice. 
Depending on the situation, enrichment, stratified, or biomarker strategy designs were 
advocated. However, it was acknowledged that these may not always be feasible and 
subgroup analyses of RCTs, or even single-arm studies, may be permissible. 
Few of the papers provided clear guidance on when the laboratory procedures should 
be finalised or the threshold of a continuous biomarker selected. When these issues were 
discussed, there was little agreement and some suggestions included “locking” the assay 
on conclusion of the analytical validation, clinical validation, or clinical utility stage.  
The criteria for entry into and completion of each stage were also considered. These were 
rarely discussed in detail, beyond indicating that a previous stage should be completed. 
Interestingly, it was noted in two papers that prior to undertaking any research, the 
feasibility of development of a biomarker useful in addressing a given clinical problem 
should be established.50,130 
8.1.2 WHAT PREDICTIVE BIOMARKERS HAVE BEEN DEVELOPED? 
Chapter 3 investigated the predictive biomarkers included in EMA licensing. To facilitate 
analysis of the identified information, the idea of a B-I-D combination was introduced.  
The systematic review of EMA licensing identified 49 B-I-D combinations. This was fewer 
than expected, given the large research effort in this area. The number of B-I-D 
combinations considered by the EMA each year was small, reaching a maximum of 
seven. 
The majority of stratified medicines were found in cancer (60% of B-I-D combinations) and 
HIV treatments (31% of B-I-D combinations). There were also rare cases of biomarkers used 
in other disease areas such as HCV or cystic fibrosis.  
Most of the drugs were licensed and in three cases a negative recommendation was 
issued by the EMA. Ten of the 49 identified B-I-D combinations involved orphan drugs, 
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reflecting stratification of rare diseases. In the majority of cases the biomarker was 
included in the indication or contraindication at the time of the first licensing of the drug.  
All the identified biomarkers were molecular. In 45 B-I-D combinations the biomarker 
predicted drug efficacy and in four – drug safety. 
8.1.3 HOW WAS THE EVIDENCE CONSIDERED? 
Chapter 4 aimed to determine the issues that were important in decisions on licensing of 
a drug with predictive biomarkers in the indication or contraindication. 
Text analysis of EMA documentation relevant to the B-I-D combinations identified in 
Chapter 3 was undertaken. Forty one criteria grouped into 13 themes were identified from 
the 49 cases of recommendations. The most frequently commented on were:  
 theme 1: population (31 cases), 
 theme 2: study design (34 cases), 
 theme 7: clinical efficacy evidence (49 cases), 
 theme 8: toxicity (48 cases), 
 theme 9: context (40 cases), 
 theme 13: pre-efficacy evidence supporting the drug (33 cases). 
There were situations when some of the criteria were considered not met, however this did 
not preclude a positive recommendation. In some cases the study design was considered 
poor, yet the drug was licensed. Little attention was given to issues related to the 
biomarker assay (theme 10), as it was commented on in ten cases only. 
Critical issues in negative recommendations were also considered. The most frequently 
discussed were criteria within theme 7. In such cases, the evidence supporting the drug 
efficacy was considered insufficient. Other critical issues were related to theme 1, 2, and 
12 (pre-efficacy evidence supporting the biomarker).  
One B-I-D combination (alipogene tiparvovec for LPL protein positive lipoprotein lipase 
deficiency) was first given a negative recommendation but after EMA reconsidered the 
evidence, drug authorisation followed. This was analysed in more detail in a case study. It 
appeared that the two opposing conclusions were based on the same evidence, 
however in each case a different perspective was adopted by the EMA. For the positive 
recommendation, more weight was given to the context: lack of any alternative 
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treatment and rarity of the condition. This was in line with theme 9 being amongst the 
most frequently considered. 
8.1.4 WHAT WAS THE EVIDENCE? 
Chapter 5 aimed to investigate the level of evidence sufficient to include a predictive 
biomarker in an indication or contraindication. This was attempted in an analysis of the 
evidence base underpinning EMA decisions. The evidence standards for B-I-D 
combinations that were given a positive recommendation were compared with those for 
refusals of marketing authorisation. 
The criteria used in this chapter were based on the themes identified in Chapter 4 
together with general methodological concerns and focused on the evidence relating to 
the biomarker. These were concerned with the:  
1. population, 
2. design,  
3. type of primary outcome,  
4. sample size, and  
5. findings.  
Radial plots were constructed to summarise the evidence from these five criteria. In 
addition, the replication of findings of a single study and the consistency of the biomarker 
assay within a B-I-D combination were investigated. 
No clear picture was obtained of the standards required by the EMA. It appeared that 
the evidence was considered within a given context, rather than required to meet a 
certain standard. The available data were analysed in three sets of B-I-D combinations: in 
two of these the biomarkers predicted treatment efficacy and the drugs either did, or did 
not have an orphan designation; in the third, the biomarkers predicted treatment safety.  
For biomarkers predicting treatment efficacy and drugs without an orphan designation, 
the identified evidence levels varied. In two cases of negative recommendations, it 
appeared that the promising results of a single study have not been replicated. However, 
this was also the case for some of the B-I-D combinations which received a positive 
recommendation. Enrichment designs constituted 38% of studies in this part of the 
dataset, possibly reflecting a high proportion of targeted treatments. Non-randomised 
designs comprised 19% of the dataset and were frequently used in addition to RCTs. 
Sixteen percent of the studies were retrospective subgroup analyses. Some of these 
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included a relatively small subgroup of patients from the original study (for example 33% in 
the CO.17 trial237,238). Cross-sectional subgroup analyses were observed relatively 
frequently (16%) and only in HIV. This approach is likely due to the disease-specific 
context, which will be discussed below. 
For drugs with an orphan designation there was also little, if any, clear difference between 
the evidence base supporting the positive and negative recommendations. The majority 
of studies for these B-I-D combinations were either non-randomised (41%), mainly single-
arm, or case series and reports (48%). Ten percent of the studies were enrichment RCTs. It 
was however clear that in some cases patient numbers were relatively large with single-
arm studies including up to 353 patients.196 It appears that in such situations a randomised 
trial would have been feasible and would have provided more robust evidence. 
For biomarkers predicting treatment safety, the evidence requirements were minimal. In 
three of the four B-I-D combinations such a biomarker was based on the understanding of 
the drug mechanism of action or metabolism. However, in the fourth B-I-D combination, 
the biomarker was evaluated in a biomarker-strategy RCT. 
Only 15 B-I-D combinations were supported by studies which all used the same assay to 
evaluate the biomarker. The details of laboratory procedures were rarely reported, both in 
the EMA documents and the publications matched to the identified studies.  
8.1.5 HOW DID THE EVIDENCE COMPARE TO METHODOLOGY? 
Chapter 6 set out to compare the trials methodology suggested in Tajik 201378 to the 
evidence collected in Chapter 5. This was undertaken to assess the validity and limitations 
of the methodological framework proposed in the published review. The framework was 
also used to further evaluate the EMA dataset. 
Tajik 201378 contained six trial designs (single-arm, enrichment, randomise-all and three 
variants of biomarker-strategy RCT) that could provide information on one or more of 
eight questions. Of the 152 studies that had sufficient data to identify their design, 86 
matched those proposed in Tajik 2013.78  
The framework was therefore modified to include seven major study designs, four of which 
were further divided into subtypes. In particular, lower-level designs were added (case 
reports and series, other types of single-arm trials and non-RCT comparative studies). Six 
additional questions that could be addressed by studies were also identified. The Tajik 
201378 framework also appeared to strongly support study designs, that seemed to have 
little application in practice (three types of biomarker-strategy design).13 
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It was also noted that in published papers authors’ conclusions seemed to be mainly 
addressing questions possible to answer based on the study design, although there were 
cases where conclusions beyond these appeared to be made. The study labels used in 
publications did not often reflect the biomarker aspect of the study. 
The evidence supporting the 49 B-I-D combinations with available study designs was 
evaluated using the expanded framework. The questions addressed by these studies were 
considered. Information on whether the biomarker was predictive and the benefit of 
implementing a biomarker-based strategy was available only for 14 B-I-D combinations. In 
the remaining B-I-D combinations, studies mainly investigated activity or effectiveness 
within biomarker-defined patient groups. Some studies also investigated the correlation 
between the biomarker status and study outcome, or the prevalence of the biomarker in 
patients not responding to treatment.  
8.1.6 WHAT LABORATORY PROCEDURES WERE CHOSEN FOR ERCC1 EVALUATION AND WHY? 
Chapter 7 described a case study of ERCC1 expression in NSCLC to predict response to 
platinum-based chemotherapy. It attempted to identify the reasons for and the 
consequences of no standardisation in laboratory methods used for biomarker 
evaluation.  
A systematic review of trials that were either ongoing or completed since 2007 was 
undertaken. This was followed by a survey of trialists aiming to explore the variation in 
some analytical and pre-analytical factors, as well as the motivation for the choice of a 
particular biomarker assay.  
The systematic review identified 33 trials, ranging from phase 0 to phase IV. Fifteen of the 
studies used ERCC1 as an integral part of their design: either in a biomarker strategy (five 
single-arm, nine RCTs) or stratified design (one RCT). A reply to the survey was received for 
16 trials. 
Large differences were identified in the laboratory procedures and the tumour specimens 
used for ERCC1 evaluation. The most frequently used assays were RTqPCR (nine trials) and 
IHC (five trials). In seven cases the assay was NR. Even in cases when the same assay was 
used, the details of laboratory procedures were often dissimilar. This was particularly 
evident for the primers used in RTqPCR. The methods of tumour tissue collection also 
differed between studies. The identified variation did not appear to depend on the stage 
of the trial or the year of its initiation. 
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These discrepancies were possibly reflected in the proportion of patients classed as 
ERCC1 positive. Based on the replies to the questionnaire, this ranged from 25% to 78%.  
The rationale for the choice of a particular laboratory procedure was explored in the 
survey. This was often reported as based on experience of either the laboratory or the 
researchers involved, although for three trials published literature was also referred to.  
8.2 MISMATCH BETWEEN THEORY AND PRACTICE IN TRIAL DESIGN 
This thesis investigated a hypothesis that there is a mismatch between the theoretical 
proposals and the practice of stratified medicine research. Such discrepancies were 
found in a number of areas.  
8.2.1 MAIN FEATURES OF THE MISMATCH 
Out of the three major trial designs proposed in the methodological literature, the 
enrichment design was most frequently used and comprised 28% of the studies in the EMA 
dataset. It was most commonly encountered in B-I-D combinations where the biomarker 
predicted efficacy and the drug did not have an orphan designation. A single biomarker 
strategy trial was identified and there were no stratified designs.  
Subgroup analyses of RCTs constituted 25% of all studies in the EMA dataset and were only 
identified for efficacy biomarkers and drugs without an orphan designation. The majority 
of these were either retrospective or cross-sectional. The cross-sectional subgroup analysis 
was not mentioned in the theoretical literature, however it was commonly used in HIV 
trials.  
A relatively large proportion (27%) of the identified studies were non-randomised. These 
mainly comprised single-arm trials investigating the drug in biomarker positive patients, a 
design not recognised in Tajik 2013.78 The majority of such studies were part of the 
evidence base for B-I-D combinations where the drug had an orphan designation.  
Another relatively large group of studies were case series and reports in which the 
biomarker status was evaluated. These comprised 17% of the EMA dataset, however they 
accounted for almost half of the studies supporting drugs with an orphan designation. 
Again, these were not recognised in the theoretical literature, but seemed to be 
frequently used in research on rare conditions.  
Finally, in four B-I-D combinations (including three with the biomarker predicting safety) 
there were no studies that supported the biomarker. It appeared that the 
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recommendations were based solely on the understanding of the mechanism of drug 
action or metabolism. Such an approach has not been encountered in the 
methodological literature reviewed in Tajik 2013.78 In addition, Chapter 2 identified two 
frameworks focusing on development of safety biomarkers. However, none of these 
proposed omission of clinical investigation of potential predictive biomarkers.51,134 
Further investigation of stratified medicine practice was undertaken in the ERCC1 case 
study in Chapter 7. In spite of the lack of validation, this biomarker was often integral to 
the design, with one stratified and 14 biomarker strategy trials (five single-arm and nine 
RCTs). The relatively high frequency of biomarker strategy designs seems counterintuitive. 
Prior to the initiation of these trials the evidence supporting ERCC1 was relatively weak 
and the analytical validity of the available assays was apparently not established. In such 
a case a biomarker-stratified trial would have been more appropriate.49,61  
8.2.2 POSSIBLE REASONS FOR THE MISMATCH 
Understanding the reasons for the identified mismatch requires consideration of the fact 
that different scenarios may necessitate different approaches. In fact, the context in 
which research is undertaken was already identified as an important factor in Chapter 4 
and Chapter 5.  
Predictive biomarkers may be discovered at different stages of drug development:  
 before clinical development,  
 during clinical development, and  
 after marketing authorisation.91  
All of these result in different research designs appearing more appropriate from the 
perspective of a drug developer.  
For biomarkers identified prior to clinical development, an enrichment design might be 
the most attractive, possibly limiting the scale of the necessary research. There are 
numerous examples of targeted treatments where such a strategy has been 
implemented, including trastuzumab. 
Identification during clinical development may be, in some ways, the most challenging. It 
can possibly lead to either enrichment or stratified trials, depending on the exact time of 
biomarker discovery and the strength of the evidence supporting it. Such a case was 
however not observed in the dataset. 
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When biomarkers are identified after marketing authorisation, retrospective subgroup 
analyses using data from completed trials may be most convenient. This is exemplified by 
the KRAS mutation to predict the lack of response to cetuximab and panitumumab.  
Selection of designs will most likely depend on financial and time constraints. A large 
number of designs identified in the EMA dataset may offer substantial savings compared 
to more informative ones. For example, an enrichment trial requires less patients overall 
and possibly, a shorter follow-up compared to a stratified one. The other disincentives to 
undertaking a stratified design are the opportunity costs of such an investment.112 
However, an enrichment trial still requires screening all the eligible patients and may 
therefore result in a relatively long recruitment period.49  
From the perspective of a drug developer, prior to marketing, stratification may be 
actually advantageous when there is limited confidence in the biomarker. It may allow 
identification of a possible stratum of patients with improved response, and therefore a 
market where the price may be increased. If the biomarker turns out not to be predictive, 
it does not preclude future use of the drug in the unstratified population.112  
When there are completed studies with available biological specimens, undertaking 
retrospective subgroup analyses will require much less time and resources than 
conducting new trials.1 This often also corresponds to a situation when the drug is already 
on the market and the pharmaceutical company will likely lose future profits due to the 
shrinking demand for the drug and unlikely increase in its price.112 Therefore, investment in 
new trials will not appear attractive. Yet, there are examples, where an introduction of a 
predictive biomarker post-marketing actually increased the use of a drug. For abacavir 
treatment of HIV, the possibility of occurrence of a hypersensitivity reaction resulted in 
limiting its use. Introduction of a biomarker predictive of safety (HLA-B*5701 allele) 
increased the use of this drug in clinical practice.319 
Another mismatch was observed in cases of drugs with an orphan designation, where 
single-arm studies, case series and reports were extensively used. From the numbers of 
patients included in these research designs it appeared that more robust studies could 
have been undertaken. However practical reasons may explain the relative rarity of more 
adequate designs. The types of studies that were identified may be more convenient to 
undertake. They do not require randomisation, or blinding. Also, to ensure a sufficient 
number of patients for an RCT, an international trial may be required. These may be 
difficult to set up compared to smaller studies conducted within one country.  
In addition, the majority of such studies were identified in cancer. Arguably, in this clinical 
area a response may be relatively easily observed based on tumour shrinkage or the drop 
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in the concentration of leukemic cells in the blood. Such a response would be highly 
unlikely without treatment. However, the establishment of the correlation between tumour 
response and more clinically relevant outcomes, for instance overall survival, may be 
problematic,320,321 with examples of research providing mixed conclusions on the 
association.322-324 
There may also be ethical reasons for the choice of a particular trial design. When there is 
strong biological evidence suggesting that a treatment would not benefit biomarker-
negative patients, it may be unethical to expose them to possible adverse effects,257 
particularly if there are alternative treatments available. These considerations would 
generally result in trials including only biomarker positive patients. 
In Chapter 7 a biomarker strategy design was often used where a stratified design 
appeared more appropriate due to the limitations in the biomarker. Possibly, ethical 
reasons influenced the selection of the trial methodology. In this case, the biomarker use 
was to result in withdrawal of the standard care and this would be ethically problematic 
for patients likely to benefit. A similar case was identified for HLA-B*5701 allele predicting 
abacavir safety. This again resulted in withdrawal of potentially beneficial treatment and 
therefore the most appropriate design appeared to be a biomarker strategy trial.  
As noted in the methodological literature, the biological rationale for the use of the 
biomarker may impact on the design choice. In cases when there is strong evidence that 
a treatment would not benefit biomarker negative patients, there may be little reason to 
invest time and money in such research. This is generally the case for targeted drugs, 
which have been developed for patients positive for a particular biomarker. For example 
trastuzumab, discussed in detail in Chapter 2, was developed to bind the HER2 protein, 
therefore it was highly unlikely to provide benefit to patients whose tumours do not express 
this biomarker. Stratified and biomarker strategy designs may be used in cases where 
there is less biological evidence in support of the biomarker.  
Biological reasons are also responsible for the cross-sectional subgroup analyses identified 
in the EMA dataset. These were commonly used to identify viral resistance mutations 
predicting lack of response to HIV treatments. These studies can only determine the 
prevalence of the biomarker positive patients in non-responders. Although this evidence is 
highly limited, it has been used to support B-I-D combinations. More robust trials may not 
be feasible due to either possible presence of viral resistance mutations at low, sub-
detection level at baseline, or the evolution of such mutations in response to treatment.  
Different designs may also appear appealing depending on who is investigating potential 
predictive biomarkers. Due to the nature of the EMA dataset, this discussion 
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predominantly focused on the perspective of pharmaceutical companies. However, for 
example policymakers may be more interested in the consequences of implementation 
of a treatment strategy using a predictive biomarker. This would naturally result in a 
preference for the biomarker strategy design. Academic trials may be more likely to 
investigate potential biomarkers for existing treatments with a weaker evidence base, 
leading to more stratified trials.  
Furthermore, Chapter 6 identified that different designs are capable of answering 
different questions. Although it may appear beneficial to be able to collect as much 
information as possible, there are always opportunity costs of the research that may be 
conducted. In a proportion of cases, it may not be necessary to answer all questions. For 
purposes such as drug licensing the efficacy of the drug in the biomarker positive patients 
may be sufficient. This, of course, may result in difficulties in surmounting the so called 
“fourth hurdle” of reimbursement. For institutions such as the National Institute of Health 
and Care Excellence whether a biomarker is truly predictive could be of huge 
importance, as this may have implications for the cost-effectiveness of the treatment 
strategy. 
Finally, as noted in Chapter 1, there is a relative lack of regulatory standards focusing on 
predictive biomarker research, possibly resulting in suboptimal trials being conducted.91 
This may also add to the observed mismatch. 
8.3 OTHER OBSERVATIONS 
Apart from addressing the main hypothesis of this thesis, further observations were made 
on some issues important to this field. These are briefly discussed below. 
8.3.1 PROCEDURES FOR BIOMARKER EVALUATION  
The laboratory procedures for evaluation of predictive biomarkers rarely seemed to be 
considered of high importance. This was reflected by the criteria identified in Chapter 4. In 
addition, insufficient details were often reported in identified papers (Chapter 5) and 
study records (Chapter 7) to allow identification of the exact laboratory methods used. 
The importance of analytical validity of biomarkers appeared insufficiently considered in 
methodology, research practice and interpretation. It was infrequently discussed in EMA 
documents in Chapter 4 and omitted in a number of frameworks in Chapter 2. Chapter 7 
found that insufficiently validated biomarkers were used in clinical trials, including phase III 
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and IV. The choice of the assay for a clinical trial in some cases seemed to be motivated 
by the experience of a research group, rather than considerations of validity.  
It may be argued that validation of predictive biomarkers is expensive, particularly if it 
requires new studies.112 However, evaluation of biomarkers within trials may itself be costly. 
Also investigation of non-validated biomarkers may then result in generation of noise, 
rather than useful information.325,326 This was shown in the example of ERCC1, where 
findings obtained using a non-validated biomarker led to unnecessary trials. Therefore, 
contrary to some arguments, thorough validation of a biomarker early on in the 
development process may in fact result in a more efficient development strategy and 
facilitate engagement with regulators.112 
The issue of the biomarker threshold also seems to be rarely addressed. Little consideration 
was given to this topic both in papers addressing biomarker development in Chapter 2, 
and those reporting research in Chapter 5. As shown in Chapter 7, threshold selection can 
often be arbitrary. For example, some studies decided to retrospectively select a median 
value as the cut-off. However, there was no reason to believe that approximately 50% of 
patients would not respond to the treatment.  
An interesting approach to selecting threshold values was proposed in the FDA 
framework.47 It suggested that a grey zone may exist between the biomarker positive and 
negative patients. In such a grey zone, the decision on treatment cannot be based on 
the biomarker value, due to either inaccuracies in biomarker evaluation or uncertainty 
around the measurement of the clinical outcome. Based on the accuracy of available 
biomarker assays, for example the HercepTest, such grey zones may possibly be common. 
These should be recognised and taken into account in treatment decisions.  
Another approach to continuous biomarkers where a trial is undertaken including patients 
irrespective of their biomarker values has been proposed in the literature. No threshold is 
selected, but patient level survival curves are developed. These could allow individual 
treatment decisions to be made for each patient.327 Although this design seems to offer a 
more personalised approach, there may be some practical limitations to its 
implementation in clinical practice, including the challenges in funding such strategies. 
8.3.2 ROLE OF THE WIDER CONTEXT 
One of the recurring issues identified in this thesis was the impact of the context on the 
research undertaken and its interpretation. This seems intuitive and is often taken into 
account, at least to some extent, in methodological papers. These, for example, suggest 
 243 
 
that for targeted drugs an enrichment design might be most appropriate. However, issues 
such as the biomarker threshold (for continuous biomarkers) and accuracy seem to be 
rarely considered in the context in which the biomarker is developed. When there are few 
or no alternative treatments available, biomarkers that are good at ruling out patients 
unlikely to benefit may be appropriate. However, in situations where there are multiple 
options to choose from, biomarkers good at identifying patients most likely to respond 
may be more important. 
Another issue related to the wider context is use of information from other clinical areas to 
inform decisions. This was observed in some cases in the EMA dataset in Chapter 4. In 
some cases, evidence from other indications of the same drug or other drugs with a 
similar mechanism of action was used. One such example involved consideration of 
cetuximab for treatment of EGFR expressing NSCLC. It was noted that there appeared to 
be no effect of KRAS mutation status on treatment efficacy, which would normally be 
expected in the class of EGFR targeted treatments. Therefore, together with other 
reasons, this led to a negative recommendation for this drug.209 Formal incorporation of 
such considerations into trial designs, particularly for rare diseases, have been discussed in 
the theoretical literature,328,329 however their implementation in practice may be 
challenging.330 
8.3.3 CLINICAL AREAS 
It appears that successful stratified medicines have been developed mainly for cancer 
and HIV treatment. These diseases appear to naturally lend themselves to stratification. 
Cancer can be driven by a wide range of somatic mutations,27 differing between 
tumours.331 These can be used as targets for new drugs.75,332 Similarly, in HIV and a number 
of other viral diseases, there is a range of virus genotypes, which can be controlled by 
different drugs.75  
However, there are other clinical areas where there is large variability in patient response, 
and thus potential need for predictive biomarkers, such as mental health.333 Development 
of stratified medicines in these areas may be a difficult task.334 These diseases are often 
more complex, less well understood and their diagnosis based on symptoms, rather than 
molecular biology.333 This may render identification of relevant molecular biomarkers 
challenging. There have been some efforts to use other types of biomarkers, such as 
electroencephalography to predict response to treatment for major depressive 
disorder.335,336 These however do not seem ready for implementation in clinical practice. 
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Even in the clinical areas where stratified medicines are available, resistance to treatment 
may often emerge by evolutionary mechanisms.75,337 In addition, in HIV drug-resistant 
genotypes may be transmitted during primary infection.244 However, these may be 
present in quantities below detection level, at least using standard laboratory 
techniques.245 A similar problem exists in cancer where intra-tumour heterogeneity has 
been identified as an important problem.338 This may arise from the both genetic and non-
genetic differences between cells in the same tumour. It has also been shown that there 
are differences between primary tumours and metastatic sites.331,339 As different tumour 
cells may be characterised by different biomarkers, these may in fact be eligible for 
different treatments.339  
Combination therapy may offer profound improvements in treatment of evolving 
conditions and a way to address tumour and viral heterogeneity. This idea has already 
been implemented in HIV, where standard therapy involves drugs from different classes 
with different mechanisms of action.75 Improvements compared to monotherapy have 
also been shown in some cancers, for example in a trial investigating a combination of 
nivolumab and ipilimumab in melanoma.339 Such approaches may however require 
evaluation of biomarkers in multiple tumour samples, preferably from both the primary 
tumour and metastatic sites (if these are present). Implementation of combination 
therapy in cancer may also face some barriers. In particular, the high cost of cancer 
drugs may limit the use of combination therapy in practice. In addition, if a combination 
of stratified medicines is to be investigated, this may result in trials in small sub-
populations.75 As was shown in Chapter 5 and 6, the research methodology standards for 
such cases are relatively poor, and there may be a need to both further develop the 
available research designs and improve the research practice. 
8.4 STRENGTHS AND WEAKNESSES 
This thesis looked at both the theory and practice and therefore the identifications of 
these two aspects of stratified medicine needs to be considered.  
The theory was identified in two steps. First, a systematic review of frameworks for staged 
evaluation was undertaken in Chapter 2. This was based on broad literature searches and 
inclusion decisions were undertaken by two independent reviewers. However, the 
extraction, synthesis of data and construction of models was undertaken by one reviewer 
only and therefore some subjectivity might have been involved. 
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Secondly, the theoretical literature on trials methodology was identified in a published 
systematic review.78 This was found to have some limitations. However, these were unlikely 
to have led to missing major designs proposed in the literature. Further, there are 
arguments suggesting that systematic reviews of methodology do not need to identify all 
relevant papers, as there is a large repetition and the required information is not 
quantitative in nature.261,340 
The evidence on practice was obtained primarily from the EMA dataset and also from a 
case study of ERCC1 in platinum-based chemotherapy for NSCLC. Both datasets were 
identified in a systematic review with broad searches and two independent reviewers 
making inclusion decisions. However, again some limitations may be introduced by the 
data extraction and analysis being undertaken by one reviewer only. 
The use of the EMA dataset was in some cases limited by the level of detail included in the 
available documentation. This was addressed by an attempt to identify published papers 
that matched the studies in the dataset. This was not always possible, as some of these 
were reported in insufficient detail and others appeared to be unpublished.  
For identification of the issues considered by the EMA, documents were used that possibly 
do not provide a faithful record of actual discussions. These may still give some indication 
of the problems judged important enough to be reported. 
The EMA dataset was used for comparison of the theoretical literature to real cases of 
stratified medicine research. This dataset was somewhat selected and may not be 
representative of all stratified medicine. As licensing decisions were considered, only 
evidence supporting relatively successful drugs and biomarkers was included. Although 
there were a few cases where the EMA issued a negative recommendation, these were 
still representative of relatively strong cases. In situations where the evidence was 
extremely weak, a licensing application was probably not submitted. However, if the 
evidence in the EMA dataset is considered to represent the stronger cases, it appears to 
be painting a rather negative picture of stratified medicine.  
A different picture, at least with respect to trials methodology, emerged from the review 
of studies investigating ERCC1 in NSCLC in Chapter 7. This dataset included a high 
proportion of trials not sponsored by the pharmaceutical industry. It also provided a 
snapshot of the trials undertaken over a short period of time investigating a single 
predictive biomarker.  
The data available from ongoing trials databases are usually limited and do not always 
allow an understanding of the trial methodology and laboratory procedures to be 
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achieved. To address this, a survey of clinical trials was undertaken. A reply was only 
received from 48% of trials, in spite of a reminder being sent. This is a relatively low 
response rate. However, the identified lack of laboratory procedure standardisation 
across trials is likely to provide a picture of at least some stratified medicine research. 
8.5 IMPLICATIONS 
In spite of the wealth of methodological literature, there seem to be serious limitations in 
the actual research being undertaken. There appears to be little consistency in the 
standards for predictive biomarker development and evaluation. The interpretation of 
research evidence often takes into account the wider context. This is not surprising, 
however better understanding and incorporation of the context into research 
methodology may be necessary. 
The frequently used enrichment design is appropriate when the drug is very unlikely to 
provide benefit to biomarker negative patients. However, some doubts may exist as to 
whether the understanding of disease biology and drug mechanism of action is always 
sufficient to limit the investigation to biomarker positive patients. In addition, to use the 
enrichment design, acceptable analytical validity of the laboratory procedure to 
evaluate the biomarker needs to be established. However, these conditions do not 
always appear to be met. As shown by the example of BRAF mutations, the initial 
subgroup for which the treatment was developed proved to be narrower than that which 
actually benefited. This was discovered due to the inaccuracy of the assay used to 
evaluate the biomarker.176 Another example is provided by trastuzumab. Research 
suggesting that patients with HER2 expression levels below the original threshold may also 
benefit led the American Society for Clinical Oncology to modify the criteria for classifying 
patients as positive.341 This resulted in an increase in the proportion of patients eligible for 
treatment with trastuzumab.342 
Undertaking trials using biomarkers that have not been appropriately validated may result 
in large numbers of patients receiving suboptimal treatments, as well as substantial loss of 
resources. This was investigated in the ERCC1 case study, which is likely not an isolated 
case. Even when the biomarker does not influence the patient flow in the study, 
conducting analyses using non-validated assays should be an exception, as these may 
result in large costs and spurious findings. These can potentially lead to unnecessary trials, 
as shown for ERCC1. 
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The use of cross-sectional subgroup analyses in HIV led to limited evidence in support of 
the biomarker. The findings of such studies are often supported by in vitro assays, however 
these may not always translate into clinical outcomes.75 There is therefore a need to 
further understand and possibly improve the existing methodology that may be 
applicable to such situations. 
The relatively low number of biomarkers predictive of safety suggests these may need to 
be further developed, as adverse events related to treatment are still an important 
problem.10 It can be however argued that introduction of biomarkers predictive of 
efficacy improves the safety profile of a treatment. Assuming a random distribution of 
adverse events across all patients treated with a drug, the benefit-to-risk ratio will improve 
if a smaller number of non-responders are treated. There are cases where adverse events 
are more common in patients who are more likely to respond to treatment. For example, 
there is possibly a higher incidence of rash in patients responding to EGFR inhibitors.343 In 
such cases the benefit-to-risk ratio will however be no worse, as the mean efficacy will 
improve.112  
The clinical areas where predictive biomarkers have been developed are limited. There 
are few stratified medicines outside of cancer and viral diseases. This may be due to a 
number of barriers which were already discussed, however some of these concerns could 
potentially be addressed by more sound and transparent standards for biomarker 
development. 
Few studies investigated the problem of patients whose biomarker status cannot be 
established. The reasons may be varied and include the difficulty in access to tumour 
tissue (for example in lung cancer) and poor quality of samples.61,326 There were only five 
studies in the EMA dataset that attempted this. Presumably, such patients are often 
excluded from trials with a biomarker-driven design. However, these may constitute a 
substantial proportion of patients in clinical practice. The size of such a population is 
unclear, however based on a survey of laboratories evaluating EGFR mutation in NSCLC, 
this may be as much as 10% of all samples.344 Some recent trials, for example FOCUS4,82 
have incorporated this subgroup into their design. 
Finally, one of the observations in this thesis was the poor reporting of biomarker 
evaluation methods in the identified trials. These details are necessary to replicate the 
findings of trials and use them for secondary research and decision making in healthcare. 
This is particularly important, given that variation in the laboratory procedures may result in 
large differences in the biomarker values. Reporting guidelines may be necessary for 
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stratified medicine trials, possibly similar to those proposed for prognostic tumour marker 
studies (REMARK).220 
8.6 PRIORITIES FOR FUTURE RESEARCH 
Two major areas of priority have been identified in this thesis. 
8.6.1 SYSTEM FOR BIOMARKER EVALUATION AND HIERARCHY OF EVIDENCE 
No clear standards for biomarker evaluation were identified. Establishment of such 
standards could potentially be facilitated by consensus on the strategies for development 
of predictive biomarkers. Implementation of a rigid, sequential framework, as those 
reviewed in Chapter 2 may not be feasible. This was recognised when in 2005 the FDA 
published a concept paper describing such a framework. It met with criticism for being 
inflexible,345 resulting in it not being implemented. However, a set of issues to be 
addressed within a biomarker development programme may be sufficient. Analytical 
validation of biomarkers and development of broad consensus on the appropriate 
laboratory procedures needs to take place at a time that will facilitate efficient 
development of stratified medicines and prevent cases such as that described in Chapter 
7. 
In terms of methodology for investigating clinical utility, more attention should be given to 
the choice of a correct trial design. An agreement on a hierarchy of evidence taking into 
account the context of biomarker development would be ideal.  
8.6.2 BIOMARKER THRESHOLD 
Issues associated with the threshold for continuous biomarkers were rarely considered. Its 
choice, however, may be crucial to the predictive biomarker evaluation and 
maximisation of patient benefit. The optimal point (or range of points) in the biomarker 
development process for the identification of a threshold should be established. There is 
also a need for clear methodological standards for the determination of a cut-off, which 
would take into account the uncertainties in the evaluation of biomarker values. It needs 
to be recognised that revisions to the threshold may be necessary in some cases. The 
impact of such revisions on the interpretation of previous research should also be 
considered. 
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Such decisions should ideally be undertaken by a multidisciplinary panel. However, more 
thought is required on the appropriate composition of such a panel. There may also be a 
need for a mechanism that would allow standardisation of the threshold across different 
research teams. 
8.7 CONCLUSIONS 
This thesis identified the theoretical proposals for development and evaluation of stratified 
medicines. It also analysed a large sample of studies that represent the research practice 
in this area. This was done by investigating the reasons for and the evidence underlying 
EMA recommendations. In addition, practice was investigated in a case study of ERCC1 
for prediction of response to platinum-based chemotherapy in NSCLC.  
The theory and practice were then compared and a mismatch between the two was 
identified. It appeared to be a result of both the practice not following some theoretical 
requirements, and the underdevelopment of methodology for certain situations.  
Areas where further methodological developments may be necessary were identified 
and potential barriers to the implementation of the most appropriate methodology 
discussed.  
The major research priorities identified in this thesis were development of a clear hierarchy 
of biomarker research designs and development of methodology related to the 
biomarker threshold.  
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aCML  atypical chronic myelogenous (or myeloid or myelocytic) leukemia  
ADME absorption, distribution, metabolism and excretion 
AIDS acquired immune deiciency syndrome 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukaemia 
ART anti retroviral therapy 
AUC area under the curve 
BC breast cancer 
B-I-D Biomarker-Indication-Drug 
BM biomarker 
BSC best supportive care 
CAT Committee for Advanced Therapies 
CFTR Cystic Fibrosis Transmembrane Conductance Regulator 
CHMP Committee for Human Medicinal Products 
CI confidence interval 
CML chronic myelogenous (or myeloid or myelocytic) leukemia 
CMML  chronic myelomonocytic leukaemia  
CNS central nervous system 
CR complete response 
DAVG4 time weighted mean change in plasma HIV-1 RNA (log10 copies/ml) from 
baseline to week 4 
DAVG24 time weighted mean change in plasma HIV-1 RNA (log10 copies/ml) from 
baseline to week 24 
DLT dose limiting toxicity 
DNA deoxyribonucleic acid 
ECOG PS Eastern Cooperative Oncology Group performance status 
EGFR epidermal growth factor receptor 
EMA European Medicines Agency 
EPAR European Public Assessment Report 
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ERCC1 Excision Repair Cross-Complementation Group 1 
FDA Food and Drug Administration 
FISH fluorescence in situ hybridization 
FFPE formalin fixed paraffin embedded 
FOLFOX-4 chemotherapy regimen comprising folinic acid (leucovorin), fluorouracil, 
and oxaliplatin 
GWAS genome wide association study 
HAART highly active antiretroviral therapy 
HER2 human epidermal growth factor receptor 2 
HIV human immunodeficiency virus 
HLA-B the human leukocyte antigen, class I B 
HMG high mobility group 
HR hazard ratio 
IHC immunohistochemistry 
IOM Institute of Medicine 
iv. inravenous 
KRAS Kirsten rat sarcoma viral oncogene homolog 
mg miligrams 
mRNA messenger RNA 
N number 
NA not available 
N/A not applicable 
NER nucleotide excision repair 
NNRTI non-nucleoside reverse-transcriptase inhibitors 
NPV negative predictive value (of a test) 
NRTI nucleoside reverse-transcriptase inhibitors 
NR not reported 
NSCLC non-small cell lung cancer 
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OD once daily 
OS overall survival 
PCR polymerase chain reaction 
PD progressive disease 
PDGFR Platelet-derived growth factor receptor 
PDGFR Platelet-derived growth factor receptor alpha 
PE paraffin embedded 
PFS progression free survival 
PI protease inhibitor 
PPV positive predictive value (of a test) 
PR partial response 
RCT randomised controlled trial 
RNA ribonucleic acid 
ROC receiver operator characteristic 
RT-PCR reverse transcriptase polymerase chain reaction 
RTqPCR reverse transcriptase quantitative polymerase chain reaction 
s.c. subcutaneous 
SD standard deviation (for continuous data) 
SD stable disease (in context of assessment of tumour response) 
SE standard error 
TTP time to progression 
WHO World Health Organisation 
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Adaptive trial design - includes an opportunity for modification of specified aspects of the 
“design and hypotheses based on analysis of data (usually interim data) from subjects in 
the study”1 
Basket trials - investigate a single drug in a range of diseases; often utilised as discovery 
tools  
Biomarker – accorfing to US National Institute of Health workshop: “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention.”2  
Biomarker strategy design - patients are included in the trial irrespective of their biomarker 
status, patients are randomised to receive biomarker-determined therapy or therapy 
independent of the biomarker status; outcomes in both arms are compared 
Case report – detailed report on individual patient(s) management, here defined as 
including five patients or less 
Case series - small observational study without a clear design, here defined as including 
more than five patients 
Diagnostic biomarker - “used in people with signs or symptoms to aid assessing whether 
they have a condition.”3 
Efficacy biomarker – biomarker predictive of treatment efficacy 
Enrichment (or targeted) design - only biomarker positive patients are included in the trial 
– they are randomised to a different treatment and the effect is assessed in biomarker 
positive patients only. 
Factual statement – usually referred to as a positive statement, however this term will not 
be used to avoid confusion; describes a fact without providing any value judgement  
ICD10 classification-  
Main study (EMA) – studies labelled as “main” within the EMA documentation generally 
form the major part of the evidence supporting a drug indication; these are often 
accompanied by studies labelled as “supportive”  
Necessary condition – if A is a necessary condition for B to happen, if the condition A is 
not met, B will not happen (~A → ~B) 
Non-RCT biomarker study - any non-randomised study where the biomarker evaluation is 
part of the study design 
Normative statement – provides a value judgement 
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Orphan drug – possessing a designation granted by the EMA to drugs intended for the 
treatment of a life-threatening or chronically debilitating condition which is either 
affecting no more than 5 in 10,000 people in the EU or when the revenue is unlikely to 
cover the investment in drug development.4 
Predictive biomarker – used: (1) for prediction of patient outcome (either in terms of 
efficacy or safety), and (2) in the context of a particular treatment. 
Prognostic biomarker - “associated with a differential outcome regardless of the therapy 
given, even if choice of therapy is available”.5 
Prospective-retrospective design – using specimens and dara from a completed RCT; a 
protocol should be developed to test the biomarker hypothesis prior to any analysis of 
archived specimens 
RCT subgroup analysis (cross-sectional) - patients are included in the trial irrespective of 
their biomarker status, after conclusion of the trial a subgroup of patients (either from one 
treatment arm only or from multiple treatment arms) is identified based on outcome (for 
example lack of response to treatment) and the biomarker (or a panel of biomarkers) is 
assessed in this group – the final information provided is the prevalence of the biomarker 
in the subgroup of patients 
RCT subgroup analysis (prospective) - patients are included in the trial irrespective of their 
biomarker status, a subgroup analysis based on the biomarker is planned in the study 
protocol and the biomarker is measured in the beginning of the trial 
RCT subgroup analysis (retrospective) - patients are included in the trial irrespective of 
their biomarker status, after the conclusion of the trial a biomarker subgroup of interest is 
identified, the biomarker status is tested (using, for example, archival tumour samples) and 
a subgroup analysis is performed 
Safety biomarker – in this thesis: biomarker predictive of treatment safety 
Scientific Discussion (EMA) – document discussing the properties and clinical evidence 
supporting a drug in detail; published on EMA website 
Single-arm biomarker strategy study – equivalent to the biomarker-strategy arm of the 
biomarker-strategy RCT 
Single-arm study including only biomarker positive patients – equivalent to one arm of the 
enrichment design 
Single arm study including patients irrespective of biomarker status - all patients are 
included irrespective of biomarker status and all receive the experimental treatment; the 
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biomarker is measured in all included patients to identify a subgroup responding to the 
treatment 
Stratified design - patients are included in the trial irrespective of their biomarker status 
and randomisation is stratified by the biomarker status; the analysis plan involves the use 
of the biomarker information 
Stratified medicine – approach where “a patient can be found to be similar to a cohort 
that has historically exhibited a differential therapeutic response using a biomarker that 
has been correlated to that differential response.”6 
Sufficient condition – if A is a sufficient condition for B to happen, if the condition A is met, 
B will happen (A → B) 
Summary of Product Characteristics (EMA) – document that sets out the position of the 
drug obtained in the assessment process and summarises its properties and clinical use 
together with the clinical trial evidence that was considered by the EMA;7 published on 
EMA website 
Supportive study (EMA) – studies labelled as “supportive” within the EMA documentation 
often accompany main studies supporting a drug indication and may be less robust, still 
ongoing without mature data, or reporting on the effectiveness of the drug in a slightly 
different population 
Umbrella trials - investigate multiple drugs associated with multiple predictive biomarkers; 
patients are assigned to the appropriate treatment based on their biomarker status 
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3.1. HER2 DISCOVERY 
In the early 1980s information started to emerge on the involvement in cancer of a family 
of proteins called erbB epidermal growth factor receptor tyrosine kinases. The first 
member of this family to be discovered was the EGFR.8 It was established that apart from 
stimulating cell growth and proliferation, activation of EGFRs in tumour cells may help 
them to evade the immune system, which normally would destroy the cancerous cells.9 
In vitro and in vivo experiments showed that DNA from certain neuroblastoma and 
glioblastoma cell lines was capable of inducing cancer in non-cancerous tissues.10 By the 
mid-1980s these cell lines were discovered to contain a new member of the erbB protein 
family, which was called “p185”, reflecting its relative molecular mass of 185,000. Because 
of its similarity to EGFR, p185 was thought to also perform the role of a growth factor 
receptor. The hypothetical gene coding for this protein was named “neu”. It was 
speculated that the gene has a normal counterpart (proto-oncogene), which, on 
mutation may become oncogenic.11  
Further research, published in 1985, led to the identification of the DNA sequence coding 
p185. The protein was found in a range of non-cancerous human tissues. The ligand for 
p185 was unknown. However, based on structural similarity, this protein was considered to 
be closely related to the human EGFR and was thus called “human EGF receptor 2”, or 
HER2 for short.12,13 
A year after the publication of the HER2/neu sequence, another paper demonstrated 
that a particular point mutation is sufficient to turn the proto-oncogenic HER2 into its 
oncogenic version.14  
3.2. CLINICAL SIGNIFICANCE OF HER2 
The first large-scale study exploring the clinical significance of HER2 was published in 1987. 
It analysed tumour tissue samples from 189 women with breast cancer. HER2 amplification 
(increase in the number of gene copies) was evaluated in 103 primary breast tumours 
using Southern blotting. The gene was amplified in 19 (18%) of the cases and it appeared 
to be correlated with lymph node involvement. The number of HER2 gene copies varied 
from two to over 20. To investigate HER2 further, 86 breast tumours from patients with 
node-positive disease were used. These were considered more likely to include cases of 
HER2 amplification. In this group of patients the HER2 gene was amplified in 34 (40%) 
patients. The correlation of HER2 amplification with the number of nodes involved 
appeared even stronger. When data on survival and time to relapse for the 86 node 
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positive patients was considered, it was found that HER2 amplification appeared to be a 
very good prognostic factor – second only to the number of nodes involved. Importantly, 
the vast majority of HER2 genes evaluated for amplification appeared normal – mutation 
was detected in three cases only.15  
It was thus proposed that HER2 amplification (potentially leading to an increase in the 
protein product) results in a more aggressive breast cancer, at least in node-positive 
patients.15 Subsequent attempts at replication of these findings in further small studies by 
other teams led to mixed results.8  
A large retrospective study, including 526 patients with breast cancer was then 
undertaken by scientists involved in the original prognostic study. In a multivariate analysis 
it found that in 345 node-positive patients HER2 amplification (evaluated using Southern 
blotting) was an independent predictor of both relapse and overall survival. Again, the 
only superior predictive factor was the number of involved nodes. For the remaining 181 
patients with node-negative disease HER2 amplification was not a significant prognostic 
factor.16 
To confirm the biological rationale for this association, further investigation was 
undertaken into the relationship between HER2 gene amplification and expression at the 
level of RNA (evaluated using Northern blotting) and protein (evaluated using both 
immunohistochemistry (IHC) and Western blotting). Sufficient samples were available from 
187 patients to evaluate them using all four laboratory techniques. This was done without 
knowledge of the results of the other assays. A strong correlation between the results 
obtained using all four laboratory techniques was found. However, in18 cases there was 
clear HER2 over-expression measured both at RNA and protein level, but no gene 
amplification. The results obtained for RNA levels and Western blotting were less 
convincing.16 
The suggestion that increased expression of the HER2 proto-oncogene (non-mutated 
gene) may be sufficient to drive cancer was then confirmed in in vitro experiments.17 It 
was later shown that overexpression of HER2 also appears to help tumour cells evade the 
immune system.18  
3.3. DRUG DISCOVERY 
Although several groups attempted to use monoclonal antibodies to inhibit growth of cell 
lines overexpressing HER2,8 it was the Genetech research that lead to a successful 
compound.8 
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In 1989 human tumour cells overexpressing HER2 were treated with a number of different 
mouse antibodies directed against the extracellular part of the HER2 protein. In particular, 
one of these (muMAb 4D5) led to the most extensive in vitro inhibition of tumour 
proliferation and showed high specificity for HER2. It also appeared that this antibody 
sensitised tumour cells to control by the immune system.19 Other studies followed, 
exploring a range of antibodies to HER2. One such study investigated 10 mouse 
monoclonal antibodies20 and again the most promising appeared to be muMAb 4D5. This 
antibody was selected by Genetech for further development.9 Interestingly, one of the 
antibodies also investigated at that time was muMAb 2C4, later developed into 
pertuzumab.21  
3.4. PRE-CLINICAL DEVELOPMENT OF MUMAB 4D5 AND PHASE I TRIAL 
Discovery of the muMAb 4D5 antibody was followed by in vivo proof of concept studies. 
In one such study mice with human breast and ovarian tumour xenografts overexpressing 
HER2 were used. The animals were injected with a range of muMAb 4D5 doses and a 
control antibody inactive against HER2. Ten days after initiation of treatment, the weight 
of the tumours was shown to decrease with an increase in dose of the antibody. It was 
also shown, using a radioactive iodine–labelling, that the muMAb 4D5 localised to the 
tumour tissue overexpressing HER2.9 
As muMAb 4D5 was a molecule of mouse origin, it was likely that using it in human 
patients would result in an immune reaction – the production of human anti-mouse 
antibodies. This was confirmed in a phase I trial including 12 patients with HER2 
overexpressing breast and ovarian tumours. It showed that muMAb 4D5 was well 
tolerated and localised to tumour tissue, but a human anti-mouse response was observed, 
limiting the therapeutic use of muMAb 4D5.9 
3.5. PRE-CLINICAL DEVELOPMENT OF THE HUMANISED ANTIBODY  
To address the issue of development of the immune reaction, a series of humanised 
antibodies were prepared and investigated in in vitro experiments. An antibody labelled 
huMAb 4D5-8 showed the highest affinity for HER2 and one of the best inhibitions of cell 
proliferation. It was also shown to have little effect on a cell line obtained from normal 
tissue, thus promising limited adverse events.22 HuMAb 4D5-8 later became known as 
trastuzumab, or Herceptin.8  
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Further animal research showed that trastuzumab appeared to have synergistic 
interactions with certain chemotherapeutic drugs such as cisplatin, docetaxel and 
cyclophosphamide. It was also demonstrated to have an acceptable safety profile when 
administered over a long period to a range of animals including primates.8 The research 
into this drug was therefore advanced to phase I clinical trials. 
3.6. PHASE I TRIALS OF TRASTUZUMAB 
Three phase I trials of trastuzumab were undertaken, as shown in Table 5. Recruitment to 
the first one opened in June 1992 and closed for the last one in March 1993. All of these 
trials included patients with refractory metastatic breast cancer whose tumour was 
overexpressing HER2 (although the assay used to evaluate the biomarker was not 
reported). The earliest trial (Ho407g) investigated a single dose of the drug. The following 
two trials investigated a weekly dose schedule of trastuzumab either as monotherapy 
(Ho452g),23 or in combination with cisplatin (Ho453g).24  
Table 5 Phase I trials of trastuzumab 
Study Ho407g8,9,23-25 Ho452g8,9,23-25 Ho453g8,9,23-25 
Number of patients 16 17 15 
Inclusion criteria Refractory metastatic breast cancer, HER2 positive 
HER2 evaluation NR NR NR 
Design Open-label single-arm including only biomarker positive (details of dose escalation NR) 
Recruitment of first-
last patient  
1 June 1992 - 27 July 1992 9 November 1992 – 4 March 
1993 
6 October 1992 – 26 
October 1992 
Treatment trastuzumab (single dose 
10-500 mg iv.) 
trastuzumab (weekly dose 
10-500 mg iv.) 
trastuzumab (weekly dose 
10-500 mg iv.) + cisplatin 
(50 or 100 mg/m2) 
Outcomes assessed Safety, maximum tolerated dose,  pharmacokinetics 
iv. intravenous; NR – not reported 
These studies showed that administration of trastuzumab was safe. A dose limiting toxicity 
was not reached.25 The half-life of the drug was established to be 8.3 days.8 There was 
also no evidence of development of anti-trastuzumab immune response. Encouragingly, 
four patients in the combination trial with cisplatin demonstrated objective response to 
treatment.9 
Based on these results a dose schedule for phase II trials was established. It was to involve 
a 250 mg loading dose followed by 100 mg weekly dose. This was expected to ensure 
that for over 90% of patients, the target blood serum concentration anticipated to 
provide clinical benefit would be exceeded.26 Such a schedule was also considered 
appropriate due to the safety profile of the drug.9  
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3.7. PHASE II TRIALS OF TRASTUZUMAB 
The phase II trials are shown in Table 6. These recruited patients between March 1993 and 
September 1996 and evaluated trastuzumab as monotherapy(Baselga 199626 and 
Cobleigh 199927) or in combinations with cisplatin (Pegram 199828). The largest and final 
phase II trial introduced a new dose schedule based on body mass.27  
Table 6 Phase II trials of trastuzumab 
Study Baselga 199626 Pegram 199828 Cobleigh 199927 
Number of patients 46 39 222 
Inclusion criteria Metastatic breast 
cancer, HER2 positive 
Metastatic breast cancer, 
resistant to 
chemotherapy, HER2 
positive 
Metastatic breast cancer, 
resistant to chemotherapy, 
HER2 positive 
HER2 evaluation Tumour tissue - IHC 
using muMAb 4D5;  
Threshold: ≥25% cells 
staining positive 
Tumour tissue – IHC using 
muMAb 4D5;  
Threshold: >10% cells 
staining 2+ (light to 
moderate) or 3+ 
(moderate to strong) 
Tumour tissue - IHC using 
muMAb 4D5 and CB11*;  
Threshold: >10% cells staining 
2+ (light to moderate) or 3+ 
(moderate to strong) 
Design Open-label single-arm including only biomarker positive 
Recruitment of first-
last patient  
15 March 1993 - 14 
June 199423 
31 March 1993 – 25 May 
199423 
12 June 1995 - 25 September 
199623 
Treatment Trastuzumab (iv. 250 
mg initial dose 
followed by 100 mg 
weekly for 10 weeks); 
possibility of 
subsequent 
maintenance if no 
progression 
Trastuzumab (iv. 250 mg 
initial dose followed by 
100 mg weekly for 8 
weeks) + cisplatin (75 
mg/m2 on day 1, 29 and 
57); possibility of 
subsequent maintenance 
if no progression 
Trastuzumab (iv. 4 mg/kg 
initial dose followed by 2 
mg/kg weekly until 
progression); on progression 
allowed: continuation of 
treatment, increase in dose to 
4 mg/kg, discontinuation, 
additional treatment  
Major outcomes 
assessed 
overall response 
duration of response 
TTP 
overall response 
duration of response 
TTP 
overall response 
duration of response 
TTP 
Overall survival 
Follow-up NR, 43 patients were 
assessable at day 77 
NR; 37 patients were 
assessable at day 70 
NR 
Main  results At day 77 (n=43):  
1 CR, 4 PR, 16 SD, 22 
PD 
For non-PD patients 
given maintenance 
therapy  median 
TTP=5.1 months (range 
NR) 
At day 70 (n=37):  
0 CR, 8 PR, 10 SD, 19 PD; 
For non-PD patients given 
maintenance therapy 
median TTP=5.3 months 
(range 1.6, 18) 
Tumour response (n=213):  
Investigator assessment: 9 CR, 
37 PR, 74 SD, 93 PD; 
independent committee 
assessment: 8 CR and 26 PR, 
NR SD, NR PD; 
Median time to treatment 
failure = 5.4 months (range 0, 
27.4 months) 
TTP NR 
Median overall survival 13 
months (range 0, >30) 
IHC – immunohistochemistry, iv. intravenous; NR – not reported, TTP – time to progression, CR – complete 
response, PR – partial response, SD – stable disease, PD – progressive disease 
*The reason why and how these were combined was not reported 
These trials were all single-arm and evaluated the drug only in HER2 IHC positive patients. 
The IHC assay utilised the muMAb 4D5 antibody across all three trials. However, in the 
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largest trial an additional antibody was used (CB11*).27 The threshold for considering 
patients as HER2 positive was also changed from ≥25% of cells staining positive in the first 
trial26 to >10% cells staining either lightly (referred to as 2+) or strongly (referred to as 3+) in 
the following two.27,28 
The percentage of patients in the monotherapy trials who responded to treatment (either 
CR or PR) was 11%26 and 15% (or 21% when assessed by investigators).27 19% of the 
patients responded to the combination of trastuzumab with cisplatin.28 The median time 
to loss of response ranged from 5.1 to 5.4 months. In the combination therapy trial the 
median overall survival was 13 months (range 0, >30 months). The drug was also shown to 
be relatively safe and anti-trastuzumab antibodies were not detected.26-28 
3.1. DEVELOPMENT OF COMMERCIAL ASSAY (HERCEPTEST) 
In December 1996 Genetech started a partnership with a diagnostics company (DAKO) 
to develop a commercial HER2 expression assay - HercepTest.29,30 
A number of reproducibility studies were also undertaken, as shown in Table 7.  
HercepTest was also compared to the assay used in clinical trials (IHC, antibody NR) in a 
study using breast cancer specimens not obtained in any of the trastuzumab trials. It was 
assumed that concordance between the two assays lower than 75% would be 
unacceptable. 1190 tumour specimens were evaluated using the clinical trial assay. All 
positive specimens (n=274) and an equal number of negative specimens selected 
randomly were then evaluated using HercepTest. Results of the study are summarised in 
Table 8, showing a 79% (95% CI: 76, 82%) concordance between the two tests for the 
dichotomous classification. Based on the data the sensitivity of HercepTest was 0.79 
(95%CI: 0.73, 0.83) and specificity of 0.78 (95% CI: 0.73, 0.83).31 There were however 
relatively large discrepancies with regard to the 2+/3+ staining. 
 
                                                                
* The reason why and how these were combined was not reported 
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Table 7 Reproducibility studies undertaken in development of HercepTest 
Study type Details 
Intra-run Five specimens were examined three times each in a random order. Both 
manual and automated laboratory procedures were used and the 
investigators were unaware of which specimen they were evaluating. There 
were no discordant results obtained with regards to classifying samples as 
positive or negative.31 
Inter-run Five specimens were examined in multiple runs (number NR) in a random 
order. The investigators were blind to which specimen they were evaluating. 
The reproducibility was described as satisfactory (further details NR).31 
Inter-
laboratory 
40 fresh specimens were evaluated by 6 laboratories using both manual and 
automated laboratory procedures. Three of the laboratories produced invalid 
results. The reasons for this were available in two cases, where the exact 
laboratory procedures were not followed. As a result, the kit labelling was 
improved. The agreement between the results obtained by the three 
laboratories which provided valid results ranged from 82 to 90% for the 
dichotomous (positive/ negative) classification, corresponding to 15 
discrepant results. A further 12 discrepant results were produced for the 2+ 
and 3+ classification.31 
Lot-to-lot Three different lots of HercepTest were used in a single laboratory to evaluate 
three cell lines with known levels of HER2 expression, two breast tumours 
expressing HER2 and HER2 negative tonsil tissue. All three lots produced 
identical results for the cell lines and tonsil tissue. Two lots produced identical 
results for the tumour tissues. One lot produced one discrepant result for the 
breast cancer sample.31 
 
Table 8 Study evaluating HercepTest accuracy in 574 tumour tissue samples31 
  Clinical trial assay 
  negative positive 
 0 and 1+ 2+ 3+ 
H
e
rc
e
p
Te
st
 
negative 0 and 1+ 215 50 8 
positive 
2+ 53 57 16 
3+ 6 36 107 
To confirm the accuracy of HercepTest, another study was undertaken using 168 breast 
tumour specimens which had been previously characterised using five different methods 
of HER2 evaluation, including IHC. The results are shown in Table 9, indicating 85% 
concordance (95% CI: 78, 89%), a sensitivity of 0.6 (95% CI: 0.5, 0.7) and a specificity of 1 
(95% CI: 0.95, 1). No information was available on the 2+ and 3+ classification.31 
 304 
 
Table 9 Study evaluating HercepTest accuracy in 168 well characterised tumour samples31 
 Reference classification 
negative positive 
HercepTest 
negative 99 26 
positive 0 43 
In 1998 HercepTest was approved by the FDA as “an aid in the assessment of patients for 
whom Herceptin (trastuzumab) treatment is being considered.”29,30 
3.2. PHASE III TRIAL 
A randomised phase III trial (known as H0648g) recruited 469 HER2 positive patients with 
progressive metastatic breast cancer between June 1995 and March 1997. Their 
biomarker status was determined using IHC (antibody was NR) where 2+ or 3+ staining in 
>10% of cells was classed as positive.32 The details of this trial are shown in Table 10. It is 
also included in the datasets in Chapter 5 and Chapter 6 in the main text. 
The trial demonstrated that trastuzumab added to chemotherapy was superior to 
chemotherapy alone. It also appeared that the benefit was higher in the group of 
patients treated with trastuzumab and paclitaxel compared to trastuzumab and 
anthracycline + cyclophosphamide. The authors also noted that patients with a 3+ IHC 
score seemed to be obtaining more benefit than those with 2+. 63 patients in the trial 
suffered from cardiac dysfunction and 51 of these were treated with trastuzumab. The 
mechanism of cardiotoxicity was however unclear.32 
3.1. MARKETING AUTHORISATION 
The FDA considered trastuzumab in a fast-track process and as a result it was approved in 
1998 in combination with paclitaxel for first-line treatment of HER2 positive metastatic 
breast cancer patients and as a single agent for second and third line therapy.30 
An application was submitted to the EMA in the beginning of 1999 and was approved in 
the middle of 2000 in a similar indication to the FDA.33 
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Table 10 Phase III trial of trastuzumab 
Study Slamon 200132 
Number of patients 469 (235 trastuzumab + chemotherapy, 234 chemotherapy) 
Inclusion criteria Progressive metastatic breast cancer, no prior chemotherapy for 
metastatic disease, HER2 positive 
HER2 evaluation Tumour tissue – IHC; antibody NR;  
Threshold: >10% cells staining positive 
Design Enrichment; open-label24 
Recruitment of first-last patient  12 June 1995 – 7 March 199730 
Treatment  Trastuzumab (iv. 4 mg/kg initial dose followed by 2 mg/kg weekly 
until progression) + chemotherapy (as below); on progression 
allowed: continuation of treatment, increase in dose to 4 mg/kg, 
discontinuation, additional treatment 
 Chemotherapy: anthracycline (doxorubicin 600 mg/m2 or epirubicin 
75 mg/m2) + cyclophosphamide (600 mg/m2) or paclitaxel (175 
mg/m2) if patients received previous anthracycline once every three 
weeks for a minimum of six cycles 
Major outcomes assessed Primary: TTP 
Secondary:  
 overall response 
 duration of response 
 time to treatment failure 
 overall survival 
Follow-up NR, median time in the trial for chemotherapy  25 weeks (range 1, 131), 
chemotherapy + trastuzumab  40 weeks (range 1, 127) 
Main  results Intention to treat analysis:* 
Median TTP: trasatuzumab + chemotherapy 7.4 months, chemotherapy 
4.6 months, p<0.001 
Overall response: trasatuzumab + chemotherapy 50%, chemotherapy 
32%, p<0.001 
Median duration of response: trasatuzumab + chemotherapy 9.1 months, 
chemotherapy 6.1 months, p<0.001 
Median time to treatment failure: trasatuzumab + chemotherapy 6.9 
months, chemotherapy 4.5 months, p<0.001 
overall survival: : trasatuzumab + chemotherapy 25.1 months, 
chemotherapy 20.3 months, p=0.046 (including patients who switched 
from chemotherapy alone to trastuzumab + chemotherapy due to 
treatment failure) 
IHC – immunohistochemistry, iv. intravenous; NR – not reported, TTP – time to progression 
*hazard ratios were NR 
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APPENDIX 4. SEARCH STRATEGIES FOR SYSTEMATIC REVIEW OF 
FRAMEWORKS OF STAGED EVALUATION OF PREDICTIVE BIOMARKERS 
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4.1. MEDLINE 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to 
Present> 
Carried out on 07.01.2015. 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     phased.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (5315) 
2     hierarchical.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (37558) 
3     staged.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (16475) 
4     model.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (1423241) 
5     approach.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (878336) 
6     evaluation.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (1253214) 
7     1 or 2 or 3 (59295) 
8     4 or 5 or 6 (3245155) 
9     7 and 8 (21584) 
10     guideline$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (301661) 
11     framework$.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (152603) 
12     roadmap.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (1961) 
13     10 or 11 or 12 (449540) 
14     9 or 13 (469139) 
15     Biological Markers/ (175450) 
16     Tumor Markers, Biological/ (93623) 
17     Biomarkers, Pharmacological/ (1201) 
18     Individualized Medicine/ (5941) 
19     Drug Screening Assays, Antitumor/ (21186) 
20     Pharmacogenetics/ (9628) 
21     Toxicogenetics/ (649) 
22     Genetic Markers/ (47655) 
23     Gene Expression Profiling/ (91749) 
24     Marker$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (719775) 
25     Biomarker$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (115125) 
26     Classifier$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (11772) 
27     Predict*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (1093899) 
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28     24 or 25 or 26 (781406) 
29     27 and 28 (118237) 
30     Individuali?ed Medicine.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (6218) 
31     Pharmacogen*.mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary 
concept word, unique identifier] (15569) 
32     Stratified Medicine.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (104) 
33     Personali?ed Medicine.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (5065) 
34     precision medicine.mp. (284) 
35     15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 29 or 30 or 31 or 32 or 33 or 34 (493363) 
36     14 and 35 (11376) 
 
 
 
4.2. EMBASE 
Database: Embase <1974 to 2015 January 05> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     phased.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] (6113) 
2     hierarchical.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (39712) 
3     staged.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] (21720) 
4     model.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] (2625154) 
5     approach.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (1059104) 
6     evaluation.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (1344948) 
7     1 or 2 or 3 (67476) 
8     4 or 5 or 6 (4585673) 
9     7 and 8 (27878) 
10     guideline$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (431448) 
11     framework$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (162544) 
12     roadmap.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (2292) 
13     10 or 11 or 12 (587261) 
14     9 or 13 (612687) 
15     Biological Markers/ (137099) 
16     Tumor Markers, Biological/ (49703) 
17     Biomarkers, Pharmacological/ (260) 
18     Individualized Medicine/ (10590) 
19     Drug Screening Assays, Antitumor/ (139987) 
20     Pharmacogenetics/ (14531) 
21     Toxicogenetics/ (833) 
22     Genetic Markers/ (30004) 
23     Gene Expression Profiling/ (60233) 
24     Marker$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (831692) 
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25     Biomarker$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (162357) 
26     Classifier$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] (12908) 
27     Predict*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] (1282207) 
28     24 or 25 or 26 (900565) 
29     27 and 28 (139228) 
30     Individuali?ed Medicine.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (559) 
31     Pharmacogen*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (26595) 
32     Stratified Medicine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] (174) 
33     Personali?ed Medicine.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] (14881) 
34     precision medicine.mp. (327) 
35     15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 29 or 30 or 31 or 32 or 33 or 34 (537243) 
36     14 and 35 (15182) 
 
 
 
 
4.3. INTERNET 
Searches were carried out 29.07.2015 using google.co.uk and a combination of terms for 
the field of stratified medicine and for frameworks: 
stratified medicine terms frameworks terms 
stratified medicine framework 
predictive biomarker guideline 
pharmacogenomics phased evaluation 
 roadmap 
 
Websites of the EMA and FDA were also searched using the terms for stratified medicine 
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Guideline author and year      
Ref ID in main database (in frameworks database)     
Clinical context that the paper refers to     
Basis background information on what lead to development of the framwork (for example experience, consensus conference) 
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8.1. MODEL II (ALONGSIDE PHASED DRUG EVALUATION) 
8.1.1. IDENTIFIED FRAMEWORKS 
Three papers were identified that matched model II (alongside phased drug evaluation), 
as shown in Table 11.34-36 These were published in 200935,36 or 201134 and included four34,35 
or six stages.36 Two of these focused on predictive biomarkers in cancer34,35 and one on –
omics biomarkers in cardiovascular disease.36 The authors were based in the UK34,35 or 
Canada.36 None of the papers reported the basis for the frameworks.  
Table 11 Frameworks matched to model II  
Framework Stages 
(number) 
Scope Country/ region Basis 
Garcia 201134 4 cancer; parallel drug and predictive 
biomarker development 
UK NR 
Hodgson 200935 4 predictive biomarkers in cancer UK NR 
Lin 200936 6 cardiovascular disease; -omics 
biomarkers 
Canada NR 
NR – not reported  
As shown in Table 2.10, all included frameworks matched well the stages in the proposed 
model. The only exception was that an implementation stage was only present in one 
paper.36 
Table 12 Labels and stage numbers in identified frameworks matched to model II 
Stage Garcia 201134 Hodgson 200935 Lin 200936 
Pre-clinical (1) 
Preclinical discovery and 
analytical assay validation 
(1) 
Pre-clinical 
(1-3) 
(1) Discovery 
(2) Internal validation 
(3) External validation 
phase I trial (2) 
Phase I trial clinical 
qualification 
(2) 
Phase 1 (biomarker 
validation) 
(4) 
clinical trial (phase I, II) 
phase II trial (3) 
Phase II trial clinical 
qualification 
(3) 
Phase 2 trial against 
comparator in biomarker 
+ve and -ve patients 
(4) 
Clinical trial (phase I, II) 
phase III trial (4) 
Phase III trial clinical 
qualification 
(4) 
Phase 3 Preparation for 
commercial launch 
(5) 
Large clinical trial (phase III) 
implementation 
 
 
(6) 
Continued surveillance 
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8.1.2. STUDY DESIGNS AND OUTCOMES OF EACH STAGE 
Table 14 presents the proposed study designs and outcomes of each of the stages 
identified for this model. 
Pre-clinical 
The suggested study designs for the pre-clinical stage were reported in two papers and 
these were: literature reviews,35,36 pre-clinical models (details NR),35 case-control studies 
and data-mining.36 One framework suggested initial discovery study should be replicated 
for external validation.36 Apart from identification of the candidate biomarker,35,36 it was 
suggested this stage should provide understanding of the biomarker biology and assess 
performance characteristics of the assay.36 
Phase I trials 
The design of biomarker evaluation in phase I trials was not reported. However, two 
frameworks suggested that at this stage either the “clinical usefulness”,34 or the 
evaluability and prevalence of the biomarker should be established.35 
Phase II trials 
Two papers provided information on phase II trials.34,35 One paper suggested either 
conducting an RCT (stratified design or randomised discontinuation design for prolonged 
stable disease), or deciding a study may not be needed if sufficient evidence is available 
from a phase I expansion cohort. This should provide evidence on the usefulness of the 
biomarker in a clinical setting and reproducibility, validity and variability of the assay.34 The 
second paper suggested conducting a study to evaluate the benefit/risk ratio in all 
patients and biomarker-defined subgroups without specifying the design.35 
Phase III trials 
Again, the same two papers reported on the details of phase III trials.34,35 Only one of 
these dentified relevant study designs  
 RCT with biomarker-based inclusion criteria for biomarkers with high predictive 
value (most likely referring to an enrichment design), or  
 stratified RCT otherwise.34 
The outcome of this stage was demonstration of biomarker utility – according to two 
papers34,35 and not reported in one.36 One paper also proposed that at this stage the 
biomarker assay should be finalised.35 
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Implementation 
None of the papers provided details of the implementation stage. 
8.1.3. CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
As shown in Table 45, the criteria for entry to some of the stages were included in two 
papers,34,35 and for completion in one paper for one stage.34  
It was suggested that to enter the pre-clinical stage some understanding of the drug 
mechanism of action is required.34  
There was no information on phase I trial phase. For entry into phase II trial “data on 
biomarker evaluability and prevalence and estimate of effect size” was required in one 
paper.35 To complete phase II another paper suggested clinical validity should be 
demonstrated.34  
Prior to a phase III trial one paper proposed clinical validity of the assay needs to be 
shown.34 No information on the implementation stage was available. 
Table 45 Model II criteria for stage entry and completion  
 
Garcia 201134 Hodgson 200935 Lin 200936 
Stage Entry Completion Entry Completion Entry Completion 
Pre-
clinical 
some 
understanding 
of how the drug 
kills tumour cells 
NR NR NR NR  
 
NR 
Phase I 
trial 
NR NR NR NR NR NR 
Phase II 
trial 
NR clinical validity 
shown 
“data on 
biomarker 
evaluability and 
prevalence and 
estimate of effect 
size” 
NR NR NR 
Phase III 
trial 
clinical validity 
of the assay 
NR NR NR NR NR 
impleme
ntation 
N/A N/A N/A N/A NR NR 
N/A – not applicable; NR – not reported;  
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Table 14 Model II study designs and outcomes assessed within studies  
 
Garcia 201134 Hodgson 200935 Lin 200936 
Stage Study design Outcomes  Study 
design 
Outcomes Study design Outcomes  
Pre-
clinical 
NR NR review 
or pre-
clinical 
models 
predictive hypothesis NR directly, likely 
refers to case-
control study; 
Also data- and 
literature-mining 
techniques 
replicate initial 
study in a new 
cohort - external 
validation 
 identify candidate biomarkers; 
 understand biomarker biology  
 parameters for selection of 
biomarker candidates - use with 
cost-effectiveness and potential 
impact on management to select 
biomarkers for development 
 "assay performance 
characteristics, and clinical 
validation” showing “link of the 
biomarker with a biological 
process or clinical end point" 
Phase I 
trial 
NR Biomarker 
clinically useful 
(identifies likely to 
respond); 
NR evaluability and 
prevalence of 
biomarker 
NR NR 
Phase II 
trial 
depending on NPV and PPV: 
 may not be needed - large 
expansion cohort (phase I) and 
reliable established assay 
 PPV and NPV low: RCT (new 
drug vs. placebo) stratified by 
biomarker  
 randomised discontinuation (if 
drug results in prolonged stable 
disease) - after treatment 
randomise to drug or placebo 
Biomarker 
clinically useful 
(identifies likely to 
respond); 
reproducibility, 
validity and 
variability of assay 
by testing multiple 
baseline samples 
NR examine the 
benefit/risk ratio in all 
potential patients 
within an existing 
indication and 
compare it with the 
benefit/ risk ratio in a 
sub-set of patients as 
defined by the 
candidate predictive 
biomarker. 
NR NR 
Phase III 
trial 
RCT 
 biomarker-based inclusion  - 
high predictive value 
 stratified - less previous 
evidence  
Biomarker can 
select patients 
most likely to 
benefit 
NR  clinical utility of 
biomarker 
 assay converted 
to final format 
NR NR 
impleme
ntation 
N/A N/A N/A N/A NR NR 
N/A – not applicable; NR – not reported; RCT – randomised controlled trial; PPV – positive predictive value; NPV – negative predictive value 
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8.2. MODEL III (MULTI-MARKER CLASSIFIER) 
8.2.1. IDENTIFIED FRAMEWORKS 
There were seven papers37-43 that described frameworks matched to model III (multi-
marker classifier). Five of these were published since 2011, however two were older 
(published in 200543 and 200638). These are described in more detail in Table 47. The 
number of major stages varied between two and five and four of the frameworks also 
contained from four to 16 sub-stages.38,40-42 None of the frameworks was focused 
exclusively on predictive biomarkers. One of the frameworks specified the clinical area for 
which it was intended as cancer.43 Three papers reported the basis of the proposed 
framework and this was: literature searches,39 a committee with members from a variety 
backgrounds (including governmental, regulatory and clinical),40 and experience from an 
observational study.42 Four of the papers were written by authors based in the USA,38-40,42,43 
one in Korea37 and one in Japan. 41 
Table 47 Frameworks matched to model III 
Framework Stages 
(number) 
Scope Country
/ region 
Basis 
Cho 201237 5 predictive and 
prognostic biomarkers 
Korea NR 
Ginsburg 
200638 
5 (+ 7 sub-
stages) 
genomic biomarkers USA NR 
Ioannidis 
201139 
5 proteomic biomarkers USA literature searches (details NR) 
IOM 201240 2 (+ 9 sub-
stages) 
-omics tests to guide 
patient treatment 
USA “IOM committee was convened to help 
clarify questions about how to effectively 
develop omics-based tests to enable 
progress toward improving patient outcomes; 
with support from NCI, FDA, the Centers for 
Disease Control and Prevention, the U.S. 
Department of Veterans Affairs, the American 
Society for Clinical Pathology, and the 
College of American Pathologists” 
Matsui 
201341 
3 (+ 4 sub-
stages) 
multigene classifiers; 
mainly predictive, but 
also prognostic 
Japan NR 
Shahzad 
201242 
2 (+ 16 
sub-
stages) 
any gene expression 
biomarker panel; 
systems biology 
approach 
USA experience from an observational study 
(CARGO) 
Simon 
200543 
5 cancer; multigene 
expression classifiers 
(mainly prognostic) 
USA NR 
NR – not reported;  
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The order of stages in the identified frameworks was generally in agreement with that 
proposed for model III with one exception (Ginsburg 200638), as shown in Table 2.11. All 
frameworks included stages corresponding to identification of candidate biomarkers, 
prediction model development, external validation and clinical utility. The pre-discovery 
stage was not included in two41,43 and internal validation in one framework.38 
Implementation was only included in two frameworks.38,39 
8.2.2. STUDY DESIGNS AND OUTCOMES OF EACH STAGE 
Pre-discovery 
As shown in Table 48, the study designs in the pre-discovery phase reflected the different 
sources of data to be later used for discovery. Where reported, these were: cell-line 
experiments,37 genetic association studies38 and a pilot of a multicentre study.42 The 
outcomes of this phase generally included: formulation of a question to be addressed,42 
collection of data (of sufficient quality) from experiments,37-40 a validated discovery 
platform38,39 and a protocol for a multicentre study.42 
Table 48 Model III: pre-discovery stage 
Framework Study design outcomes 
Cho 201237 Cell line experiments to collect 
genomic or genetic characteristics 
and patterns of drug activity 
Normalised data 
Ginsburg 200638 Genetic association studies Collect clinical and biological data; validate 
discovery platform 
Ioannidis 201139 NR Discovery tools - refine old or develop new: 
 characterisation and improvement of analytical 
validity 
 data quality control 
 standardisation of laboratory procedures and 
database annotations 
IOM 201240 NR Quality controlled data collected 
Matsui 201341 N/A N/A 
Shahzad 201242 Pilot multicentre study Formulated question of interest 
protocol for multicentre study and logistics including 
training needs (modified after pilot study) 
Simon 200543 N/A N/A 
N/A – not applicable; NR – not reported;  
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Table 49 Labels and stage numbers in identified frameworks matched to model III  
stage Cho 201237 Ginsburg 200638 Ioannidis 201139 IOM 201240 Matsui 201341 Shahzad 201242 Simon 200543 
pre-
discovery 
(1-2) 
(1) Data 
collection 
(2) Quality 
control/ pre-
processing 
(1-2) 
(1) Biomarker 
discovery 
(2) Clinical and 
biological data 
collection 
 
(1) 
(1) Analytical 
tools 
(1.1.1) 
(1) Discovery and 
Test Validation Stage 
(1.1)Discovery Phase 
(1.1.1) Step 1: Data 
Quality Control 
 (1.1-1.2) 
(1) phased 
approach 
(1.1) Clinical 
phenotype 
consensus definition 
(1.2) Establishment of 
study logistics 
(1.2.1) initial protocol 
(1.2.2) feasibility 
studies 
(1.2.3) pilot studies 
(1.2.4) problem 
identification 
(1.2.5) trouble 
shooting 
(1.2.6) protocol 
modification 
(1.2.7) individual 
training 
(1.2.8) new protocol 
 
identification 
of candidate 
biomarkers 
(3) 
(3) Identification 
of candidate 
biomarkers 
(1, 2.1) 
(1) Biomarker 
discovery 
(2.1) Biomarker 
validation 
(2) 
(2) Clinically 
oriented 
discovery 
(1.1.2) 
(1.1.2) Step 2: 
Computational 
Model Development 
and Cross-Validation 
(1.1) 
(1)Developing 
genomic signatures 
(1.1) gene 
screening 
(1.3) 
(1.3) Candidate 
gene discovery 
(1) 
(1) developing a 
genomic classifier 
prediction 
model 
developmen
t 
(4) 
(4) Construction 
of prediction 
model 
(3) 
(3) Predictive 
model 
development 
(2) 
(2) Clinically 
oriented 
discovery 
(1.1.2) 
(1.1.2) Step 2: 
Computational 
Model Development 
and Cross-Validation 
(1.2 - 2.1) 
(1.2) ranking and 
selection 
(2) prediction 
analysis 
(2.1) development 
of predictor 
(1.4-1.5.1) 
(1.4) Differential 
Gene List Validation/ 
Verification 
(1.5) Molecular 
Classifier Algorithm 
Development 
(1.5.1) identification 
of classifier genes 
and cutoff 
(1) 
(1) developing a 
genomic classifier 
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stage Cho 201237 Ginsburg 200638 Ioannidis 201139 IOM 201240 Matsui 201341 Shahzad 201242 Simon 200543 
internal 
validation 
(4) 
Construction of 
prediction model 
 (3) 
Validation 
(1.1.2) 
Step 2: 
Computational 
Model Development 
and Cross-Validation 
(2.2) 
Clinical validation 
of predictors 
(1.5.2) 
Independent Testing 
of Selected Classifier 
Genes 
(2-3) 
(2) Internal validation 
of a classifier in 
developmental 
studies 
(3) Evaluating if 
classifier is superior to 
existing prognostic 
factors 
external 
validation 
(4) 
Construction of 
prediction model 
(5) 
Implementation 
(5.1) Development 
of diagnostic test 
(3) 
Validation 
(1.1.3 - 1.2) 
(1.1.3) Step 3: 
Confirmation on an 
Independent 
Dataset  
(1.1.4) Step 4: 
Release of Data, 
Code, and the Fully 
Specified 
Computational 
Procedures to the 
Scientific Community 
(1.2) Test Validation 
Phase 
(1.2.1) Analytical 
Validatiton 
(1.2.3) Clinical/ 
Biological Validation 
(1.2.4) 
implementation of 
the new test in the 
workflow and quality 
management system 
of the CLIA-certified 
laboratory 
(2.2) 
Clinical validation 
of predictors 
(1.6) 
External Classifier 
Validation/ Testing 
(4) 
Translation of 
platforms and 
demonstrating assay 
reproducibility 
clinical utility (5) 
Independent 
validation of 
prediction 
(4) 
Decision support 
tool development 
(4) 
Clinical 
application 
(2) 
Evaluation for 
Clinical Utility and 
Use Stage 
(3) 
Biomarker-Based 
Clinical Trials for 
(2) 
Comparison against 
standard of care & 
personalized use 
(5) 
Independent 
validation of 
genomic classifier 
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stage Cho 201237 Ginsburg 200638 Ioannidis 201139 IOM 201240 Matsui 201341 Shahzad 201242 Simon 200543 
Assessing Clinical 
Utility 
implementat
ion 
 (5) 
Implementation 
(5.2) Health 
professional and 
public education 
(5.3) Development 
of clinical 
guidelines 
(5.4) Regulatory 
oversight in 
laboratories 
(5.5) Cost-
effectiveness 
(5.6) Privacy 
(4-5) 
(4) Clinical 
application  
(5) Post-clinical 
appraisal 
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Identification of candidate biomarkers 
The study designs suggested for this stage are shown in Table 50. These were mainly 
focused around different statistical techniques, such as two-sample t-tests, variant t-tests, 
empirical Bayes methods,37 or variety of pattern recognition techniques38). One paper 
suggested two different approaches that can be used on their own or in combination: 
non-hypothesis driven and hypothesis driven discovery.42 Another paper suggested that 
the findings should be replicated in a new study and biological plausibility studies carried 
out to investigate the relationship between the biomarker and the outcome.38 
Table 50 Model III: identification of candidate biomarkers 
Framework Study design outcomes 
Cho 201237 Data analysis (various statistical approaches possible) candidate genes 
Ginsburg 200638  data analysis of genetic association study  
 replication of genetic association studies;  
 biological plausibility studies of biological rationale for the 
biomarkers 
candidate markers 
Ioannidis 201139 
Transparent statistical analysis (details NR) 
multi-marker profiles 
IOM 201240 NR NR 
Matsui 201341 
Multiple approaches possible; most popular: separate statistical 
tests for each gene to test the null hypothesis of no association  
identification of 
genes 
Shahzad 201242 
Analysis of data from a multicentre study: 
 non-hypothesis-driven, "whole-genome wide approach” 
Bioinformatics can be used to identify differentially expressed 
genes "in relationship to the concurrent phenotype of interest" 
 hypothesis-driven, knowledge-based approach (can involve 
a literature review) - "focusing on known genes " 
 both approaches can be combined 
Laboratory techniques: array-based non-supervised approach 
may require additional assays (eg. RT-PCR) to confirm findings 
identification of 
genes 
Simon 200543 
NR NR 
NR – not reported;  
Prediction model development 
As shown in Table 51, a variety of statistical models have been suggested here including 
linear discriminant analysis, support vector machines, Bayesian regression, partial least 
squares, principal component regression.37 Three papers identify two major tasks within this 
stage:  
3) selection of biomarkers to be included in the classifier (feature selection) and  
4) construction of the prediction model.40,41,43  
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The IOM 2012 framework suggested using approaches for development of the classifier 
(split sample and cross-validation) which correspond to what other papers describe as 
internal validation of the model.40  
Table 51 Model III: prediction model development stage 
Framework Study design outcomes 
Cho 201237 Classification methods (various approaches possible) multivariate 
prediction model 
Ginsburg 200638 Methods include classical biostatistical methods and pattern 
recognition techniques 
predictive model 
Ioannidis 201139 Transparent statistical analysis (details NR) multi-marker profiles 
IOM 201240  feature selection (based on data analysis and prior 
knowledge) 
 development of model by: 
 splitting data into training and testing set, or 
 cross-validation 
development of 
model 
Matsui 201341  Selection of genes for clinical platform (based on 
magnitude of association or effect size and possibly 
biological understanding) 
 Prediction model construction - statistical models: 
univariate models; hierarchical mixture models 
prediction model 
Shahzad 201242 Use validated genes to identify classifier (details NR) classifier 
Simon 200543 Developing a classifier: 
 establish type of statistical model (linear classifiers are 
usually sufficient) 
 feature selection - number small enough to be used in 
practice 
classifier 
Internal validation 
Internal validation, as shown in Table 52, was often described as involving two main 
approaches: 
 Split-sample - where the available sample of patients is divided into a training set 
(used for model development) and a separate test set (used for testing the 
performance of the classifier),40-43 
 Cross-validation – where statistical techniques using a single set of patients for both 
development and validation of the classifier are implemented;37,39-43 
One paper referred to cross-validation as less preferred and performed in the situation of 
low availability of patient samples.40  
Generally, the aim of internal validation was to assess the performance of the classifier. 
The details of statistical measures used for these purpose were reported in two frameworks 
and these were mainly measures of accuracy such as classification error rate,37,43 AUC 
ROC,37 Sen, Spe, PPV and NPV.43 
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Table 52 Model III: internal validation stage 
Framework Study design outcomes 
Cho 201237 various statistical techniques including: leave-one-out 
approach, random splitting 
Assessment of the model 
performance using measures 
such as: 
 classification error rate, 
 AUC ROC, 
 product of posterior 
classification probabilities,  
 misclassification-penalized 
posterior. 
Ginsburg 200638 N/A N/A 
Ioannidis 201139 statistical techniques: internal cross-validation or 
bootstrapping methods 
estimates of classification 
accuracy 
IOM 201240 Internal validation integrated into model 
development: 
 training set/test set approach – preferred (“two 
distinct datasets, (…) each composed of 
independent samples that have been collected 
and processed by different investigators at 
different institutions”) 
 cross-validation – limited availability of samples 
(“using a single dataset, by dividing the data into 
multiple segments, and iteratively fitting the 
model to all but one segment and then 
evaluating its performance on the remaining 
segment”) 
Evaluation of model 
performance 
Matsui 201341 “typically using validation techniques such as split-
sample or cross-validation” 
“predictive accuracy for the 
study population from which the 
predictor was built” 
Shahzad 201242 
Two approaches: 
 "collected patient samples are typically randomly 
split into separate training and validation sets. (…) 
genes identified in the training set and are tested 
in a validation set to estimate the degree of 
misclassification"  
 "leave-one-out cross validation (…) involves using 
a single observation from the original sample as 
the validation data, and the remaining 
observations as the training data. This is repeated 
such that each observation in the sample is used 
once as the validation data." 
degree of misclassification 
Simon 200543 
two approaches to internal validation: 
 split-sample validation - “partitioning the set of 
samples into a training set and a test set” 
 cross-validation – “based on repeated model 
development and testing on random data 
partitions (..) many variants of cross-validation and 
bootstrap resampling for classification problems” 
 estimate overall error rate 
 for split-sample validation 
possible to estimate 
characteristics such as 
sensitivity, specificiy, PPV 
and NPV 
N/A – not applicable; AUC – area under the curve;  ROC – receiver operator characteristic, PPV – positive 
predictive value; NPV – negative predictive value; 
External validation 
As shown in Table 53, the stages mapped to external validation all seem to identify this 
stage with conducting a new study on an independent sample of patients. In addition 
some of the frameworks advocated this should be a large-scale39 and/or multicentre 
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study,37,40 involving a diverse population,39 relevant to the intended use of the test.40,41 In 
some frameworks it was also proposed that the analysis should be blind to patient 
outcomes and ideally performed by investigators not involved in model development.39,40 
One paper also suggested that collection and processing of biological samples should be 
carried out by a laboratory  that was not involved in model development.40 According to 
one framework this should be a study testing a hypothesis that the classifier score 
distinguishes the phenotype in question.42  
The outcomes of this stage generally involve showing the adequate performance of the 
classifier, which in some papers is defined in terms of test accuracy,38,41,42 precision38,42 and 
reproducibility.38,42,43 Two papers also mentioned showing the generalisability of the 
test.39,40 One paper suggested specifying the type of the analyte to be used.38 Another 
advised investigation of the influence of specimen handling on the results of the test 
(including issues such as “operator-to-operator variation, run-to-run variation, lot-to-lot 
variation of reagents, plate-to-plate variation, and section-to-section variation of the 
plates used to run the test”).42 One paper postulated a prototype test platform should be 
developed at this stage,38 while another two suggested standardisation of the test.40,43 
Investigation of cost-effectiveness of the biomarker use was also mentioned at this 
stage.38 
One paper proposed conducting a separate analytical laboratory study, where the test is 
used on samples with known biomarker values aiming to quantify the test characteristics 
(such as analytical Sen, Spe and limit of detection).40  
One framework also suggested that at the end of external validation, the data and 
computer code used for the classifier should be made available to the scientific 
community or at least the regulators to provide independent verification of the results 
obtained.40  
Clinical utility 
The clinical utility stage reported in Table 54 generally involved carrying out a new study, 
with the exception of one framework which only recommended testing the classifier in 
comparison to the standard of care without providing further details.42  
The remaining papers advocated a clinical trial, usually a randomised one.37,39-41,43 The 
suggested designs differed depending on the situation and, where reported, these were:  
 enrichment,  
 biomarker-strategy and  
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 prospective subgroup analysis of an RCT, and 
 prospective-retrospective.40,41,43  
Table 53 Model III: external validation stage 
Framework Study design outcomes 
Cho 201237 multicentre validation (details NR) performance of statistical model tested 
Ginsburg 
200638 
study in other assembled populations and/or 
biological samples  develop prototype platform 
 retest the predictor 
 "development of an easy, cost-effective, 
accurate and reliable test assay" 
 precision and reproducibility  
 “analytical problems (…) such as the 
type of controls to use, turnaround time, 
throughput, detection limit, accuracy, 
quantification, on-site availability and 
portability, cost of replicate analysis, and 
normalization.” 
 specify type of analyte to be used 
Ioannidis 
201139 large-scale studies performed by “many 
diverse teams in various populations” 
Ideally ”analysis (…) by different investigators 
than those involved in the original analysis” 
 adequate classification performance  
 show generalisability  
IOM 201240  'analytical laboratory studies on samples 
with known biomarker values; “using 
specimens comparable to [those] on 
which the test will eventually be used, 
with known or expected characteristics 
related to the test being validated. If 
necessary, an alternative to using a 
limited supply of valuable clinical 
specimens with known or expected test 
results is the use of control materials that 
will provide known or expected test results 
and can be spiked into negative clinical 
specimens” 
 study “using an independent set of 
samples not used in the generation” of 
the model and ideally “blinded to any 
outcome or phenotypic data”; 
“independent specimen and clinical 
dataset must be relevant to the intended 
use” of the test “Ideally, the specimens 
(…) will have been collected at a 
different point in time, at different 
institutions, from a different patient 
population, with samples processed in a 
different laboratory”  
 “data and meta-data used for 
development of the candidate omics-
based test should be made available” 
with computer code and fully specified 
computational development procedures 
for of the candidate omics-based test – to 
scientific community or at least the FDA 
 quantify technical variations of a test 
performed on patient specimens or 
spiked control materials 
 test characteristics including: “accuracy, 
precision, reproducibility, linearity, 
reportable range, analytical sensitivity 
and specificity, and limit of detection” 
 defined computational procedures and 
data management procedures 
 two possible levels of evidence: 
 Lower Level: “Independent sets of 
specimens and clinical data 
collected at a single institution using 
carefully controlled protocols, with 
samples from the same patient 
population” 
 Higher Level: “Independent sets of 
specimens and clinical data 
collected at multiple institutions” 
 broad applicability of test 
 “verification of results by the scientific 
community” 
 standard operating procedure  
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Framework Study design outcomes 
Matsui 
201341 “using an independent set of samples, possibly 
from a more relevant population for clinical 
application of the predictor." 
 predictive accuracy (usually proportion 
of correct classification, sensitivity and 
specificity) 
 “establish that the predictive accuracy is 
statistically higher than that expected 
when there is no relationship between 
genomic data and the clinical variable" 
Shahzad 
201242 
Study in independent patient sample to test 
the pre-specified hypothesis that the classifier 
score distinguishes phenotype in question  
 establish test reproducibility and 
demonstrate acceptable precision  
 may include "documentation of 
diagnostic performance across 
thresholds and description of correlations 
to clinical variables"  
 “effect of different variables associated 
with the specimen handling process” on 
test results 
Simon 
200543 
New study designed to show reproducibility 
(inter- and intra-laboratory) 
 standardized assay 
 evaluation of reproducibility 
NR – not reported; 
Some papers indicated there may be a possibility of another study design as an 
alternative to a randomised trial. These were an observational study39 and a single arm 
study including only biomarker positive patients where the event rate is very low.43  
This stage should lead to establishing the clinical utility37,39-41,43 and a fully developed, 
standardised classifier.37,39 It should also provide information on how feasible is using the 
classifier in clinical practice.41 
Implementation 
Only two papers reported any details of implementation,38,39 as shown in Table 55. Both of 
these considered this stage appropriate for investigation of cost-effectiveness. One of the 
papers suggested at this stage issues such as education, policy and regulation of the test 
should be considered.38 The other one included audit of the actual use in practice and 
cost-utility of the test.39  
8.2.3. CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
Five of the six papers reported on at least some of the criteria for entry into a stage37,39-43 
as shown in Table 56.  
For pre-discovery it was proposed by one paper that the phenotype of interest should be 
defined (for example the outcome to be predicted)42. In another paper it was suggested 
that prior to embarking on any classifier research it should be considered whether it is 
possible to develop a classifier to address a given problem (for example in terms of the 
required sensitivity and specificity).40 
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For entry into the discovery stage it was proposed that adequate quality 40 or adequately 
normalised data37 should be available and study infrastructure and logistics established.42 
Table 54 Model III (multi-marker classifier): clinical utility stage 
Framework Study design outcomes 
Cho 201237 RCT 
 usefulness of prediction model 
 developed assay 
Ginsburg 
200638 
clinical trial (details NR) NR 
Ioannidis 
201139 
observational or randomised studies  possible refinement or 
expansion of applications 
 “incremental value over 
standard information” (usually 
reclassification), impact on 
decision-making 
 clinical standardization, possible 
commercialization of test 
 impact on surrogate (non-
clinical or clinical) and “hard” 
outcomes 
IOM 201240 clinical study design consulted with regulators, 
depends on intended use of the test and availability of 
“appropriate archived specimens”: 
 prospective–retrospective (especially when 
prospective not feasible) 
 prospective trial with test that “does not direct 
patient management”: 
 subgroup analysis – biomarker results can be 
generated at start or end of trial 
 stratified  
 prospective trial with test that “does direct patient 
management” 
 enrichment – “clinical utility of some of the 
test-designated categories is already 
established or assumed and need not be re-
evaluated” 
 biomarker strategy– “fully defined and 
validated omics-based test”; direct 
assessment of utility  
Test evaluated for clinical use 
Matsui 
201341 
RCTs: 
 biomarker strategy, 
 enrichment - if "compelling biological evidence for 
believing that biomarker-negative patients will not 
benefit” 
 Randomize-All Designs 
 with a single, completely specified biomarker 
(prospective subgroup analysis) - no 
compelling evidence biomarker negative will 
not benefit;  
 more complex designs with biomarker 
development and validation 
establish that: 
 biomarker actionable in clinical 
practice 
 use of the biomarker leads to 
improved outcome in patients 
and patient benefit 
Shahzad 
201242 
test classifier compared with standard care (details NR) clinical acceptance 
Simon 
200543 preferably prospective clinical trials: 
 biomarker-strategy,  
 enrichment  
 single arm including only biomarker positive 
(low event rate) 
 possibly prospective-retrospective 
 prospective subgroup analysis of RCT and 
splitting type I error (little faith in classifier) 
establish patient benefit from using 
the classifier 
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Table 55 Model III (multi-marker classifier): implementation stage 
Framework Study design outcomes 
Cho 201237 N/A N/A 
Ginsburg 
200638 
 education of health professionals and public on the 
use of genomic biomarkers 
 Include genomic biomarkers in clinical guidelines 
 regulation of tests and oversight of laboratory 
standards 
 cost-effectiveness analysis 
 develop policy to regulate patient privacy 
 implement biomarker into 
clinical practice 
 cost-effectiveness 
Ioannidis 
201139 cost-effectiveness analyses 
Audit of: 
 appropriate use 
 improved outcomes  
 “cost-utility based on actual use" 
 cost-utility  
 test adopted to clinical 
practice 
 monitoring of test use 
IOM 201240 N/A N/A 
Matsui 
201341 
N/A N/A 
Shahzad 
201242 
N/A N/A 
Simon 
200543 
N/A N/A 
N/A – not applicable; NR – not reported;  
For entry into prediction model construction the requirements provided were a 
manageable number of candidate genes37 and data of sufficient quality.40  
To initiate internal validation, it was claimed a model needs to be completed.40,41 For 
external validation, complete model40,41 and satisfactory results from internal validation 
were required.40,43  
To initiate investigation of clinical utility two papers required completion of discovery and 
validation of the model.39,40 One of these also highlighted that at this point the classifier 
needs to be “locked-down”. 40  
None of the papers reported the requirements for entry into the implementation stage. 
Only one paper reported the criteria for completion of one stage (internal validation in 
the proposed model) and it was: “A candidate omics-based test should be defined 
precisely, including the molecular measurements, the computational procedures, and the 
intended clinical use of the test”.40
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Table 56 Entry criteria for stages of model III (multi-marker classifier) 
stage Cho 201237 Ginsburg 
200638 
Ioannidis 
201139 
IOM 201240 Matsui 201341 Shahzad 201242 Simon 
200543 
pre-
discovery 
NR NR 
 
NR considering if potential classifier 
“has a reasonable chance of 
demonstrating clinical validity and 
utility. For example, the sensitivity 
and specificity needed, particularly 
in light of the prevalence of the 
condition in the population” 
N/A consensus on 
phenotype 
definition 
N/A 
identification 
of candidate 
biomarkers 
adequate 
data 
normalisatio
n 
NR NR data of adequate quality NR established 
multicentre 
infrastructure and 
logistics for sample 
processing 
NR 
prediction 
model 
development 
candidate 
genes 
limited to "a 
few 
hundred" 
NR NR data of adequate quality NR NR NR 
internal 
validation 
NR N/A NR model developed "a completely specified genomic 
signature is needed. Complete 
specification (…) includes not only 
the list of component genes, but also 
the mathematical form used to 
combine genomic data for the 
genes used in the signature, weights 
for the relative importance of the 
genes, and cut-off values when 
making classification." 
NR NR 
external 
validation 
NR NR NR “discovery and confirmation of a 
candidate omics-based test” 
Same as internal validation NR  satisfactory 
internal 
validaty 
clinical utility NR NR discovery 
and 
validation  
“fully defined, validated, and 
locked-down clinical test” 
NR NR NR 
implementati
on 
N/A NR NR N/A N/A N/A N/A 
N/A – not applicable; NR – not reported;  
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8.3. MODEL IV (SAFETY) 
8.3.1. IDENTIFIED FRAMEWORKS 
Two papers published within the last five years were identified that described a framework 
that matched model IV (safety), shown in Table 57. One proposed four,44 and the other - 
five stages45. Both of these papers appeared to focus on a situation when drugs are 
already on the market when new safety biomarkers are identified. One focused on 
biomarkers for prediction of adverse events in a paediatric population,45  and the other 
on identification of a range of biomarkers relevant to safety.44 Both papers were based on 
the experience and practice of organisations that aim to discover and develop safety 
biomarkers – one based in Canada45 and one in the EU.44 
Table 57 Frameworks matched to model IV (safety) 
Framework Stages 
(number) 
Scope Country/ 
region 
Basis 
Loo 201245 5 prediction of 
paediatric 
adverse events 
Canada experience of Canadian Pharmacogenomics 
Network for Drug Safety (adverse drug reactions 
“surveillance network that predominantly 
operates within Canadian pediatric teaching 
hospitals”) 
Matheis 
201144 
4 adverse event 
biomarkers 
(predictive, 
diagnostic, 
monitoring) 
EU proposed by Safer and Faster Evidence-based 
Translation consortium, “a public–private 
partnership comprising 20 partners from the 
pharmaceutical industry, small–medium 
enterprises, academic institutions and clinical 
units of excellence with representatives from the 
European Medicines Agency (EMA) as external 
observers and advisors. It operates under the 
framework of the EU Innovative Medicines 
Initiative Joint Undertaking"44 
Neither of the two papers described a framework that exactly matched the stages 
proposed for model IV, as shown in Table 2.12. Some of activities corresponding to the 
stages in model IV were mentioned in one paper outside of the sequence of stages for 
the framework.44  
The unique characteristic of this model is that it appears to suggest progression into 
investigation of biomarker utility immediately after preclinical investigation and analytical 
validation.  
8.3.2. STUDY DESIGNS AND OUTCOMES OF EACH STAGE 
The study designs and outcomes relevant to each stage are reported in Table 60. 
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Surveillance  
For this stage one paper suggested recruitment of patients with adverse events and 
matched controls.45 Although this stage was not explicitly identified in the other paper, it 
did propose that a dedicated biobank should be established.44 None of the papers 
discussed the outcomes of this stage. 
Table 58 Labels and stage numbers in identified frameworks matched to model IV (safety) 
 
Loo 201045 Matheis 201144 
surveillance (1) 
Active surveillance, patient recruitment 
and collection of data and biomaterial 
(NR as stage, but setting up a dedicated 
biobank discussed) 
discovery (2) 
Identification of gene variants and 
replication of findings 
 
(1) 
Candidate biomarker identification 
pre-clinical (3) 
Pharmacokinetic and functional 
validation 
(NR as stage, but referred to as pre-
requisite to stage 2) 
analytical 
validation 
 
(2) 
Exploratory phase 
clinical utility (4) 
Prospective clinical studies to evaluate 
diagnostic utility 
(3) 
Confirmatory phase 
implementation (5) 
Determination of the cost-effectiveness 
of diagnostic testing 
(4) 
Submit for regulatory approval 
Discovery 
The discovery stage was based on a case-control study approach in one framework, 
utilising candidate gene approach supplemented by GWAS and followed by a 
replication study in a different population.45 The other paper did not provide extensive 
detail on this stage and advocated the use of a literature review, databases and a 
biobank.44 None of the papers discussed the outcomes of this stage. 
Pre-clinical 
Pre-clinical mechanism investigation was described in one framework and was based on 
in vitro and animal model studies.45 None of the papers discussed outcomes of this stage. 
Analytical validation 
This stage was described in one framework only and involved a small study in healthy 
subjects and patients comparing the biomarker test under investigation to the gold 
standard. The suggested outcomes to be assessed were the performance of the test 
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(sensitivity, specificity, PPV, NPV, ROC AUC, or partial ROC AUC), the biological variability 
of the biomarker and stability of the analyte after sampling.44 
Clinical utility 
Studies addressing clinical utility of the biomarker were described as either:  
 a prospective clinical trial aiming to establish the utility of the predictive biomarker 
in preventing adverse events,45 or 
 a study in a large patient population (“proof of performance”) aiming to establish 
biomarker performance and threshold. 44 
Implementation  
There was no information on the study designs or outcomes of the implementation stage. 
8.3.3. CRITERIA FOR ENTRY AND COMPLETION OF STAGES 
These criteria were described only in Matheis 2011 for two stages,44 as shown in Table 60.  
Entry into the analytical validation stage was to be based on pre-clinical and clinical 
evidence supporting the biomarker and discussion of the validation protocol with 
regulatory agencies. Completion of this stage was to be based on “assay acceptance 
criteria” defined prior to undertaking the validation and, if applicable, in accordance 
with regulatory guidance. For biomarker utility only entry criteria were described and 
these were presentation of the results of analytical validation to regulatory agencies. 
Table 59 Entry and completion criteria for stages of model IV (safety) papers 
 Loo 201045 Matheis 201144 
Stage entry completion entry completion 
surveillance NR NR NR NR 
discovery NR NR NR NR 
pre-clinical NR NR NR NR 
analytical 
validation 
N/A N/A biomarker “supported by solid 
scientific evidence and a clear 
rationale based on available 
preclinical and clinical data" 
study protocol “discussed with 
regulatory agencies " 
assay acceptance criteria 
“defined in the standard 
validation procedure and are, if 
applicable, in accordance with 
EMA and FDA guidelines" 
clinical utility NR NR results of exploratory studies 
presented to regulatos 
NR 
implementation NR NR NR NR 
N/A – not applicable; NR – not reported; 
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Table 60 Model IV (safety) study designs and outcomes assessed within studies  
 
Loo 201045 Matheis 201144 
Stage Study design Outcomes assessed Study design Outcomes assessed 
surveillance Recruitment (multisite) of patients with adverse 
events and matched controls; collection of 
clinical data and biological samples 
NR NR for stage (set up 
biobank) 
NR 
discovery Splitting patient sample into: 
(1) discovery: case-control study - usually 
patients from one area (homogeneity) 
- candidate gene approach - key genes 
involved in drug biotransformation or toxicity 
- GWAS– possibly complementary strategy - 
not limited by a priori set of genes; generates a 
larger number of false-positives; needs large 
sample size to identify true positives, 
(2) replication in a different population  - 
ensures generalisability and limits false positives 
NR mainly literature review, 
databases and biobank 
NR 
pre-clinical pharmacokinetic and functional studies to 
support relevance of identified genes in the 
mechanism of drug toxicity: in vitro assays 
(overexpression or knock-down of associated 
gene expression) or animal models 
NR NR NR 
analytical 
validation 
N/A N/A proof of translation - 
"conducted with small 
groups of healthy subjects 
or patients (…) for testing 
the translational value of 
selected biomarker 
candidates in comparison 
to current gold standards" 
Selection of best biomarkers based on: 
 sensitivity, specificity, PPV, NPV,  
 biomarker variability in healthy 
volunteers and patients, 
 impact of covariates (e.g. age, 
gender)on biomarker values 
 in vivo stability biomarker metabolism 
and circadian rhythm effects),"  
 "stability after sampling" 
 "characteristics of the intended 
assay" 
 ROC AUC, or partial ROC AUC 
clinical utility prospective clinical trial where appropriate utility in preventing 
adverse events 
proof of performance - in 
large patient populations 
 biomarker threshold 
 biomarker performance 
implementation NR NR NR NR 
N/A – not applicable; NR – not reported;   
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
3β-Hydroxy-
Δ5-C27-
steroid 
oxidoreduct
ase 
deficiency 
defines disease Digestive 
System Diseases 
Metabolism, 
Inborn Errors 
Treatment of inborn errors in primary bile acid synthesis due to  3β-Hydroxy-Δ5-C27-steroid 
oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and 
adolescents aged 1 month to 18 years and adults. Treatment must be initiated and monitored by 
an experienced hepatologist or a paediatric hepatologist in the case of paediatric patients 
cholic acid 
(Orphacol) 
activated 
protein C 
(APC) 
resistance 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of Zoely. Should any of 
the conditions appear for the first time during Zoely use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated  protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies,  lupus 
anticoagulant). ... 
nomegestrol 
acetate / 
estradiol 
(Zoely) 
activated 
protein C 
(APC) 
resistance 
ICD10 Contraception Female contraception  
EVRA is intended for women of fertile age. The safety and efficacy has been established in women 
aged 18 to 45 years 
Contraindications: 
EVRA should not be used in the presence of one of the following disorders. If one of these disorders 
occurs during the use of EVRA, EVRA must be discontinued immediately(...) 
● Possible hereditary predisposition for venous or arterial thrombosis, such as activated protein C 
(APC-) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinemia, and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
norelgestromin 
/ ethinyl 
estradiol 
(EVRA) 
activated 
protein C 
(APC) 
resistance 
ICD10 Contraception Oral contracepon. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of IOA. Should any of 
the conditions appear for the first time during IOA use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol (IOA) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
adverse 
cytogenetic
s 
associated with 
another 
treatment 
NR treatment of acute myeloid leukaemia (AML) in elderly patients who have one or more of the 
following: adverse cytogenetics, secondary AML, ≥ 70 years old or significant co-morbidities and 
are therefore not considered suitable for intensive chemotherapy. Safety and efficacy have been 
assessed in studies of patients ≥ 65 years old (see section 5.1) 
Clofarabine 
(Evoltra) 
ALT diagnostic Hepatitis C, 
Chronic 
Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or 
HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation. 
The efficacy of Interferon-alfa-2a in the treatment of hepatitis C is enhanced when combined with 
ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to 
ribavirin.  
recombinant 
human 
interferon-alfa-
2a (Alpheon) 
ALT diagnostic Hepatitis B, 
Chronic 
Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection (see section 5.1)  
in adults with:  
§ compensated liver disease and evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or 
fibrosis.  
§ decompensated liver disease (see section 4.4)  
For both compensated and decompensated liver disease, this indication is based on clinical trial 
data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With 
respect to patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1. 
Entecavir 
(Baraclude) 
ALT diagnostic Hepatitis B, 
Chronic 
Hepsera is indicated for the treatment of chronic hepatitis B in adults with: 
• compensated liver disease with evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and 
fibrosis 
• decompensated liver disease. 
adefovir 
dipivoxil 
(Hepsera) 
ALT diagnostic Hepatitis B, 
Chronic 
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral 
replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBeAg), 
elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or 
fibrosis. 
interferon alfa-
2b (IntronA; 
Viraferon) 
ALT diagnostic Hepatitis B, 
Chronic 
Zeffix is indicated for the treatment of chronic hepatitis B in adults with:  
- ƒcompensated liver disease with evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or 
fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative 
antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).  
- decompensated liver disease in combination with a second agent without cross-resistance to  
lamivudine (see section 4.2).  
Lamivudine 
(Lamivudine 
Teva; Zeffix) 
ALT diagnostic Hepatitis B, 
Chronic 
Pegasys is indicated for the treatment of HBeAg-positive or HBeAg-negative chronic hepatitis B in 
adult patients with compensated liver disease and evidence of viral replication, increased ALT and 
histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1).  
peginterferon 
alfa-2a 
(Pegasys) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
ALT diagnostic Hepatitis C, 
Chronic 
Tritherapy:  
Rebetol in combination with boceprevir and peginterferon alfa-2b is indicated for the treatment of 
chronic hepatitis C (CHC) genotype 1 infection in adults patients (18 years of age and older) with 
compensated liver disease who are previously untreated or who have failed previous therapy.  
Please refer to peginterferon alfa -2b and boceprevir SmPCs when using Rebetol in combination 
with these medicines.  
Bitherapy:  
Rebetol is indicated for the treatment of chronic hepatitis C virus infection in adults, children 3 
years of age and older and adolescents and must only be used as part of a combination regimen 
with peginterferon alfa-2b or interferon alfa-2b.  Rebetol monotherapy must not be used.  
Please refer to interferon alfa-2b and peginterferon alfa-2b SmPCs when using Rebetol in 
combination with these medicines.  
There is no safety or efficacy information on the use of Rebetol with other forms of interferon (i.e., 
not alfa-2b).  
Previously untreated (naïve) patients 
Adult patients (18 years of age or older): Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients with chronic hepatitis C genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with interferon alfa-2b or peginterferon alfa-2b, for the treatment of 
adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with 
elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid 
(HCV-RNA).  
• bitherapy – for the treatment of CHC infection in combination with peginterferon alfa-2b for 
patients with compensated cirrhosis and/or clinically stable HIV co-infection (see section 4.4).  
Bitherapy 
Paediatric patients (children 3 years of age and older and adolescents): Rebetol is indicated, in a 
combination regimen with peginterferon alfa-2b or interferon alfa-2b, for the treatment of children 
3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, 
without liver decompensation, and who are positive for HCV-RNA. When deciding to not to defer 
treatment until adulthood, it is important to consider that the combination therapy induced a 
growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be 
made on a case by case basis (see section 4.4).  
Previously treated patients 
Adult patients: Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients having CHC genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with peginterferon alfa-2b, for the treatment of patients with chronic 
hepatitis C who have failed previous treatment with interferon alpha (pegylated or nonpegylated) 
alone or in combination with ribavirin (see section 5.1).  
• bitherapy - in combination with interferon alfa-2b, for the treatment of patients with chronic  
Ribavirin 
(Rebetol; 
Ribavirin 
BioPartners; 
Ribavirin Mylan 
(previously 
Ribavirin Three 
Rivers); 
Ribavirin Teva; 
Ribavirin Teva 
Pharma B.V.) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to 
interferon alfa monotherapy but who have subsequently relapsed.  
ALT diagnostic Hepatitis B, 
Chronic 
Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver 
disease and evidence of viral replication, persistently elevated serum alanine aminotransferase 
(ALT) levels and histological evidence of active inflammation and/or fibrosis. 
Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral 
agent with a higher genetic barrier to resistance is not available or appropriate. 
See section 5.1 for details of the study and specific patient characteristics on which this indication is 
based. 
Telbivudine 
(Sebivo) 
ALT diagnostic Hepatitis B, 
Chronic 
Viread (...) indicated for the treatment of chronic hepatitis B (see section 5.1) in  
adults for whom a solid dosage form is not appropriate with:  
· compensated liver disease, with evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or 
fibrosis  
· decompensated liver disease (see sections 4.4, 4.8 and 5.1).  
Viread (..) also indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of 
age for whom a solid dosage form is not appropriate with:  
· compensated liver disease and evidence of immune active disease, i.e. active viral replication, 
persistently elevated serum ALT levels and histological evidence of active inflammation and/or 
fibrosis (see sections 4.4, 4.8 and 5.1).  
tenofovir 
disoproxil 
fumarate 
(Viread) 
ALT diagnostic Hepatitis B, 
Chronic 
Zeffix is indicated for the treatment of chronic hepatitis B in adults with:  
ƒ compensated liver disease with evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or 
fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative 
antiviral agent with a higher genetic barrier is not available or appropriate (see in  
section 5.1).  
ƒ decompensated liver disease in combination with a second agent without cross-resistance to 
lamivudine (see section 4.2).  
Lamivudine 
(Zeffix) 
ALT diagnostic Prostatic 
Neoplasms 
Contraindications: 
· Hypersensitivity to cabazitaxel, to other taxanes, or to any excipients of the formulation including 
polysorbate 80.  
· Neutrophil counts less than 1,500/mm3.  
· Hepatic impairment (bilirubin ≥1 x ULN, or AST and/or ALT≥1.5 × ULN).  
· Concomitant vaccination with yellow fever vaccine (see section 4.5).  
Cabazitaxel 
(Jevtana) 
ALT diagnostic Hypertension, 
Pulmonary 
Contraindications:  
(...) 
Elevated aminotransferases prior to initiation of treatment (aspartate aminotransferase (AST) 
and/or alanine aminotransferase (ALT) > 3 x ULN)... 
sitaxentan 
sodium (Thelin) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
ALT diagnostic Hypertension, 
Pulmonary 
Scleroderma, 
Systemic 
Contraindications: 
(...) Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or  
alanine aminotransferases (ALT), greater than 3 times the upper limit of normal (see section 4.4)… 
bosentan 
monohydrate 
(Tracleer) 
ALT diagnostic Hypertension, 
Pulmonary 
Contraindications: 
(…) Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or 
alanine aminotransferases (ALT))>3xULN (see sections 4.2 and 4.4)... 
Ambrisentan 
(Volibris) 
ALT diagnostic HIV Infections Contraindications; 
(…) Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN 
until baseline ASAT/ALAT are stabilised < 5 ULN… 
Nevirapine 
(Viramune; 
Nevirapine 
Teva) 
antibodies 
against IgA 
diagnostic Immunologic 
Deficiency 
Syndromes 
Guillain-Barre 
Syndrome 
Bone Marrow 
Transplantation 
Purpura, 
Thrombocytope
nic, Idiopathic 
Mucocutaneou
s Lymph Node 
Syndrome 
Contraindications: 
Hypersensitivity to the active substance or to any of the excipientslisted in section 6.1 (see 
alsosection 4.4). 
Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA. 
Patients with hyperprolinaemia. 
human normal 
immunoglobuli
n (ivig) 
(Privigen) 
anti-dsDNA  monitoring Lupus 
Erythematosus, 
Systemic 
Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive 
systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti-dsDNA 
and low complement) despite standard therapy (see section 5.1). 
Belimumab 
(Benlysta) 
antiphospho
lipid 
antibodies  
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of Zoely. Should any of 
the conditions appear for the first time during Zoely use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol 
(Zoely) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
antithrombi
n-III 
deficiency 
ICD10 Contraception Female contraception  
EVRA is intended for women of fertile age. The safety and efficacy has been established in women 
aged 18 to 45 years 
Contraindications: 
EVRA should not be used in the presence of one of the following disorders. If one of these disorders 
occurs during the use of EVRA, EVRA must be discontinued immediately (...) 
● Possible hereditary predisposition for venous or arterial thrombosis, such as activated protein C 
(APC-) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinemia, and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
norelgestromin 
/ ethinyl 
estradiol 
(EVRA) 
antithrombi
n-III 
deficiency 
defines disease Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of IOA. Should any of 
the conditions appear for the first time during IOA use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol (IOA) 
antithrombi
n-III-
deficiency 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of Zoely. Should any of 
the conditions appear for the first time during Zoely use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol 
(Zoely) 
AST diagnostic   Contraindications: 
· Hypersensitivity to cabazitaxel, to other taxanes, or to any excipients of the formulation including 
polysorbate 80.  
· Neutrophil counts less than 1,500/mm3.  
· Hepatic impairment (bilirubin ≥1 x ULN, or AST and/or ALT≥1.5 × ULN).  
· Concomitant vaccination with yellow fever vaccine (see section 4.5).  
Cabazitaxel 
(Jevtana) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
AST diagnostic Hypertension, 
Pulmonary 
Contraindications:  
(...) Elevated aminotransferases prior to initiation of treatment (aspartate aminotransferase (AST) 
and/or alanine aminotransferase (ALT) > 3 x ULN)... 
sitaxentan 
sodium (Thelin) 
AST diagnostic Hypertension, 
Pulmonary 
Scleroderma, 
Systemic 
Contraindications: 
(...) Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or 
alanine aminotransferases (ALT), greater than 3 times the upper limit of normal (see section 4.4)… 
bosentan 
monohydrate 
(Tracleer) 
AST diagnostic Hypertension, 
Pulmonary 
Contraindications: 
(...)  Baseline values of hepatic aminotransferases (aspartate aminotransferases (AST) and/or 
alanine aminotransferases (ALT))>3xULN (see sections 4.2 and 4.4).  
Ambrisentan 
(Volibris) 
AST diagnostic HIV Infections Contraindications; 
(…) Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN 
until baseline ASAT/ALAT are stabilised < 5 ULN… 
Nevirapine 
(Viramune; 
Nevirapine 
Teva) 
autoantibod
y-positive 
diagnostic Lupus 
Erythematosus, 
Systemic 
Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive 
systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g positive anti-dsDNA 
and low complement) despite standard therapy (see section 5.1). 
Belimumab 
(Benlysta) 
B-cell ICD10 Leukemia, 
Lymphocytic, 
Chronic, B-Cell 
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia 
(BCLL) for whom fludarabine combination chemotherapy is not appropriate.  
Alemtuzumab 
(MabCampat
h) 
B-cell ICD10 Lymphoma, 
Non-Hodgkin 
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell 
nonHodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisolone) chemotherapy.  
Rituximab 
(MabThera) 
B-cell ICD10 Lymphoma, 
Follicular 
[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in 
previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in 
combination with chemotherapy has not been established. 
[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed 
or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). 
ibritumomab 
tiuxetan 
(Zevalin) 
B-cell ICD10 Lymphoma, 
Non-Hodgkin 
Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or 
refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). The benefit of pixantrone treatment 
has not been established in patients when used as fifth line or greater chemotherapy in patients 
who are refractory to last therapy 
pixantrone 
dimaleate 
(Pixuvri) 
BMI defines disease Obesity As an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2), or 
overweight patients (BMI > 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or 
dyslipidaemia (see section 5.1) 
Rimonabantri
monabant 
(Acomplia) 
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Biomarker Exclusion 
reason 
Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
BMI defines disease Obesity alli is indicated for weight loss in adults who are overweight (body mass index, BMI >= 28 kg/m2) 
and should be taken in conjunction with a mildly hypocaloric, lower-fat diet 
Orlistat (Alli 
(previously 
Orlistat GSK)) 
C1 inhibitor 
deficiency 
ICD10 Angioedemas, 
Hereditary 
Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in 
adults (with C1-esterase-inhibitor deficiency). 
Icatibant 
(Firazyr) 
C1 inhibitor 
deficiency 
ICD10 Angioedema for use as replacement treatment in acute attacks of angioedema in patients with congenital C1 
inhibitor activity deficiency 
recombinant 
human C1 
inhibitor 
(Rhucin) 
C1 inhibitor 
deficiency 
ICD10 Angioedemas, 
Hereditary 
Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary 
angioedema (HAE) due to C1 esterase inhibitor deficiency.  
conestat alfa 
(Ruconest) 
carcinoemb
ryonic 
antigen 
non-therapeutic Radionuclide 
Imaging 
Colorectal 
Neoplasms 
CEA-Scan is indicated only in patients with histologically-demonstrated carcinoma of the colon or 
rectum for imaging of recurrence and/or metastases. CEA-Scan is employed for diagnostic use 
only, in the above mentioned patients, as an adjunct to standard non-invasive imaging 
techniques, such as ultrasonography or CT scan, in the following situations: 
Patients with evidence of recurrence and/or metastatic carcinoma of the colon or rectum, who 
are undergoing an evaluation for extent of disease, such as prior to surgical resection and/or other 
therapy, or 
Patients with suspected recurrence and/or metastatic carcinoma of the colon or rectum in 
association with rising levels of carcinoembryonic antigen (CEA). 
Arcitumomab 
(CEA-Scan) 
CD 30+ diagnostic Hodgkin 
Disease 
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+  
Hodgkin lymphoma (HL):  
1. following autologous stem cell transplant (ASCT) or  
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a  
treatment option 
brentuximab 
vedotin 
(Adcetris) 
CD20+ diagnostic Lymphoma, 
Non-Hodgkin 
MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell 
nonHodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisolone) chemotherapy.  
Rituximab 
(MabThera) 
CD20+ diagnostic Lymphoma, 
Follicular 
[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in 
previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in 
combination with chemotherapy has not been established. 
[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed 
or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). 
ibritumomab 
tiuxetan 
(Zevalin) 
CD4 monitoring Sarcoma, 
Kaposi 
For treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts (< 200 CD4 
lymphocytes/mm3) and extensive mucocutaneous or visceral disease.  
Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-
doxorubicin 
hydrochloride 
(Caelyx) 
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KS patients with disease that has progressed with, or in patients intolerant to, prior combination 
systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, 
bleomycin and standard doxorubicin (or other anthracycline).  
CD4 non-therapeutic Mumps 
Rubella 
Immunization 
Measles 
Contraindications: 
(…) Humoral or cellular (primary or acquired) immunodeficiency, including 
hypogammaglobulinemia and dysgammaglobulinemia and AIDS, or symptomatic HIV infection or 
an age-specific CD4+ T lymphocyte percentage <25% (see section 4.4). In severely 
immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, 
measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of 
disseminated measles vaccine virus infection have been reported... 
virus, live 
attenuated, 
measles, virus, 
live 
attenuated, 
mumps, virus, 
live 
attenuated, 
rubella (M-M-
RVAXPRO) 
CD4 non-therapeutic Mumps 
Chickenpox 
Rubella 
Immunization 
Measles 
Contraindications: 
(…) Humoral or cellular (primary or acquired) immunodeficiency, including 
hypogammaglobulinemia and dysgammaglobulinemia and AIDS, or symptomatic HIV infection or 
a CDC Class 2 or higher or an age-specific CD4+ T-lymphocyte percentage <25% (see section 4.4). 
In severely immunocompromised individuals inadvertently vaccinated with measles-containing 
vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct 
consequence of disseminated measles vaccine virus infection have been reported... 
virus, live 
attenuated, 
measles, virus, 
live 
attenuated, 
mumps, virus, 
live 
attenuated, 
rubella, virus, 
live 
attenuated, 
varicella 
(Proquad) 
CD4 monitoring HIV Infections SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) 
infected adults, adolescents and children 3 years of age and older. SUSTIVA has not been 
adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 
50 cells/mm3,or after failure of protease inhibitor (PI) containing regimens. Although cross-
resistance of efavirenz with PIs has not been documented, there are at present insufficient data on 
the efficacy of subsequent use of PI based combination therapy after failure of regimens 
containing SUSTIVA. For a summary of clinical and pharmacodynamic information, see section 5.1. 
Efavirenz 
(Stocrin; 
Sustiva; 
Efavirenz Teva) 
Child-Pugh 
score 
diagnostic HIV Infections Contraindications: 
(…) Patients with moderate or severe (Child-Pugh B or C) hepatic impairment… 
Tipranavir 
(Aptivus) 
Child-Pugh 
score 
diagnostic Angina, 
Unstable 
Acute Coronary 
Contraindications: 
(…) Severe hepatic impairment (Child Pugh class C).  
Prasugrel 
(Efient) 
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Syndrome 
Myocardial 
Infarction 
Child-Pugh 
score 
diagnostic HIV Infections Contraindications; 
(…) Patients with severe hepatic impairment (Child-Pugh C) or pre-treatment ASAT or ALAT > 5 ULN 
until baseline ASAT/ALAT are stabilised < 5 ULN… 
Nevirapine 
(Viramune; 
Nevirapine 
Teva) 
Child-Pugh 
score 
diagnostic Hypertension, 
Pulmonary 
Contraindications:  
(...) Mild to severe hepatic impairment (Child-Pugh Class A-C)… 
sitaxentan 
sodium (Thelin) 
Child-Pugh 
score 
diagnostic Hypertension, 
Pulmonary 
Scleroderma, 
Systemic 
Contraindications: 
(...) Moderate to severe hepatic impairment, i.e.,Child-Pugh class Bor C (see section 5.2)… 
bosentan 
monohydrate 
(Tracleer) 
Child-Pugh 
score 
diagnostic Hepatitis C, 
Chronic 
Contraindications: 
(…) HCV/HIV patients with cirrhosis and a Child-Pugh score ≥ 6… 
peginterferon 
alfa-2b 
(PegIntron; 
ViraferonPeg) 
Child-Pugh 
score 
diagnostic Hepatitis B, 
Chronic 
Contraindications: 
(…) Initiation of Pegasys is contraindicated in HIV-HCV patients with cirrhosis and a Child-Pugh 
score ≥ 6, except if only due to indirect hyperbilirubinemia caused by drugs such as atazanavir and 
indinavir... 
peginterferon 
alfa-2a 
(Pegasys) 
congenital 
factor IX 
deficiency 
ICD10 Hemophilia B Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX 
deficiency) 
nonacog alfa 
(BeneFIX) 
congenital 
factor VIII 
deficiency 
ICD10 Hemophilia A Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII 
deficiency).  
ADVATE does not contain von Willebrand Factor in harmacologically effective quantities and is 
therefore not indicated in von Willebrand disease.  
octocog alfa 
(Advate) 
creatine 
phosphokin
ase 
elevation 
diagnostic Dyslipidemias Contraindications: 
(…) Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed 
creatine phosphokinase (CK) elevation above 5 times the upper limit of normal (ULN) under 
previous statin treatment (see section 4.4).  
fenofibrate / 
pravastatin 
(Pravafenix) 
CYP2D6  metabolic HIV Infections Contraindications: 
(…) Agenerase with ritonavir must not be co-administered with medicinal products with narrow 
therapeutic windows that are highly dependent on CYP2D6 metabolism, e.g. flecainide and 
propafenone (see section 4.5)… 
Amprenavir 
(Agenerase) 
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CYP3A metabolic HIV Infections Contraindications: 
(…) Co-administration of APTIVUS with low dose ritonavir, with active substances that are highly 
dependent on CYP3A for clearance, and for which elevated plasma concentrations are 
associated with serious and/or life-threatening events, is contraindicated... 
Tipranavir 
(Aptivus) 
CYP3A metabolic HIV Infections Contraindications: 
(...) Eviplera should not be co-administered with the following medicinal products as significant 
decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction or 
gastric pH increase), which may result in loss of therapeutic effect of Eviplera... 
emtricitabine / 
rilpivirine / 
tenofovir 
disoproxil 
(Eviplera) 
CYP3A metabolic Hepatitis C, 
Chronic 
Contraindications: 
(…) Concomitant administration with active substances that are highly dependent on CYP3A for 
clearance and for which elevated plasma concentrations are associated with serious and/or life-
threatening events. These active substances include alfuzosin, amiodarone, bepridil, quinidine, 
astemizole, terfenadine, cisapride, pimozide, ergot derivatives (dihydroergotamine, ergonovine, 
ergotamine, methylergonovine), lovastatin, simvastatin, atorvastatin, sildenafil or tadalafil (only 
when used for treatment of pulmonary arterial hypertension) and orally administered midazolam or 
triazolam. Concomitant administration with Class Ia or III antiarrhythmics, except for intravenous 
lidocaine (see section 4.5). 
Concomitant administration of INCIVO with active substances that strongly induce CYP3A e.g. 
rifampicin, St John's wort (Hypericum perforatum), carbamazepine, phenytoin and phenobarbital 
and thus may lead to lower exposure and loss of efficacy of INCIVO... 
Telaprevir 
(Incivo) 
CYP3A metabolic HIV Infections Contraindications: 
(…) Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A. 
Kaletra should not be co-administered with medicinal products that are highly dependent on 
CYP3A for clearance and for which elevated plasma concentrations are associated with serious 
and/or life threatening events. These medicinal products include... 
lopinavir / 
ritonavir 
(Kaletra) 
CYP3A4 metabolic HIV Infections Contraindications: 
(...) Agenerase must not be administered concurrently with medicinal products with narrow 
therapeutic windows that are substrates of cytochrome P450 3A4 (CYP3A4). Co-administration may 
result in competitive inhibition of the metabolism of these medicinal products and create the 
potential for serious and/or life-threatening adverse events such as cardiac arrhythmia (e.g. 
amiodarone, bepridil, quinidine, terfenadine, astemizole, cisapride, pimozide), respiratory 
depression and /or prolonged sedation (e.g. oral triazolam and oral midazolam (for caution on 
parenterally administered midazolam, see section 4.5)) or peripheral vasospasm or ischaemia and 
ischaemia of other tissues, including cerebral or myocardial ischaemia (e.g. ergot derivatives)... 
Amprenavir 
(Agenerase) 
CYP3A4 metabolic HIV Infections Contraindications: 
(…) Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, 
bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and 
efavirenz / 
emtricitabine / 
tenofovir 
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methylergonovine). Competition for cytochrome P450 (CYP) 3A4 by efavirenz could result in 
inhibition of metabolism and create the potential for serious and/or life-threatening adverse 
reactions (for example, cardiac arrhythmias, prolonged sedation or respiratory depression) (see 
section 4.5)... 
disoproxil 
(Atripla) 
CYP3A4 metabolic Peripheral 
Vascular 
Diseases 
Acute Coronary 
Syndrome 
Contraindications: 
(…) Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, 
clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as co-administration may 
lead to a substantial increase in exposure to ticagrelor (see section 4.4 and 4.5)... 
Ticagrelor 
(Possia) 
factors VII, 
VIII or IX 
ICD10 Hemophilia B 
Thrombasthenia 
Factor VII 
Deficiency 
Hemophilia A 
NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding 
in those undergoing surgery or invasive procedures in the following patient groups: 
• in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 
Bethesda Units (BU) 
• in patients with congenital haemophilia who are expected to have a high anamnestic response 
to factor VIII or factor IX administration 
• in patients with acquired haemophilia 
• in patients with congenital FVII deficiency 
• in patients with Glanzmann’s thrombasthenia with antibodies to GP IIb – IIIa and/or HLA, and with 
past or present refractoriness to platelet transfusions. 
eptacog alfa 
(activated) 
(NovoSeven) 
G6PD 
deficiency 
ICD10 Hyperuricemia Contraindications: 
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  
G6PD deficiency and other cellular metabolic disorders known to cause haemolytic anaemia.  
Hydrogen peroxide is a by-product of the conversion of uric acid to allantoin. In order to prevent 
possible haemolytic anaemia induced by hydrogen peroxide, rasburicase is contraindicated in 
patients with these disorders. 
Rasburicase 
(Fasturtec) 
G6PD 
deficiency 
ICD10 Methemoglobin
emia 
Contraindications: 
· Hypersensitivity to the active substance, or to any other thiazine dyes  
· Patients with Glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of 
haemolytic anaemia  
· Patients with sodium nitrite-induced methaemoglobinaemia  
· Patients with methaemoglobinaemia due to chlorate poisoning  
· Deficiency in NADPH reductase.  
Methylthionini
um chloride 
(Methylthionini
um chloride 
Proveblue) 
genetic 
testing 
(familial 
lipoprotein 
lipase 
deficiency) 
defines disease Hyperlipoprotei
nemia Type I 
Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) 
and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The 
diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients 
with detectable levels of LPL protein (see section 4.4). 
alipogene 
tiparvovec 
(Glybera) 
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genotype 1 associated with 
another 
treatment 
Hepatitis C, 
Chronic 
Tritherapy:  
Rebetol in combination with boceprevir and peginterferon alfa-2b is indicated for the treatment of 
chronic hepatitis C (CHC) genotype 1 infection in adults patients (18 years of age and older) with 
compensated liver disease who are previously untreated or who have failed previous therapy.  
Please refer to peginterferon alfa -2b and boceprevir SmPCs when using Rebetol in combination 
with these medicines.  
Bitherapy:  
Rebetol is indicated for the treatment of chronic hepatitis C virus infection in adults, children 3 
years of age and older and adolescents and must only be used as part of a combination regimen 
with peginterferon alfa-2b or interferon alfa-2b.  Rebetol monotherapy must not be used.  
Please refer to interferon alfa-2b and peginterferon alfa-2b SmPCs when using Rebetol in 
combination with these medicines.  
There is no safety or efficacy information on the use of Rebetol with other forms of interferon (i.e., 
not alfa-2b).  
Previously untreated (naïve) patients 
Adult patients (18 years of age or older): Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients with chronic hepatitis C genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with interferon alfa-2b or peginterferon alfa-2b, for the treatment of 
adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with 
elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid 
(HCV-RNA).  
• bitherapy – for the treatment of CHC infection in combination with peginterferon alfa-2b for 
patients with compensated cirrhosis and/or clinically stable HIV co-infection (see section 4.4).  
Bitherapy 
Paediatric patients (children 3 years of age and older and adolescents): Rebetol is indicated, in a 
combination regimen with peginterferon alfa-2b or interferon alfa-2b, for the treatment of children 
3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, 
without liver decompensation, and who are positive for HCV-RNA. When deciding to not to defer 
treatment until adulthood, it is important to consider that the combination therapy induced a 
growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be 
made on a case by case basis (see section 4.4).  
Previously treated patients 
Adult patients: Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients having CHC genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with peginterferon alfa-2b, for the treatment of patients with chronic 
hepatitis C who have failed previous treatment with interferon alpha (pegylated or nonpegylated) 
alone or in combination with ribavirin (see section 5.1).  
• bitherapy - in combination with interferon alfa-2b, for the treatment of patients with chronic  
Ribavirin 
(Rebetol; 
Ribavirin 
BioPartners; 
Ribavirin Mylan 
(previously 
Ribavirin Three 
Rivers); 
Ribavirin Teva; 
Ribavirin Teva 
Pharma B.V.) 
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hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to 
interferon alfa monotherapy but who have subsequently relapsed.  
genotype 1 associated with 
another 
treatment 
Hepatitis C, 
Chronic 
Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, 
children 3 years of age and older and adolescents and must only be used as part of a 
combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.  
There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e., 
not alfa-2b).  
Naïve patients  
Adult patients: Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment 
of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, 
without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for 
hepatitis C viral ribonucleic acid HCV-RNA (see section 4.4).  
Children 3 years of age and older and adolescents: Ribavirin Teva is intended for use, in a 
combination regimen with interferon alfa2b, for the treatment of children and adolescents 3 years 
of age and older, who have all types of chronic hepatitis C except genotype 1, not previously 
treated, without liver decompensation, and who are positive for HCV-RNA.  
When deciding to not to defer treatment until adulthood, it is omportant to consider that the 
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. 
The decision to treat should be made on a case by case basis (see section 4.4).  
Previous treatment failure patients  
Adult patients: Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment 
of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT 
at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed. 
(see  
section 5.1). 
Ribavirin 
(Ribavirin 
BioPartners; 
Ribavirin Mylan 
(previously 
Ribavirin Three 
Rivers); 
Ribavirin Teva; 
Ribavirin Teva 
Pharma B.V.) 
GH receptor 
mutations 
defines disease Laron Syndrome For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with 
severe primary insulin-like growth factor-1 deficiency (Primary IGFD).  
Severe Primary IGFD is defined by:  
· height standard deviation score £ –3.0 and  
· basal IGF-1 levels below the 2.5th percentile for age and gender and  
· GH sufficiency.  
· Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic 
treatment with pharmacologic doses of anti-inflammatory steroids.  
Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling 
pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be 
expected to respond adequately to exogenous GH treatment. It is recommended to confirm the 
diagnosis by conducting an IGF-1 generation test.  
Mecasermin 
(Increlex) 
H5N1 
subtype of 
non-therapeutic Influenza, 
Human 
Active immunisation against H5N1 subtype of Influenza A virus.  
This indication is based on immunogenicity data from healthy subjects from the age of 18 years 
Influenza virus 
surface 
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Influenza A 
virus 
Immunization 
Disease 
Outbreaks 
onwards following administration of two doses of the vaccine containing A/turkey/Turkey/1/05 
(H5N1)-like strain (see section 5.1).  
antigens*, 
inactivated:<b
r />A/Viet 
Nam/1194/200
4 (H5N1) 
&ndash; like 
strain used 
(NIBRG-14)<br 
/><br />* 
produced in 
eggs (Aflunov) 
HBeAg doesn’t 
distinguish 
Hepatitis B, 
Chronic 
Baraclude is indicated for the treatment of chronic hepatitis B virus (HBV) infection (see section 5.1)  
in adults with:  
§ compensated liver disease and evidence of active viral replication, persistently elevated serum 
alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or 
fibrosis.  
§ decompensated liver disease (see section 4.4)  
For both compensated and decompensated liver disease, this indication is based on clinical trial 
data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With 
respect to patients with lamivudine-refractory hepatitis B, see sections 4.4 and 5.1. 
Entecavir 
(Baraclude) 
HBeAg diagnostic Hepatitis B, 
Chronic 
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral 
replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBeAg), 
elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or 
fibrosis. 
interferon alfa-
2b (IntronA; 
Viraferon) 
HBeAg doesn’t 
distinguish 
Hepatitis B, 
Chronic 
Pegasys is indicated for the treatment of HBeAg-positive or HBeAg-negative chronic hepatitis B in 
adult patients with compensated liver disease and evidence of viral replication, increased ALT and 
histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1).  
peginterferon 
alfa-2a 
(Pegasys) 
HBV-DNA non-therapeutic Immunization, 
Passive 
Hepatitis B 
Liver 
Transplantation 
Prevention of hepatitis B virus (HBV) re-infection in HBV-DNA negative patients ≥ 6 months after liver 
transplantation for hepatitis B induced liver failure. 
Zutectra is indicated in adults only.  
The concomitant use of adequate virostatic agents should be considered, if appropriate, as 
standard of hepatitis B re-infection prophylaxis 
human 
hepatitis&nbsp
;B 
immunoglobuli
n (Zutectra) 
HBV-DNA diagnostic Hepatitis B, 
Chronic 
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral 
replication (presence of DNA of hepatitis B virus (HBV-DNA) and hepatitis B antigen (HBeAg), 
elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or 
fibrosis. 
interferon alfa-
2b (IntronA; 
Viraferon) 
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HCV 
antibodies 
diagnostic Hepatitis C, 
Chronic 
Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or 
HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation. 
The efficacy of Interferon-alfa-2a in the treatment of hepatitis C is enhanced when combined with 
ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to 
ribavirin.  
recombinant 
human 
interferon-alfa-
2a (Alpheon) 
HCV 
genotype 
prognostic Hepatitis C, 
Chronic 
Adult patients:  
Viraferon is indicated for the treatment of adult patients with chronic hepatitis C who have 
elevated transaminases without liver decompensation and who are positive for serum HCV-RNA or 
anti-HCV (see section 4.4).  
The best way to use Viraferon in this indication is in combination with ribavirin.  
Chidren and adolescents:  
Viraferon is intended for use, in a combination regimen with ribavirin, for the treatment of children 
and adolescents 3 years of age and older, who have chronic hepatitis C, not previously treated, 
without liver decompensation, and who are positive for serum HCV-RNA. The decision to treat 
should be made on a case by case basis, taking into account any evidence of disease progression 
such as hepatic inflammation and fibrosis, as well as prognostic factors for response, HCV 
genotype and viral load. The expected benefit of treatment should be weighed against the safety 
findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).  
interferon alfa-
2b (Viraferon) 
HCV 
genotype 
associated with 
another 
treatment 
Hepatitis C, 
Chronic 
Adults (tritherapy): 
ViraferonPeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the 
treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and 
older) with compensated liver disease who are previously untreated or who have failed previous 
therapy (see section 5.1).  
Please refer to the ribavirin and boceprevir Summary of Product Characteristics (SmPCs) when 
ViraferonPeg is to be used in combination with these medicines.  
Adults (bitherapy and monotherapy): 
ViraferonPeg is indicated for the treatment of adult patients (18 years of age and older) with CHC 
who are positive for hepatitis C virus RNA (HCV-RNA), including patients with compensated cirrhosis 
and/or co-infected with clinically stable HIV (see section 4.4).  
ViraferonPeg in combination with ribavirin (bitherapy) is indicated for the treatment of CHC 
infection in adult patients who are previously untreated including patients with clinically stable HIV 
coinfection and in adult patients who have failed previous treatment with interferon alpha 
(pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy 
(see section 5.1).  
Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or 
contraindication to ribavirin.  
Please refer to the ribavirin SmPC when ViraferonPeg is to be used in combination with ribavirin.  
Paediatric population (bitherapy): 
ViraferonPeg is indicated in a combination regimen with ribavirin for the treatment of children 3 
years of age and older and adolescents, who have chronic hepatitis C, previously untreated, 
peginterferon 
alfa-2b 
(ViraferonPeg) 
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without liver decompensation, and who are positive for HCV-RNA. 
When deciding not to defer treatment until adulthood, it is important to consider that the 
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. 
The decision to treat should be made on a case by case basis (see section 4.4).  
Please refer to the ribavirin SmPC for capsules or oral solution when ViraferonPeg is to be used in 
combination with ribavirin. 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Adult patients with histologically proven chronic hepatitis C who are positive for HCV antibodies or 
HCV RNA and have elevated serum alanine aminotransferase (ALT) without liver decompensation. 
The efficacy of Interferon-alfa-2a in the treatment of hepatitis C is enhanced when combined with 
ribavirin. Alpheon should be given alone mainly in case of intolerance or contra-indication to 
ribavirin.  
recombinant 
human 
interferon-alfa-
2a (Alpheon) 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C 
virus (HCV) infection e.g. those who have elevated serum transaminase levels without 
decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). 
Consideration should be given to current official guidance on the appropriate use of interferons for 
the treatment of patients with chronic hepatitis C. 
Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to 
ribavirin. 
interferon 
alfacon-1 
(Infergen) 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Before initiating treatment with IntronA, consideration should be given to the results from clinical 
trials comparing IntronA with pegylated interferon (see section 5.1).  
Adult patients IntronA is indicated for the treatment of adult patients with chronic hepatitis C who 
have elevated transaminases without liver decompensation and who are positive for hepatitis C 
virus RNA (HCV RNA) (see section 4.4).  
The best way to use IntronA in this indication is in combination with ribavirin.  
Children 3 years of age and older and adolescents IntronA is indicated, in a combination regimen 
with ribavirin, for the treatment of children 3 years of age and older and adolescents, who have 
chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for 
HCV-RNA.  
When deciding not to defer treatment until adulthood, it is important to consider that the 
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain 
The decision to treat should be made on a case by case basis (see section 4.4) 
interferon alfa-
2b (IntronA; 
Viraferon) 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Pegasys is indicated for the treatment of chronic hepatitis C in adult patients who are positive for 
serum HCV-RNA, including patients with compensated cirrhosis and/or co-infected with clinically 
stable HIV (see section 4.4).  
The optimal way to use Pegasys in patients with chronic hepatitis C is in combination with ribavirin.  
The combination of Pegasys and ribavirin is indicated in naive patients and patients who have 
failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in 
peginterferon 
alfa-2a 
(Pegasys) 
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Therapeutic 
area 
Indication/ Contraindication (if relevant) text Drug 
combination therapy with ribavirin.  
Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Adults (tritherapy): 
PegIntron in combination with ribavirin and boceprevir (tritherapy) is indicated for the treatment of 
chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and older) with 
compensated liver disease who are previously untreated or who have failed previous therapy (see 
section 5.1).  
Please refer to the ribavirin and boceprevir Summary of Product Characteristics (SmPCs) when 
PegIntron is to be used in combination with these medicines.  
Adults (bitherapy and monotherapy): 
PegIntron is indicated for the treatment of adult patients (18 years of age and older) with CHC who 
are positive for hepatitis C virus RNA (HCV-RNA), including patients with compensated cirrhosis 
and/or co-infected with clinically stable HIV (see section 4.4).  
PegIntron in combination with ribavirin (bitherapy) is indicated for the treatment of CHC infection in 
adult patients who are previously untreated including patients with clinically stable HIV co-infection 
and in adult patients who have failed previous treatment with interferon alpha (pegylated or 
nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy (see section 
5.1).  
Interferon monotherapy, including PegIntron, is indicated mainly in case of intolerance or 
contraindication to ribavirin.  
Please refer to the ribavirin SmPC when PegIntron is to be used in combination with ribavirin.  
Paediatric population (bitherapy): 
PegIntron is indicated in a combination regimen with ribavirin for the treatment of children 3 years 
of age and older and adolescents, who have chronic hepatitis C, previously untreated, without 
liver decompensation, and who are positive for HCV-RNA. 
When deciding not to defer treatment until adulthood, it is important to consider that the 
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. 
The decision to treat should be made on a case by case basis (see section 4.4).  
Please refer to the ribavirin SmPC for capsules or oral solution when PegIntron is to be used in 
combination with ribavirin.  
peginterferon 
alfa-2b 
(PegIntron; 
ViraferonPeg) 
HCV RNA diagnostic Hepatitis C, 
Chronic 
Tritherapy:  
Rebetol in combination with boceprevir and peginterferon alfa-2b is indicated for the treatment of 
chronic hepatitis C (CHC) genotype 1 infection in adults patients (18 years of age and older) with 
compensated liver disease who are previously untreated or who have failed previous therapy.  
Please refer to peginterferon alfa -2b and boceprevir SmPCs when using Rebetol in combination 
with these medicines.  
Bitherapy:  
Rebetol is indicated for the treatment of chronic hepatitis C virus infection in adults, children 3 
years of age and older and adolescents and must only be used as part of a combination regimen 
with peginterferon alfa-2b or interferon alfa-2b.  Rebetol monotherapy must not be used.  
Ribavirin 
(Rebetol; 
Ribavirin 
BioPartners; 
Ribavirin Mylan 
(previously 
Ribavirin Three 
Rivers); 
Ribavirin Teva; 
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Biomarker Exclusion 
reason 
Therapeutic 
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Indication/ Contraindication (if relevant) text Drug 
Please refer to interferon alfa-2b and peginterferon alfa-2b SmPCs when using Rebetol in 
combination with these medicines.  
There is no safety or efficacy information on the use of Rebetol with other forms of interferon (i.e., 
not alfa-2b).  
Previously untreated (naïve) patients 
Adult patients (18 years of age or older): Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients with chronic hepatitis C genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with interferon alfa-2b or peginterferon alfa-2b, for the treatment of 
adult patients with chronic hepatitis C, not previously treated, without liver decompensation, with 
elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid 
(HCV-RNA).  
• bitherapy – for the treatment of CHC infection in combination with peginterferon alfa-2b for 
patients with compensated cirrhosis and/or clinically stable HIV co-infection (see section 4.4).  
Bitherapy 
Paediatric patients (children 3 years of age and older and adolescents): Rebetol is indicated, in a 
combination regimen with peginterferon alfa-2b or interferon alfa-2b, for the treatment of children 
3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, 
without liver decompensation, and who are positive for HCV-RNA. When deciding to not to defer 
treatment until adulthood, it is important to consider that the combination therapy induced a 
growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be 
made on a case by case basis (see section 4.4).  
Previously treated patients 
Adult patients: Rebetol is indicated for:  
• tritherapy - in combination with peginterferon alfa-2b and boceprevir for the treatment of adult 
patients having CHC genotype 1 infection with compensated liver disease.  
• bitherapy - in combination with peginterferon alfa-2b, for the treatment of patients with chronic 
hepatitis C who have failed previous treatment with interferon alpha (pegylated or nonpegylated) 
alone or in combination with ribavirin (see section 5.1).  
• bitherapy - in combination with interferon alfa-2b, for the treatment of patients with chronic  
hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to 
interferon alfa monotherapy but who have subsequently relapsed.  
Ribavirin Teva 
Pharma B.V.) 
HCV-RNA diagnostic Hepatitis C, 
Chronic 
Adults (tritherapy): 
ViraferonPeg in combination with ribavirin and boceprevir (tritherapy) is indicated for the 
treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients (18 years of age and 
older) with compensated liver disease who are previously untreated or who have failed previous 
therapy (see section 5.1).  
Please refer to the ribavirin and boceprevir Summary of Product Characteristics (SmPCs) when 
ViraferonPeg is to be used in combination with these medicines.  
Adults (bitherapy and monotherapy): 
peginterferon 
alfa-2b 
(ViraferonPeg) 
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Therapeutic 
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Indication/ Contraindication (if relevant) text Drug 
ViraferonPeg is indicated for the treatment of adult patients (18 years of age and older) with CHC 
who are positive for hepatitis C virus RNA (HCV-RNA), including patients with compensated cirrhosis 
and/or co-infected with clinically stable HIV (see section 4.4).  
ViraferonPeg in combination with ribavirin (bitherapy) is indicated for the treatment of CHC 
infection in adult patients who are previously untreated including patients with clinically stable HIV 
coinfection and in adult patients who have failed previous treatment with interferon alpha 
(pegylated or nonpegylated) and ribavirin combination therapy or interferon alpha monotherapy 
(see section 5.1).  
Interferon monotherapy, including ViraferonPeg, is indicated mainly in case of intolerance or 
contraindication to ribavirin.  
Please refer to the ribavirin SmPC when ViraferonPeg is to be used in combination with ribavirin.  
Paediatric population (bitherapy): 
ViraferonPeg is indicated in a combination regimen with ribavirin for the treatment of children 3 
years of age and older and adolescents, who have chronic hepatitis C, previously untreated, 
without liver decompensation, and who are positive for HCV-RNA. 
When deciding not to defer treatment until adulthood, it is important to consider that the 
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. 
The decision to treat should be made on a case by case basis (see section 4.4).  
Please refer to the ribavirin SmPC for capsules or oral solution when ViraferonPeg is to be used in 
combination with ribavirin. 
HER2 does not 
identify 
subgroups 
Breast 
Neoplasms 
Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients 
with metastatic breast cancer. For further information as to human epidermal growth factor 
receptor 2 (HER2) status, please refer to section 5.1.  
Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients 
with metastatic breast cancer in whom treatment with other chemotherapy options including 
taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and 
anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be 
excluded from treatment with Avastin in combination with capecitabine. For further information as 
to HER2 status,  
please refer to section 5.1.  
Bevacizumab 
(Avastin) 
HER2 associate with 
other treatment 
Breast 
Neoplasms 
TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant  
treatment of patients with:  
· operable node-positive breast cancer  
· operable node-negative breast cancer  
For patients with operable node-negative breast cancer, adjuvant treatment should be restricted 
to patients eligible to receive chemotherapy according to internationally established criteria for 
primary therapy of early breast cancer (see section 5.1).  
TAXOTERE in combination with doxorubicin is indicated for the treatment of patients with locally 
advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this 
condition.  
Docetaxel 
(Docefrez; 
Docetaxel 
Teva; 
Docetaxel 
Winthrop; 
Docetaxel 
Winthrop; 
Taxotere; 
Docetaxel 
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Therapeutic 
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Indication/ Contraindication (if relevant) text Drug 
TAXOTERE monotherapy is indicated for the treatment of patients with locally advanced or 
metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have 
included an anthracycline or an alkylating agent.  
TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with 
metastatic breast cancer whose tumours over express HER2 and who previously have not received 
chemotherapy for metastatic disease.  
TAXOTERE in combination with capecitabine is indicated for the treatment of patients with locally 
advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy 
should have included an anthracycline.  
Accord; 
Docetaxel 
Kabi; 
Docetaxel 
Mylan) 
histology, 
tumour 
disease subtype Soft Tissue 
Sarcoma 
Soft tissue sarcoma (STS) 
Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft 
Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have 
progressed within 12 months after (neo) adjuvant therapy.  
Efficacy and safety has only been established in certain STS histological tumour subtypes (see 
section 5.1). 
Pazopanib 
(Votrient) 
homozygou
s 
prognostic Hypercholester
olemia 
Kynamro was expected to be used to treat patients with an inherited disease causing high blood 
cholesterol levels, called familial hypercholesterolaemia. It was initially expected to be used to 
treat two closely related forms of the disease called ‘severe heterozygous’ and ‘homozygous’ 
familial hypercholesterolaemia. During the assessment of Kynamro, the indication was restricted to 
patients with homozygous familial hypercholesterolaemia only. 
mipomersen 
sodium 
(Kynamro) 
IgA 
antibodies 
diagnostic Immunologic 
Deficiency 
Syndromes 
Guillain-Barre 
Syndrome 
Bone Marrow 
Transplantation 
Purpura, 
Thrombocytope
nic, Idiopathic 
Mucocutaneou
s Lymph Node 
Syndrome 
Contraindications: 
(…) Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA... 
human normal 
immunoglobuli
n 
(Flebogamma 
DIF) 
IgA 
antibodies 
diagnostic Immunologic 
Deficiency 
Syndromes 
Guillain-Barre 
Syndrome 
Contraindications: 
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  
Hypersensitivity to human immunoglobulins, especially in patients with antibodies against IgA. 
human normal 
immunoglobuli
n (ivig) (Kiovig) 
 390 
 
Biomarker Exclusion 
reason 
Therapeutic 
area 
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Bone Marrow 
Transplantation 
Purpura, 
Thrombocytope
nic, Idiopathic 
Mucocutaneou
s Lymph Node 
Syndrome 
IgE diagnostic Asthma Xolair is indicated in adults, adolescents and children (6 to <12 years of age). 
Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) 
mediated asthma (see section 4.2). 
Adults and adolescents (12 years of age and older) 
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent 
allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and 
who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time 
awakenings and who have had multiple documented severe asthma exacerbations despite daily 
highdose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. 
Children (6 to <12 years of age) 
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent 
allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and 
frequent daytime symptoms or night-time awakenings and who have had multiple documented 
severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting 
inhaled beta2-agonist. 
Omalizumab 
(Xolair) 
IGF-1 diagnostic Laron Syndrome For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with 
severe primary insulin-like growth factor-1 deficiency (Primary IGFD).  
Severe Primary IGFD is defined by:  
· height standard deviation score £ –3.0 and  
· basal IGF-1 levels below the 2.5th percentile for age and gender and  
· GH sufficiency.  
· Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic 
treatment with pharmacologic doses of anti-inflammatory steroids.  
Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling 
pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be 
expected to respond adequately to exogenous GH treatment. It is recommended to confirm the 
diagnosis by conducting an IGF-1 generation test.  
Mecasermin 
(Increlex) 
IGF-1 associated with 
another 
treatment 
Acromegaly Treatment of patients with acromegaly who have had an inadequate response to surgery and/or 
radiation therapy and in whom an appropriate medical treatment with somatostatin analogues 
did not normalize IGF-I concentrations or was not tolerated.  
Pegvisomant 
(Somavert) 
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Therapeutic 
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Indication/ Contraindication (if relevant) text Drug 
IGF-1 gene 
defects 
disease subtype Laron Syndrome For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with 
severe primary insulin-like growth factor-1 deficiency (Primary IGFD).  
Severe Primary IGFD is defined by:  
· height standard deviation score £ –3.0 and  
· basal IGF-1 levels below the 2.5th percentile for age and gender and  
· GH sufficiency.  
· Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic 
treatment with pharmacologic doses of anti-inflammatory steroids.  
Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling 
pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be 
expected to respond adequately to exogenous GH treatment. It is recommended to confirm the 
diagnosis by conducting an IGF-1 generation test.  
Mecasermin 
(Increlex) 
N-
acetylgluta
mate 
synthase 
primary 
deficiency 
defines disease Amino Acid 
Metabolism, 
Inborn Errors 
Propionic 
Acidemia 
Carbaglu is indicated in treatment of  
• hyperammonaemia due to N-acetylglutamate synthase primary deficiency. 
• hyperammonaemia due to isovaleric acidaemia. 
• hyperammonaemia due to methymalonic acidaemia. 
• hyperammonaemia due to propionic acidaemia. 
carglumic 
acid 
(Carbaglu) 
non-Q wave ICD10 Angina, 
Unstable 
Myocardial 
Infarction 
INTEGRILIN is intended for use with acetylsalicylic acid and unfractionated heparin. 
INTEGRILIN is indicated for the prevention of early myocardial infarction in adults presenting with 
unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain 
occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac 
enzymes. Patients most likely to benefit from INTEGRILIN treatment are those at high risk of 
developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms 
including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal 
Coronary Angioplasty) (see section 5.1).  
Eptifibatide 
(Integrilin) 
NSTEMI disease subtype Angioplasty, 
Transluminal, 
Percutaneous 
Coronary 
Acute Coronary 
Syndrome 
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary 
intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) 
undergoing primary PCI. 
Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment 
elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. 
Angiox should be administered with aspirin and clopidogrel. 
Bivalirudin 
(Angiox) 
NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Acute Coronary 
Syndrome 
Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non 
ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including 
patients managed medically, and those who are managed with percutaneous coronary 
intervention (PCI) or coronary artery by-pass grafting (CABG)… 
Ticagrelor 
(Brilique) 
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NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:  
· Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic 
stroke (from 7 days until less than 6 months) or established peripheral arterial disease.  
· Patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy… 
Clopidogrel 
(Clopidogrel 
1A Pharma; 
Clopidogrel 
Acino; 
Clopidogrel 
Hexal; 
Clopidogrel 
ratiopharm 
GmbH; 
Clopidogrel 
Zentiva 
(previously 
Clopidogrel 
Winthrop); 
Iscover) 
NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Myocardial 
Infarction 
Clopidogrel is indicated in: 
• Adult patientssuffering from myocardial infarction (from a few days until less than 35 days), 
ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial  
disease. 
• Adult patientssuffering from acute coronary syndrome: 
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA). 
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy. 
clopidogrel 
besilate 
(Clopidogrel 
Apotex; 
Grepid) 
NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Atrial Fibrillation 
Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy 
clopidogrel 
hydrogen 
sulphate 
(Clopidogrel 
BMS; 
Clopidogrel 
Teva 
(hydrogen 
sulphate); 
Plavix - non-
generic; Zyllt) 
NSTEMI disease subtype Peripheral 
Vascular 
Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
clopidogrel 
hydrochloride 
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Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy. 
(Clopidogrel 
HCS; 
Clopidogrel 
Teva Generics 
B.V.) 
NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Clopidogrel is indicated in:  
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), 
ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.  
• Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA)  
 - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy.  
clopidogrel 
hydrobromide 
(Clopidogrel 
Teva Pharma 
B.V.) 
NSTEMI disease subtype Acute Coronary 
Syndrome 
Myocardial 
Infarction 
DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already 
taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination 
medicinal product for continuation of therapy in:  
· Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction) including patients undergoing a stent placement following percutaneous 
coronary intervention  
· ST segment elevation acute myocardial infarction in medically treated patients eligible for 
thrombolytic therapy… 
clopidogrel / 
acetylsalicylic 
acid 
(DuoCover; 
DuoPlavin) 
NSTEMI disease subtype Angina, 
Unstable 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST 
segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial 
infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI)… 
Prasugrel 
(Efient) 
NSTEMI disease subtype Peripheral 
Vascular 
Diseases 
Acute Coronary 
Syndrome 
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non 
ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including 
patients managed medically, and those who are managed with percutaneous coronary 
intervention (PCI) or coronary artery by-pass grafting (CABG)… 
Ticagrelor 
(Possia) 
Philadelphia 
chromosom
e 
ICD10 Leukemia, 
Myelogenous, 
Chronic, BCR-
ABL Positive 
Glivec is indicated for the treatment of· adult and paediatric patients with newly diagnosed 
Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom 
bone marrow transplantation is not considered as the first line of treatment. 
Imatinib 
(Glivec) 
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· adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha 
therapy, or in accelerated phase or blast crisis. 
Philadelphia 
chromosom
e 
ICD10 Leukemia, 
Myelogenous, 
Chronic, BCR-
ABL Positive 
SPRYCEL is indicated for the treatment of adult patients with:  
§ newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia 
(CML) in the chronic phase.  
Dasatinib 
(Sprycel) 
Philadelphia 
chromosom
e 
ICD10 Leukemia, 
Myelogenous, 
Chronic, BCR-
ABL Positive 
Tasigna is indicated for the treatment of adult patients with newly diagnosed Philadelphia 
chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase. 
Nilotinib 
(Tasigna) 
post-GH 
receptor 
pathway 
mutations 
defines disease Laron Syndrome For the long-term treatment of growth failure in children and adolescents from 2 to 18 years with 
severe primary insulin-like growth factor-1 deficiency (Primary IGFD).  
Severe Primary IGFD is defined by:  
· height standard deviation score £ –3.0 and  
· basal IGF-1 levels below the 2.5th percentile for age and gender and  
· GH sufficiency.  
· Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic 
treatment with pharmacologic doses of anti-inflammatory steroids.  
Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling 
pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be 
expected to respond adequately to exogenous GH treatment. It is recommended to confirm the 
diagnosis by conducting an IGF-1 generation test.  
Mecasermin 
(Increlex) 
protease 
inhibitor (PI) 
experience
d  
associated with 
another 
treatment 
HIV Infections Agenerase, in combination with other antiretroviral agents, is indicated for the treatment of 
protease inhibitor (PI) experienced HIV-1 infected adults and children above the age of 4 years. 
Agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic 
enhancer of amprenavir (see sections 4.2 and 4.5). The choice of amprenavir should be based on 
individual viral resistance testing and treatment history of patients (see section 5.1).  
The benefit of Agenerase boosted with ritonavir has not been demonstrated in PI naïve patients 
(see section 5.1) 
Amprenavir 
(Agenerase) 
protease 
inhibitor (PI) 
experience
d  
associated with 
another 
treatment 
HIV Infections APTIVUS, co-administered with low dose ritonavir, is indicated for combination antiretroviral 
treatment of HIV-1 infection in highly pre-treated adults and adolescents 12 years of age or older 
with virus resistant to multiple protease inhibitors. APTIVUS should only be used as part of an active 
combination antiretroviral regimen in patients with no other therapeutic options.  
This indication is based on the results of two phase III studies, performed in highly pre-treated adult 
patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors 
and of one phase II study investigating pharmacokinetics, safety and efficacy of APTIVUS in mostly 
treatment-experienced adolescent patients aged 12 to 18 years (see section 5.1).  
In deciding to initiate treatment with APTIVUS, co-administered with low dose ritonavir, careful 
Tipranavir 
(Aptivus) 
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consideration should be given to the treatment history of the individual patient and the patterns of 
mutations associated with different agents. Genotypic or phenotypic testing (when available) and 
treatment history should guide the use of APTIVUS. Initiation of treatment should take into account 
the combinations of mutations which may negatively impact the virological response to APTIVUS, 
co-administered with low dose ritonavir (see section 5.1).  
protein C 
deficiency 
ICD10 Protein C 
Deficiency 
Purpura 
Fulminans 
CEPROTIN is indicated in purpura fulminans and coumarin-induced skin necrosis in patients with 
severe congenital protein C deficiency. Furthermore CEPROTIN is indicated for short-term 
prophylaxis in patients with severe congenital protein C deficiency if one or more of the following 
conditions are met:  
· surgery or invasive therapy is imminent  
· while initiating coumarin therapy  
· when coumarin therapy alone is not sufficient  
· when coumarin therapy is not feasible.  
human protein 
C (Ceprotin) 
protein C 
deficiency 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of Zoely. Should any of 
the conditions appear for the first time during Zoely use, the medicinal product should be stopped 
immediately(...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated  
protein C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies,  
lupus anticoagulant)... 
nomegestrol 
acetate / 
estradiol 
(Zoely) 
protein C 
deficiency 
ICD10 Contraception Female contraception  
EVRA is intended for women of fertile age. The safety and efficacy has been established in women 
aged 18 to 45 years 
Contraindications: 
EVRA should not be used in the presence of one of the following disorders. If one of these disorders 
occurs during the use of EVRA, EVRA must be discontinued immediately (...) 
● Possible hereditary predisposition for venous or arterial thrombosis, such as activated protein C 
(APC-) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinemia, and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
norelgestromin 
/ ethinyl 
estradiol 
(EVRA) 
protein C 
deficiency 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
nomegestrol 
acetate / 
estradiol (IOA) 
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Indication/ Contraindication (if relevant) text Drug 
for ethinylestradiol containing COCs are considered applicable to the use of IOA. Should any of 
the conditions appear for the first time during IOA use, the medicinal product should be stopped 
immediately(...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
protein S  
deficiency 
ICD10 Contraception Female contraception  
EVRA is intended for women of fertile age. The safety and efficacy has been established in women 
aged 18 to 45 years 
Contraindications: 
EVRA should not be used in the presence of one of the following disorders. If one of these disorders 
occurs during the use of EVRA, EVRA must be discontinued immediately(...) 
● Possible hereditary predisposition for venous or arterial thrombosis, such as activated protein C 
(APC-) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinemia, and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
norelgestromin 
/ ethinyl 
estradiol 
(EVRA) 
protein S 
deficiency 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of Zoely. Should any of 
the conditions appear for the first time during Zoely use, the medicinal product should be stopped 
immediately(...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol 
(Zoely) 
protein S 
deficiency 
ICD10 Contraception Oral contraception. 
Contraindications: 
COCs should not be used in the presence of any of the conditions listed below. As no 
epidemiological data are yet available with 17β-estradiol containing COCs, the contraindications 
for ethinylestradiol containing COCs are considered applicable to the use of IOA. Should any of 
the conditions appear for the first time during IOA use, the medicinal product should be stopped 
immediately. (...) 
• Hereditary or acquired predisposition for venous or arterial thrombosis, such as activated protein 
C (APC) resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, 
hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulant)... 
nomegestrol 
acetate / 
estradiol (IOA) 
 397 
 
Biomarker Exclusion 
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Therapeutic 
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Indication/ Contraindication (if relevant) text Drug 
QTc interval  prognostic Thyroid 
Neoplasms 
Contraindications: 
(...)Patients with a QTc interval over 480 msec.  
• Concomitant use of vandetanib with the following medicinal products known to also prolong the 
QTc interval and / or induce Torsades de pointes: Arsenic, cisapride, erythromycine intravenous 
(IV), toremifene, mizolastine, moxifloxacine, Class IA and III antiarrhythmics (see section 4.5).  
Vandetanib 
(Caprelsa) 
rheumatoid 
factor 
does not 
identify a 
subgroup 
Arthritis, 
Juvenile 
Rheumatoid 
Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in 
children and adolescents from the age of 2 years who have had an inadequate response to, or 
who have proved intolerant of, methotrexate.  
Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an 
inadequate response to, or who have proved intolerant of, methotrexate.  
Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an 
inadequate response to, or who have proved intolerant of, conventional therapy.  
Enbrel has not been studied in children aged less than 2 years 
Etanercept 
(Enbrel) 
serum CA 
125 
non-therapeutic Radionuclide 
Imaging 
Ovarian 
Neoplasms 
Positive diagnosis of relapsing ovarian adenocarcinoma when serum CA 125 is increased without 
positive results of ultrasound or computerised tomography scan. 
Igovomab 
(Indimacis 125) 
STEMI disease subtype Angioplasty, 
Transluminal, 
Percutaneous 
Coronary 
Acute Coronary 
Syndrome 
Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary 
intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) 
undergoing primary PCI. 
Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment 
elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. 
Angiox should be administered with aspirin and clopidogrel. 
Bivalirudin 
(Angiox) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Acute Coronary 
Syndrome 
Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non 
ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]);  
including patients managed medically, and those who are managed with percutaneous coronary 
intervention (PCI) or coronary artery by-pass grafting (CABG)… 
Ticagrelor 
(Brilique) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:  
· Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic 
stroke (from 7 days until less than 6 months) or established peripheral arterial disease.  
· Patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy... 
Clopidogrel 
(Clopidogrel 
1A Pharma; 
Clopidogrel 
Acino; 
Clopidogrel 
Hexal; 
Clopidogrel 
ratiopharm 
GmbH; 
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Clopidogrel 
Zentiva 
(previously 
Clopidogrel 
Winthrop); 
Iscover) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Myocardial 
Infarction 
Clopidogrel is indicated in: 
• Adult patientssuffering from myocardial infarction (from a few days until less than 35 days), 
ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• Adult patientssuffering from acute coronary syndrome: 
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA). 
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy. 
clopidogrel 
besilate 
(Clopidogrel 
Apotex; 
Grepid) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Atrial Fibrillation 
Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy 
clopidogrel 
hydrogen 
sulphate 
(Clopidogrel 
BMS; 
Clopidogrel 
Teva 
(hydrogen 
sulphate); 
Plavix; Zyllt) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA).  
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy. 
clopidogrel 
hydrochloride 
(Clopidogrel 
HCS; 
Clopidogrel 
Teva Generics 
B.V.) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Stroke 
Acute Coronary 
Clopidogrel is indicated in:  
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), 
ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.  
• Adult patients suffering from acute coronary syndrome:  
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
clopidogrel 
hydrobromide 
(Clopidogrel 
Teva Pharma 
B.V.) 
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Syndrome 
Myocardial 
Infarction 
myocardial infarction), including patients undergoing a stent placement following percutaneous 
coronary intervention, in combination with acetylsalicylic acid (ASA)  
 - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated 
patients eligible for thrombolytic therapy.  
STEMI disease subtype Acute Coronary 
Syndrome 
Myocardial 
Infarction 
DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already 
taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination 
medicinal product for continuation of therapy in:  
· Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave 
myocardial infarction) including patients undergoing a stent placement following percutaneous 
coronary intervention  
· ST segment elevation acute myocardial infarction in medically treated patients eligible for 
thrombolytic therapy… 
clopidogrel / 
acetylsalicylic 
acid 
(DuoCover; 
DuoPlavin) 
STEMI disease subtype Angina, 
Unstable 
Acute Coronary 
Syndrome 
Myocardial 
Infarction 
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST 
segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial 
infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI)… 
Prasugrel 
(Efient) 
STEMI disease subtype Myocardial 
Infarction 
Metalyse is indicated in adultsfor the thrombolytic treatment of suspected myocardial infarction 
with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute 
myocardial infarction (AMI) symptoms.  
Tenecteplase 
(Metalyse; 
Tenecteplase 
Boehringer 
Ingelheim 
Pharma GmbH 
& Co. KG) 
STEMI disease subtype Peripheral 
Vascular 
Diseases 
Acute Coronary 
Syndrome 
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of 
atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non 
ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including 
patients managed medically, and those who are managed with percutaneous coronary 
intervention (PCI) or coronary artery by-pass grafting (CABG). 
Ticagrelor 
(Possia) 
STEMI disease subtype Myocardial 
Infarction 
Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with 
persistent ST elevation or recent left Bundle Branch Block within 12 hours after the onset of acute 
myocardial infarction AMI symptoms. 
Reteplase 
(Rapilysin) 
T2 lesion monitoring Multiple 
Sclerosis 
Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple 
sclerosis for the following adult patient groups: 
- Patients with high disease activity despite treatment with a beta-interferon. 
These patients may be defined as those who have failed to respond to a full and adequate course 
fingolimod 
hydrochloride
&nbsp 
(Gilenya) 
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Indication/ Contraindication (if relevant) text Drug 
(normally at least one year of treatment) of beta-interferon. Patients should have had at least 1 
relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial 
MRI or at least 1 Gadolinium-enhancing lesion. A “non-responder” could also be defined as a 
patient with an unchanged or increased relapse rate or ongoing severe relapses, as compared to 
the previous year. 
or 
- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more 
disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain  
MRI or a significant increase in T2 lesion load as compared to a previous recent MRI. 
T2 lesion monitoring Multiple 
Sclerosis 
TYSABRI is indicated as single disease modifying therapy in highly active relapsing remitting multiple 
sclerosis for the following patient groups: 
• Adult patients aged 18 years and over with high disease activity despite treatment with a 
betainterferon.  
These patients may be defined as those who have failed to respond to a full and adequate course 
(normally at least one year of treatment) of beta-interferon. Patients should have had at least 1 
relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial 
Magnetic Resonance Image (MRI) or at least 1 Gadolinium-enhancing lesion. A “nonresponder” 
could also be defined as a patient with an unchanged or increased relapse rate or ongoing 
severe relapses, as compared to the previous year. 
or 
• Adult patients aged 18 years and over with rapidly evolving severe relapsing remitting multiple 
sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium 
enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous 
recent MRI. 
Natalizumab 
(Tysabri) 
take up 
technetium 
[99mTc]-
labelled 
biphosphon
ates on 
bone scan 
diagnostic Pain 
Cancer 
Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic 
skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan.  
The presence of osteoblastic metastases which take up technetium (99mTc)-labelled 
biphosphonates should be confirmed prior to therapy. 
samarium 
[<sup>153</su
p>Sm] 
lexidronam 
pentasodium 
(Quadramet) 
T-cell  ICD10 Precursor T-Cell 
Lymphoblastic 
Leukemia-
Lymphoma 
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia 
(TALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has 
relapsed following treatment with at least two chemotherapy regimens. 
Due to the small patient populations in these disease settings, the information to support these 
indications is based on limited data. 
Nelarabine 
(Atriance) 
T-cell  ICD10 Lymphoma, T-
Cell, Cutaneous 
Targretin capsules are indicated for the treatment of skin manifestations of advanced stage 
cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment 
Bexarotene 
(Targretin) 
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T-cell  ICD10 Lymphoma, T-
Cell 
treatment of adult patients with peripheral T-cell lymphoma (PTCL) (nodal, other extranodal and 
leukaemic/disseminated) who have progressed after at least one prior therapy 
Pralatrexate 
(Folotyn) 
T-cell  ICD10 Lymphoma, 
Non-Hodgkin 
treatment of adults with peripheral T-cell lymphoma that no longer responds to or has come back 
after at least two previous therapies 
Romidepsin 
(Istodax) 
tetrahydrobi
opterin 
deficiency  
defines disease Phenylketonuria
s 
Kuvan is indicated for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric 
patients of 4 years of age and over with phenylketonuria (PKU) who have been shown to be 
responsive to such treatment (see section 4.2). 
Kuvan is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adult and paediatric 
patients with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such 
treatment (see section 4.2). 
Sapropterin 
(Kuvan) 
Tg non-therapeutic Thyroid 
Neoplasms 
Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine 
imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post-
thyroidectomy patients maintained on hormone suppression therapy (THST).  
Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels 
on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up 
by assaying rh TSH-stimulated Tg levels.  
Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 
GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have 
undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do 
not have evidence of distant metastatic thyroid cancer (see section 4.4).  
thyrotropin 
alfa 
(Thyrogen) 
viral 
resistance  
associated with 
another 
treatment 
HIV Infections Viramune is indicated in combination with other anti-retroviral medicinal products for the 
treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.4).  
Most of the experience with Viramune is in combination with nucleoside reverse transcriptase 
inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical  
experience and resistance testing (see section 5.1).  
Nevirapine 
(Viramune; 
Nevirapine 
Teva) 
viral 
resistance  
associated with 
another 
treatment 
HIV Infections Viramune is indicated in combination with other anti-retroviral medicinal products for the 
treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.4).  
Most of the experience with Viramune is in combination with nucleoside reverse transcriptase 
inhibitors (NRTIs). The choice of a subsequent therapy after Viramune should be based on clinical 
experience and resistance testing (see section 5.1).  
Nevirapine 
(Viramune) 
virus 
serotype 
non-therapeutic Rotavirus 
Infections 
Immunization 
RotaShield is indicated for active immunisation of infants aged 6 weeks to 30 weeks for prevention 
of severe clinical manifestations of gastro-enteritis caused by rotavirus serotypes 1, 2, 3 and 4 of 
group A. 
rotavirus 
serotype 1 
reassortant, 
rotavirus 
serotype 2 
reassortant, 
rotavirus 
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serotype 3 
rhesus, 
rotavirus 
serotype 4 
reassortant 
(Rotashield) 
α-L-
iduronidase 
deficiency 
defines disease Mucopolysacch
aridosis I 
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed 
diagnosis of Mucopolysaccharidosis I (MPS I; α-L-iduronidase deficiency) to treat the 
nonneurological manifestations of the disease (see section 5.1). 
Laronidase 
(Aldurazyme) 
Δ4 
-3-
Oxosteroid-
5β-
reductase 
deficiency 
defines disease Digestive 
System Diseases 
Metabolism, 
Inborn Errors 
Treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid 
oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and 
adolescents aged 1 month to 18 years and adults. Treatment must be initiated and monitored by 
an experienced hepatologist or a paediatric hepatologist in the case of paediatric patients 
cholic acid 
(Orphacol) 
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B-I-D 
combination 
Biomarker Indication Drug 
ALKNC ALK Non-Small-Cell Lung Carcinoma crizotinib 
BRMV BRAF Melanoma vemurafenib 
CCR5HM CCR5 tropism HIV maraviroc 
CD33AG CD-33 Acute Myeloid Leukemia  gemtuzumab 
ozogamicin 
D816VSI D816V mutation in c-Kit Systemic Mastocytosis imatinib 
DPDCC DPD deficiency Colorectal Neoplasms, Colonic 
Neoplasms, Stomach Neoplasms, Breast 
Neoplasms 
capecitabine 
DPDST DPD deficiency Stomach Neoplasms tegafur/ 
gimeracil/ 
oteracil 
EGFR(E)CC EGFR expression Colorectal Neoplasms cetuximab 
EGFR(E)NC EGFR expression Non-Small-Cell Lung Carcinoma cetuximab 
EGFR(E)NE EGFR expression Non-Small-Cell Lung Carcinoma erlotinib 
EGFR(M)NE EGFR mutation Non-Small-Cell Lung Carcinoma erlotinib 
EGFR(M)NG EGFR mutation Non-Small-Cell Lung Carcinoma gefitinib 
EpCAMAC EpCAM expression Ascites Cancer catumaxomab 
ERBF oestrogen receptor  Breast Neoplasms fulvestrant 
ERBT oestrogen receptor  Breast Neoplasms toremifene 
FIP1L1HI FIP1L1-PDGFRα 
rearrangement 
Hypereosinophilic Syndrome imatinib 
G1CB genotype 1 HCV Chronic Hepatitis C bocepravir 
G1CT genotype 1 HCV Chronic Hepatitis C telaprevir 
G55CI G551D Cystic Fibrosis ivacaftor 
HDDP hormone dependent Prostatic Neoplasms degarelix 
HER2BE HER2 expression Breast Neoplasms everolimus 
HER2BL HER2 expression Breast Neoplasms lapatinib 
HER2BP HER2 expression Breast Neoplasms pertuzumab 
HER2BT HER2 expression Breast Neoplasms trastuzumab 
HER2ST HER2 expression Stomach Neoplasms trastuzumab 
HLAHA HLA-B*5701 allele HIV abacavir 
HRBE hormone receptor Breast Neoplasms everolimus 
HRBZ hormone receptor Breast Neoplasms zoledronic acid 
KitGI Kit (CD 117) positive Gastrointestinal Stromal Tumors imatinib 
KRASCC KRAS mutation Colorectal Neoplasms cetuximab 
KRASCP KRAS mutation Colorectal Neoplasms panitumumab 
LPLNH LPL protein Hyperlipoproteinemia Type I alipogene 
tiparvovec 
NMMc NADPH Methaemoglobinaemia methylthioninu
m chloride 
PDGFRMI PDGFR gene re-
arrangements 
Myelodysplastic-Myeloproliferative 
Diseases 
imatinib 
PHPD Philadelphia chromosome  Precursor Cell Lymphoblastic Leukemia-
Lymphoma 
dasatinib 
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Biomarker Indication Drug 
PHPI Philadelphia chromosome  Precursor Cell Lymphoblastic Leukemia-
Lymphoma 
imatinib 
t(15;19)AA t(15;17) translocation and/or 
PML/RAR-α gene 
Acute Promyelocytic Leukemia arsenic trioxide 
VRHAm viral resistance HIV amprenavir 
VRHAt viral resistance HIV atazanavir 
VRHD viral resistance HIV darunavir  
VRHEET viral resistance HIV efavirenz/ 
emtricitabine/ 
tenofovir 
disoproxil 
VRHEm viral resistance HIV emtricitabine 
VRHEn viral resistance HIV enfuvirtide 
VRHERT viral resistance HIV emticitabine/ 
rilpivirine h/ 
tenofovir df 
VRHF viral resistance HIV fosamprenavir 
VRHL viral resistance HIV lopinavir/ 
ritonavir  
VRHNel viral resistance HIV nelfinavir 
VRHR viral resistance HIV rilpivirine 
VRHTe viral resistance HIV tenofovir 
VRHTr Viral resistance HIV tipranavir 
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B-I-D combination   
ref  
drug  
biomarker  
indication  
disease area  
orphan designation  
biomarker (efficacy/ toxicity)  
authorised   
comments  
population in studies in accordance with the population 
identified by the drug indication - text to support item  
comments  
condition*  
design of the biomarker/ treatment evaluation 
adequate - text to support item  
comments  
condition*  
primary outcome appropriate - text to support item  
comments  
condition*  
sample size adequate - text to support item  
comments  
condition*  
sufficient proportion of patients with biomarker status 
available - text to support item  
comments  
condition*  
representativeness of the subgroup of patients with the 
biomarker status available - text to support item  
comments  
condition*  
evidence supporting the drug (irrespective of 
biomarker) based on the results for the primary outcome 
in studies - text to support item  
comments  
condition*  
evidence supporting the biomarker based on the results 
for the primary outcome in studies - text to support item  
comments  
condition*  
evidence supporting the drug (irrespective of 
biomarker) based on the results for any outcomes - text 
to support item  
comments  
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condition*  
evidence supporting the biomarker  based on the results 
for any outcomes - text to support item  
comments  
condition*  
evidence supporting the drug (irrespective of 
biomarker) based on the results for secondary outcomes 
- text to support item  
comments  
condition*  
evidence supporting the biomarker based on the results 
for secondary outcomes - text to support item  
comments  
condition*  
evidence was sufficient to conclude that drug 
(irrespective of biomarker) provides clinical benefit - text 
to support  
comments  
condition*  
evidence was sufficient to conclude that biomarker 
provides clinical benefit - text to support  
comments  
condition*  
toxicity acceptable  
comments  
condition*  
drug addressed an unmet clinical need  
comments  
condition*  
novel mechanism of action/ new active substance  
comments  
condition*  
ammendments to trials acceptable  
comments  
condition*  
availability of biomarker test on the market/ clear 
guidelines for test  
comments  
condition*  
imbalances between groups in trials acceptable  
comments  
condition*  
consistency of results across subgroups (other than the 
biomarker)  
comments  
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condition*  
sufficient long term data provided  
comments  
condition*  
benefit-risk balance  
comments  
condition*  
level of possible bias acceptable  
comments  
condition*  
supporting evidence from drugs with similar mechanism   
comments  
condition*  
evidence from pharmacology suppporting biomarker  
comments  
condition*  
evidence from previous studies (for example indication 
is being broadened etc.)  
comments  
condition*  
evidence from pre-clinical/ in vitro studies to support 
biomarker  
comments  
condition*  
no further data required  
comments  
condition*  
quality of the product acceptable  
comments  
condition*  
preclinical studies provide adequate information  
comments  
condition*  
no cross resistance with other available treatments 
observed  
comments  
condition*  
sufficient evidence to support selected dose and/or 
duration of treatment  
comments  
condition*  
sufficient evidence to support the B-I-D compared with 
other available treatment options  
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comments  
condition*  
evidence from mechanism of action to support 
biomarker  
comments  
condition*  
more acceptable route/ mode of delivery  
comments  
condition*  
ADME/ pharmacokinetics characterised sufficiently  
comments  
condition*  
statistical approach to data analysis adequate  
comments  
condition*  
biomarker prognostic of poor outcome  
comments  
condition*  
biomarker test accurate  
comments  
condition*  
???  
comments  
condition*  
conclusions supported by published meta-analysis or 
other literature sources  
comments  
condition*  
information on how biomarker was assessed in studies 
sufficient  
comments  
condition*  
correlation between expression level and effect  
comments  
condition*  
results reproduced  
comments  
condition*  
* Possible values: met, partly, not met, discussed only, not discussed 
 Original criteria 
 New criteria 
 
  
 
APPENDIX 12. SUMMARY OF STUDIES SUPPORTING B-I-D 
COMBINATIONS 
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ALK mutation – NSCLC – crizotinib 
Study Design Population Interventions  Biomarker measurement Results  
A808100146-49 
 
EMA status: 
main 
 
Phase I/II 
 
N=170* 
 
Status: 
ongoing  
Biomarker evaluation: non-
randomised only positive 
 
design: single arm; two 
stages: (1) dose 
escalation, (2) response in 
a population selected 
based on the first stage 
 
follow-up: 120 days 
 
primary outcome: 
Objective Response Rate 
(the percent of patients in 
the Response Evaluable 
(RE) population achieving 
a confirmed CR or 
confirmed PR according to 
RECIST) 
dose escalation 
part: advanced 
malignancies; 
second part 
(based on 
response in first): 
ALK-
rearrangement 
positive patients 
with advanced 
NSCLC 
A) crizotinib 250 mg 
orally twice daily in 
continuous 4-week 
cycles; to be taken 
approximately 12 
hours apart 
B) crizotinib 250 mg 
orally twice daily in 
continuous 3-week 
cycles; to be taken 
approximately 12 
hours apart 
 
samples: unstained slides from formalin-
fixed, paraffin embedded (FFPE) tumor 
samples 
 
method: "analyzed prospectively by 
means of FISH with the use of an ALK 
break-apart (or split-signal) probe. (…) 
Reverse-transcriptase–polymerase-chain-
reaction (RT-PCR) assays for specific 
EML4-ALK fusions and  
immunohistochemical analyses for ALK 
protein were performed retrospectively 
on a subgroup of FFPE tumor samples." (70 
of 82 samples (85%) were confirmed to be 
FISH-positive by a central laboratory)48 
 
threshold: FISH-positive if more than 15% 
of scored tumor cells had split ALK 5′ and 
3′ probe signals or had isolated 3′ signals 
 
group N BM+ BM- 
A 125 125 0 
B 35 0 35 
 
 
121 pre-treated ALK+ 
patients,** day 120: 3 patients 
had confirmed CRs, and 70 
patients had confirmed PRs, 
for an investigator-assessed 
ORR of 60.3% (95% CI: 51.0%, 
69.1%) 
 
Data for ALK- patients NR 
                                                                
* NSCLC patients only 
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Study Design Population Interventions  Biomarker measurement Results  
A808100549,50 
EMA status: 
supportive 
 
Phase II 
 
N=340* 
 
Status: 
ongoing  
Biomarker evaluation: non-
randomised only positive 
 
design: single arm 
 
follow-up: 120 days 
 
primary outcome: 
Objective Response Rate 
(details NR) 
locally advanced 
or metastatic 
ALK-positive 
NSCLC who have 
received at least 
1 prior 
chemotherapy 
regimen 
Crizotinib 250 mg orally 
twice daily 
 
samples: NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- 
340 340 0 
 
 
156 patients of 340 
responded: 4 CR, 152 PR 
A808100749 
 
EMA status: 
supportive 
 
Phase III 
 
N= 347 
 
Status: 
ongoing  
Biomarker evaluation: 
enrichment 
 
design: randomised 1:1, 
stratified by ECOG 
performance status, brain 
metastases, and prior (yes, 
no) EGFR TKI treatment 
 
follow-up: NR 
 
primary outcome: PFS 
(based on Independent 
Radiology Review) 
ALK-positive, 
advanced 
NSCLC patients 
who received 
only one prior 
platinum-based 
chemotherapy 
regimen 
A) crizotinib starting 
dose of 250 mg twice 
daily 
B) standard care 
chemotherapy 
pemetrexed (500 
mg/m2, on Day 1 of 
every cycle) or 
docetaxel (75 mg/m2, 
on Day 1 of every 
cycle) 
 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 173 173 0 
B 174 174 0 
 
 
PFS (number of patients 
included in analysis NR): 7.7 
(95% CI: 6.0, 8.8) and 3.0 (95% 
CI: 2.6, 4.3) months in crizotinib 
and chemotherapy arm, 
respectively: HR 0.487 (95% CI: 
0.371, 0.638, p-value <0.0001) 
                                                                
* the largest number of patients identified in the EMA data 
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BRAF V600 mutation – melanoma - vemurafenib 
Study Design Population Interventions  Biomarker measurement Results  
BRIM 3 
(NO25026)51,52 
 
EMA status: 
main 
 
Phase III 
 
N=675 
 
Status: 
ongoing 
(modified for 
efficacy*)  
Biomarker evaluation: 
enrichment 
 
design: randomised 1:1; 
stratified by cancer stage, 
ECOG PS, region and 
serum lactate 
dehydrogenase level 
follow-up: median 3.8 
months for vemurafenib 
and 2.3 months for 
dacarbazine 
primary outcome: overall 
survival (time from 
randomization to death 
from any cause) 
adults with 
unresectable 
previously 
untreated stage 
IIIC or IV 
melanoma 
A) vemurafenib 960 mg 
twice daily orally; dose 
reductions for adverse 
effects prespecified; 
discontinued on 
progression (unless 
investigator and sponsor 
consider continuation 
beneficial) 
B) dacarbazine 1000 mg 
per square m of body 
surface area by iv infusion 
for 3 weeks; dose 
reductions for adverse 
effects prespecified; 
discontinued on 
progression (unless 
investigator and sponsor 
consider continuation 
beneficial) 
samples: tumour tissue (details NR) 
 
method: Cobas 4800 BRAF V600E 
Mutation Test†, Roche Molecular 
Systems (real time PCR); in one of 5 
central laboratories 
 
threshold: N/A 
 
group N BM+ BM- 
A 337 337 0 
B 338 338 0 
 
 
“Study was stopped after an 
interim analysis for efficacy. 
The protocol was amended in 
January 2011 to allow patients 
in the dacarbazine group to 
cross over to vemurafenib. 
Data used in SciD is from 
October 2011.” 
Overall survival (with 
censoring at crossover): HR = 
0.62 (95%CI 0.49, 0.77); 
p<0.0001; favours 
vemurafenib 
Overall survival (without 
censoring at crossover): HR = 
0.67 (95% CI 0.54, 0.84); 
p=0.0003 
 
NP2265753,54 
 
EMA status: 
supportive 
 
Phase II 
 
N=132 
 
Status: 
completed 
Biomarker evaluation: 
single arm only positive 
 
design: uncontrolled 
(details NR) 
follow-up: NR (data for 
median PFS 6.1 months) 
primary outcome: best 
overall response rate 
(assessed by independent 
review committee using 
RECIST criteria) 
adults previously 
treated 
metastatic 
melanoma 
Vemurafenib 960 mg twice 
daily orally; until progression 
or withdrawal from study 
samples: tumour tissue (details NR) 
 
method: Roche CoDx BRAF mutation 
assay 
 
threshold: N/A 
 
N BM+ BM- 
132 132 0 
 
 
Best overall response rate: 
response was observed in 69 
patients - 52% of all patients in 
the study (95% CI: 43, 61). The 
reported responses were 3 
CR, 66 PR and 39 SD. 
 
                                                                
* Protocol was amended in January 2011 after an interim analysis demonstrated superiority of vemurafenib: patients in dacarbazine group crossed over to vemurafenib; data 
used in Scientific Discussion from October 2011 
† The test was found to identify patients with V600E mutation; retrospective sequencing studies have shown it also detects V600D and V600K with lower sensitivity 
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CCR5 – HIV- maraviroc 
Study Design Population Interventions  Biomarker measurement Results  
MOTIVATE 155,56 
 
EMA status: 
main 
 
Phase III 
 
N=601 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: 3-arm RCT; double 
blind; randomisation 2:2:1; 
stratified by use of 
enfuviritide and HIV-1 RNA 
level at screening (log10 - 
transformed copies per ml) 
 
follow-up: 48 weeks 
 
primary outcome: mean 
change in levels of HIV-1 
RNA from baseline to week 
48 
age ≥ 16 years; CCR5 
tropic; experienced 
drugs from 3 different 
categories 
All with optimised 
background therapy: 
A) maraviroc 300 mg 
(or 150 mg if the 
optimised background 
therapy included 
delavirdine); oral; 
once daily (plus 
placebo once daily) 
B) maraviroc 300 mg 
(or 150 mg if the 
optimised background 
therapy included 
delavirdine); oral; 
twice daily (total daily 
dose 600 mg or 300 
mg) 
C) placebo twice daily 
samples: blood 
 
method: using a phenotypic assay 
(Trofile, Monogram Biosciences) 
 
threshold: N/A 
 
group N BM+ BM- 
A 241 241 0 
B 240 240 0 
C 120 120 0 
 
 
only combined results for 
MOTIVATE 1 and 2  available: 
maraviroc 300mg twice daily 
(n=426) -1.84; optimised 
background (n=209) -0.78; 
difference -1.05 (97.5%CI: -1.33, -
0.78); p<0.0001 
MOTIVATE 255,56 
 
EMA status: 
main 
 
Phase III 
 
N=474 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: 3-arm RCT; double 
blind; randomisation 2:2:1; 
stratified by use of 
enfuviritide and HIV-1 RNA 
level at screening 
 
follow-up: 48 weeks 
 
primary outcome: mean 
change in levels of HIV-1 
RNA from baseline to week 
48 (log10 - transformed 
copies per ml) 
age ≥ 16 years; CCR5 
tropic; experienced 
drugs from 3 different 
categories 
All with optimised 
background therapy: 
A) maraviroc 300 mg 
(or 150 mg if the 
optimised background 
therapy included 
delavirdine); oral; 
once daily (plus 
placebo once daily) 
B) maraviroc 300 mg 
(or 150 mg if the 
optimised background 
therapy included 
delavirdine); oral; 
twice daily (total daily 
dose 600 mg or 300 
mg) 
C) placebo twice daily 
samples: blood 
 
method: using a phenotypic assay 
(Trofile, Monogram Biosciences) 
 
threshold: N/A 
 
group N BM+ BM- 
A 186 186 0 
B 194 194 0 
C 94 94 0 
 
 
only combined results for 
MOTIVATE 1 and 2  available: 
maraviroc 300mg twice daily 
(n=426) -1.84; optimised 
background (n=209) -0.78; 
difference -1.05 (97.5%CI: -1.33, -
0.78); p<0.0001 
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Study Design Population Interventions  Biomarker measurement Results  
Saag 200955,57 
 
EMA status: 
supportive 
 
Phase IIb 
 
N=190 
 
Status: 
completed  
Biomarker evaluation: 
enrichment (negative) 
 
design: 3-arm RCT; double 
blind; randomisation 1:1:1 
 
follow-up: 24 weeks 
 
primary outcome: change 
in levels of HIV-1 RNA from 
baseline to week 24 (log10 
- transformed copies per 
ml) 
age ≥ 16 years; 
CXCR4, dual of 
mixed tropic HIV-1 
infection; at least 1 
previous treatment 
All with optimised 
background therapy: 
A) maraviroc 300 mg 
once daily; 150 mg if 
concomitant 
treatment with potent 
CYP3A4 inhibitors; oral) 
B) maraviroc 300 mg 
twice daily; 150 mg if 
concomitant 
treatment with potent 
CYP3A4 inhibitors (total 
daily dose 600 mg or 
300 mg); oral 
C) placebo NR 
samples: blood 
 
method: Trofile assay, Monogram 
Biosciences 
 
threshold: N/A 
 
group N BM+ BM- 
A 63 0 63 
B 63 0 63 
C 64 0 64 
 
 
only reported that no harm was 
seen compared to placebo 
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CD-33 expression – AML – gemtuzumab ozogamicin 
Study Design Population Interventions  Biomarker measurement Results 
0903B1-201-
US/CA58,59 
 
EMA status: 
main 
 
Phase II 
 
N=84 
 
Status: 
completed 
Biomarker evaluation: single arm only positive 
 
design: uncontrolled Simon 2-stage 
 
follow-up: NR; median overall survival 4.9 
months (for all three studies) 
 
primary outcome: complete remission 
(defined as 1) absence of leukemic blasts in 
peripheral blood; 2) ≤5% leukemic blasts in the 
bone marrow measured in bone marrow 
aspirates or biopsy samples; 3) peripheral 
blood counts with hemoglobin at least 9 
mg/dL, absolute neutrophil count at least 
1500/microL, and platelets at least 
100,000/mictoL; and 4) red blood cell 
transfusion independence for at least 2 weeks 
and platelet transfusion independence for at 
least 1 week. Determination of remission was 
evaluated approximately 28 days after last 
dose of gemtuzumab ozogamicin) 
CD33 positive; untreated 
first recurrence of AML; 
18 years or older; initial 
complete remission of at 
least 6 months 
gemtuzumab 
ozogamicin two 
doses of 9 mg/m2 
as 2-hour 
intravenous infusion 
with 14-28 days 
between doses 
 
samples: bone marrow (details 
NR) 
 
method: analysis of bone 
marrow aspirates and 
immunotyping 
 
threshold: N/A 
 
N BM+ BM- 
84 84 0 
 
 
complete 
remission was 
achieved in 14 
patients 
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Study Design Population Interventions  Biomarker measurement Results 
0903B1-202-
EU58,59 
 
EMA status: 
main 
 
Phase II 
 
N=95 
 
Status: 
completed 
Biomarker evaluation: single arm only positive 
 
design: uncontrolled (details NR) 
 
follow-up: NR; median overall survival 4.9 
months (for all three studies) 
 
primary outcome: complete remission 
(defined as in 0903B1-201-US/CA) 
CD33 positive; untreated 
first recurrence of AML; 
18 years or older; initial 
complete remission of at 
least 6 months; prior 
hematopoietic stem cell 
transplant allowed 
gemtuzumab 
ozogamicin two 
doses of 9 mg/m2 
as 2-hour 
intravenous infusion 
with 14-28 days 
between doses 
samples: bone marrow (details 
NR) 
 
method: analysis of bone 
marrow aspirates and 
immunotyping 
 
threshold: N/A 
 
CD33 was assessed in all 
patients and only positive 
patients were included in the 
study 
 
N BM+ BM- 
95 95 0 
 
 
complete 
remission was 
achieved in 13 
patients 
0903B1-203-
US/EU58,59 
 
EMA status: 
main 
 
Phase II 
 
N=98 
 
Status: 
completed 
Biomarker evaluation: single arm only positive 
 
design: uncontrolled Simon 2-stage 
 
follow-up: NR; median overall survival 4.9 
months (for all three studies) 
 
primary outcome: complete remission 
(defined as in 0903B1-201-US/CA) 
CD33 positive; AML in 
first relapse; age 60 
years or older with initial 
remission of at least 3 
months 
gemtuzumab 
ozogamicin two 
doses of 9 mg/m2 
as 2-hour 
intravenous infusion 
with 14-28 days 
between doses 
samples: bone marrow (details 
NR) 
 
method: analysis of bone 
marrow aspirates and 
immunotyping 
 
threshold: N/A 
 
N BM+ BM- 
98 98 0 
 
complete 
remission was 
achieved in 8 
patients 
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D816V mutation in c-Kit -  systemic mastocytosis - imatinib 
Study Design Population Interventions  Biomarker measurement Results  
Heinrich 200860,61 
 
EMA status: 
unclear 
 
Phase II 
 
N=5 
 
Status: completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: single-arm 
"exploratory", "proof of 
concept" 
 
follow-up: NR 
 
primary outcome: tumour 
response based on blood 
counts and bone marrow 
analyses 
patients with 
systemic 
mastocytosis; 
age ≥15 years  
imatinib 400 mg daily 
with escalation to 300 
or 400 mg twice daily 
if no significant 
improvement after 4 
to 8 weeks of therapy 
samples: pathology specimens 
 
method: PCR amplification of genomic DNA for KIT 
(exons 9, 11, 13 and 17); screened for mutations 
using denaturating, high-pressure liquid 
chromatography (WAVE, Transgenomic, Inc.) 
 
threshold: N/A 
 
N BM+ BM- 
5 3-4* 0-2 
 
 
NR 
other studies60 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=30 
 
Status: completed 
Biomarker evaluation: NR 
 
design: a collection of patient 
data from studies; unclear if a 
systematic review 
 
follow-up: NR 
 
primary outcome: NR 
unclear: 
systemic 
mastocytosis; 
age NR 
imatinib (details NR) 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
30 3 0-27† 
 
 
NR 
DPD deficiency - colon, colorectal gastric and breast cancer - capecitabine 
No studies – based on mechanism of action/ metabolism62 
                                                                
* number of patients with mutation inconsitent based on the study report: "Activating point mutations in exon 17 of KIT were found in four cases of systemic mastocytosis 
(D816V, three cases; D816T, one case; Fig. 3) and one case of mast cell leukemia (D816V). No specimens were available for analysis from the other three patients with 
systemic mastocytosis." (however only 5 patietns with systemic mastocytosis were included in the study) 
† EMA document reports 3 positive patients; not clear if the remaining are negative or unknown and if 3 positive patietns include patietns from Heinrich 2008 
 423 
 
DPD deficiency - gastric cancer - tegafur/ gimeracil/ oteracil: mechanism of action 
No studies – based on mechanism of action/ metabolism63 
EGFR expression – colorectal cancer - cetuximab 
Study Design Population Interventions  Biomarker measurement Results  
BOND64,65 
 
EMA status: 
main 
 
Phase II 
 
N=329 
 
Status: 
completed  
Biomarker evaluation: enrichment 
 
design: RCT; open-label; 
randomised 2:1; stratified by 
Karnofsky PS, previous treatment 
(w/ or w/out oxaliplatin) and centre 
(minimisation) 
 
follow-up: NR 
 
primary outcome: rate of 
confirmed radiologic tumour 
response assessed by independent 
review committee; using modified 
WHO criteria: CR - complete 
disappearence of all measurable 
elsions w/out appearance of new 
ones; PR: at least 50% reduction in 
volume (sum of products of largest 
perpendicular diameters) of 
bidimentionally measurable lesions 
and absence of progression in 
other lesions, no appearance of 
new ones; SD: reduction in volume 
less than 50% or increase less than 
25%, no new lesions; PD: increase in 
volume over 25% and appearance 
of new lesions 
stage IV 
colorectal 
adenocarcino
ma; 
progression on 
irinotecan 
A) cetuximab (iv infusion 
400 mg/m2 at day 1; 
followed by weekly 
infusions of 250 mg/m2; 
premedication w/ 
histamine-receptor 
antagonist at least 
before first dose; until 
disease progression or 
unacceptable toxicity) + 
irinotecan 
B) cetuximab 
monotherapy (iv infusion 
400 mg/m2 at day 1; 
followed by weekly 
infusions of 250 mg/m2; 
premedication w/ 
histamine-receptor 
antagonist at least 
before first dose; until 
disease progression or 
unacceptable toxicity) 
 
samples: paraffin-embedded 
tumour specimen 
 
method: immunohistochemistry at 
a central location in Germany - 
EGFR diagnostic kit (Dako 
Cytomation) 
 
threshold: NR 
 
group N BM+ BM- 
A 218 217 1 
B 111 110 1 
 
 
objective response rates: 
combination (n=218) 22.9% 
(95%CI: 17.5, 29.1); 
monotherapy (n=111) 10.8% 
(95%CI: 5.7, 18.1) 
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Study Design Population Interventions  Biomarker measurement Results  
IMCL CP02-
014164,66 
 
EMA status: 
supportive 
 
Phase II 
 
N=57 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: response rate 
(details NR) 
stage IV 
colorectal 
cancer; 
progression 
w/in 6 months 
of completing 
irinotecan 
therapy 
cetuximab 
monotherapy (iv over 1-
2 hours weekly for 6 
weeks; treatment 
repeated in absence of 
disease progression or 
unacceptable toxicity; 
dose NR) 
samples: tumour; details NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- 
57 57 0 
 
 
objective esponse rate 
(CR+PR): (n=57) 8.8% (95% CI: 
2.9, 19.3) 
IMCL CP02-
992364,67 
 
EMA status: 
supportive 
 
Phase II 
 
N=138 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: : response rate 
(details NR) 
advanced 
colorectal 
carcinoma; 
disease 
progression at 
any time after 
receiving 
irinotecan 
cetuximab (iv; day 1: 10 
min test dose => no 
grade 4 anaphylactic 
reaction => loading 
dose over 2 h; 
maintanence over 1 
hour on days 8, 15, 22, 
29 and 36; repeat 
courses every 6 weeks if 
no progression or 
unacceptable toxicity; 
dose NR) + irinotecan 
samples:  
 
method:  
 
threshold: N/A 
 
N BM+ BM- 
138 138 0 
 
 
objective esponse rate 
(CR+PR): (n=138) 15.2% (95% 
CI: 9.7, 22.3) 
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EGFR expression – NSCLC - cetuximab 
Study Design Population Interventions  Biomarker measurement Results  
CA22509968-70 
 
EMA status: 
main 
 
Phase III 
 
N=676 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(retrospective) 
 
design: RCT; open-label; 
randomised 1:1; stratified by site; 
ECOG PS (0 or 1) and intended 
taxane; initially designed as phase II 
study (10 months after accrual 
initiation protocol amended to 
phase III and accrual increased 
from 300 to 660 patients) 
 
follow-up: NR 
 
primary outcome: PFS based on 
assessment by independent 
radiologic review committee 
adult; wet stage 
IIB or IV NSCLC or 
recurrent after 
chemo- or 
radiotherapy 
NSCLC 
A) cetuximab (iv 
infusion starting dose 
400 mg/m2 over 2 h - 
day 1; from day 8 at 
250 mg/m2 over 1h 
once a week; until 
progression or 
untolerable toxicity) + 
chemotherapy 
(carboplatin + taxane: 
paclitaxel or 
docetaxel) 
B) chemotherpay 
(carboplatin + taxane: 
paclitaxel or docetxel) 
 
samples: formalin-fixed, paraffin-
embedded tissue samples, as blocks or 
5-micro meter - thick unstained sections 
from most recent diagnostic tumour 
biopsy available 
 
method: immunohistochemistry using 
PharmDx Kit (Dako, Carpinteria, CA) 
 
threshold: one or more tumour cells 
showed staining 
 
group N BM+ BM- BM? 
A 338 66 11 261 
B 338 65 6 267 
 
 
(n=676) HR=0.902 
(95%CI: 0.761, 1.069) 
Subgroup NR 
FLEX68,71 
 
EMA status: 
main 
 
Phase III 
 
N=1125 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; 
randomised 1:1; stratified by ECOG 
PS (0-1 vs 2) and tumour stage (wet 
IIIB vs IV) 
 
follow-up: median 23.8 months in 
both groups 
 
primary outcome: overall survival 
from time of randomisation until 
death; calculated in months 
adults; EGFR+ 
advanced (stage 
wet IIIB or IV) 
NSCLC; 
chemotherapy 
naïve 
A) cetuximab (iv 
infusion at starting 
dose 400 mg/m2 over 
2 hours on day 1; from 
day 8 at 250 mg/m2 
over 1h once a week; 
premedication with 
antihistamine on day 1 
and recommended on 
other; until progression) 
+ chemotherapy 
(cisplatin + vinorelbine) 
B) chemotherapy 
(cisplatin + vinorelbine) 
samples: tumour tissue (details NR) 
 
method: immunohistochemistry 
(DakoCytomation pharmDxTM 
immunohistochemistry kit, Dako, 
Glostrup, Denmark) 
 
threshold: evidence of EGFR expression 
in at least one positively stained tumour 
cell 
 
group N BM+ BM- 
A 557 557 0 
B 568 568 0 
 
 
(n=1125) HR=0.871 (95% 
CI: 0.762, 0.996) 
(stratified by ECOG PS 
and tumour stage) 
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Study Design Population Interventions  Biomarker measurement Results  
Rosell 200768,72 
 
EMA status: 
supportive 
 
Phase II 
 
N=86 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; 
randomised 1:1 
 
follow-up: NR 
 
primary outcome: best overall 
response rate (based on number of 
patients achieving a PR or CR as 
best overall response) 
adult; wet stage 
IIB or IV EGFR-
expressing 
NSCLC; no prior 
chemotherapy 
A) cetuximab (iv 
infusion starting dose 
400 mg/m2 over 2 h on 
day 1; from day 8 at 
250 mg/m2 over 1h 
once a week; 
premedication with 
antihistamine; until 
progression or 
unacceptable toxicity) 
+ chemotherapy 
(cisplatin + vinorelbine) 
B) chemotherapy 
(cisplatin + vinorelbine) 
samples: primary tumour and/or 
metastases (details NR) 
 
method: immunohistochemistry (Dako 
EGFR pharmDx Kit) 
 
threshold: at least 1% of malignant cells 
were EGFR detectable with respest to 
positive control 
 
group N BM+ BM- 
A 43 43 0 
B 43 43 0 
 
 
best overall response 
rate: cetuximab (n=43) 
34.9% (95%CI: 21.0, 
50.9), standard (n=43) 
27.9 (95%CI: 15.3, 43.7); 
OR=1.38 (95%CI: 0.55, 
3.46) 
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EGFR expression – NSCLC - erlotinib 
Study Design Population Interventions  Biomarker measurement Results  
BR.2173-75 
 
EMA status: 
main 
 
Phase III 
 
N=731 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (prospective) - 
participation in "correlative 
studies" was optional 
 
design: RCT; double blind 
randomised 2:1 
(erlotinib:placebo); stratified 
using dynamic minimisation 
by centre, number of prior 
regimens, prior platinum 
therapy, best response to 
prior therapy and ECOG PS 
 
follow-up: NR 
 
primary outcome: overall 
survival (details NR) 
adults; stage IIIB or 
IV NSCLC after the 
failure of one or 
two prior 
chemotherapy 
regimens 
Background best 
supportive care: 
A) erlotinib 150 mg 
orally once daily 
B) placebo once 
daily 
 
samples: cancer tissue from 
diagnostic or resection specimens - 
paraffin blocks or 10-20 unstained 
slides 
 
method: immunohistochemistry in a 
central laboratory that used Dako 
EGFR PharmDx kits 
(DakoCytomation) 
 
threshold: positivity - more than 10% 
of cells staining at any intensity for 
EGFR 
 
group N BM+ BM- BM? 
A 488 117 93 278 
B 243 67 48 128 
 
 
Overall OS: HR = 0.73 (95% CI: 
0.60-0.87, p=0.001); median 
erlotinib 6.7 months (95% CI: 5.5, 
7.8 months), placebo 4.7 months 
(95% CI: 4.1, 6.3 months) 
EGFR+ (n=185) OS: HR = 0.68 (95% 
CI: 0.5, 0.9); median erlotinib 8.6 
months (95% CI: NR), placebo 3.7 
months (95% CI: NR) 
EGFR- (n=141) OS: HR = 0.93 (95% 
CI: 0.6, 1.4); median erlotinib 5.0 
months (95% CI: NR), placebo 5.4 
months (95% CI: NR) 
EGFR unmeasured (n=405) OS: HR 
= 0.77 (95% CI: 0.6, 1.0); median 
erlotinib 6.3 months (95% CI: NR), 
placebo 5.5 months (95% CI: NR) 
Perez-Soler 
200473,76 
 
EMA status: 
main 
 
Phase II 
 
N=57 
 
Status: 
supportive 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details 
NR) 
 
follow-up: NR 
 
primary outcome: response 
rate (percentage of patients 
with partial or complete 
response according to WHO 
criteria determined by an 
investigator) 
adults, stage IIIB or 
IV NSCLC after the 
failure of prior 
platinum-based 
chemotherapy 
erlotinib 150 mg/ day 
orally in the morning; 
dose increase to 200 
mg/day or reduction 
due to toxicity 
allowed; minimum 
treatment for 8 
weeks; maximum 52 
weeks with potential 
to continue beyond 
52 weeks if 
potentially beneficial 
 
samples: tumour specimen (details 
NR) 
 
method: immunohistochemistry 
(details NR) 
 
threshold: positivity - more than 10% 
of cells staining for EGFR 
 
N BM+ BM- 
57 57 0 
 
 
"2 achieved a CR and 5 had a 
best response of PR as 
determined by both WHO and 
RECIST, for an objective response 
rate of 12.3% (95% CI, 5.1 – 23.7%). 
Twenty-two patients had SD 
(38.6%) and 28 patients (49.1%) 
had progressive disease (PD)" 
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EURTAC77,78 
 
EMA status: 
main 
 
Phase III 
 
N=173 
 
Status: 
ongoing  
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
centrally randomised 1:1; 
stratified by type of EGFR 
mutation and ECOG PS 
 
follow-up: median 18.9 for 
erlotinib and 14.4 for 
chemotherapy 
 
primary outcome: PFS 
(time from randomisation 
to the date when disease 
progression was first 
observed or death 
occurred) 
adults with stage 
IIIB (with pleural 
effusion) or IV 
NSCLC; not 
previously treated 
for metastatic 
disease 
A) erlotinib 150 mg daily; 
orally 
B) standard 
chemotherapy 3 week iv 
cycles: (75 mg/m2 
cisplatin + 75 mg/m2 
docetaxel on day 1) or 
(75 mg/m2 cisplatin on 
day 1 + 1250 mg/m2 
gemcitabine on day 1 
and 8) or (if ineligible for 
cisplatin: AUC6 + 75 
mg/m2 docetaxel on 
day 1 or AUC5 
+1000g/m2 gemcitabine 
on day 1 and 8) 
 
samples: tumour specimens from original 
biopsy obtained before any treatment 
was given 
 
method: Sanger sequencing (exons 19 
and 21); confirmed by PCR: exon 19 
deletions with FAM-labelled primer in an 
ABI prism 3130 DNA analyser (Applied 
Biosystems) and L868R mutations in exon 
21 with FAM MGB-labelled probe for the 
wild-type and VIC MGB-labelledprobe for 
the mutant sequence 
 
threshold: N/A 
 
group N BM+ BM- 
A 86 86 0 
B 87 87 0 
 
 
interim analysis: PFS HR = 
0.42 (95% CI 0.27-0.64, 
p<0.0001); median PFS 
erlotinib; 9.7 months 
chemotherapy 5.2 months 
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CALGB3040677,
79,80 
 
EMA status: 
supportive 
 
Phase II 
 
N=181 
 
Status: 
completed  
Biomarker evaluation: 
subgroup (prospective) 
 
design: RCT (details NR) 
 
follow-up: median 38 
months 
 
primary outcome: PFS 
(time from randomisation 
to disease progression or 
death) 
adults with primary 
lung 
adenocarcinoma; 
stage IIIB with 
pleural effusion or 
IV; no prior 
chemotherapy, 
erlotinib or other 
EGFR targeted 
drugs; radiation 
and surgery had to 
be completed at 
least 3 weeks prior 
to enrollment; 
never or light 
smokers 
A) erlotinib 
monotherapy 50 mg/ 
day until disease 
progression or 
unacceptable toxicity; 
dose reductions for 
toxicity allowed to 100 or 
50 mg/day 
B) erlotinib (as erlotinib 
group) + chemotherapy 
(up to 6 cycles of 
paclitaxel 200 mg/m2 
every 21 days and 
carboplatin AUC 6 every 
21 days - standard dose 
reductions allowed for 
toxicity) 
samples: cancer tissue (details NR) 
 
method: using a sensitive heteroduplex 
method coupled with enzymatic 
digestion; positive findings were 
independently verified and subjected to 
sequencing 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 81 33 44 4* 
B 100 33 54 13 
 
 
Overall (median?) PFS: 
erlotinib 6.7 months; [80% 
CI, 4.7 to 8.2 months]); 
chemotherapy plus 
erlotinib 6.0 months; [80% 
CI, 5.6-7.3 months]) 
with EGFR mutations: 
(median?) PFS: erlotinib 
16.4 months [80% CI, 12.1 
to 23.8]; chemotherapy + 
erlotinib 17.2 months [80% 
CI, 11.1 to 27.6] 
no EGFR mutation: NR 
unknown EGFR mutation 
status: NR 
Laskin 200977,81 
 
EMA status: 
supportive 
 
Phase II 
 
N=65 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details 
NR) 
 
follow-up: 8 weeks 
 
primary outcome: non-
progression at 8 weeks 
(detaile NR) 
"stage IIIB/IV 
NSCLC; no prior 
chemo; ECOG ≤2; 
at least 2 of the 
following 4 criteria: 
women, never-
smokers, Southeast 
Asian origin, 
adenocarcinoma 
and/or BAC" 
erlotinib oral 150 mg/ 
day until disease 
progression  
 
samples: pre-treatment tumour samples 
(probably fresh frozen biopsy) 
 
method: sequencing using "traditional 
methods" (details NR) 
 
threshold: N/A 
 
N BM+ BM- BM? 
65 19 32 14 
 
 
52 patients had not 
progressed after 8 weeks 
NR for EGFR mutation 
subgroups 
                                                                
* 17 patients had insufficient tissue material for analysis 
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OPTIMAL77,82 
 
EMA status: 
supportive 
 
Phase III 
 
N=165 
 
Status: 
ongoing 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
randomised 1:1 by 
dynamic minimisation (Mini 
Randomisation software, v. 
1.5); stratified by EGFR 
mutation type, histological 
subtype and smoking 
status 
 
follow-up: NR 
 
primary outcome: PFS 
(time from randomisation 
to first confirmed disease 
progression or death from 
any cause) 
adults with 
advanced or 
recurrent stage IIIB-
IV NSCLC; no 
previous systemic 
therapy for 
advanced disease 
A) erlotinib oraly; 150 
mg/day until disease 
progression or 
unacceptable toxicity 
B) chemotherapy up to 
4 cycles of platinum-
based chemotherapy (iv 
gemcitabine 1000 
mg/m2 on day 1 and 8 + 
iv carboplatin AUC = 5 
on day 1) 
samples: tumour sample - fresh or paraffin 
embedded 
 
method: PCR-based direct sequencing 
(exon 19 deletion or exon 21 L858R point 
mutation) 
 
threshold: N/A 
 
group N BM+ BM- 
A 83 83 0 
B 82 82 0 
 
 
median PFS was erlotinib 
13.1 months, carb/gem 4.6 
months; PFS HR = 0.16 [95% 
CI, 0.10 to 0.26]; p <0.0001 
Paz-Ares 
201077 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1809 
 
Status: N/A 
Biomarker evaluation: NR 
 
design: literature review 
(details NR) 
 
follow-up: NR 
 
primary outcome: median 
PFS 
NSCLC; details 
unclear - not only 
first line therapy 
A) erlotinib 150 mg/ day 
orally (12 studies) 
B) gefitinb 250 mg/day 
orally or 500 mg/day 
orally (39 studies) 
C) chemotherapy: 
platinum-based/ 
docetaxel/ standard (9 
studies) 
samples: tumour tissue (details NR) 
 
method: variety of techniques (details NR) 
 
threshold: N/A 
 
group N BM+ BM- 
A 365 NR NR 
B 1069 NR NR 
C 375 NR NR 
 
 
For patients treated 
predominantly in the first-
line setting, median PFS 
was erlotinib (57%* of all 
patients in review) 12.5 
months (range 10.0 – 16.0 
months), gefitinib (57%* of 
all patients in review) 9.9 
months (range 9.0 – 10.9 
months), chemotherapy 
(95%* of all patients in 
review) 6.0 months (range 
4.5 – 6.7 months) 
                                                                
* unclear if analysis includes only data for patients treated with first line therapy or studies wher most patients were receiving first-line treatment 
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Rosell 200977,83 
 
EMA status: 
supportive 
 
Phase NR 
 
N=217 
 
Status: 
completed  
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; patients 
screened prospectively for 
EGFR mutations; patients 
with mutations were 
considered for erlotinib 
treatment 
 
follow-up: median 14 
months (range, 1 to 42) 
 
primary outcome: NR 
stage IIIB with 
pleural effusion or 
IV NSCLC* 
erlotinib 150 mg/ day 
until disease progression 
or intolerable adverse 
events 
samples: cancer tissue from original 
biopsy before any treatment - either 
paraffin-embedded (2060 of 2105 
screened) or fresh specimens 
 
method: exon 19 deletions by length 
analysis after PCR amplification with FAM-
labeled primer in an ABI Prism 3130 DNA 
Analyzer (Applied Biosystems); exon 21 
point mutations in codon 858 with 5' 
nuclease PCR assay (TaqMan) using FAM 
and VIC MGB-labeled probes for the wild 
type sequence; all mutants were 
confirmed by DNA sequencing 
 
threshold: N/A 
 
N BM+ BM- 
217 217 0 
 
 
median PFS (n = 217) 14.0 
months (95% CI, 11.2 to 
16.7) 
                                                                
* participating centres included more samples from patietns likely to have EGFR mutations (women, never smokers, adenocarcinoma) - possible bias/confounding? 
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SATURN77 
 
EMA status: 
supportive 
 
Phase III 
 
N=889 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (prospective) 
 
design: RCT; double-blind; 
randomised 1:1; stratified 
(minimisation) by EGFR 
expression, disease stage, 
ECOG PS, chemotherapy 
regimen, smoking status 
and region 
 
follow-up: median 11.4 
months for erlotinib and 
11.5 for placebo 
 
primary outcome: PFS 
(tumour response classified 
by RECIST 1.0 criteria; scans 
every 6 weeks for 48 weeks 
and every 12 weeks 
thereafter) 
maintenance in 
locally advanced 
or metastatic 
patients stable 
after 4 cycles of 
platinum-based 
chemotherapy 
A) erlotinib 150 mg oraly 
once daily until disease 
progression, 
unacceptable toxicity or 
death 
B) placebo until disease 
progression, 
unacceptable toxicity or 
death 
 
samples: tumour tissue (details NR) 
 
method: using DNA lysates from 
macrodissected or microdissected tissue 
samples with minimum tumour-cell 
content 60%; exons 18-21 of EGFR 
amplified using PCR (nested primers) and 
sequenced 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 438 22 199 217 
B 451 27 189 235 
 
 
Overall NR 
EGFR mutation + (n=49): 
from the clinical cut-off for 
overall survival (May 17, 
2009): PFS HR 0.23 ([95% CI, 
0.12 to 0.45]; log-rank p < 
0.0001); median erlotinib 
46.1 weeks [95% CI, 33.7 to 
59.6]; placebo 13.0 weeks 
[95% CI, 11.6 to 21.3] 
EGFR mutation - (n=388): 
from the clinical cut-off for 
overall survival (May 17, 
2009): HR = 0.78 ([95% CI: 
0.64; 0.96], p=0.0182); 
median PFS erlotinib 12.0 
weeks (95% CI, 10.9 to 12.7 
weeks), placebo 8.9 
weeks (95% CI, 6.3 to 11.4 
weeks) 
EGFR mutation unknown: 
NR 
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INTEREST84,85 
 
EMA status: 
main 
 
Phase III 
 
N=1466 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (prospective) 
 
design: RCT; open-label; 
randomised 1:1 with dynamic 
balancing with respect to 
histology (adenocarcinoma 
vs other), performance status, 
previous platinum 
chemotherapy (refractory vs 
non-refractory), previous 
paclitaxel (refractory vs non-
refractory vs none), number 
of previous regimens (one vs 
two), smoking history (ever vs 
never), and study site 
 
follow-up: NR 
 
primary outcome: overall 
survival from the date of 
randomisation to the date of 
death due to any cause or 
last date that the patient was 
known to be alive 
patients with locally 
advanced or 
metastatic NSCLC 
that progressed or 
recurred after at 
least one previous 
platinum-based 
chemotherapy (up 
to two), no previous 
therapy with an 
EGFR tyrosine 
kinase inhibitor 
A) gefitinib 250 mg per 
day orally; until disease 
progression, 
unacceptable toxic 
effects, or patient or 
physician request to 
discontinue treatment 
B) docetaxel 75 mg/m² 
in a 1-h infusion every 3 
weeks (could be 
reduced to 
60 mg/m² to reduce 
toxic eff ects); until 
disease progression, 
unacceptable toxic 
effects, or patient or 
physician request to 
discontinue treatment 
samples: paraffin-embedded archival 
diagnostic tumour tissue 
 
method: "direct gene sequencing of 
exons 18–21 of chromosome seven. 
Patients were positive if we detected 
a mutation in the EGFR gene in both 
the forward and reverse directions in 
at least one of the three independent 
PCR products derived from the tumour 
DNA"; testing performed by 
"approved commercial laboratories" 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 733 22 119 529 
B 733 22 134 577 
 
 
Overall OS (primary - per 
protocol analysis): gefitinib 
(n=723) vs docetaxel (n=710) 
HR = 1.020 (95% CI: 0.905, 
1.150, p=0.7332) 
EGFR mutation +: OS (primary 
- per protocol analysis): 
gefitinib (n=22) vs docetaxel 
(n=22) HR = 0.832 (95% CI: 
0.414, 1.670, p=0.6043) 
EGFR mutation -: OS (primary - 
per protocol analysis): 
gefitinib (n=119) vs docetaxel 
(n=134) HR = 1.015 (95% CI: 
0.776, 1.327, p=0.9131) 
EGFR mutation unknown: OS 
(primary - per protocol 
analysis): gefitinib (n=592) vs 
docetaxel (n=572) HR = 1.027 
(95% CI: 0.904, 1.167, 
p=0.6808) 
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IPASS84,86 
 
EMA status: 
main 
 
Phase III 
 
N=1217 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (prospective) 
 
design:RCT; open-label; non-
inferiority; randomised 1:1; 
using dynamic balancing 
with respect to performance 
 
follow-up: median 5.6 months 
 
primary outcome: PSS (from 
the date of randomization to 
the earliest sign of disease 
progression, as determined 
by means of the RECIST) 
first-line treatment 
adults in East Asia 
with stage IIIB or IV 
NSCLC 
(adenocarcinoma, 
including 
bronchoalveolar 
carcinoma), 
nonsmokers (had 
smoked <100 
cigarettes in their 
lifetime) or former 
light smokers (had 
stopped smoking 
at least 15 years 
previously and had 
a total of ≤10 pack-
years of smoking), 
no previous 
chemotherapy or 
biologic or 
immunologic 
therapy 
A) gefitinib 250 mg per 
day, administered 
orally; until disease 
progression, 
unacceptable toxic 
effects, request by 
patient or physician, 
serious noncompliance 
with protocol 
B) chemotherapy (up 
to 6 3-week cycles: on 
day 1 paclitaxel 200 
mg/m2 of body-
surface area (iv over 3-
hours) followed 
immediately by 
carboplatin (AUC 5.0 
or 6.0 mg/ ml per 
minute, iv over 15 to 60 
minutes); same 
discontinuation 
reasons) 
samples: tumour tissue(details NR) 
 
method: analysed at two central 
laboratories to determine biomarker 
status; patients were "considered to 
be positive for the EGFR mutation if 1 
of 29 EGFR mutations was detected 
with the use of the amplification 
refractory mutation system (ARMS) 
and the DxS EGFR29 mutation-
detection kit" details of mutations 
assessed NR 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 609 132 91 386 
B 608 129 85 394 
 
 
Overall PFS: gefitinib (n=609) 
vs carboplatin + pacliaxel 
(n=608) HR = 0.741 (95% CI: 
0.651, 0.845, p<0.0001) 
EGFR mutation+: PFS: gefitinib 
(n=132) vs carboplatin + 
pacliaxel (n=129) HR = 0.482 
(95% CI: 0.362, 0.642, 
p<0.0001) 
EGFR mutation-: PFS: gefitinib 
(n=91) vs carboplatin + 
pacliaxel (n=85) HR = 2.853 
(95% CI: 2.048, 3.975, 
p<0.0001) 
EGFR mutation unknown: PFS: 
gefitinib (n=386) vs 
carboplatin + pacliaxel 
(n=394) HR = 0.684 (95% CI: 
0.579, 0.808, p<0.0001) 
EGFR mutation known: PFS: 
gefitinib (n=223) vs 
carboplatin + pacliaxel 
(n=214) HR = 0.853 (95% CI: 
0.690, 1.055, p=0.1426) 
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ISEL84,87,88 
 
EMA status: 
main 
 
Phase III 
 
N=1692 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: RCT; double-blind; 
randomised 2:1 by 
minimisation 
 
follow-up: median follow-up 
7.2 months 
 
primary outcome: overall 
survival from the date of 
randomisation to the date of 
a patient’s death; 
participants alive at data 
cutoff were censored in the 
analysis at the last time they 
were known to be alive 
patients with locally 
advanced or 
metastatic NSCLC 
that was not 
curable with 
surgery or 
radiotherapy, who 
had received one 
or two previous 
chemotherapy 
regimens and were 
refractory to 
(recurrent or 
progressive disease 
within 90 days of 
the last 
chemotherapy 
dose) or intolerant 
of their latest 
chemotherapy 
regimen 
A) gefitinib 250 
mg/day until 
unacceptable toxic 
effects occurred, 
consent was 
withdrawn, or the 
patient was no longer 
deriving clinical 
benefit 
B) placebo 
 
samples: tumour sample (details NR) 
 
method: "analyzed primarily by DNA 
sequencing of exons 18 to 24, and 
secondarily using the amplification 
refractory mutation system (ARMS) 
assay (allelespecific polymerase chain 
reaction [PCR]) to detect the exon 21 
L858R point mutation and the most 
common exon 19 deletion (del G2235-
A2249). Patients were mutation 
positive if a mutation in the EGFR gene 
was detected either by ARMS or by 
gene sequencing in both forward and 
reverse directions in at least two 
independent PCR products from 
tumor DNA. Sequence alterations 
detected in more than one amplicon 
were considered true mutations" 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 1126 21 132 973 
B 562 5 57 500 
 
 
Overall OS: HR = 0.89 (95% CI: 
0.77, 1.02, p=0.0871); favours 
gefitinib 
EGFR mutation + OS: 10 
deaths (seven of 21 patients 
receiving gefitinib; three of 
five patients receiving 
placebo) 
EGFR mutation OS: 130 deaths 
(93 of 132 patients receiving 
gefitinib; 37 of 57 patients 
receiving placebo) 
EGFR mutation unknown: NR 
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V-15-3284,89 
 
EMA status: 
supportive 
 
Phase III 
 
N=490 
 
Status: 
completed  
Biomarker evaluation: 
subgroup (prospective) 
 
design: RCT; open-label; 
noninferiority; randomisation 
stratified by sex, performance 
status, histology, and study 
site 
 
follow-up: median 21 months 
 
primary outcome: overall 
survival "from date of random 
assignment to date of death 
as a result of any cause, or 
data were censored at the 
last date the patient was 
known to be alive" 
apanese patients 
with pretreated, 
locally 
advanced/metast
atic (stages IIIB to 
IV) or recurrent 
NSCLC 
A) gefitinib 250 
mg/day orally until 
disease progression, 
intolerable toxicity, or 
discontinuation for 
another reason 
B) docetaxel every 3 
weeks as a 1-hour 
intravenous infusion of 
60 mg/m2 until disease 
progression, intolerable 
toxicity, or 
discontinuation for 
another reason 
samples: tumour tissue (details NR) 
 
method: direct sequencing of exon 18 
to 21 of chromosome 7 
 
threshold: N/A 
 
group N BM+ BM- 
A 245 NR* NR 
B 244 NR NR 
 
 
Overall study failed to meet 
non-inferiority objective;  
NR for EGFR mutation 
determined subgroups 
                                                                
* 31 (54.4%) of 57 patients in whom mutation was measured (in both groups) had EGFR mutation–positive tumors 
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Heiss 201090,91 
 
EMA status: 
main 
 
Phase II/III 
 
N=258 
 
Status: 
completed 
Biomarker evaluation:  
 
design: RCT; open-label; 
randomised 2:1; stratified by 
cancer (ovarian vs. not 
ovarian) and country 
 
follow-up: 7 months 
 
primary outcome: puncture-
free survival (time to first need 
for therapeutic puncture or 
death after treatment, 
whichever occurred first) 
adult malignant 
ascites secondary 
to epithelial 
cancer, requiring 
paracentesis 
A) catumaxomab (6 
hour intraperitoneal 
infusion on day 0, 3, 7 
and 10 at 10, 20, 50 
and 150 
microgrograms) + 
paracentesis 
B) paracentesis only 
 
samples: ascites fluid (details NR) 
 
method: immunohistochemistry: 
anti-EpCAM antibody HO-3 (the 
parental antibody of 
catumaxomab; 
TRION Pharma, Munich, Germany) 
 
threshold: at least 400 EpCAM+ 
cells per 106 cells 
 
group N BM+ BM- 
A 170 170 0 
B 88 88 0 
 
 
median puncture-free survival: 
catumaxomab 46 days (95% CI: 
35, 53), control 11 days (95% CI: 9, 
16), p (log-rank test) < 0.0001 
Burges 200790,92 
 
EMA status: 
supportive 
 
Phase I/II 
 
N=23 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; dose 
escalation 
 
follow-up: 28 days after last 
infusion 
 
primary outcome: NR 
female adult 
patients with 
malignant ascites 
due to ovarian 
carcinoma 
catumaxomab (6 hour 
intraperitoneal infusion 
on day 0, 3, 6, 9 and 
13; at 5 to 250 
microgrograms)  
samples: ascites fluid (details NR) 
 
method: immunohistochemistry: 
anti-EpCAM antibody HO-3 (the 
parental antibody of 
catumaxomab; TRION Pharma, 
Munich, Germany) 
 
threshold: more than 400 EpCAM+ 
cells per 106 cells 
 
N BM+ BM- 
23 23 0 
 
 
necessity for peritoneal puncture 
(28+/- 4 days from start of last 
infusion) - 1 patient needed 
puncture; MTD was established at 
200 micrograms 
 438 
 
Study Design Population Interventions  Biomarker measurement Results  
Ruf 201090,93 
 
EMA status: 
supportive 
 
Phase II 
 
N=13 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm 
pharmacokinetic (details NR) 
 
follow-up: NR 
 
primary outcome: loacal and 
systemic catumaxomab 
concentrations 
ascites due to 
cancer (no 
criteria for prior 
treatments) 
catumaxomab (6 hour 
intraperitoneal infusion 
on day 0, 3, 6 or 7 and 
10; at 10, 20, 50 and 
150 microgrograms) 
samples: ascites fluid (details NR) 
 
method: immunohistochemistry 
(details NR) 
 
threshold: at least 400 EpCAM+ 
cells per 106 cells 
 
N BM+ BM- 
23 23 0 
 
primary outcome data NR; need 
for peritoneal puncture: 5 
patients; not necessary in 7 and 
one died without need of 
puncture 
oestrogen receptor – breast cancer - fulvestrant 
Study Design Population Interventions  Biomarker measurement Results  
002094-96 
 
EMA status: 
main 
 
Phase III 
 
N=451 
 
Status: 
completed 
Biomarker evaluation: enrichment* 
 
design: RCT; open-label; superiority 
study with retrospective switch to 
non-inferiority after no significant 
difference was shown 
 
follow-up: median 15.1 months (for 
trial 0020 and 0021) 
 
primary outcome: TTP (number of 
days from randomisation until 
disease progression or death from 
any cause) 
postmenopausal 
women with locally 
advanced or 
metastatic breast 
cancer with 
objective evidence 
of disease 
progression or 
recurrence on 
adjuvant 
endocrine therapy 
or following first-line 
endocrine therapy 
for advanced 
disease 
A) fulvestrant 250 mg as 
a once-monthly intra-
muscular injection (5 ml) 
until disease progression 
or withdrawal from trial 
(due to toxicity, non-
complience or 
withdrawal of consent) 
B) anastrozole 1 mg 
once daily orally  until 
disease progression or 
withdrawal from trial 
(due to toxicity, non-
complience or 
withdrawal of consent) 
 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- BM? 
A 222 156 15 51 
B 229 173 19 37 
 
 
overall TTP HR = 0.98 
(95%CI: 0.80, 1.21, 
p=0.84) favours 
fulvestrant 
NR for oestrogen 
receptor expressing 
only 
                                                                
* included patients with evidence of tumour hormone sensitivity: prior sensitivity to hormonal therapy or known estrogen receptor or progesterone receptor positivity 
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002194-96 
 
EMA status: 
main 
 
Phase III 
 
N= 400 
 
Status: 
completed 
Biomarker evaluation: enrichment* 
 
design: RCT; double-blind; 
superiority study with retrospective 
switch to non-inferiority after no 
significant difference was shown 
 
follow-up: median 15.1 months (for 
trial 0020 and 0021) 
 
primary outcome: TTP (number of 
days from randomisation until 
disease progression or death from 
any cause) 
postmenopausal 
women with locally 
advanced or 
metastatic breast 
cancer with 
objective evidence 
of disease 
progression or 
recurrence on 
adjuvant 
endocrine therapy 
or following first-line 
endocrine therapy 
for advanced 
disease 
A) fulvestrant 250 mg as 
a once-monthly intra-
muscular injection (2 x 
2.5 ml)  until disease 
progression or 
withdrawal from trial 
(due to toxicity, non-
complience or 
withdrawal of consent) 
B) anastrozole 1 mg 
once daily orally until 
disease progression or 
withdrawal from trial 
(due to toxicity, non-
complience or 
withdrawal of consent) 
 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- BM? 
A 206 170 23 13 
B 194 156 22 16 
 
 
Overall TTP HR = 0.92 
(95% CI: 0.74, 1.14, 
p=0.43), favours 
fulvestrant 
NR for oestrogen 
receptor expressing 
only 
000494,97 
 
EMA status: 
supportive 
 
Phase II 
 
N=19 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; 2 parts: part I - 1 
month with assessments at day 0, 1, 
3, 7, 10, 14, 21 and 28; part II - 6 
months with assessment once a 
month 
 
follow-up: 6 months 
 
primary outcome: partial or 
complete response (details NR) 
postmenopausal 
women with 
advanced breast 
cancer who have 
relapsed on 
tamoxifen therapy 
fulvestrant once a 
month by intramuscular 
injection: part I: 1 ml (50 
mg); part II: either 2 ml 
(100mg) + 5 x 5 ml (250 
mg) or 6 x 5 ml (250 mg) 
samples: NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- 
19 19 0 
 
 
among patients who 
received the 250 mg 
dose (n=19) 7 had PR 
and 6 SD for at least 6 
months 
                                                                
* included patients with evidence of tumour hormone sensitivity: prior sensitivity to hormonal therapy or known estrogen receptor or progesterone receptor positivity 
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O-15-2294 
 
EMA status: 
supportive 
 
Phase II 
 
N=30 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: objective tumour 
response (details NR) 
postmenopausal 
women who 
relapsed on 
tamoxifen or 
toremifene after 
initial response 
fulvestrant (details NR) samples: NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- 
30 30 0 
 
 
objective tumour 
response in 23.3% of 
patients 
SAKK94,98 
 
EMA status: 
supportive 
 
Phase II 
 
N=86 
 
Status: 
ongoing 
Biomarker evaluation: non-
randomised only positive* 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: initially objective 
response, duration of response, 
time to progression and time to 
treatment failure; after interim 
analysis changed to clinical benefit 
(clinical benefit - objective 
response (complete or partial) or 
stable disease for at least 24 weeks) 
postmenopausal 
women with 
metastatic breast 
cancer and 
objective evidence 
of disease 
progression after at 
least 12 weeks of 
treatment with 
aromatase 
inhibitors 
fulvestrant 250 mg in one 
5-ml intramuscular 
injection every 28 (+/- 3) 
days until disease 
progression, withdrawal 
due to unacceptable 
toxicity or withdrawal of 
consent 
samples: NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- BM? 
86 73 2 11 
 
 
(n=32) 6% PR 28% SD, 
66% PD; and clinical 
benefit in 34% of 
patients 
                                                                
* evidence of tumour hormone sensitivity: estrogen receptor and/or progesterone receptor expression, at least 12 months of previous hormonal therapy before relapse or 
stabilisation for at least 3 months during endocrine therapy 
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Gershanovich 
199799,100 
 
EMA status: 
main 
 
Phase III 
 
N=463 
 
Status: 
completed 
Biomarker evaluation: unclear 
 
design: RCT; open-label (details 
NR) 
 
follow-up: median 20.5 months 
 
primary outcome: response rate 
and TTP (response defined 
according to WHO criteria for 
measurable disease and ECOG 
criteria for non-measurable but 
evaluable bone disease; time to 
progression NR) 
 
postmenopau
sal women 
with 
"previously 
untreated, 
inoperable, 
primary, 
residual, 
metastatic or 
recurrent 
breast 
cancer" 
A) toremifene 60 mg tablet once a 
day; for at least 2 months; could 
be discontinued due to intolerable 
toxicity, rapid disease progression 
or non-complience 
B) toremifene 240 mg: 2 60 mg 
tablets twice a day; for at least 2 
months; could be discontinued 
due to intolerable toxicity, rapid 
disease progression or non-
complience 
C) tamoxifen 40 mg tablet once a 
day; for at least 2 months; could 
be discontinued due to intolerable 
toxicity, rapid disease progression 
or non-complience 
samples: tumour (details NR) 
 
method: NR 
 
threshold: ER concentration at least 
10 fmol/mg protein or ER unknown 
 
group N BM+ BM- BM? 
A 157 48 5 104 
B 157 50 2 105 
C 149 44 6 99 
 
 
overall; only pooled 
estimate across all 
main studies 
reported; response 
rate (toremifene 60 
mg vs. tamoxifen) 
was -0.8% (90% CI: -
4.8, 3.2 %; p=0.744); 
TTP HR = 0.91 (90% 
CI: 0.81, 1.02, 
p=0.158); OS HR = 
1.00 (90% CI: 0.86, 
1.16, p=0.966) 
 
oestrogen receptor 
positive; only 
pooled estimate 
across all main 
studies reported; 
response rate 
(toremifene 60 mg 
vs. tamoxifen) was -
3.4% (90% CI: -9.0, 
2.1 %; p=0.312); TTP 
HR = 0.93 (90% CI: 
0.80, 1.08, p=0.407); 
OS HR = 1.06 (90% 
CI: 0.97, 1.29, 
p=0.651) 
oestrogen receptor 
negative; NR 
Hayes 
199599,101 
 
EMA status: 
main 
 
Phase III 
 
N=648 
 
Status: 
completed 
Biomarker evaluation: unclear 
 
design: RCT; open label; 
equivalence trial; stratified by 
presence of bone metastases 
(yes vs. no); originally two 
identical trials by the same 
sponsor; results were combined 
and analysed as a single study 
 
follow-up: NR 
 
primary outcome: NR 
postmenopau
sal or 
perimenopaus
al women 
with 
metastatic 
(apart from 
brain) breast 
cancer; 
previous 
tamoxifen 
allowed 
A) toremifene one 60 mg tablet a 
day orally till breast cancer 
progression, intolerable toxicity, 
serious incurrent ilness or patient 
non-complience 
B) toremifene one 200 mg tablet a 
day orally till breast cancer 
progression, intolerable toxicity, 
serious incurrent ilness or patient 
non-complience 
C) tamoxifen two 10 mg tablets a 
day orally till breast cancer 
progression, intolerable toxicity, 
serious incurrent ilness or patient 
non-complience 
samples: tumour (details NR) 
 
method: NR 
 
threshold: ER concentration at least 
10 fmol/mg protein or ER unknown 
 
group N BM+ BM- BM? 
A 221 147 14 60 
B 212 123 16 73 
C 215 130 21 64 
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Pyrhonen 
199799,102 
 
EMA status: 
main 
 
Phase III 
 
N=415 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(prospective) 
 
design: RCT; double-blind; 
stratified by wheather the 
patients had measurable disease 
 
follow-up: median 25.2 months 
 
primary outcome: reponse rate 
and TTP (responses evaluated 
according to the WHO criteria 
adopted by the UICC, response 
was accepted only if confirmed 
at two consecutive evaluations 2 
months apart; time to progression 
(TTP) "was defined as the time 
between randomization and 
onset of relapse or disease  
progression ") 
postmenoupo
usal 
metastatic or 
recurrent 
breast 
cancer; prior 
adjuvant 
therapy 
allowed 
A) toremifene 60 mg tablet orally 
once daily for at least 2 months; 
until disease progression or 
adverse events precluding use of 
the drug 
B) tamoxifen 40 mg tablet orally 
once daily for at least 2 months; 
until disease progression or 
adverse events precluding use of 
the drug 
 
samples: tumour (details NR) 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- BM? 
A 214 117 4 93 
B 201 114 3 84 
 
 
oestrogen receptor 
unknown; only 
pooled estimate 
across all main 
studies reported; 
response rate 
(toremifene 60 mg 
vs. tamoxifen) was -
2.5% (90% CI: -3.2, 
8.3 %; p=0.469); TTP 
HR = 0.87 (90% CI: 
0.74, 1.06, p=0.267); 
OS HR = 0.86 (90% 
CI: 0.67, 1.09, 
p=0.294) 
 
FIP1L1-PDGFRα  rearrangement - HES/CEL - imatinib 
Study Design Population Interventions  Biomarker measurement Results  
Cervetti 
2005103,104 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=2 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 12 months and 
13 years 
 
primary outcome: N/A 
adult with HES A) imatinib 100 
mg/day 
B) interferon-α 5 
MUI/day three 
times a week 
 
samples: bone marrow (details NR) 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 1 1 0 
B 1 1 0 
 
 
complete hematological response 
(duration ≥12 months) on imatinib; NR for 
interferon-α 
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Chung 
2006103,105 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 2 months 
 
primary outcome: N/A 
adult with HES imatinib 100 
mg/day and 
prednisolone 
gradually 
discontinued over 2 
months 
samples: NR 
 
method: single-step RT-PCR and 
nested PCR 
 
threshold: N/A 
 
N BM+ BM- 
1 1* 0 
 
 
complete hematological response 
(duration ≥2 months) 
Cools 2003103 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=17 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: non-randomised 
comparative (details NR) 
 
follow-up: NR 
 
primary outcome: N/A 
adults with 
HES 
A) imatinib 100-400 
mg/day (patients 
with symptomatic 
disease) 
B) other (details NR) 
 
samples: blood (details NR) 
 
method: nested PCR 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 11 5 5 1 
B 6 4 2 0 
 
 
Overall 9 complete hematological 
responses (duration 3-16 months), 1 
transient response, 1 no response 
FIP1L1-PDGFRA positive 5 complete 
hematological responses (duration 3-9 
months) 
FIP1L1-PDGFRA negative 3 complete 
hematological responses (duration 3-16 
months), 1 transient, 1 none 
FIP1L1-PDGFRA unknown 1 complete 
hematological response (duration 3 
months) 
Frickhofen 
2004103,106 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: approximately 
10 months  
 
primary outcome: N/A 
adult with CEL imatinib 200 
mg/day 
 
samples: blood (details NR) 
 
method: nested RT-PCR (as in Cools 
2003) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete hematological response 
(duration ≥248 days) 
                                                                
* patient negative using single-step RT-PCR and weakly positive using nested PCR 
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Imashuku 
2005103,107 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 62 weeks 
 
primary outcome: N/A 
adult with HES imatinib 100 
mg/day increased 
to 200 mg/day 
 
samples: NR 
 
method: FISH (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 0 1 
 
 
1 transient hematological response 
(duration 30 weeks) 
Klion 2004103,108 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=7 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case series 
 
follow-up: 6 months 
 
primary outcome: N/A 
adults with 
HES 
Imatinib single daily 
oral dose of 400 
mg; possibility of 
interruption and 
restarting at a 
lower dose due to 
adverse events 
 
 
samples: peripheral blood (details NR) 
 
method: nested PCR (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
7 7 0 
 
 
7 complete hematological responses 
(duration 1-3 months) 
La Starza 
2005103,109 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=26 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: non-randomised 
comparative (details NR) 
 
follow-up: ranging from 6 
to 204 months; no data for 
2 patients 
 
primary outcome: NR 
20 patients 
with HES/CEL; 
6 who did not 
satisfy WHO 
criteria; one 
patient was 10 
years old 
(other were 
adults) 
A) imatinib 100-600 
mg/day + other 
treatments 
(including steroids, 
interferon-alpha, 
hydroxyurea) 
B) other including 
steroids, interferon-
α, hydroxyurea 
 
samples: NR 
 
method: interphase FISH (details NR) 
 
threshold: N/A 
 
group N BM+ BM- 
A 12 7 5 
B 14 3 11 
 
 
Overall imatinib: 8 complete 
hematological responses (duration 2-25 
months), 3 none; other: NR 
FIP1L1-PDGFRA positive imatinib: 6 
complete hematological responses 
(duration 2-11 months); other: NR 
FIP1L1-PDGFRA negative imatinib: 2 
complete hematological responses 
(duration 19-25 months), 3 none; other: 
NR 
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Malagola 
2004103,110 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 120 days 
 
primary outcome: N/A 
adult with CEL imatinib 100 
mg/day increased 
by 100 
mg/day/week to 
400 mg/day 
samples: NR 
 
method: RT-PCR (as in Martinelli 2004) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
1 complete hematological responses 
(duration ≥120 days) 
Martinelli 
2004103,111 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 17 months 
 
primary outcome: N/A 
adult with HES imatinib 600 
mg/day  
samples: peripheral blood and bone 
marrow 
 
method: RT-PCR (as in Cools 2003) 
done retrospectively on diagnostic 
sample 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
1 complete hematological response 
(duration ≥17 months) 
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Martinelli 
2006103,112 
 
EMA status: 
unclear 
 
Phase II 
 
N=59 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (prospective) 
 
design: single-arm (details 
NR) 
 
follow-up: median 4 
months (range 2-39 
months) 
 
primary outcome: NR 
patients with 
HES, age ≥17 
years 
imatinib 100/day 
increased by 100 
mg/day each 
week up to 400 
mg/day and 
continued for at 
least 4 weeks in 
case of no 
response and for 
period 'beneficial 
for patient' if 
response; first year: 
dose adjustments 
for adverse events; 
later: at 
investigator 
discretion 
 
samples: bone marrow (details NR) 
 
method: nested RT PCR as in Cools 
2003 
 
threshold: N/A 
 
N BM+ BM- 
59 23 36 
 
 
Overall 26 complete hematological 
responses (duration 1-44 months), 9 
partial response, 22 none, 2 unknown, 4 
NR 
FIP1L1-PDGFRA positive 23 complete 
hematological responses (duration 1-44 
months), 4 NR 
FIP1L1-PDGFRA negative 3 complete 
hematological responses (duration 1-44 
months), 9 partial response, 22 none, 2 
unknown 
Muller 2006 
103,113 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=2 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 16 and 21 
months 
 
primary outcome: N/A 
adults with 
HES 
imatinib 100 mg 
every 2 days to 600 
mg/day 
samples: peripheral blood, bone 
marrow 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
2 1 1 
 
 
FIP1L1-PDGFRA positive: 1 complete 
hematological responses (duration ≥21 
months) 
FIP1L1-PDGFRA negative: 1 complete 
hematological responses (duration ≥16 
months) 
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Musial 2005 
103,114 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 6 months 
 
primary outcome: N/A 
adult with HES imatinib 100 
mg/day for the first 
3 months and 100 
mg every other 
day afterwards 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
1 complete hematological responses 
(duration ≥6 months) 
Musto 2004 103 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=4 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 10 months 
 
primary outcome: N/A 
adult with HES imatinib 100 
mg/day (possible 
escalation to 400 to 
800 mg/day) 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- BM? 
4 1 0 3 
 
 
FIP1L1-PDGFRA positive: 1 complete 
hematological response (duration ≥9 
months) 
FIP1L1-PDGFRA unknown: 2 complete 
hematological responses (duration ≥12 
months), 1 none 
Roche-
Lestienne 
2005103,115 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=35 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: non-randomised 
comparative (details NR) 
 
follow-up: NR 
 
primary outcome: NR 
adults with 
HES 
A) imatinib 100-200 
mg/day 
B) other (details NR) 
 
samples: blood (dtails NR) 
 
method: nested PCR (as in Cools 2003) 
 
threshold: N/A 
 
group N BM+ BM- 
A 9 4 5 
B 26 2 24 
 
 
Data only for imatinib available 
FIP1L1-PDGFRA positive: 4 complete 
hematological responses (duration 2 
months and NR) 
FIP1L1-PDGFRA negative: 1 complete 
hematological response (duration NR), 4 
none 
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Rose 2004103 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 1 year 
 
primary outcome: N/A 
adult with HES imatinib 200 
mg/day  
samples: blood (details NR) 
 
method: nested PCR (as in Cools 2003) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
1 complete hematological response 
(duration ≥12 months) 
Rotoli 2004103 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up:  
 
primary outcome: N/A 
adult with HES imatinib 200 
mg/day reduced 
to 100 mg/day 
after 2 weeks 
 
samples: NR 
 
method: "cytogenetics, FISH and 
molecular analysis" 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
1 complete hematological response 
(duration ≥17 months) 
Smith 
2004103,116 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=3 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 4 - 8 months 
 
primary outcome: N/A 
adults with 
HES/CEL 
imatinib 400-
600/day 
samples: blood (details NR) 
 
method: nested PCR (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
3 2 1 
 
 
FIP1L1-PDGFRA positive: 2 complete 
hematological responses (duration 7-8 
months) 
FIP1L1-PDGFRA negative: 1 complete 
hematological response (duration 4 
months followed by relapse) 
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Vanderberghe 
2004103,117 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=17 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: non-randomised 
comparative (details NR) 
 
follow-up: NR 
 
primary outcome: N/A 
adults with 
idiopathic 
HES/CEL 
A) imatinib initial 
dose of 100 
mg/day followed 
by a tapered 
maintenance dose 
B) other treatment 
including 
corticosteroids, 
hydroxyurea, bone 
marrow transplant, 
interferon-α, etc. 
 
samples: blood or bone marrow  
 
method: RT-PCR (details NR) 
 
threshold: N/A 
 
group N BM+ BM- 
A 5 4 1 
B 12 4 8 
 
 
FIP1L1-PDGFRA positive: 4 complete 
hematological response (duration 4 
months and NR); other: 1 complete, 2 
partial, 1 NR 
FIP1L1-PDGFRA negative: 1 no 
hematological response; other: 3 
complete, 3 partial, 1 stable, 1 none 
Wolf 2004103 
 
EMA status: 
unclear 
 
Phase N/A 
 
N=1 
 
Status: 
completed 
Biomarker evaluation: 
none 
 
design: case report 
 
follow-up: 18 months 
 
primary outcome: N/A 
adult with HES imatinib 100 
mg/day reduced 
to 100 mg once a 
week and 
increased to 100 
mg/day 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
1 0 1 
 
 
1 complete hematological response 
(duration ≥24 months) 
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RESPOND-
2118,119 
 
EMA status: 
main 
 
Phase III 
 
N=403 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
1:2:2; stratified by previous 
response (nonresponse vs. 
relapse)  and HCV 
subgenotype (1a vs. 1b) 
 
follow-up: 72 weeks 
 
primary outcome: sustained 
virologic response 
(undetectable HCV RNA 
levels (measured with the 
use of the TaqMan 2.0 assay, 
Roche Diagnostics) for 24 
weeks after the completion 
of therapy) 
HCV with 
responsivenes
s to interferon 
and either 
"nonresponse" 
(decrease in 
HCV RNA 
level, but 
detectable) 
or relapse 
A) boceprevir 4 weeks: peginterferon 
alfa-2b + ribavirin; 24 weeks: boceprevir 
(oral 800 mg 3 times daily) + 
peginterferon alfa-2b + ribavirin; => 
nothing OR if HCV RNA detectable from 
week 8 onwards - 32 weeks: 
peginterferon alfa-2b + ribavirin + 
placebo 
B) boceprevir 4 weeks: peginterferon 
alfa-2b + ribavirin; => 44 weeks: 
boceprevir (oral 800 mg 3 times daily) + 
peginterferon alfa-2b + ribavirin 
C) placebo 4 week s: peginterferon 
alfa-2b + ribavirin => 44 weeks: 
peginterferon alfa-2b + ribavirin + 
placebo 
 
All treatments discontinued if at HCV 
RNA was detectable at week 12 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 162 162 0 
B 161 161 0 
C 80 80 0 
 
 
sustained virologic 
response was: in 
placebo group 17 
(21.3%), guided 
therapy (n=162) 95 
(58.6%; p<0.0001 for 
difference with 
placebo) and fixed 
therapy (n=161) 107 
(66.5%; p<0.0001 for 
difference with 
placebo) 
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SPRINT-2118,120 
 
EMA status: 
main 
 
Phase III 
 
N=1099 
 
Status: 
completed 
Biomarker evaluation: 
enrichment* 
 
design: RCT; double-blind; 
randomised 1:1:1; two 
cohorts based on self-
reported ethnicity (black vs. 
non black) and stratified by 
HCV RNA level (maximum 
400,000 IU per ml vs more) 
 
follow-up: 72 weeks 
 
primary outcome: sustained 
virologic response 
(undetectable HCV RNA 
levels (measured with the 
use of the TaqMan 2.0 assay, 
Roche Diagnostics) for 24 
weeks after the completion 
of therapy) 
adult, chronic 
HCV, no prior 
treatment 
A) boceprevir 4 weeks: peginterferon 
alfa-2b + ribavirin; 24 weeks: boceprevir 
(oral 800 mg 3 times daily) + 
peginterferon alfa-2b + ribavirin; => 
nothing OR if HCV RNA detectable from 
week 8 onwards - 20 weeks: 
peginterferon alfa-2b + ribavirin + 
placebo 
B) boceprevir 4 weeks: peginterferon 
alfa-2b + ribavirin; => 44 weeks: 
boceprevir (oral 800 mg 3 times daily) + 
peginterferon alfa-2b + ribavirin 
C) placebo 4 weeks: peginterferon alfa-
2b + ribavirin => 44 weeks: peginterferon 
alfa-2b + ribavirin + placebo 
 
All treatments discontinued if at HCV 
RNA was detectable at week 24 
samples: blood plasma 
 
method: Trugene assay (Bayer 
Diagnostics) for purposes of 
randomization and by sequencing 
of the nonstructural 5B (NS5B) region 
(Virco) for subsequent 
analyses 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 368 358 0 10 
B 366 354 0 12 
C 363 348 0 15 
 
 
sustained virologic 
response was: in 
placebo group 137 
(37.7%), guided 
therapy (n=368) 233 
(63.3%; p<0.0001 for 
difference with 
placebo) and fixed 
therapy (n=366) 242 
(66.1%; p<0.0001 for 
difference with 
placebo) 
P05685 118,121 
 
EMA status: 
supportive 
 
Phase III 
 
N= 201 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
randomised 1:2 
 
follow-up: 3.5 years 
 
primary outcome: sustained 
virologic response 
(undetectable HCV RNA by 
TaqMan 2.0 assay (Roche 
Diagnostics)) 
adults with 
HCV who 
failed previous 
treatmen 
A) boceprevir 4 weeks: peginterferon 
alfa-2a + ribavirin; => 44 weeks 
peginterferon alfa-2a + ribavirin + 
bocepravir (oral; 800 mg 3 times a day); 
treatment stopped if no response at 12 
weeks 
B) placebo 4 weeks: peginterferon alfa-
2a + ribavirin; => 44 weeks peginterferon 
alfa-2a + ribavirin + placebo; treatment 
stopped if no response at 12 weeks 
samples: NR 
 
method: NR 
 
threshold: N/A 
group N BM+ BM- 
A 134 134 0 
B 67 67 0 
 
 
sustained virologic 
response was: in 
placebo group 14 
(20.9%), boceprevir 
86 (64.2%; p<0.0001 
for difference with 
placebo) 
                                                                
* patients with HCV genotype 1 or patietns for whom it could not be determined 
 452 
 
genotype 1 – HCV - telaprevir 
Study Design Population Interventions  Biomarker measurement Results  
ADVANCE122,123 
 
EMA status: 
main 
 
Phase III 
 
N=1095 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
stratified according to 
genotype 1 subtype (a, b 
or unknown) and baseline 
viral load (> or < 800000 
IU/ml) 
 
follow-up: 72 weeks 
 
primary outcome: 
sustained viral response 
(proportion of patients 
who had undetectable 
plasma HCV RNA 24 weeks 
after the last planned dose 
of study treatment) 
genotype 1 HCV, 
chronic hepatitis C, 
age 18-70 years 
A) telaprevir (oral; 750 mg every 8 
hours w/ food) for 12 weeks + 
peginterferon-ribavirin; extended 
rapid virologic responders followed 
by 12 weeks of peginterferon-
ribavirin; for non-responders - by 36 
weeks of peginterferon-ribavirin 
B) telaprevir (oral; 750 mg every 8 
hours w/ food) for 8 weeks and 
placebo for 4 weeks + 
peginterferon-ribavirin; extended 
rapid virologic responders followed 
by 12 weeks of peginterferon-
ribavirin; for non-responders - by 36 
weeks of peginterferon-ribavirin 
C) placebo + peginterferon-
ribavirin for 12 weeks; 
peginterferon-ribavirin for 36 weeks 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 365 365 0 
B 365 365 0 
C 365 365 0 
 
 
sustained viral response: 
telaprevir 12 weeks vs 
placebo: OR = 3.95 (95% 
CI: 2.87, 5.45); for 8 weeks 
vs. placebo: OR = 2.92 
(95%CI: 2.14, 3.99) 
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Study Design Population Interventions  Biomarker measurement Results  
ILLUMINATE122,12
4 
 
EMA status: 
main 
 
Phase III 
 
N=540 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
non inferiority; only patients 
with rapid virologic 
response at week 4 and 12 
were randomised at week 
20 of the study; non-
resoponders non-randomly 
allocated 
 
follow-up: 48-72 weeks 
 
primary outcome: 
sustained virologic 
response (undetectable 
HCV RNA level at the end 
of treatment phase 24 
weeks after the last 
planned dose of study 
medication) 
chronic infection 
with genotype 1 
HCV; age 18-70 
years; treatment 
naïve; 
A) telaprevir (orally; 750 mg every 
8 hours) with peginterferon and 
ribavirin for 12 weeks + rapid 
virologic response: 12 weeks of 
peginterferon and ribavirin 
B) telaprevir (orally; 750 mg every 8 
hours) with peginterferon and 
ribavirin for 12 weeks + rapid 
virologic response: 36 weeks of 
peginterferon and ribavirin 
C) telaprevir* (orally; 750 mg every 
8 hours) with peginterferon and 
ribavirin for 12 weeks + no rapid 
virologic response: 36 weeks of 
peginterferon and ribavirin 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 162 162 0 
B 160 160 0 
C 118 118 0 
 
 
sustained virologic 
response at week 24: (12 
week vs 36 week extra 
treatment for reponders) 
OR = 1.62 (95%CI: 0.77, 
3.38) favours 12 week 
extra treatment; sustained 
virologic response was 
acheved by 76 patients in 
the non-randomised arm 
                                                                
* non-random allocation 
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Study Design Population Interventions  Biomarker measurement Results  
REALIZE122,125 
 
EMA status: 
main 
 
Phase III 
 
N=663 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
stratified by viral load (> or 
< 800,000 IU/ml) and 
previous response to 
treatment (no response, 
partial response, relapse); 
randomised 2:2:1 
 
follow-up: 72 weeks 
 
primary outcome: 
sustained virologic 
response (undetectable 
plasma HCV RNA 24 weeks 
after the last planned dose 
of study drug) 
genotype 1 HCV; 
previous treatment 
with peginterferon 
and ribavirin (at 
least 80% of 
intended dose); no 
SVR; age 10-70 
A) telaprevir (orally; 750 mg every 
8 hours) + peginterferon-ribavirin 
for 12 weeks => 
placebo+peginterferon-ribavirin for 
4 weeks => peginterferon-ribavirin 
for 32 weeks 
B) placebo with peginterferon-
ribavirin for 4 weeks => telaprevir 
(delayed) (orally; 750 mg every 8 
hours) + peginterferon-ribavirin for 
12 weeks => peginterferon-ribavirin 
for 32 weeks 
C) placebo with peginterferon-
ribavirin for 16 weeks => 
peginterferon-ribavirin for 32 weeks 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 266 266 0 
B 264 264 0 
C 133 133 0 
 
 
SVR - difference from 
placebo: teleprevir vs. 
placebo: 46.8% (95% CI: 
36.8, 56.7%); teleprevir 
(delayed) vs. placebo: 
49.8% (95%CI: 39.9, 59.7%) 
EXTEND122,126 
 
EMA status: 
supportive 
 
Phase NR 
 
N=400 
 
Status: 
ongoing 
Biomarker evaluation: non-
randomised only positive 
 
design: prospective cohort 
study including patients 
who had been treated 
with telaprevir in Phase 2 
studies 
 
follow-up: 3 years 
 
primary outcome: 1) 
Proportion maintaining 
undetectable HCV RNA 
after achieving SVR on 
telaprevir; 2) Change in 
HCV variants with 
decreased sensitivity to 
telaprevir over time in 
subjects failing to achieve 
SVR following telaprevir 
NR A) telaprevir patients who 
achieved SVR 
B) telaprevir patients without SVR 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A NR NR NR 
B NR NR NR 
 
 
SVR patients - interim 
analysis (based on 123 
patients) - none of the 
patients follwed up for a 
median 22.13 months 
(range: 5.1 to 35.2 months) 
had a relapse; patients 
without SVR - NR 
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G551D mutation – cystic fibrosis - ivacaftor 
Study Design Population Interventions  Biomarker measurement Results  
VX08-770-
102127,128 
 
EMA status: 
main 
 
Phase III 
 
N=167 
 
Status: 
completed  
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; 
randomised 1:1, stratified 
according to age (<18 years vs. 
≥18 years) and pulmonary 
function (<70% vs. ≥70% of the 
predicted FEV1) 
 
follow-up: 24 and 48 weeks 
 
primary outcome: absolute 
change from baseline in percent 
predicted FEV1 measured at 
week 24 
Cystic 
fibrosis 
patients of 
both sexes 
aged 12 
years and 
older; 
G551D-CFTR 
mutation in 
at least 1 
allele 
A) ivacaftor 150 mg every 
12 hours for 48 weeks (24 
weeks + 24 weeks of an 
extension period); 
recommended that 
subjects remain on stable 
medication regimens for 
their CF 
B) placebo 
recommended that 
subjects remain on stable 
medication regimens for 
their CF 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 84 84 0 
B 83 82 1* 
 
 
adjusted mean absolute change 
from baseline through week 24 in 
percent predicted FEV1 (n=83 
ivacaftor, n=78 placebo) was 
greater in the ivacaftor group 
(10.39%) than the placebo group 
(-0.18%); a difference in favour to 
ivacaftor of 10.58% (95% 
CI: 8.57, 12.59) 
VX08-770-
103127 
 
EMA status: 
main 
 
Phase III 
 
N=52 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; 
randomised 1:1; FEV1 severity 
strata 
 
follow-up: 24 and 48 weeks 
 
primary outcome: absolute 
change from baseline in percent 
predicted FEV1 measured at 
week 24 
aged 6 to 11 
years with 
cystic fibrosis 
and the 
G551D 
mutation in 
at least 1 
allele 
A) ivacaftor 150 mg every 
12 hours for 48 weeks (24 
weeks + 24 weeks of an 
extension period) 
B) placebo (details NR) 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+† BM- 
A 26 25-26 0-1 
B 26 25-26 0-1 
 
 
at week 24 the mean absolute 
change (n=52) was also greater in 
the ivacaftor group (12.58%) than 
the placebo group (0.13%) with an 
estimated treatment difference for 
ivacaftor versus placebo of 12.45% 
(95% CI: 6.56, 18.34) 
                                                                
* one patient was found to be G551D mutation negative after inclusion (included in data analysis) 
† one patient was found not to have G551D mutation; unclear from which arm 
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Study Design Population Interventions  Biomarker measurement Results  
VX08-770-
104127 
 
EMA status: 
supportive 
 
Phase II 
 
N=140 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; 
randomised 4:1 
 
follow-up: 16 weeks 
 
primary outcome: mean absolute 
change from baseline in percent 
predicted FEV1 measured at 
Week 16 
Cystic 
fibrosis; age 
12 years and 
older who 
were 
homozygous 
for the 
F508del 
mutation in 
the CFTR 
gene and 
who had 
FEV1 ≥40% 
predicted 
A) ivacaftor 150 mg every 
12 hours 
B) placebo (details NR) 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A NR NR NR 
B NR NR NR 
 
 
primary outcome at week 16 
(n=NR) 1.5 percentage points in 
the ivacaftor and -0.2 percentage 
points in the placebo 
group; estimated treatment 
difference was 1.7 percentage 
points (95% CI: -0.6, 4.1, p=0.15) 
VX08-770-
105127 
 
EMA status: 
supportive 
 
Phase NR 
 
N=192 
 
Status: 
ongoing 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm extension study 
 
follow-up: approximately 96 
weeks 
 
primary outcome: NR 
patients 
who 
completed 
treatment in 
studies 102 
or 103 were 
eligible 
ivacaftor 150 mg every 12 
hours 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
192 192 0 
 
 
study 102:  
initially ivacafor: improvement in 
percent predicted FEV1 was 
maintained after additional 24 
and 48 weeks of treatment with 
ivacaftor in study 105, i.e. the 
mean absolute change in percent 
predicted FEV1 (SD) was 10.3 
(9.31) and 9.5 (10.13), respectively. 
Initially placebo: improvement in 
percent predicted FEV1: 10.0 (9.52) 
and 8.0 (8.14) at weeks 24 and 48, 
respectively 
study 103:  
initially ivacafor: mean absolute 
change from baseline in percent 
predicted FEV1 (SD) of 10.1 (14.18) 
at week 24 
initially placebo: improvement in 
percent predicted FEV1 was 7.5 
(10.90) at week 24 
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Hormone dependency – prostate cancer - degarelix 
Study Design Population Interventions  Biomarker measurement Results  
FE 200486 
CS21129,130 
 
EMA status: 
main 
 
Phase III 
 
N=610* 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
randomised 1:1:1; stratified 
by geographical region 
and body weight; non-
inferiority 
 
follow-up: 12 months 
 
primary outcome: 
Cumulative probability of 
testosterone ≤ 0.5 ng/mL at 
any monthly measurement 
from 28 to 364 days 
adult patients with 
histologically confirmed 
adenocarcinoma of the 
prostate, all stages, requiring 
androgen ablation treatment, 
including patients with rising 
PSA after having undergone 
curative prostatectomy or 
radiotherapy; serum 
testosterone > 1.5ng/mL; 
Previous or current hormonal 
management of prostate 
cancer was not allowed, 
except in patients having 
undergone localized therapy 
of curative intent in which 
neoadjuvant or adjuvant 
hormonal therapy for ≤ 6 
months was accepted 
A) degarelix s.c. starting 
dose of 240 mg (given as 
two ×3 mL injections) and 
thereafter 12 monthly 
(every 28 days) 
maintenance doses of 80 
mg (one 4 mL injection of 
20 mg/mL) 
B) degarelix s.c. starting 
dose of 240 mg (given as 
two ×3 mL injections) and 
thereafter 12 monthly 
(every 28 days) 
maintenance doses of 160 
mg (40 mg/mL) 
C) leuprolide 12-monthly 
(every 28 days) i.m. 
injections 7.5 mg (given as 
one injection of ≈ 1 mL 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 207 NR NR 
B 202 NR NR 
C 201 NR NR 
 
 
for 80mg maintenance 
dose (n=207): 5 T>0.5 
ng/mL, 202 censored 
(97.2%, 95% CI: 
93.5;98.8%); for 160 mg 
maintenance 3 T>0.5 
ng/mL, 199 censored 
(98.3%, 95% CI: 
94.8;99.4%), for 
leuprolide 7 T>0.5 
ng/mL, 194 censored 
(96.4%, 95% CI: 
92.5;98.2%) 
                                                                
* 620 randomised, but 10 did not receive allocated treatment 
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HER2 expression (negative) – breast cancer - everolimus 
Study Design Population Interventions  Biomarker measurement Results  
BOLERO-2131,132 
 
EMA status: 
main 
 
Phase III 
 
N=724 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-
blind; randomised 2:1; 
stratified by presence of 
visceral metastasis and 
previous sensitivity to 
endocrine therapy 
 
follow-up: median 17.7 
months 
 
primary outcome: PFS 
based on radiographic 
studies assessed by local 
investigators 
"ER-positive, human 
epidermal growth 
factor receptor type 
2 (HER2) – 
nonamplified 
advanced breast 
cancer whose 
disease was 
refractory to previous 
letrozole or 
anastrozole" 
A) everolimus oral (10 
mg daily) + exemestane 
(25 mg daily) until 
disease progression, 
unacceptable toxicity, 
or withdrawal of consent 
B) placebo + 
exemestane (25 mg 
daily) until disease 
progression, 
unacceptable toxicity, 
or withdrawal of consent 
 
samples: NR 
 
method: by protein or gene analysis 
(details NR) 
 
threshold: NR 
 
group N BM+ BM- BM? 
A 485 483 0 2* 
B 239 239 0 0 
 
 
median PFS: everolimus 7.82 
months (95% CI: 6.93, 8.48), 
placebo 3.19 months (95% 
CI: 2.76, 4.14), HR = 0.45 (95% 
CI: 0.38, 0.54, p<0.0001), 
favours everolimus 
Baselga 
2009131,133 
 
EMA status: 
supportive 
 
Phase II 
 
N=270 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: RCT; double-
blind; randomised 1:1 
 
follow-up: 16 weeks 
 
primary outcome: 
objective response rate 
“assessed with modified 
WHO criteria by clinical 
palpation (monthly), 
ultrasound (monthly), 
and bidirectional 
mammography (months 
2 and 4)" 
"women aged 18 
years or older with 
postmenopausal, 
histologically 
confirmed, ER-
positive (assessed 
locally), untreated, 
stage M0 breast 
cancer who had a 
primary palpable 
tumor greater than 2 
cm in diameter by 
imaging and who 
were candidates for 
mastectomy or 
breast conserving 
surgery" 
A) everolimus 10 mg + 
letrozole 2.5 mg for 16 
weeks - last dose taken 
within 24 hours of surgery 
(could be discontinued 
in less than 16 weeks for 
progressive disease or 
on patient or 
investigator request) 
B) placebo + letrozole 
2.5 mg for 16 weeks - last 
dose taken within 24 
hours of surgery (could 
be discontinued in less 
than 16 weeks for 
progressive disease or 
on patient or 
investigator request) 
samples: baseline core biopsy 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- BM? 
A 138 12 95 31 
B 132 14 91 27 
 
 
Overall objective response 
rate (1) by ultrasound 
everolimus (n=129) 77 (59.7%, 
95% CI: 51.2, 68.2), placebo 
(n=122) 58 (47.5%, 95% CI: 8.7, 
56.4), Chi-squared p=0.0268; 
(2) by palpitation everolimus 
(n=129) 86 (66.7%, 95% CI: 
58.5, 74.8), placebo (n=122) 
67 (54.9%, 95% CI: 46.1, 63.7), 
Chi-squared p=0.0283 
 
results NR based on HER2 
status 
                                                                
* missing status 
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HER2 expression  – breast cancer - lapatinib 
Study Design Population Interventions  Biomarker measurement Results  
EGF100151134-
136 
 
EMA status: 
main 
 
Phase III 
 
N=399 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
randomised 1:1 (permuted 
blocks of 6), stratified by 
disease stage and the 
presence or absence of 
visceral disease 
 
follow-up: NR 
 
primary outcome: TTP (time 
from randomization to disease 
progression (defined 
according to RECIST criteria, 
modified to include lesions 
that were 15 to 19 mm in 
diameter as assessed by 
methods other than spiral CT) 
or death due to breast 
cancer) 
"locally 
advanced breast 
cancer (a T4 
primary tumor 
and stage IIIB or 
IIIC disease) or 
metastatic breast 
cancer that had 
progressed after 
treatment with 
regimens that 
included an 
anthracycline, a 
taxane, and 
trastuzumab"; no 
previous 
capecitabine 
A) lapatinib 1250 mg daily, 
1 hour before or after 
breakfast, on a continuous 
basis + capecitabine 2000 
mg/m2 in two divided doses 
on days 1 through 14 of a 
21-day cycle until 
investigator identified 
disease progression or 
unacceptable toxicity; 
possiblility of temporarily 
stopping or termination due 
to toxicity 
B) capecitabine 2500 
mg/m2 in two divided doses 
on days 1 through 14 of a 
21-day cycle until 
investigator identified 
disease progression or 
unacceptable toxicity 
samples: tumour (details NR) 
 
method: immunohistochemical 
analysis or immunohistochemical 
analysis with gene amplification on 
fluorescence in situ hybridization at 
local institution 
 
threshold: 3+ staining by IHC only or 
2+ by IHC + FISH 
 
group N BM+ BM- 
A 198 197 1 
B 201 201 0 
 
 
at the end of enrollment 
TTP: median lapatinb 
(n=198) 27.1 weeks, 
capecitabine only (n=201) 
18.6 weeks; HR = 0.57 (95% 
CI: 0.43, 0.77, p=0.00013) 
favours lapatinib 
EGF103659 
and French 
ATU134,137 
 
EMA status: 
supportive 
 
Phase IV 
 
N=3330 
 
Status: 
ongoing 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: clinical 
benefit 
advanced or 
metastatic BC, 
progression (by 
modified RECIST) 
after prior 
therapy, 
including all of 
the following: 
anthracycline, 
taxane, and 
trastuzumab 
alone or in 
combination with 
other therapy 
lapatinib + capecitabine 
(details NR) 
samples: tumour (details NR) 
 
method: immunohostochemistry or 
FISH (reported for EGF103659 only) 
 
threshold: +3 by IHC or FISH positive 
(reported for EGF103659 only) 
 
N BM+ BM- 
3330 NR NR 
 
 
Reported only for patients 
with brain metastases 
(n=137): 3 CR, 21 PR, 56 SD, 
14 PD, 43 unknown 
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Study Design Population Interventions  Biomarker measurement Results  
EGF105084134,13
8 
 
EMA status: 
supportive 
 
Phase II 
 
N=242 
 
Status: 
completed  
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; wo 
cohorts: A: ECOG PS 0 to 1 
and 1 or 2 prior trastuzumab 
regimens; B: ECOG PS 2 
and/or >2 prior trastuzumab 
regimens 
 
follow-up: NR 
 
primary outcome: central 
nervous system (CNS) 
objective response (Brain MRIs 
obtained every 8 weeks; 
either CR or PR (≥50% 
reduction in the volumetric 
sum of all CNS lesions), and no 
progression of extra-CNS 
disease) 
breast cancer 
with new and/or 
progressive brain 
metastases after 
completion of 
whole-brain 
radiotherapy or 
stereotactic 
radiosurgery; prior 
treatment w/ 
trastuzumab 
lapatinib monotherapy (750 
mg twice a day)  
samples: cancer tissue (details NR) 
 
method: immunohistochemistry or 
fluorescence in situ hybridization 
 
threshold: 3+ immunohistochemistry 
or evidence of gene amplification 
by fluorescence in situ hybridization 
 
N BM+ BM- 
242 242 0 
 
 
16/242 experienced ≥ 50% 
volumetric reduction 
in an extension study 
(combination 
therapy)10/49 
experienced ≥ 50% 
volumetric reduction 
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Study Design Population Interventions  Biomarker measurement Results  
EGF30001 134 
 
EMA status: 
supportive 
 
Phase III 
 
N=580 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: RCT; double-blind; 
stratified by stage and sites of 
metastatic 
disease 
 
follow-up: NR 
 
primary outcome: TTP (time 
from random assignment until 
disease progression or death 
because of disease under 
study) 
advanced breast 
cancer (stage III 
or IV) previously 
untreated in the 
metastatic 
setting; either 
HER2-negative 
(per the enrolling 
site) or HER2-
unknown breast 
cancer 
A) lapatinib oral 1,500 mg 
daily + paclitaxel 175 
mg/m2 iv every 3 weeks (for 
up to six cycles) until 
disease progression, 
withdrawal as a result of 
toxicity, or withdrawal of 
consent 
B) placebo + paclitaxel 175 
mg/m2 iv every 3 weeks (for 
up to six cycles) until 
disease progression, 
withdrawal as a result of 
toxicity, or withdrawal of 
consent 
 
samples: tumor specimens from 
pretreatment or archived, 
paraffin-embedded breast cancer 
tissue 
 
method: "HER2 gene amplification 
status was analyzed by PathVision 
FISH (Abbott Laboratories, Abbott 
Park, IL), and HER-2 protein 
expression status was analyzed by 
Dako HercepTest IHC (Dako, 
Carpinteria, CA)." 
 
threshold: FISH positive or IHC 3+ if 
FISH status was unknown 
 
group N BM+ BM- BM? 
A 291 49 202 40 
B 288 37 204 47 
 
 
HER2+ median TTP: 
lapatinib (n=52) 8.1 weeks 
(IQR: 4.6, 12.9), control 
(n=39) 5.8 weeks (IQR: 4.6, 
8.3), HR=0.57 (95%CI: 0.34, 
0.90, p=0.011) favours 
lapatinib; HER2+ (ref 319): 
median TTP: lapatinib 
(n=49) 36.4 weeks (IQR 
NR), control (n=37) 25.1 
weeks (IQR NR), HR=0.53 
(95%CI: 0.31, 0.89, p=0.005) 
favours lapatinib 
HER2- NR 
HER2 unknown NR 
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HER2 expression  – breast cancer - pertuzumab 
Study Design Population Interventions  Biomarker measurement Results  
CLEOPATRA139,1
40 
 
EMA status: 
main 
 
Phase III 
 
N=808 
 
Status: 
completed  
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
randomised 1:1, stratified by 
geographic region and prior 
treatment (prior adjuvant or 
neoadjuvant chemotherapy 
vs. none) 
 
follow-up: median 19.3 months 
 
primary outcome: PFS (“time 
from randomization to the first 
documented radiographic 
evidence of progressive disease 
according to (…) RECIST 
(version 1.0) or death from any 
cause within 18 weeks after the 
last independent assessment of 
tumors") 
"HER2-positive 
metastatic breast 
cancer who had not 
received 
chemotherapy or 
biologic therapy for 
their metastatic 
disease" 
A) pertuzumab (loading dose 840 
mg -> 420 mg every 3 weeks) + 
trastuzumab (loading dose 8 
mg/kg -> 6 mg/kg every 3 weeks) 
+ docetaxel (75 mg/m2 every 3 
weeks, could be increased to 
100 mg/m2) until disease 
progression or unacceptable 
toxicity 
B) placebo + trastuzumab 
(loading dose 8 mg/kg -> 6 
mg/kg every 3 weeks) + 
docetaxel (75 mg/m2 every 3 
weeks, could be increased to 
100 mg/m2) until disease 
progression or unacceptable 
toxicity 
 
samples: cancer tissue (details 
NR) 
 
method: confirmed centrally, 
by immunohistochemistry or 
fluorescence in situ 
hybridization 
 
threshold: IHC 3+ or FISH 
amplification ratio ≥2.0 
 
group N BM+ BM- 
A 402 402 0 
B 406 406 0 
 
 
median PFS: 
pertuzumab (n=402) 
18.5 months (95% CI: 
15, 23), placebo 
(n=406) 12.4 months 
(95% CI: 10, 13), HR = 
0.62 (95% CI: 0.51, 
0.75, p<0.0001), 
favours pertuzumab 
Baselga 
2010139,141 
 
EMA status: 
supportive 
 
Phase II 
 
N=66 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; Simon’s two-
stage design 
 
follow-up: 28 weeks 
 
primary outcome: objective 
response rate (ORR) and/or the 
clinical benefit rate (CBR) (ORR; 
confirmed CR or PR; CBR:  total 
number of objective responses 
plus SD > 6 months; determined 
according to RECIST) 
HER2+ metastatic 
breast cancer who 
received ≤ 3 
chemotherapy lines 
before study entry 
and had lately 
progressed on 
trastuzumab 
pertuzumab (loading dose 840 
mg iv on day 2 -> following 
cycles 420 mg) + trastuzumab 
according to the same dose 
schedule as before study entry; 
for 8 cycles, but could be 
continued afterwards 
samples: NR 
 
method: NR 
 
threshold: NR 
 
N BM+ BM- 
66 66 0 
 
 
ORR was 24.2% (16 
patients - based on 
paper); CBR was 50% 
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Study Design Population Interventions  Biomarker measurement Results  
NeoSphere139,14
2 
 
EMA status: 
supportive 
 
Phase II 
 
N=417 
 
Status: 
completed  
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
centrally randomised (1:1:1:1) 
"with the adaptive 
randomisation method and 
stratified by operable, locally 
advanced, and inflammatory 
breast cancer, and by positivity 
for oestrogen or progesterone 
receptors" 
 
follow-up: NR 
 
primary outcome: pathological 
CR in the breast (absence of 
invasive neoplastic cells at 
microscopic examination of the 
primary tumour at surgery; 
remaining in-situ lesions 
allowed) 
adult women with 
HER2-positive, 
operable (T2–3, N0–1, 
M0), locally 
advanced (T2–3, N2–
3, M0 or T4a–c, any 
N, M0), or 
inflammatory (T4d, 
any N, M0) breast 
cancer with primary 
tumours larger than 2 
cm in diameter, no 
previous cancer 
therapy 
A) pertuzumab 4 iv cycles: 
pertuzumab (840 mg, followed 
by 420 mg every 3 weeks) + 
docetaxel (75 mg/m², 
escalating, if tolerated, to 100 
mg/m² every 3 weeks) 
B) trastuzumab 4 iv cycles: 
trastuzumab (every 3 weeks at 8 
mg/kg (cycle 1), followed by 6 
mg/kg) + docetaxel (75 mg/m², 
escalating, if tolerated, to 100 
mg/m² every 3 weeks) 
C) trastuzumab 4 iv cycles: 
trastuzumab (every 3 weeks at 8 
mg/kg (cycle 1), followed by 6 
mg/kg) + docetaxel (75 mg/m², 
escalating, if tolerated, to 100 
mg/m² every 3 weeks) + 
pertuzumab (840 mg, followed 
by 420 mg every 3 weeks) 
D) trastuzumab 4 iv cycles: 
trastuzumab (every 3 weeks at 8 
mg/kg (cycle 1), followed by 6 
mg/kg) + pertuzumab (840 mg, 
followed by 420 mg every 3 
weeks) 
samples: tumour (details NR) 
 
method: HER2 
immunohistochemistry and 
fluorescence or chromogenic 
in-situ hybridisation 
 
threshold: HER2 
immunohistochemistry 3+ or 2+ 
and positive for fluorescence or 
chromogenic in-situ 
hybridisation 
 
group N BM+ BM- 
A 96 96 0 
B 107 107 0 
C 107 107 0 
D 107 107 0 
 
 
"The results of the 
analysis of the 
primary endpoint 
demonstrate very 
similar pCR 
[pathological 
complete response] 
rates in the treatment 
arms A (T+D 
[trastuzumab + 
docetaxel]: 29%) and 
D (Ptz+D 
[pertuzumab + 
docetaxel]: 24.0%)" 
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HER2 expression  – breast cancer - trastuzumab 
Study Design Population Interventions  Biomarker measurement Results  
H0648g24,32 
 
EMA status: 
unclear 
 
Phase III 
 
N=469 
 
Status: 
completed  
Biomarker evaluation: enrichment 
 
design: RCT; open-label (details NR) 
 
follow-up: "median time in the study 
was 40 weeks (range, 1 to 127) in the 
group given chemotherapy plus 
trastuzumab, as compared with 25 
weeks (range, 1 to 131) in the group 
given chemotherapy alone" 
 
primary outcome: TTP (evaluation for 
response at weeks 8 and 20 and then 
at 12-week intervals by members of an 
independent response-evaluation 
committee unaware of treatment 
assignments; disease progression was 
defined as an increase of more than 
25 % in the dimensions of any 
measurable lesion) 
Metastatic 
breast cancer 
with no prior 
therapy for 
metastatic 
disese 
A) trastuzumab (iv; loading 
dose 4 mg/kg, followed by 2 
mg/kg once a week, until 
evidence of disease 
progression) + chemotherapy 
(as in chemotherapy group) 
B) chemotherapy 
anthracycline (doxorubicin 60 
mg/m2 or epirubicin 75 mg 
/m2) + cyclophosphamide (600 
mg/m2) if no previous 
anthracycline, or paclitaxel 
(175 mg/m2) otherwise; every 3 
weeks for 6 cycles; additional 
cycles at investigator’s 
discretion 
samples: tumour tissue (details 
NR) 
 
method: IHC at a central 
laboratory  
 
threshold: "moderate staining 
(…) (a score of 2+) or more 
than moderate staining 
(referred to as a score of 3+) in 
more than 10 percent of tumor 
cells" 
 
group N BM+ BM- 
A 235 235 0 
B 234 234 0 
 
 
only data for patients 
treated with 
paclitaxel was 
considered: median 
TTP: trastuzumab + 
paclitaxel (n=89) 7.4 
months, paclitaxel 
(n=89) 4.6 months, 
p=0.0001 
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H0649g24,27 
 
EMA status: 
unclear 
 
Phase III 
 
N=222 
 
Status: 
completed 
Biomarker evaluation: non-randomised 
only positive 
 
design: single-arm (details NR) 
 
follow-up: median 12.8 months 
 
primary outcome: objective tumor 
response (at baseline, week 8, 16, and 
24, and every 12 weeks; by 
independent response evaluation 
committee (blind to treatment)) 
progressive 
metastatic 
breast cancer 
after one or two 
cytotoxic 
chemotherapy 
regimens for 
metastatic 
disease 
trastuzumab iv; loading dose 4 
mg/kg, followed by weekly 2 
mg/kg over 90 minutes; if 
infusion was well tolerated, 
shortened to 30 minutes; on 
disease progression investigator 
could continue at 2 mg/kg, 
increase to 4 mg/kg of 
discontinue treatment 
samples: tumor tissue, collected 
either at the time of primary 
diagnosis or at recurrence 
 
method: IHC by a core 
research pathology laboratory 
using 4D5 and CB11 murine 
monoclonal anti-HER2 
antibodies (staining meeting 
threshold from at least one of 
the antibodies required) 
 
threshold: 2+ or 3+ 
overexpression observed in 
over 
10% of the tumor cells 
 
N BM+ BM- 
222 222 0 
 
 
overall response rate 
(n=222) ORR = 34 
(15%) (95%CI: 11, 
21%) 
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HER2 expression  – stomach cancer - trastuzumab 
Study Design Population Interventions  Biomarker measurement Results  
ToGA143,144 
 
EMA status: 
main 
 
Phase III 
 
N=594 
 
Status: 
completed  
Biomarker evaluation: enrichment 
 
design: RCT; open-label; 
randomised 1:1 by use of a 
randomised block design with 
block sizes of four patients, via a 
central interactive voice 
recognition system; stratified 
according to ECOG PS, 
chemotherapy regimen, extent of 
disease, primary cancer site, and 
measurability of disease 
 
follow-up: median 17.1 months in 
chemotherapy and 18.6 months in 
chemotherapy + trastuzumab arm 
 
primary outcome: overall survival 
(time from randomisation until 
death from any cause) 
inoperable locally 
advanced, 
recurrent, or 
metastatic 
adenocarcinoma 
of the stomach or 
gastro-
oesophageal 
junction 
A) trastuzumab (iv; 
loading dose 8 mg/kg 
over 90 min(on day 1) 
followed by 6 mg/kg over 
30 min every 3 weeks) + 
chemotherapy (as in 
chemotherapy group) 
B) chemotherapy 6 3-
week cycles: 
capecitabine (1000 
mg/m2 orally 2x day for 14 
days) or fluorouracil (800 
mg/m2/day iv over 5 days 
)  + cisplatin (80 mg/m2 iv 
over 2 hours) - chosen at 
the investigator’s 
discretion 
 
samples: tumour (details NR) 
 
method: centrally tested with 
immunohistochemistry (HercepTest, 
Dako, Denmark]) and fluorescence in-
situ hybridisation (FISH; HER2 FISH 
pharmDx, Dako); new set of 
immunohistochemistry scoring criteria 
were developed that are specific for 
gastric cancer (in attached Word 
document) 
 
threshold: 3+ on immunohistochemistry 
or FISH positive (HER2:CEP17 ratio ≥2) 
 
group N BM+ BM- 
A 298 298 0 
B 296 296 0 
 
 
overall survival: 
hazard ratio = 0.74; 
95% CI (95% CI: 
0.60-0.91), p = 
0.0046; favours 
trastuzumab 
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HLA-B*5701 allele – HIV - abacavir 
Study Design Population Interventions  Biomarker measurement Results  
PREDICT-1145-148 
 
EMA status: 
unclear 
 
Phase IV 
 
N=1956 
 
Status: 
completed 
Biomarker evaluation: biomarker strategy 
 
design: RCT; double blind; stratified by self 
reported race (white vs non-white), history 
of antiretroviral therapy, and intention to 
commence a new reverse-transcriptase 
inhibitor between the day of screening 
visit and day 1 of trial 
 
follow-up: 6 weeks 
 
primary outcome: rate of clinically 
diagnosed hypersensitivity reaction (no 
predefined criteria); rate of 
immunologically confirmed hypersensitivity 
reaction to abacavir (clinically diagnosed 
reaction that was confirmed by a positive 
result on epicutaneous patch testing 6 to 
10 weeks after clinical diagnosis) 
HIV positive 
patients 
eligible for 
abacavir 
treatments 
A) abacavir (with 
prior HLA-B*5701 
screening) 
B) abacavir (no prior 
screening) 
 
samples: blood samples collected 
from all patients during the evaluation 
period 
 
method: using DNA-sequence–based 
typing (central laboratory) and a 
sequence-specific oligonucleotide 
probe method (Laboratory  
Corporation of America), with 
additional DNA sequencing for 
patients for whom the probe results 
were positive 
 
threshold: N/A 
 
group N BM+ BM- 
A 980 55* 925 
B 976 54 922 
 
 
NR in EMA documents, 
based on trial report: 
clinically diagnosed 
hypersensitivity 
reaction OR = 0.40 
(95% CI: 0.25, 0.62) 
favours screening; 
immunologically 
confirmed OR = 0.03 
(95% CI: 0.00, 0.19) 
favours screening; 
                                                                
* 55 positive patients from screening group excluded from the study after randomisation 
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Hormone receptor expression – breast cancer - everolimus 
Study Design Population Interventions  Biomarker measurement Results  
BOLERO-2131,132 
 
EMA status: 
main 
 
Phase III 
 
N=724 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
randomised 2:1; stratified 
by presence of visceral 
metastasis and previous 
sensitivity to endocrine 
therapy 
 
follow-up: median 17.7 
months 
 
primary outcome: PFS 
based on radiographic 
studies assessed by local 
investigators 
"ER-positive, human 
epidermal growth 
factor receptor type 2 
(HER2) – nonamplified 
advanced breast 
cancer whose disease 
was refractory to 
previous letrozole or 
anastrozole" 
A) everolimus oral (10 mg 
daily) + exemestane (25 mg 
daily) until disease 
progression, unacceptable 
toxicity, or withdrawal of 
consent 
B) placebo + exemestane 
(25 mg daily) until disease 
progression, unacceptable 
toxicity, or withdrawal of 
consent 
 
samples: NR 
 
method: by protein or gene 
analysis (details NR) 
 
threshold: NR 
 
group N BM+* BM- 
A 485 485 0 
B 239 239 0 
 
 
median PFS: everolimus 7.82 
months (95% CI: 6.93, 8.48), 
placebo 3.19 months (95% CI: 
2.76, 4.14), HR = 0.45 (95% CI: 
0.38, 0.54, p<0.0001), favours 
everolimus 
Baselga 
2009131,133 
 
EMA status: 
supportive 
 
Phase II 
 
N=270 
 
Status: 
completed 
Biomarker evaluation: 
enrichment) 
 
design: RCT; double-blind; 
randomised 1:1 
 
follow-up: 16 weeks 
 
primary outcome: 
objective response rate 
“assessed with modified 
WHO criteria by clinical 
palpation (monthly), 
ultrasound (monthly), and 
bidirectional 
mammography (months 2 
and 4)" 
"women aged 18 years 
or older with 
postmenopausal, 
histologically 
confirmed, ER-positive 
(assessed locally), 
untreated, stage M0 
breast cancer who 
had a primary 
palpable tumor 
greater than 2 cm in 
diameter by imaging 
and who were 
candidates for 
mastectomy or breast 
conserving surgery" 
A) everolimus 10 mg + 
letrozole 2.5 mg for 16 
weeks - last dose taken 
within 24 hours of surgery 
(could be discontinued in 
less than 16 weeks for 
progressive disease or on 
patient or investigator 
request) 
B) placebo + letrozole 2.5 
mg for 16 weeks - last dose 
taken within 24 hours of 
surgery (could be 
discontinued in less than 16 
weeks for progressive 
disease or on patient or 
investigator request) 
samples: baseline core biopsy 
 
method: NR 
 
threshold: NR 
 
group N BM+† BM- 
A 138 138 0 
B 132 132 0 
 
 
objective response rate (1) by 
ultrasound everolimus (n=129) 
77 (59.7%, 95% CI: 51.2, 68.2), 
placebo (n=122) 58 (47.5%, 
95% CI: 8.7, 56.4), Chi-squared 
p=0.0268; (2) by palpitation 
everolimus (n=129) 86 (66.7%, 
95% CI: 58.5, 74.8), placebo 
(n=122) 67 (54.9%, 95% CI: 
46.1, 63.7), Chi-squared 
p=0.0283 
 
                                                                
* Based on data for estrogen receptor only; 523 patients in total were progesterone receptor positive (further detail NR) 
† Based on data for estrogen receptor only 
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Hormone receptor expression – breast cancer - zoledronic acid 
Study Design Population Interventions  Biomarker measurement Results  
ABCSG-12149,150 
 
EMA status: 
main 
 
Phase III 
 
N=1803 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; 
"computer-generated adaptive 
randomisation method to assign 
treatment groups via an 
automated telephone service. 
Patients were randomly assigned 
(in a 1:1:1:1 ratio on the basis of 
Pocock and Simon’s minimisation 
method for a two-by-two factorial 
design)" 
 
follow-up: median 53 months 
 
primary outcome: DFS (time from 
randomisation to the first 
occurrence of any of the 
following: a local or regional 
recurrence, contralateral breast 
cancer, distant metastasis, 
second primary carcinoma, and 
death from any cause") 
premenopausal 
women with 
stage I or II 
oestrogen-
receptor-positive 
and/or 
progesterone-
receptor-positive 
breast cancer 
A) zoledronic acid 4 mg iv 
every 6 months + goserelin 3.6 
mg subcutaneously every 28 
days + tamoxifen 20 mg per 
day orally for 3 years 
B) zoledronic acid 4 mg iv 
every 6 months + goserelin 3.6 
mg subcutaneously every 28 
days + anastrozole 1 mg per 
day orally  for 3 years 
C) goserelin 3.6 mg 
subcutaneously every 28 days 
+ tamoxifen 20 mg per day 
orally for 3 years 
D) goserelin 3.6 mg 
subcutaneously every 28 days 
+ anastrozole 1 mg per day 
orally  for 3 years 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 450 450 0 
B 450 450 0 
C 450 450 0 
D 453 453 0 
 
 
zoledronic acid reduced 
the risk of DFS events by 
34% vs. control, HR = 0.66 
(95% CI: 0.48, 0.90, 
p=0.008); 5-year DFS 92.9% 
zoledronic acid and 89.1% 
control (data for median 
62 months follow-up 
confirm) 
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E-ZO-FAST149,151 
 
EMA status: 
supportive 
 
Phase III 
 
N=527 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; stratified 
according to postmenopausal 
status (postmenopausal vs. 
recently menopausal), baseline T-
score, and previous adjuvant 
chemotherapy 
 
follow-up: NR 
 
primary outcome: percentage 
change from baseline in the 
lumbar spine bone mineral 
density measured by DEXA scan 
at 12 months 
"postmenopausal 
or recently 
menopausal from 
ovarian-ablative 
treatments and 
had resected 
stage I to stage 
IIIa HR+ [hormone 
receptor+] EBC 
[early breast 
cancer], no 
clinical or  
radiologic 
evidence of 
recurrent or 
metastatic 
disease disease", 
baseline ECOG 
PS =<2, and LS 
and TH BMD T-
scores >= –2.0 
A) zoledronic acid 
(immediate) iv 4 mg for 15 
minutes every 6 months + oral 
calcium suppl. 500 mg + 
multivitamin tablet w/ vitamin 
D (400-800 IU) daily + 2.5 mg 
letrozole daily for 5 years or 
until disease progression 
B) zoledronic acid (delayed) 
iv 4 mg for 15 minutes every 6 
months if: BMD T-score 
decreased to <–2.0 at either 
LS or TH, any clinical fracture, 
or an asymptomatic fracture 
at 36-month evaluation + 
treatment as immediate 
group 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 263 263 0 
B 264 264 0 
 
 
bone mineral density NR in 
EMA documents;  
DFS favoured the 
immediate group, but 
results were not statistically 
significant 
Z-FAST149,152 
 
EMA status: 
supportive 
 
Phase III 
 
N=602 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; stratified 
by baseline T score and receipt of 
adjuvant chemotherapy 
 
follow-up: NR 
 
primary outcome: percentage 
change in LS BMD (L1–L4) from 
baseline to 12 months "using 
either Hologic (Hologic, Bedford, 
MA) or Lunar (GE Medical Systems 
Lunar Corporation, Madison, WI) 
dual-energy x-ray absorptiometry 
(DEXA) devices" 
postmenopausal 
women with 
early-stage 
hormone 
receptor–positive 
breast cancer 
A) zoledronic acid 
(immediate)  iv 4 mg for 15 
minutes every 6 months + oral 
calcium suppl. 1000-1200 mg 
+ multivitamin tablet w/ 
vitamin D (400-800 IU) daily + 
2.5 mg letrozole daily for 5 
years or until disease 
progression 
B) zoledronic acid (delayed) 
iv 4 mg for 15 minutes every 6 
months if: BMD T-score 
decreased to <–2.0 at either 
LS or TH, any clinical fracture, 
or an asymptomatic fracture 
at 36-month evaluation + 
treatment as immediate 
group 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 301 301 0 
B 301 301 0 
 
 
bone mineral density NR in 
EMA documents;  
DFS favoured the 
immediate group, but 
results were not statistically 
significant 
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ZO-FAST149,153 
 
EMA status: 
supportive 
 
Phase III 
 
N=1065 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; open-label; stratified 
according to adjuvant 
chemotherapy, baseline T-score, 
and menopausal status (recently 
vs established postmenopausal) 
 
follow-up: NR 
 
primary outcome: percentage 
change in spine bone mineral 
density at 12 months "using either 
Hologic (Hologic, Bedford, Mass), 
Lunar (GE Medical Systems Lunar 
Corporation, Madison, Wis), or 
Norland (Norland, Fort Atkinson, 
Wis) dual-energy x-ray 
absorptiometry (DXA) devices" 
postmenopausal 
women w/ 
estrogen 
receptor-positive 
early breast 
cancer and 
baseline lumbar 
spine and total 
hip T-scores 
above 22.0 
A) zoledronic acid 
(immediate)  immediate iv 4 
mg for 15 minutes every 6 
months + oral calcium suppl. 
500 mg + multivitamin tablet 
w/ vitamin D (400-800 IU) daily 
+ 2.5 mg letrozole daily for 5 
years or until disease 
progression 
B) zoledronic acid (delayed) 
iv 4 mg for 15 minutes every 6 
months if 1) spine or hip T-
score decreased to < 22.0; 2) 
nontraumatic clinical fracture 
or 3) asymptomatic fracture 
discovered at month-36 visit + 
treatment as immediate 
group 
 
samples: NR 
 
method: NR 
 
threshold: NR 
 
group N BM+ BM- 
A 532 532 0 
B 533 533 0 
 
 
Upfront treatment resulted 
in a significant increase in 
bone mineral density in 
lumbar spine to month 36 
after which it remained 
stable; in the delayed 
group BMD in lumbar spine 
decreased and only 
returned to values close to 
baseline in the last part of 
the study;  
secondary outcome: DFS 
HR = 0.591 (95% CI: 0.381, 
0.917) 
Kit (CD 117) – GIST - imatinib 
Study Design Population Interventions  Biomarker measurement Results  
Blanke 
2008b154,155 
 
EMA status: 
unclear 
 
Phase III 
 
N= 694 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
stratified by Zubrod 
performance status and disease 
status (measurable vs. 
nonmeasurable) 
 
follow-up: median 4.5 years 
 
primary outcome: PFS and 
overall survival 
unresectable 
GIST; no known 
brain 
metastases 
A) imatinib 400 mg orally once 
daily; dose reduction or 
interruption due to toxicity 
allowed 
B) imatinib 400 mg orally twice 
daily; dose reduction or 
interruption due to toxicity 
allowed 
 
samples: tumour (details NR) 
 
method: immunohistochemistry 
with DAKO (Carpenteria, CA) 
antibody 
 
threshold: N/A 
 
group N BM+ BM- 
A 345 345 0 
B 349 349 0 
 
 
NR 
 472 
 
Study Design Population Interventions  Biomarker measurement Results  
Demetri 
2002154,156{#176 
 
EMA status: 
unclear 
 
Phase II 
 
N=147 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; no 
stratification; blocking with 
block size of 4 
 
follow-up: median 288 days 
 
primary outcome: objective 
response according to standard 
Southwest Oncology Group 
criteria; based solely on CT or 
MRI 
unresectable 
and/or 
metastatic GIST 
A) imatinib 400 mg/day orally 
once daily with food with 
possible increase to 600 
mg/day if tumour progressed 
B) imatinib 600 mg/day orally 
once daily with food 
 
samples: tumour biopsy 
 
method: immunohistochemistry 
using polyclonal rabbit antiserum 
(A4502, Dako) 
 
threshold: N/A 
 
group N BM+ BM- 
A 73 71-73* 0-2 
B 74 72-74 0-2 
 
 
best tumour response: for 
both groups 1 CR, 98 PR, 
23 SD, 18 PD, 5 not 
evaluable, 2 unknown 
                                                                
* Two patients were later found to be biomarker negative 
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KRAS mutation – colorectal cancer - cetuximab 
Study Design Population Interventions  Biomarker measurement Results 
CO.17157-159 
 
EMA status: 
unclear 
 
Phase III 
 
N=572 
 
Status: 
completed 
Biomarker 
evaluation: subgroup 
(retrospective) 
 
design: RCT stratified 
by centre and ECOG 
PS; central 
randomisation by 
minimisation 1:1 
 
follow-up: median 
14.6 months 
 
primary outcome: OS 
(time from 
randomisation to 
death from any 
cause) 
EGFR 
expressing 
advanced 
colorectal 
cancer; prior 
lack of 
response to a 
fluoropyrimidi
ne, irinotecan 
and 
oxaliplatin or 
contraindicati
ons to these 
A) cetuximab (iv loading 
dose 400 mg/m2 over 120 
min followed by 250 mg/m2 
over 60 min once a week 
until disease progression or 
unacceptable toxicity) + 
supportive care 
B) supportive care (details 
NR) 
samples: FFPE tumour tissue samples 
from specimens collected at diagnosis; 
if tumour blocks unavailable - unstained 
slides were retrieved 
 
method: in a "blinded fashion" by 
members of BMS Department of Clinical 
Biomarkers-Oncology; DNA extraction 
using QIAmp DNA Mini Kit (Qiagen), 
PCR, primer extension sequencing with 
BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems); 
reactions were run on 3730x1 DNA 
Analyzer (Applied Biosystems), DNA 
sequence analysis with Mutation 
Surveyor v2.61 (SoftGenetics) along with 
visual inspection of each sample trace 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 287 54 38 195 
B 285 57 39 189 
 
 
Overall overal survival: (n=572): HR=0.77 
(95%CI: 0.64, 0.92); in KRAS-evaluable 
patients (n=188): HR=0.75 (95%CI: 0.537, 
1.036) 
KRAS mutant overal survival : (n=77): 
HR=0.79 (95%CI: 0.476, 1.322); 
KRAS wild-type overal survival: (n=111): 
HR=0.74 (95%CI: 0.479, 1.154); 
no data for patients with unknown 
KRAS status 
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CRYSTAL157,16
0,161 
 
EMA status: 
unclear 
 
Phase III 
 
N=1198* 
 
Status: 
completed 
Biomarker 
evaluation: subgroup 
(retrospective) 
 
design: RCT with 1:1 
randomisation; 
stratified by ECOG PS 
and region 
 
follow-up: NR 
(median 19.9 and 
18.6 months†) 
 
primary outcome: 
PFS (time from 
randomisation to 
disease progression 
or death from any 
cause within 60 days 
after the last tumour 
assessment or after 
randomisation) 
EGFR 
expressing 
metastatic 
adenocarcino
ma of colon 
or rectum, not 
resectable for 
curative 
purposes; no 
previous 
exposure to 
anti-EGFR or 
irionotecan 
treatment 
A) cetuximab on day 1 (400 
mg/m2 120 min iv infusion) 
followed by 250 mg/m2 
once a week + FOLFIRI (as 
in FOLFIRI group) till 
progression, unacceptable 
toxicity or withdrawal 
B) FOLFIRI every 14 days: 
irinotecan ( 30-90 min iv 
180mg/m2) + racemic or L- 
leucovorin (120 min iv 400 
or 200 mg/m2 respect) + 
fluorouracil in a bolus (400 
mg/m2) followed (46 hrs iv 
2400 mg/m2) till 
progression, unacceptable 
toxicity or withdrawal 
samples: paraffin-embedded tumour 
biopsy specimens 
 
method: PCR clamping and melting 
curve method (LightMix k-ras Gly12 
assay, TIB MOLBIOL); KRAS mutation in 
codons 12 and 13 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 599 105 172 322 
B 599 87 176 336 
 
 
Overall PFS: (n=1198): HR = 0.851 
(95%CI: 0.726, 0.998); in KRAS-evaluable 
patients (n=540): HR=0.822 (95%CI: 
0.645, 1.048) favours cetuximab 
KRAS mutant PFS: (n=192): HR = 1.069 
(95%CI: 0.710, 1.610); favours FOLFIRI 
KRAS wild-type PFS: (n=348): HR = 0.684 
(95%CI: 0.501, 0.934); favours 
cetuximab 
no data for patients with unknown 
KRAS status 
 
                                                                
* 1198 were treated and reported, but 1217 reported as randomised 
† Based on OS in groups 
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Study Design Population Interventions  Biomarker measurement Results 
EPIC157,162 
 
EMA status: 
unclear 
 
Phase III 
 
N=1298 
 
Status: 
completed 
Biomarker 
evaluation: subgroup 
(retrospective) 
 
design: RCT 
randomised 1:1; 
atratified by ECOG 
PS and study site 
 
follow-up: NR 
(median 10.7 and 
10.0 months*) 
 
primary outcome: OS 
(monitored every 3 
months) 
EGFR 
expressing 
metastatic 
colorectal 
cancer; failure 
within 6 
months of the 
last dose of 
first-line 
fluoropyrimidi
ne and 
oxaliplatin for 
metastatic 
disease; no 
previous 
irinotecan 
and anti-EGFR 
allowed 
A) cetuximab 400mg/m2 (iv 
over 2 hrs) then 250 mg/m2 
(iv over 1 hr) weekly; 
antihistamine premed; + 
irinotecan 350mg/m2 (or 
300 for patients at least 70, 
w/ PS 2 or prior 
abdominal/pelvic 
irradiation) (iv 90 min) every 
3 wks til progression/ 
unacceptable toxicity 
B) irinotecan 350mg/m2 (or 
300 for patients at least 70, 
w/ PS 2 or prior 
abdominal/pelvic 
irradiation) (iv 90 min) every 
3 wks til progression/ 
unacceptable toxicity 
samples: tumour (details NR) 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 648 49 97 502 
B 650 59 95 496 
 
 
Overall overal survival: (n=1298): 
HR=0.98 (95%CI: 0.85, 1.11); favours 
cetuximab; overal survival in KRAS-
evaluable patients (n=300): HR=1.25 
(95%CI: 0.947, 1.660); favours irinotecan 
KRAS mutant overal survival: (n=108): 
HR=1.28 (95%CI: 0.813, 2.005); favours 
irinotecan 
KRAS wild-type overal survival: (n=202): 
HR=1.29 (95%CI: 0.894, 1.846); favours 
irinotecan 
no data for patients with unknown 
KRAS status 
 
OPUS157,163,16
4 
 
EMA status: 
unclear 
 
Phase II 
 
N=338 
 
Status: 
completed 
Biomarker 
evaluation: subgroup 
(retrospective) 
 
design: RCT 
randomised 1:1, 
stratified by ECOG PS 
 
follow-up: NR 
(median 7.2 months†) 
 
primary outcome: 
best confirmed 
overall response rate 
(assessed by 
independent review 
committee using 
modified WHO 
criteria) 
first-
occurrence of 
a 
nonresectable
, EGFR 
expressing 
metastatic 
colorectal 
cancer; no 
prior 
treatment 
with EGFR 
targeted 
therapy or 
chemotherap
y 
A) cetuximab (initial dose 
400 mg/m2 for 2 hours, and 
250 mg/m2 weekly) + 
FOLFOX-4; until progressive 
disease or unacceptable 
toxicity 
B) FOLFOX-4: oxaliplatin 85 
mg/m2 on day 1, infused 
during 2 hours; LV 200 
mg/m2, infused during 2 
hours, followed by FU as a 
400 mg/m2 intravenous 
bolus then a 600 mg/m2 
infusion during 22 hours on 
days 1 and 2; until 
progressive disease or 
unacceptable toxicity 
samples: FFPE tumour 
method: PCR clamping and melting 
curve technique in one-step Lightcycler 
PCR reaction (Light- Mix, k-ras Gly12; TIB 
MOLBIOL, Berlin, Germany); mutation in 
codons 12 and 13; 
 
threshold: N/A 
 
KRAS mutation was assessed in 233 
(69%) of the 338 patients in the study. 
 
group N BM+ BM- BM? 
A 170 52 61 57 
B 168 47 73 48 
 
 
Overall overal response rate (CR+PR): 
cetuximab (n=169) 78 (46.2%, 95%CI: 
38.5, 54.0); FOLFOX-4 (n=168) 67 (39.9%, 
95%CI: 32.4, 47.7); p=0.243; in KRAS-
evaluable patients: cetuximab (n=113) 
54 (47.8%, 95%CI: 38.3, 57.4); FOLFOX-4 
(n=120) 50 (41.7%, 95%CI: 32.7, 51.0); 
p=0.390; 
KRAS mutant overal response rate 
(CR+PR): cetuximab (n=52) 17 (32.7%, 
95%CI: 20.3, 47.1); FOLFOX-4 (n=47) 23 
(48.9%, 95%CI: 34.1, 63.9); p=0.106; 
KRAS wild-type overal response rate 
(CR+PR): cetuximab (n=61) 37 (60.7%, 
95%CI: 47.3, 72.9); FOLFOX-4 (n=73) 27 
(37.0%, 95%CI: 26.0, 49.1); p=0.011 
no data for patients with unknown 
KRAS status 
                                                                
* Based on OS reported in each group 
† Median PFS in both groups 
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KRAS mutation – colorectal cancer - cetuximab 
Study Design Population Interventions  Biomarker measurement Results  
20020408165-167 
 
EMA status: 
main 
 
Phase III 
 
N=463 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: RCT; open-label 
(due to expected skin 
toxicity with 
panitumumab); 
randomised 1:1. stratified 
by ECOG status and 
region 
 
follow-up: median 
approximately 35 weeks 
(range 15 to 76) 
 
primary outcome: PFS from 
random assignment until 
radiologic progression 
(blinded central 
assessment) or death 
adults with 
metastatic 
colorectal 
adenocarcino
ma; disease 
progression on 
or within 6 
months of last 
administration o 
chemotherapy 
A) panitumumab 
6mg/mk every 2 
weeks as 60-minute 
iv infusion + best 
supportive care until 
disease progression 
or unacceptable 
toxicity 
B) best supportive 
care (BSC) "best 
palliative care per 
investigator 
excluding 
antineoplastic 
agents" 
 
samples: archived formalin fixed paraffin 
embedded tumour sections (mainly from 
resection of primary tumour) 
 
method: validated KRAS mutation kit (DxS 
Ltd, Manchester UK) that identifies 7 
mutations in codons 12 and 13 (Gly12Asp, 
Gly12Ala, Gly12Val, Gly12Ser, Gly12Arg, 
Gly12Cys, Gly13Asp) using allele-speciffic 
real-time PCR 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 231 124 84 23 
B 232 119 100 13 
 
 
overall At median follow–up of 
approximately 20 weeks, 193 
patients in the panitumumab and 
208 patients in the BSC alone 
group had disease progression or 
died due to any reasons; 
improvement with panitumumab; 
p<0.0001, stratified log–rank test 
wild-type KRAS median PFS in 
panitumumab 16.0 weeks, BSC 
8.0 weeks; HR=0.49, 95% CI: 0.37, 
0.65; Stratified log-rank test 
p<0.0001 
mutant KRAS median PFS in 
panitumumab 8.0 weeks, BSC 8.0 
weeks; HR=1.07, 95% CI: 0.77, 1.48 
LPL protein expression - familial lipoprotein lipase deficiency - alipogene tiparvovec 
No studies – based on mechanism of action/ metabolism168 
NADPH reductase deficiency - acquired methaemoglobinaemia – methylthionium chloride 
No studies – based on mechanism of action/ metabolism169 
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PDGFR gene re-arrangements - MDS/MPD - imatinib 
Study Design Population Interventions  Biomarker measurement Results  
Heinrich 200861,170 
 
EMA status: main 
 
Phase II 
 
N=7* 
 
Status: completed 
Biomarker evaluation: 
subgroup (retrospective) 
 
design: single-arm; 
"exploratory", "proof of 
concept" 
 
follow-up: NR 
 
primary outcome: tumor 
response based on blood 
counts and bone marrow 
analyses 
age at least 15 
years; 
myeloproliferativ
e disease 
imatinib 400 mg daily 
with escalation to 300 
or 400 mg twice daily if 
no significant 
improvement after 4 to 
8 weeks of therapy 
 
samples: NR 
 
method: protein expression of imatinib 
sensitive TKs IHC at local hospitals for 
PDGFRA and PDGFRB and confirmed by 
a central laboratory (Institute of 
Pathology, Basel, Switzerland) 
 
threshold: N/A 
 
N BM+ BM- BM? 
7 3 3 1 
 
 
overall haematological 
response: 3 CR, 1 PR, 1 PD, 
2 unknown 
PDGFR positive 2 CR, 1 PR 
PDGFR negative 1 PD, 1 
unknown 
PDGFR unknown 1 CR 
Apperley 
2002170,171 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=2 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 13 and 15 
months 
 
primary outcome: N/A 
both were adults 
with 
myeloproliferativ
e disease 
(PDGFRβ positive) 
imatinib 400 mg daily; 
route NR 
 
samples: blood, bone marrow or both 
(details NR) 
 
method: RNA reverse-transcribed and 
tested for ETV6-PDGFRB fusion by single-
step reverse-transcriptase PCR and hemi-
nested RT-PCR (limit of detection 10-5) 
 
threshold: N/A 
 
N BM+ BM- 
2 2 0 
 
 
both patients achieved 
complete hematological 
and cytogenetic response 
                                                                
* study investigated imatinib in a range of cancers positive for biomarkers possibly associated with response; only seven with MPS/MPD are included here 
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Study Design Population Interventions  Biomarker measurement Results  
Cortes 2003170,172 
 
EMA status: 
supportive 
 
Phase NR 
 
N= 
 
Status: completed 
Biomarker evaluation: NR 
 
design: single-arm; study of 
imatinib including patients 
with AML or high risk MDS 
who failed previous 
chemotherapy or were not 
eligible for chemotherapy; 
low-risk MDS eligible 
regardless of treatment 
history 
 
follow-up: median 14 
weeks (range 6-42) in 7 
atypical CML (aCML) 
patients; NR for chronic 
myelomonocytic 
leukaemia (CMML) patients 
 
primary outcome: NR 
adults with aCML 
and CMML 
imatinib single daily 
oral dose of 400mg 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
10 0 10 
 
 
none of the patients 
achieved hematological 
or cytogenetic response 
Garcia 2003170,173 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 1 year 
 
primary outcome: N/A 
adult with aCML 
(PDGFRβ positive) 
imatinib 400 mg daily; 
route and duration NR 
 
samples: peripheral blood smear 
 
method: RT-PCR analysis using specific 
primers flanking predicted breakpoints, 
confirmed by sequencing (H4-PDGFRβ) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete hematological 
and cytogenetic response 
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Study Design Population Interventions  Biomarker measurement Results  
Grand 2004170,174 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: approximately 5 
months 
 
primary outcome: N/A  
adult with a 
myeloproliferativ
e disorder 
(PDGFRβ positive) 
imatinib 400 mg daily 
(route NR); reduced to 
300 mg daily due to 
grade 4 neutropenia 
 
samples: NR 
 
method: two color FISH, RT-PCR and by 
"characterising the genomic breakpoints" 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
partial hematological 
response; data on 
cytogenetic not available 
Levine 2005170,175 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 18 months 
 
primary outcome: N/A 
adult with CMML 
(PDGFRβ positive) 
imatinib 400 mg daily; 
oral 
 
samples: NR 
 
method: FISH (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and cytogenetic response 
Magnusson 
2002170,176 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 6 months 
 
primary outcome: N/A 
adult with CMML 
(PDGFRβ positive) 
imatinib 400 mg daily; 
route NR 
samples: blood (details NR) 
 
method: RT-PCR (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
NR 
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Study Design Population Interventions  Biomarker measurement Results  
Pardanani 
2002170,177 
 
EMA status: 
supportive 
 
Phase NR 
 
N=2* 
 
Status: completed 
Biomarker evaluation: none 
 
design: single-arm (details 
NR) 
 
follow-up: first patient >12 
weeks; second patient 4 
weeks 
 
primary outcome: (1) 
symptomatic improvement; 
(2) decrease in the 
peripheral eosinophil count 
by at least 50% 
adults with 
chronic myeloid 
disease 
imatinib started at 100-
400 mg daily orally (at 
discretion of treating 
investigator); if no 
response at lower dose 
- patients treated with 
400 mg daily 
 
samples: peripheral blood or bone 
marrow mononuclear cells as well as 
purified eosinophil cell fractions 
 
method: Genomic DNA isolated from 
samples was used in the mutational 
analysis. Direct sequencing using an ABI 
377 Prism DNA sequencer (Applied 
Biosystems). 
 
threshold: N/A 
 
N BM+ BM- 
2 0 2 
 
 
patient 1: complete 
haematologic and major 
cytogenetic response; 
patient 2: no 
haematologic or 
cytogenetic response 
Pitini 2007170,178 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 12 months 
 
primary outcome: N/A 
adult with CMML 
(PDGFRβ positive) 
imatinib 400 mg daily 
(route NR) 
samples: bone marrow (details NR) 
 
method: southern blot analysis of DNA 
using a genomic PDGFBR probe (gene 
rearrangement) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and cytogenetic response 
Safley 2004170,179 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 7 months 
 
primary outcome: N/A 
adult with aCML 
(PDGFRα 
rearrangement) 
imatinib 100 mg daily 
(route NR) 
samples: bone marrow (details NR) 
 
method: nested RT-PCR (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and data not available for 
cytogenetic response 
                                                                
* Study also included 5 patients with HES 
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Study Design Population Interventions  Biomarker measurement Results  
Trempat 2003170,180 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: approximately 
12 weeks 
 
primary outcome: N/A 
adult with aCML 
(PDGFRα 
rearrangement) 
imatinib 400 mg daily 
(route NR) 
samples: NR 
 
method: FISH (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and partial cytogenetic 
response 
Vizmanos 
2004170,181 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: approximately 
18 months 
 
primary outcome: N/A 
adult with MPD 
(PDGFRβ positive) 
imatinib 400 mg 
stopped due to 
intolerance and 
started again at 200 
mg daily raised to 400 
mg daily; route NR 
samples: NR 
 
method: Southern Analysis of PDGFRB: 
"DNA digested with HindIII, BamHI, EcoRI, 
and BglII, blotted using standard 
conditions and hybridized with an 813-bp 
alphaP-dCTP-labeled PDGFRB intron 10 
probe obtained by amplification by PCR 
with primers PD3-C and PD3-D from 
normal human genomic DNA." 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and cytogenetic response 
Wilkinson 
2003170,182 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: 7 months 
 
primary outcome: N/A 
2 year old with 
MPD (PDGFRβ 
positive) 
imatinib (details NR) samples: NR 
 
method: single step RT-PCR for detection 
of PDE4DIP-PDGFRB and reciprocal 
PBGFRB-PDE4DIP fusions 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and major cytogenetic 
response 
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Study Design Population Interventions  Biomarker measurement Results  
Wittman 2004170,183 
 
EMA status: 
supportive 
 
Phase N/A 
 
N=1 
 
Status: completed 
Biomarker evaluation: none 
 
design: case report 
 
follow-up: approximately 
11 months 
 
primary outcome: N/A 
2 year old with 
aCML (PDGFRβ 
positive) 
imatinib 200 mg daily; 
route NR  
samples: bone marrow (details NR) 
 
method: RT-PCR (details NR) 
 
threshold: N/A 
 
N BM+ BM- 
1 1 0 
 
 
complete haematologic 
and cytogenetic response 
Philadelphia chromosome – ALL – dasatinib 
Study Design Population Interventions  Biomarker measurement Results  
START-L184-187 
 
EMA status: main 
 
Phase II 
 
N=36* 
 
Status: completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; details NR 
 
follow-up: NR 
 
primary outcome: Co-primary 
endpoints: major haematologic 
response (MaHR) rate and 
overall haematologic response 
(OHR) (“determined from 
hematologic laboratory values, 
bone marrow cytology and 
cytogenetics, and 
extramedullary disease”) 
≥18 years; (1) Ph+ (or 
BCR-ABL+) lymphoid 
blast phase CML w/ 
primary or acquired 
resistance to imatinib 
or intolerant to 
imatinib or (2) Ph+ ALL 
previously treated 
with standard 
induction or 
consolidation 
chemotherapy and 
had progressed or not 
responded to imatinib 
at a dose of ≥ 600 
mg/day (or 400 mg if 
intolerant to 600 mg) 
dasatinib at oral dose of 70 
mg twice a day; d ose 
modifications allowed for 
management of disease 
progression or toxicity 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
36 36 0 
 
 
MaHR rate 42% (15/36) in 
the total population; 38% 
(13/34) in the imatinib-
resistant, and 100% (2/2) in 
imatinib-intolerant; OHR 
rate was 47% (17/36) in the 
total population, and 44% 
(15/34) and 100% (2/2) in 
the imatinib-resistant and 
imatinib-intolerant  
                                                                
* Also included CML patients (NR here) 
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Study Design Population Interventions  Biomarker measurement Results  
CA180002184,188,189 
 
EMA status: 
supportive 
 
Phase I 
 
N=11* 
 
Status: completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; dose-
escalation: 3 patients "enrolled 
per cohort and followed for 4 
weeks on study drug. If one DLT 
[dose limiting toxicity] was 
observed, that dose cohort was 
expanded to 6 subjects. Dose 
escalation continued as long as 
there was < 1/3 of subjects in a 
cohort with a DLT" 
 
follow-up: "minimum of 30 days 
after the last dose of study 
therapy or until recovery from all 
toxic effects, whichever was 
longer" 
 
primary outcome: NR 
≥14 years; 
Philadelphia 
chromosome - 
positive ALL; 
hematologic 
resistance or 
intolerance to 
imatinib 
dasatinib doses ranged 
from 15 mg/day to 240 
mg/day until progression of 
disease or development of 
intolerable toxicity 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
11 11 0 
 
 
Major hematologic 
response (n=NR) 50%, 
Major cytogenetic 
response (n=NR) 80% 
                                                                
* Also included CML patients (NR here) 
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Philadelphia chromosome – ALL – imatinib 
Study Design Population Interventions  Biomarker measurement Results  
0109190,191 
 
EMA status: 
unclear 
 
Phase II 
 
N=56* 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; preliminary 
investigation 
 
follow-up: NR 
 
primary outcome: sustained 
hematologic response lasting at 
least 4 weeks: (1) complete 
hematologic response; (2) 
complete marrow response; or 
(3) partial response (fewer than 
15% blasts in peripheral blood 
and bone marrow) 
≥18 years; 
morphologicall
y confirmed 
diagnosis of 
relapsed or 
refractory Ph+ 
ALL  
imatinib 400 or 600 mg daily 
for 24 weeks and then 
continued indefinitely if the 
investigator judged further 
treatment to be of benefit; 
no concomitant anticancer 
drugs were to be 
administered 
samples:  
 
method:  
 
threshold: N/A 
 
N BM+ BM- 
56 56 0 
 
 
initial dose of 400 mg daily - 
no haematological responses  
initial dose of 600 mg daily - 
sustained haematological 
responses in 12 (26%) patients. 
Four (33%) of them achieved 
sustained complete 
hematologic response 
0114190,192 
 
EMA status: 
unclear 
 
Phase NR 
 
N=353† 
 
Status: unclear 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; providing 
expanded access to imatinib 
until it is commercially available; 
unclear from which studies 
patients came 
 
follow-up: NR 
 
primary outcome: NR 
adult patients 
with relapsed/ 
refractory Ph+ 
ALL 
imatinib orally 600 mg daily 
(permitted escalation up to 
max 400 mg twice a day) 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
353 353 0 
 
 
proportions of patients without 
progression at 12 months was 
estimated 12.4% (95% CI: 6, 
19); median TTP 3.2 months 
(95% CI: 3, 4) 
                                                                
* Included CML patients as well – only ALL reported here 
† Included CML patients as well – only ALL reported here 
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Study Design Population Interventions  Biomarker measurement Results  
03001190,193 
 
EMA status: 
unclear 
 
Phase I 
 
N=20* 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm pilot dose-
escalation study 
 
follow-up: 101 to 349 days 
 
primary outcome: NR 
Philadelphis 
chromosome–
positive ALL 
who did not 
respond to 
standard 
induction or 
consolidation 
chemotherapy 
or relapsed 
after therapy 
Imatinib successive dose 
cohorts ranging from 300 to 
1000 mg: orally once daily, 
except for 800 and 1000-mg - 
administered twice daily in 
400 and 500-mg doses; 
hydroxyurea was permitted 
(max 7 days) 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
20 20 0 
 
 
complete haematological 
response 4 (20%), marrow 
response 10 (50%) 
AAU02190 
 
EMA status: 
unclear 
 
Phase II 
 
N=19† 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: NR 
 
primary outcome: NR 
Philadelphis 
chromosome–
positive ALL 
(relapsed and 
de-novo) 
A) relapsed: imatinib 600 mg 
+ idarubicin (12 mg/m2 iv) + 
cytarabine (200 mg/m2 iv) + 
vincristine (2 mg iv) + oral 
prednisone (40 mg/m2)  
B) de-novo: "Protocol LALA 
94" including imatinib 600 mg 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 7 7 0 
B 12 12 0 
 
"Among 22 evaluable 
patients, combined imatinib 
and chemotherapy induction 
resulted in 14 (64%) complete 
haematological responses 
and all but 1 patient 
achieved a major 
cytogenetic response. There 
were 7 (88%) complete 
haematological responses 
(CHR) among 9 evaluable 
patients with CML-LBC and 
relapsed Ph+ALL and 7 (58%) 
CHR among 12 de-novo Ph+ 
ALL. Major cytogenetic 
responses were seen in all 
newly diagnosed Ph+ ALL 
patients enrolled in the study. 
(…) The one-year overall 
survival rate was 61.1 ± 13.5 
%." 
                                                                
* Included CML patients as well – only ALL reported here 
† Included CML patients as well – only ALL reported here 
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Study Design Population Interventions  Biomarker measurement Results  
ADE04190,194 
 
EMA status: 
unclear 
 
Phase III 
 
N=88* 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; two cohorts 
(concurrent and alternating 
schedule) 
 
follow-up: NR 
 
primary outcome: NR 
Ph+ALL with 
minimal 
residual 
disease after 
induction 
therapy or 
stem cell 
transplant 
A) imatinib 400-600 mg daily 
alternated with 
chemotherapy 
(cyclophosphamide 1000 
mg/m2 iv, Ara-C 75mg/m2 iv, 
oral 6-mercaptopurine 60 
mg/m2, methotrexate 15 mg 
i.th) 
B) imatinib 400-600 mg daily 
concurrent to chemotherapy 
(cyclophosphamide 1000 
mg/m2 iv, Ara-C 75mg/m2 iv, 
oral 6-mercaptopurine 60 
mg/m2, methotrexate 15 mg 
i.th) 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 43 43 0 
B 45 45 0 
 
 
"Co-administration of imatinib 
with induction phase II 
resulted in a complete 
remission in 43 (95%) out of 45 
patients and was superior to 
the alternating administration 
of chemotherapy and 
imatinib in terms of inducing 
PCR negativity for bcr-abl 
transcripts (52% versus 19%, 
p=0.01)." 
ADE10190,195 
 
EMA status: 
unclear 
 
Phase II 
 
N=55† 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; details 
NR 
 
follow-up: NR 
 
primary outcome: rate of 
hematologic remission after 
induction therapy 
newly 
diagnosed 
Philadelphia 
chromosome-
positive/BCR-
ABL+ acute 
lymphoblastic 
leukemia 
(ALL); age ≥55 
years 
A) 5-day prerandomisation 
chemotherapy with 
dexamethasone and 
cyclophosphamide -> 28 
days of single-agent oral 
imatinib at a daily dose of 
600 mg 
B) 5-day prerandomisation 
chemotherapy with 
dexamethasone and 
cyclophosphamide -> 
standard induction 
chemotherapy 
 
samples:  
 
method:  
 
threshold: N/A 
 
group N BM+ BM- 
A 28 28 0 
B 27 27 0 
 
 
"Response to induction was 
significantly superior in the 
front-line imatinib arm, as 
compared with 
chemotherapy induction 
(p=0.003): - Twenty-six of the 
27 evaluable patients 
achieved a CR (96.3%) and 
one patient a PR (3.7%). One 
patient was not evaluated at 
this time point but, like the PR 
patient, achieved a CR after 
consolidation cycle C1; - 
Thirteen (50%) of the 26 
evaluable patients enrolled in 
the induction chemotherapy 
group achieved CR, two 
patients achieved a PR (7.7%). 
Nine patients (34.6%) were 
refractory and 2 patients died 
during chemotherapy 
induction; no patient failed 
imatinib induction" 
                                                                
* Included CML patients as well – only ALL reported here 
† Included CML patients as well – only ALL reported here 
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AFR09190,196 
 
EMA status: 
unclear 
 
Phase II 
 
N=51 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: controlled non-
randomised; open-label; using 
historical controls 
 
follow-up: NR 
 
primary outcome: overall 
survival (details NR) 
age ≥55 years; 
previously 
untreated 
Philadelphia 
chromosome+ 
ALL 
A) prephase with steroids -> 
induction chemotherapy 
without imatinib -> 
Irrespective of response 
consolidation/salvage 
imatinib 600 mg daily and 
steroids 
B) chemotherapy: no steroid 
prephase -> similar induction 
+ random allocation to 
vindesine vs vincristine -> 
consolidation/ salvage w/ 
mitoxantrone and 
cytarabine -> interferon 
alpha for 3 months -> late 
consolidation with vincristine, 
doxorubicin and 
dexamethasone 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 30 30 0 
B 21 21 0 
 
 
"The projected overall survival 
is 68% at 1 year vs. 43% in the 
control group (p=0.001, log-
rank test)" 
AIT04190 
 
EMA status: 
unclear 
 
Phase II 
 
N=19 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm; pilot study 
(details NR) 
 
follow-up: NR 
 
primary outcome: NR 
age >60 years; 
Philadelphia 
chromosome+ 
ALL patients 
imatinib 800 mg in 
combination w/ steroids 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
19 19 0 
 
 
"All 18 evaluable patients 
achieved haematological CR 
and 3/18 (17%) had a 
complete molecular response 
but with detectable though 
small numbers of p190 
BCR/ABL copies by 
quantitative RT-PCR" 
 488 
 
Study Design Population Interventions  Biomarker measurement Results  
AJP01190,197 
 
EMA status: 
unclear 
 
Phase II 
 
N=80 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: median 26.7 months 
 
primary outcome: complete 
remission rate (details NR) 
newly 
diagnosed 
Philadelphia 
chromosome + 
ALL, age ≥15 
and ≤64 years, 
ECOG PS 
between 0 
and 3; 
adequate 
liver, kidney 
and heart 
function 
imatinib 600mg from day 8 to 
63 w/ daunorubicin, 
cyclophosphamide, 
vincristine and prednisolone; 
consolidation  
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
80 80 0 
 
 
complete remission in 77 
(96.2%) patients, resistant 
disease in one, early death in 
two; relapse in 20 patients 
(26%) after median remission 
of 5.2 months 
AUS01190 
 
EMA status: 
unclear 
 
Phase II 
 
N=32 
 
Status: 
completed 
Biomarker evaluation: : non-
randomised only positive 
 
design: single-arm (details NR) 
 
follow-up: median 2 years 
(range 4–36 months) 
 
primary outcome: NR 
Philadelphia 
chromosome + 
ALL (details 
NR) 
8 induction-consolidation 
courses alternating hyper-
CVAD (cyclophosphamide 
300mg/m2 on days 1-3; 
vincristine 2mg day 4 and 11; 
doxorubicine 50 mg/m2 day 
4 and dexamethasone 40 
mg daily on days 1-4 and 11-
14) with high dose 
methotrexate and ara-C, 
concurrently with 400 mg 
imatinib daily on days 1 to 
14; higher doses of imatinib 
during consolidation phase 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
32 32 0 
 
 
Complete molecular 
remission: 3 of 27 newly 
diagnosed patients after 
hyper-CVAD and imatinib 
alone; 
Complete molecular remission 
in 2 of 5 refractory Ph+ ALL 
patients after hyper-CVAD 
and imatinib alone 
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t(15;17) translocation and/or PML/RAR-α gene – APL - arsenic trioxide 
Study Design Population Interventions  Biomarker measurement Results  
97-66198,199 
 
EMA status: 
main 
 
Phase I/II 
 
N=12 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details 
NR) 
 
follow-up: NR 
 
primary outcome: NR 
APL relapse from or 
resistance to 
standard 
antileukaemic 
therapy (including 
all-trans-retinoic 
acid) (included 2 
children) 
arsenic trioxide 10 mg 
escalated to 15 mg as 
iv infusion over 2-4 
hours once a day; 
later changed to 0.15 
mg/kg/day until no 
visible blasts and 
promyelocytes in bone 
marrow 
samples: NR 
 
method: t(15;17) by FISH and PML-
RAR-alpha by reverse-transcription 
PCR 
 
threshold: N/A 
 
N BM+ BM- 
12 12 0 
 
 
11 of the 12 patients had 
complete clinical remission after 
treatment; median duration of 
remission was >5 months; 1 year 
OS was 75% and 18 month OS 
was 67%; relapse free survival at 1 
year: 55% and 18 months 36% 
PLRXAS01198,200 
 
EMA status: 
main 
 
Phase II 
 
N=40 
 
Status: 
completed 
Biomarker evaluation: non-
randomised only positive 
 
design: single-arm (details 
NR) 
 
follow-up: median 17.1 
months 
 
primary outcome: NR 
relapsed and/or 
refractory APL 
(previous treatment 
including all-trans 
retinoic acid); adults 
and children 
arsenic trioxide 0.15 
mg/kg daily until bone 
marrow remission or 
substantial toxicity 
observed; up to 
maximum of 60 doses 
 
samples: blood or bone marrow 
mononuclear cells (details NR) 
 
method: "by conventional 
cytogenetics showing t(15;17), by 
positive RT-PCR assay for PML/RAR-
alpha, or by fluorescence in situ 
hybridization (FISH) analysis that 
showed evidence of RAR-alpha or 
PML translocations"; all PCRs in a 
central laboratory 
 
threshold: N/A 
 
N BM+ BM- 
40 40 0 
 
 
34 of 40 patients achieved a 
complete clinical response; 
overall survival at 1 year 70%, at 
18 months 66%; relapse-free 
survival at 1 year 71%, 18 months 
58% 
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Viral resistance – HIV infection - amprenavir 
Study Design Population Interventions  Biomarker measurement Results  
PROAB3004201,202 
 
EMA status: 
main 
 
Phase III 
 
N=229 
 
Status: 
completed 
Biomarker evaluation: NR 
 
design: single-arm; initially 
designed as randomised 
controlled double-blind, but later 
ammended to single-arm 
 
follow-up: 48 weeks 
 
primary outcome: proportion of 
patients with plasma viral load 
below the threshold (10,000 and 
400 copies/mL of HIV-1 RNA) 
aged 4-18 years; 
HIV-1 infection 
and a viral load of 
≥400 copies/mL; 
requiring protease 
inhibitor-
containing 
therapy 
amprenavir ≥13 years of 
age, with a weight of 
≥50 kg 1200 mg twice 
daily, otherwise 20 
mg/kg twice daily oral 
capsules (or solution if 
unable to swallow) 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
N BM+ BM- 
229 NR NR 
 
 
NR for biomarker 
PROAB3006201,203 
 
EMA status: 
main 
 
Phase III 
 
N=504 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(cross-sectional) 
 
design: RCT; open-label; non-
inferiority (details NR) 
 
follow-up: 48 weeks 
 
primary outcome: success rate - 
number of patietns with HIV-1 
RNA plasma levels below the 
limit of setection (400 copies/ml) 
protease inhibitor -
naïve, nucleoside 
reverse 
transcriptase 
inhibitor 
experienced 
patients 
A) amprenavir 1200 mg 
twice daily + 
background nucleoside 
reverse transcriptase 
inhibitor 
B) indinavir 800 mg 
three times daily + 
background nucleoside 
reverse transcriptase 
inhibitor 
 
samples: blood plasma (details NR) 
 
method: amplified by RT-PCR; 
sequencing with Applied Biosystems 
377 sequencer 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 254 25 23 206 
B 250 0 0 250 
 
 
in amprenavir failures: 
19% had I50V mutation, 
21% I54L/M, 6%I84V, 15% 
V32I + I47V 
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Viral resistance – HIV infection - atazanavir 
Study Design Population Interventions  Biomarker measurement Results  
AI424009204 
 
EMA status: 
main 
 
Phase NR 
 
N=85 
 
Status: 
completed 
Biomarker evaluation: 
NR 
 
design: RCT; details NR 
 
follow-up: NR 
 
primary outcome: NR 
antiretroviral 
experienced 
adult 
patients, HIV-
1 infected, 
no history of 
AIDS-
defining 
diagnoses 
within 4 
weeks prior 
to 
randomisatio
n 
A) atazanavir 400 mg/day + 
saquinavir 1200 mg/ day + 2NRTIs 
(based on phenotypic 
susceptibility or if phenotypic 
results unavailable two 
previously untried) 
B) atazanavir 600 mg/day + 
saquinavir 1200 mg/ day + 2NRTIs 
(based on phenotypic 
susceptibility or if phenotypic 
results unavailable two 
previously untried) 
C) ritonavir 400 mg + saquinavir 
400 mg + 2NRTIs (based on 
phenotypic susceptibility or if 
phenotypic results unavailable 
two previously untried) 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 34 NR NR 
B 28 NR NR 
C 28 NR NR 
 
 
"No reliable interpretation of this 
study could be made since a high 
rate of premature discontinuation 
was observed" 
AI424043204 
 
EMA status: 
main 
 
Phase NR 
 
N=290 
 
Status: 
completed 
Biomarker evaluation: 
NR 
 
design: RCT; open-
label; non-inferiority 
(details NR) 
 
follow-up: 24 weeks 
 
primary outcome: time-
Averaged-Difference 
estimate for the 
change from baseline 
in HIV RNA level 
through week 24 
HIV-infected 
patients who 
had failed 
prior 
antiretroviral 
treatment(s) 
including 
one PI 
A) atazanavir + 2 nucleoside 
analogs 
B) lopinavir + ritonavir + 2 
nucleoside analogs 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 144 NR NR 
B 146 NR NR 
 
 
NR for biomarker 
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AI424045204,205 
 
EMA status: 
main 
 
Phase NR 
 
N=358 
 
Status: 
completed 
Biomarker evaluation: 
subgroup 
(retrospective) 
 
design: RCT; open-
label; non-inferiority 
(details NR) 
 
follow-up: 48 weeks 
 
primary outcome: Time-
Averaged-Difference 
(TAD) estimate for the 
change from baseline 
in HIV RNA level 
through 48 weeks 
antiretroviral 
experienced 
patients >16 
years, who 
had 
virological 
failure on 
two or more 
HAART 
regimens 
that 
included at 
least one 
drug from 
each class: 
PI, NNRTI, 
NRTI 
A) atazanavir (300 mg/ day) 
boosted with low dose of 
ritonavir 
B) atazanavir (400 mg/ day) in 
combination with saquinavir 
C) lopinavir/ritonavir 
 
samples:  
 
method:  
 
threshold: N/A 
 
group N BM+ BM- 
A 120 NR NR 
B 115 NR NR 
C 123 NR NR 
 
 
<4 protease gene mutations 10, 46, 
54, 82, 84, and 90: TAD HIV RNA Level 
Change From Baseline (log10 c/ml) 
at week 48: ATV300/RTV (n=84) - 
LPV/RTV (n=88): 0.06 (95% CI: -0.17, 
0.28); ATV400/SQV (n=72) - LPV/RTV 
(n=88): 0.33 (95% CI: 0.08, 0.57) 
≥4 protease gene mutations 10, 46, 
54, 82, 84, and 90: TAD HIV RNA Level 
Change From Baseline (log10 c/ml) 
at week 48: ATV300/RTV (n=6) - 
LPV/RTV (n=7): 0.71 (95% CI: 0.13, 
1.30); ATV400/SQV (n=11) - LPV/RTV 
(n=7): 0.59 (95% CI: -0.10, 1.28) 
virologic failure - known genotype 
(n=35) - emergent mutations in >20%: 
M36, M46, I54, A71, V82  
virologic failure -unknown genotype 
(n=35) - emergent mutations in 10-
20%: L10, I15, K20, V32, E35, S37, F53, 
I62, G73, I84, L90  
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Viral resistance – HIV infection - darunavir 
Study Design Population Interventions  Biomarker measurement Results  
POWER 1, 2, 
3206 
 
EMA status: 
unclear 
 
Phase NR 
 
N=1097 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: analysis of pooled 
data from POWER 1, 2 
(randomised) and 3 (pooled 
data from two non-
randomised studies) 
 
follow-up: 24 weeks 
 
primary outcome: ≥1 log10 
decrease in viral load, viral 
load > 50 copies per ml; 
change in log10 viral load at 
week 10 
adults; 
treatment 
experienc
ed; in 
combinati
on with 
ritonavir 
A) darunavir/ 
ritonavir at doses 
of 400/100 mg 
per day, 800/100 
mg per day, 
400/100 mg twice 
daily or 600/100 
mg twice daily 
B) investigator-
selected PI-
based regimen 
 
samples: NR 
 
method: Antivirogram 
(phenotypic) and 
VirtualPhenotype (genotypic) 
 
threshold: N/A 
 
group N BM+ BM- 
A 964 NR NR 
B 133 NR NR 
 
 
V11I mutation change in log10 viral load at week 
24 ((n) mean(SE)): darunavir (n=40) -1.18 (0.21); 
control (n=11) -0.77 (0.34) 
V32I mutation change in log10 viral load at week 
24 ((n) mean(SE)): darunavir (n=36) -0.82 (0.22); 
control (n=23) -0.39 (0.18) 
I47V mutation change in log10 viral load at week 
24 ((n) mean(SE)): darunavir (n=51) -1.00 (0.18); 
control (n=20) -0.30 (0.15) 
I54L mutation change in log10 viral load at week 
24 ((n) mean(SE)): darunavir (n=27) -1.19 (0.26); 
control (n=16) -0.75 (0.32);  
I54M mutation change in log10 viral load at week 
24 ((n) mean(SE)): darunavir (n=31) -0.66 (0.21); 
control (n=14) -0.24 (0.20) 
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Viral resistance – HIV infection - efavirenz / emtricitabine / tenofovir disoproxil 
Study Design Population Interventions  Biomarker measurement Results  
Gallant 
2006207-209 
 
EMA status: 
main 
 
Phase III 
 
N=517 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: RCT; open-label; non-
inferiority study; randomised 
1:1 
 
follow-up: 144 weeks 
(extended from 48 weeks) 
 
primary outcome: HIV RNA 
levels of < 400 copies per 
milliliter through week 48; 
defined according to an FDA 
algorithm 
adult patietns who 
have not received 
prior antiretroviral 
treatment 
A) once daily: 
efavirenz (600 mg) (or 
nevirapine 200 mg 
twice daily if CNS 
toxicity) + tenofovir DF 
(300 mg) + 
emtricitabine (200 
mg) as separate 
components 
B) twice daily: 
efavirenz (600 mg) (or 
nevirapine 200 mg 
twice daily if CNS 
toxicity) + fixed dose 
zidovudine (300 mg) + 
lamivudine (150 mg) 
 
samples: blood (details NR) 
 
method: at baseline sequencing with 
GeneSeq Assay; post-baseline: 
PhenoSense GT Assay 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 258 19 0 236 
B 259 29 0 228 
 
 
resistant patients developed 
mutations: efavirenz + 
emtricitabine + tenofovir 
disoproxil fumarate (analysed 
n=19):  K103N (n=8), K101E (n=3), 
G190A/S (n=2), Y188C/H (n=1), 
V108I (n=1), P225H (n=0), M184V/I 
(n=2), K65R (n=0), thymidine 
analogue associated mutations 
(n=0); Efavirenz + 
lamivudine/zidovudine (analysed 
n=29): K103N (n=18), K101E (n=3), 
G190A/S (n=4), Y188C/H (n=2), 
V108I (n=1), P225H (n=2), M184V/I 
(n=10), K65R (n=0), thymidine 
analogue associated mutations 
(n=2) 
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Viral resistance – HIV infection - emtricitabine 
Study Design Population Interventions  Biomarker measurement Results  
Benson 
2004210,211 
 
EMA status: 
main 
 
Phase III 
 
N=440 
 
Status: 
completed 
Biomarker evaluation:  
 
design: RCT; open-label; 
equivalence trial; randomised 2:1; 
stratified by PI and NNRTI 
componenet and plasma HIV-1 RNA 
level at entry 
 
follow-up: 48 weeks 
 
primary outcome: plasma HIV-1 RNA 
level at week 48 (virologic failure) 
using Roch AMPLICOR HIV-1 
MONITOR test with a limit of 
detection 400 copies/ml and 
UltraSensitive assay (limit of 
detection 50 copies/ml) (Roche, 
USA) 
(virologic failure - HIV-1 RNA > 400 
copies/ml) 
adults on a 
stable 
treatment 
containing 
lamivudine, 
an NRTI and a 
PI or NNRTI 
A) substitution of 
lamivudine 
150mg twice a 
day with 
emtricitabine 
200mg every day 
as part of stable 
triple 
combination ART 
for 48 weeks 
B) continuation of 
lamivudine 
150mg twice a 
day as part of 
stable triple 
combination ART 
for 48 weeks 
 
samples: plasma HIV-1 RNA 
 
method: nested PCR + dideoxy 
sequencing using ABI 377 
sequencing system (Applied 
Biosystems Inc., USA) using labelled 
dye terminators following standard 
techniques; if insufficient baseline 
plasma HIV-1 RNA a modified 
amplification procedure was 
performed (details NR) 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 294 16 2 276 
B 146 3 1 142 
 
 
"complete or at least partial 
(around M184) sequence analysis 
of baseline isolates was obtained 
for 23/34 virological failures (19/23 
in the emtricitabine arm and 4/11 
in the lamivudine arm). In the 
emtricitabine subset, the M184V/I 
mutation was present in 17/19 
(89.5%) isolates at baseline. In the 
lamivudine subset, the M184V 
mutation was present in 3/4 (75%) 
isolates at baseline. Genotypic 
data were available for 33/34 
patients at the time of virological 
failure. Two emtricitabine and the 
onelamivudine patients with wild 
type virus at M184 at baseline had 
developed the M184V mutation." 
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Viral resistance – HIV infection - enfuvirtide 
Study Design Population Interventions  Biomarker measurement Results  
TORO 1212,213 
 
EMA status: 
main 
 
Phase III 
 
N=501 
 
Status: 
completed 
Biomarker evaluation: subgroup (cross-
sectional) 
 
design: RCT; open-label; randomised 2:1 
using an adaptive randomisation 
scheme, stratified by plasma HIV-RNA 
level and use of newly approved or 
investigational drugs in the optimised 
background regimen 
 
follow-up: 48 weeks 
 
primary outcome: change from baseline 
to week 24 in plasma HIV-1 RNA level 
measured on logarythmic scale with 
Amplicor HIV-1 Monitor, version 1.5, Roche 
prior 
treatment 
with (but no 
mention of 
failure) 
and/or 
documented 
resistance to 
all 3 classess 
of drugs 
A) enfuvirtide 90 mg twice daily 
by subcutaneous injection to the 
abdomen, upper arm or anterior 
aspect of thigh (first by study 
personel, then patient) + 
optimised background therapy 
B) optimised background 3-5 
antiretroviral drugs selected prior 
to randomisation; changes 
allowed in case of protocol-
defined failure or toxicity 
samples: NR 
 
method: genotypic resistance 
testing by ViroLogic, San Francisco 
 
threshold: N/A 
 
group N BM+ BM- 
A 332 NR NR 
B 169 NR NR 
 
 
enfuvirtide patients 
with virological 
failure in Toro 1 and 
Toro 2 after 24 
weeks of therapy: 
almost all (185/187, 
99 %) had 
substitutions in gp41 
aa 36-45; NR for 
optimised 
background 
therapy 
TORO 2212,214 
 
EMA status: 
main 
 
Phase III 
 
N=512 
 
Status: 
completed 
Biomarker evaluation: subgroup (cross-
sectional) 
 
design: RCT; open-label;  
 
follow-up: 48 weeks 
 
primary outcome: change from baseline 
to week 24 in plasma HIV-1 RNA level 
measured on logarythmic scale with 
Amplicor HIV-1 Monitor, version 1.5, Roche 
prior 
treatment 
with (but no 
mention of 
failure) 
and/or 
documented 
resistance to 
all 3 classess 
of drugs 
A) enfuvirtide 90 mg twice daily 
by subcutaneous injection to the 
abdomen, upper arm or anterior 
aspect of thigh (first by study 
personel, then patient) + 
optimised background therapy 
B) optimised background 3-5 
antiretroviral drugs selected prior 
to randomisation; changes 
allowed in case of protocol-
defined failure or toxicity 
samples: NR 
 
method: genotypic resistance 
testing by ViroLogic, San Francisco 
 
threshold: N/A 
 
group N BM+ BM- 
A 341 NR NR 
B 171 NR NR 
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Viral resistance – HIV infection - emtricitabine / rilpivirine / tenofovir disoproxil 
Study Design Population Interventions  Biomarker measurement Results  
ECHO215,216 
 
EMA 
status: 
main 
 
Phase III 
 
N=694 
 
Status: 
complete
d 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; non-
inferiority; randomised 1:1; stratified by 
screening viral load 
 
follow-up: 100 weeks 
 
primary outcome: percentage of 
patients with confirmed response at 
week 48 
HIV-1 
infected 
adults not 
previously 
treated with 
antiretroviral 
drugs 
A) once daily:* 25 mg 
rilpivirine + 300 mg tenofovir 
disoproxil fumate + 200 mg 
emtricatabine for 96 weeks 
B) once daily: 600 mg 
efavirenz + 300 mg tenofovir 
disoproxil fumate + 200 mg 
emtricatabine for 96 weeks 
samples: NR 
 
method: viral genotyping by Virco 
BVBA (Mechelen, Belgium) with Virco 
TYPE HIV-1 assay 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 346 29† 11 342 
B 344 8 5 331 
 
 
< 50 copies/mL: 
rilpivirine 82.9%, control 
82.8%; non-inferiority at 
the 12% margin was 
met 
THRIVE215,21
7 
 
EMA 
status: 
main 
 
Phase III 
 
N=680 
 
Status: 
complete
d 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; non-
inferiority; randomised 1:1; stratified by 
viral load and background therapy 
 
follow-up: 100 weeks 
 
primary outcome: percentage of 
patients who received at least one 
dose of study drug with virological 
response at 48 weeks 
antiretroviral 
naïve HIV-1 
infected 
adults 
A) once daily:‡ rilpivirine 25 
mg + investigator selected 
background (tenofovir DF + 
emtricitabine or zidovudine + 
lamivudine or abacavir + 
lamivudine) for 96 weeks 
B) once daily: efavirenz 600 
mg  + investigator selected 
background (tenofovir DF + 
emtricitabine or zidovudine + 
lamivudine or abacavir + 
lamivudine) for 96 weeks 
samples: NR 
 
method: by Virco (Mechelen, 
Belgium) using VircoTYPE HIV-1 assay 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 340 15§ 7 318 
B 340 8 7 325 
 
 
< 50 copies/mL: 
rilpivirine 85.6% , control 
81.7%; the primary 
endpoint of non-
inferiority at the 12% 
margin was met 
                                                                
* patients had to take drugs twice daily due to double-dummy design 
† resistance mutations were assessed in 40 of 45 patients with virological failure in rilpivirine group and 13 out of 19 patietns in efavirenz group; exact numbers positive for 
mutations unclear 
‡ patients had to take drugs twice daily due to double-dummy design 
§ resistance mutations were assessed in 22 of 27 patients with virological failure in rilpivirine group and 15 out of 20 patietns in efavirenz group; exact numbers positive for 
mutations unclear 
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Viral resistance – HIV infection - fosamprenavir calcium 
Study Design Population Interventions  Biomarker measurement Results  
APV 30003218 
 
EMA status: 
main 
 
Phase III 
 
N=315 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(retrospective) 
 
design: RCT; open-label; non-
inferiority 
 
follow-up: 48 weeks 
 
primary outcome: average area 
under the curve minus baseline 
(AAUCMB) in log10 plasma HIV-1 
antiretroviral 
experienced, 
failure on a prior 
PI 
A) fosamprenavir 
calcium 700mg twice 
a day + ritonavir 
100mg twice a day + 
two active RTIs 
B) fosamprenavir 
calcium 1400mg OD + 
ritonavir 200mg OD + 
two active RTIs 
C) lopinavir 
400mg/ritonavir 
100mg twice a day + 
two active RTIs 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 105 NR NR 
B 107 NR NR 
C 103 NR NR 
 
 
In virologic sub-study 58% (19/33) 
versus 25% (7/28) patients acquired 
resistance mutations in the 
fosamprenavir and lopinavir arm 
respectively; 
protease resistance-associated 
mutations: fosamprenavir 17/39 
(44%) vs lopinavir 19/33 (58%));  
majority of protease mutations in 
the fosamprenavir arm were 
mutations previously associated 
with amprenavir resistance (I50V 
n=3, I54L n=7, I54M n=3, I84V n=11, 
V32I n=3, I47V n=5) or associated 
accessory mutations (L10F n=9, L10I 
n=3, L33F n=8, M46I/L n=10, A71V/T 
n=3, V82I n=4) 
SOLO218,219 
 
EMA status: 
main 
 
Phase III 
 
N=660 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(cross-sectional) 
 
design: RCT; open-label; stratified 
according to plasma HIV-1 RNA 
level at screening; non-inferiority 
 
follow-up: 48 weeks 
 
primary outcome: proportion of 
patients with plasma HIV-1 RNA 
levels < 400 copies/ml at 48 weeks 
using the Roche Amplicor HIV-1 
Monitor test version 1.5 (Roche 
Diagnostics, Basel, Switzerland) 
antiretroviral-
naïve HIV-1 
infected 
patients 
A) fosamprenavir 
1400 mg OD with 
ritonavir 200 mg OD + 
abacavir 300 mg 
twice a day + 
lamivudine 
150 mg BID 
B) nelfinavir 1250 mg 
twice a day + 
abacavir 300 mg 
twice a day + 
lamivudine 150 mg 
twice a day 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 322 NR NR 
B 327 NR NR 
 
 
“No genotypic or phenotypic 
amprenavir resistance was 
detected in virus from 32 patients 
failing fosamprenavir boosted OD. 
A significantly higher proportion of 
nelfinavir treated patients acquired 
primary or secondary mutations 
(27/54 (50 %; p < 0.001). Treatment 
emergent NRTI resistance was 
significantly less frequent with 
fosamprenavir boosted (4/32; 13 %) 
compared to nelfinavir treated 
patients (31/54; 57 %) (p < 0.001)." 
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Study Design Population Interventions  Biomarker measurement Results  
NEAT218,220 
 
EMA status: 
supportive 
 
Phase III 
 
N=249 
 
Status: 
completed 
Biomarker evaluation: subgroup 
(cross-sectional) 
 
design: RCT; open-label; 
randomised 2:1; non-inferiority 
 
follow-up: 48 weeks 
 
primary outcome: proportion of 
patients with plasma HIV-1 RNA 
levels < 400 copies/ml at 48 weeks 
“measured using the Roche 
Amplicor HIV-1 Ultrasensitive 
Monitor test (version 1.5, 
ultrasensitive limit of quantification 
= 50 c/mL). Samples with vRNA 
>75,000 c/mL were retested using 
the Roche Amplicor HIV-1 Monitor 
test (version 1.5, standard assay, 
limit of quantification = 400 
copies/mL)." 
ARV-naive HIV-
infected at least 
13 years of age 
(or 18 years of 
age according 
to local 
requirements) 
with plasma HIV-
1 RNA (vRNA) of 
at least 5000 
c/mL 
A) fosamprenavir 
calcium 1400 mg 
twice a day 
B) nelfinavir 1250 mg  
twice a day 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 166 NR NR 
B 83 NR NR 
 
 
NR for biomarker 
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Viral resistance – HIV infection - lopinavir / ritonavir 
Study Design Population Interventions  Biomarker measurement Results  
M98-863221 
 
EMA status: 
main 
 
Phase III 
 
N=635 
 
Status: 
ongoing 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: RCT; double-blind; 
equivalence 
 
follow-up: 48 weeks (24 week 
results available) 
 
primary outcome: proportion 
of patients with plasma HIV 
RNA levels below the limit of 
quantification (< 400 
copies/ml) at week 24 and 
time until loss of virologic 
response through week 48 
Antiretroviral 
naïve patients 
(>12 years) 
with viral load 
above 400 
copies/ml 
A) lopinavir / ritonavir 400 
mg/100 mg twice a day 
with stavudine and 
lamivudine; after week 24 
patients received nelfinavir 
at 1250 mg twice a day or 
750 mg three times a day 
B) nelfinavir 750 mg three 
times a day in combination 
with stavudine and 
lamivudine; after week 24 
patients received nelfinavir 
at 1250 mg twice a day or 
750 mg three times a day 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 326 NR NR 
B 327 NR NR 
 
 
“The absence of detection of any 
mutation is noteworthy (0/31 (0%) 
versus 21/64 (33%) in lopinavir/ 
ritonavir and nelfinavir arms 
respectively" 
M97-720221 
 
EMA status: 
supportive 
 
Phase I/II 
 
N=100 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: RCT; patients blind to 
the dose; dose ranging 
 
follow-up: 204 weeks 
 
primary outcome: NR 
Antiretroviral 
naive HIV 
infected patients 
A) lopinavir/ritonavir 
200/100 twice a day or 
400/100 mg twice a day + 
at day 22 
stavudine/lamivudine 
B) lopinavir/ritonavir 
400/100 mg twice a day + 
stavudine/lamivudine or 
400/200 mg BID + 
stavudine/lamivudine 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 32 NR NR 
B 68 NR NR 
 
 
genotypic resistance testing 
available from 11 of the 16 subjects 
who lost of virologic response at or 
prior to week 204 (in 5 subjects the 
results unavailable due to a low 
number of viral copies); none 
exhibited genotypic resistance to 
lopinavir; confirmed by phenotypic 
resistance testing; 3 subjects - 
M184V mutation in reverse 
transcriptase 
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Viral resistance – HIV infection - nelfinavir 
Study Design Population Interventions  Biomarker measurement Results  
505222 
 
EMA 
status: 
main 
 
Phase III 
 
N=93 
 
Status: 
complete
d 
Biomarker evaluation: subgroup 
(retrospective) 
 
design: RCT; double-blind for 4 weeks, 
after which placebo patients 
switched to one of the active dose 
groups; details NR 
 
follow-up: NR 
 
primary outcome: NR 
NR A) nelfinavir 500 mg three 
times a day 
B) nelfinavir 750 mg three times 
a day 
C) placebo 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A NR NR NR 
B NR NR NR 
C NR NR NR 
 
 
"The on-therapy incidence 
of the D30N substitution was 
estimated from assay of 16-
week samples from 142 
randomly selected patients 
who had received 
monotherapy in study 505 or 
combination therapy in 
study 511. The substitution 
was detected in 18/32 
monotherapy patients, but 
in only 2/22 and 1/27 on 500 
and 750 mg t.i.d. regimens 
with zidovudine and 
lamivudine. Mutations 
associated with other 
protease inhibitor 
treatments were not seen in 
any of the 142 patients." 
511222,223 
 
EMA 
status: 
main 
 
Phase III 
 
N=297 
 
Status: 
complete
d 
Biomarker evaluation: subgroup 
(retrospective) 
 
design: RCT; double-blind; 
randomisation stratified based on CD4 
cell counts 
 
follow-up: 24 weeks (+ 6 month 
blinded extension) 
 
primary outcome: quantitative 
plasma HIV RNA levels and CD4 cell 
counts; HIV RNA levels measured by 
branched chain DNA assay (bDNA; 
Chiron Corporation, Emeryville, 
California, USA) with lower limit of 
quantification 500 copies/ml; CD4 cell 
counts NR 
antiretroviral-
naive HIV-
positive 
patients 
at least 13 
years old; 
plasma HIV 
RNA at least 
15 000 
copies/m 
A) nelfinavir 500 mg three 
times a day in combination 
with zidovudine 200 mg three 
times a day and lamivudine 
150 mg twice a day twice daily 
B) nelfinavir 750  mg three 
times a day in combination 
with zidovudine 200 mg three 
times a day and lamivudine 
150 mg twice a day twice daily 
C) placebo identical capsules 
to active treatment in 
combination with zidovudine 
200 mg three times a day and 
lamivudine 150 mg twice a 
day twice daily 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 97 NR NR 
B 99 NR NR 
C 101 NR NR 
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Viral resistance – HIV infection - rilpivirine 
Study Design Population Interventions  Biomarker measurement Results  
ECHO215,216 
 
EMA status: 
main 
 
Phase III 
 
N=694 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; non-
inferiority; randomised 1:1; stratified by 
screening viral load 
 
follow-up: 100 weeks 
 
primary outcome: percentage of 
patients with confirmed response at 
week 48 
HIV-1 infected 
adults not 
previously 
treated with 
antiretroviral 
drugs 
A) once daily:* 25 mg 
rilpivirine + 300 mg tenofovir 
disoproxil fumate + 200 mg 
emtricatabine for 96 weeks 
B) once daily: 600 mg 
efavirenz + 300 mg tenofovir 
disoproxil fumate + 200 mg 
emtricatabine for 96 weeks 
samples: NR 
 
method: viral genotyping by Virco BVBA 
(Mechelen, Belgium) with Virco TYPE 
HIV-1 assay 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 346 29† 11 342 
B 344 8 5 331 
 
 
<50 copies/mL: 
rilpivirine 82.9%, 
control 82.8%; non-
inferiority at the 
12% margin was 
met 
THRIVE215,217 
 
EMA status: 
main 
 
Phase III 
 
N=680 
 
Status: 
completed 
Biomarker evaluation: enrichment 
 
design: RCT; double-blind; non-
inferiority; randomised 1:1; stratified by 
viral load and background therapy 
 
follow-up: 100 weeks 
 
primary outcome: percentage of 
patients who received at least one 
dose of study drug with virological 
response at 48 weeks 
antiretroviral 
naïve HIV-1 
infected adults 
A) once daily:‡ rilpivirine 25 
mg + investigator selected 
background (tenofovir DF + 
emtricitabine or zidovudine + 
lamivudine or abacavir + 
lamivudine) for 96 weeks 
B) once daily: efavirenz 600 
mg  + investigator selected 
background (tenofovir DF + 
emtricitabine or zidovudine + 
lamivudine or abacavir + 
lamivudine) for 96 weeks 
samples: NR 
 
method: by Virco (Mechelen, Belgium) 
using VircoTYPE HIV-1 assay 
 
threshold: N/A 
 
group N BM+ BM- BM? 
A 340 15§ 7 318 
B 340 8 7 325 
 
 
<50 copies/mL: 
rilpivirine 85.6% , 
control 81.7%; the 
primary endpoint 
of non-inferiority at 
the 12% margin 
was met 
                                                                
* patients had to take drugs twice daily due to double-dummy design 
† resistance mutations were assessed in 40 of 45 patients with virological failure in rilpivirine group and 13 out of 19 patietns in efavirenz group; exact numbers positive for 
mutations unclear 
‡ patients had to take drugs twice daily due to double-dummy design 
§ resistance mutations were assessed in 22 of 27 patients with virological failure in rilpivirine group and 15 out of 20 patietns in efavirenz group; exact numbers positive for 
mutations unclear 
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Viral resistance – HIV infection - tenofovir disoproxil fumarate 
Study Design Population Interventions  Biomarker measurement Results 
902224,225 
 
EMA 
status: 
main 
 
Phase II 
 
N= 189 
 
Status: 
complete
d 
Biomarker evaluation: subgroup 
analysis (prospective) 
 
design: double blind RCT 
randomised 2:2:2:1; after 24 
weeks placebo patients were 
crossed-over to tenofovir 300 mg 
 
follow-up: 48 weeks 
 
primary outcome: co-primary: 
time weighted mean change in 
plasma HIV-1 RNA [log10 
copies/ml] from baseline to 
weeks 4 (DAVG4) and 24 
(DAVG24) using the Ultrasensitive 
HIV-1 Monitor Test (LLQ, 50 
copies/ml) (Roche)"226) 
patients on a 
stable 
antiretroviral 
regimen (no 
more than 4 
antiretroviral 
agents) for 8 
weeks prior to 
enrolment; 
Antiretroviral 
experienced 
patients (> 4 
years) HIV RNA ≥ 
400 and ≤ 
100,000 
copies/ml 
A) tenofovir disoproxil 
fumarate 75 mg a day + 
stable antiretroviral 
therapy 
B) tenofovir disoproxil 
fumarate 150 mg a day 
+ stable antiretroviral 
therapy 
C) tenofovir disoproxil 
fumarate 300 mg a day 
+ stable antiretroviral 
therapy 
D) placebo + stable 
antiretroviral therapy 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
Viral genotype was measured at 
baseline in all patients 
 
group N BM+ BM- 
A 54 NR NR 
B 51 NR NR 
C 56 NR NR 
D 28 NR NR 
 
 
"for patients receiving tenofovir DF in 
addition to their existing regimen, a 
comparable decline in HIV-RNA was 
observed by week 48 whatever the 
genotype measured at baseline (- 
0.62 log10 copies/ml DAVG48). In 
particular, a comparable virologic 
response was observed between 
patients resistant to or susceptible to 
zidovudine (-0.57 log10 copies/ml 
versus -0.61 log10 copies/ml, 
DAVG48, respectively)." 4 patients 
developed K65R mutation (resistance 
to tenofovir) 
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Study Design Population Interventions  Biomarker measurement Results 
903224,227 
 
EMA 
status: 
main 
 
Phase III 
 
N= 602* 
 
Status: 
complete
d 
Biomarker evaluation: subgroup 
analysis (cross-sectional) 
 
design: randomised 1:1, double-
blind, stratified by baseline HIV-1 
RNA and CD4 cell count; aiming 
to establish equivalence 
between study 
 
follow-up: 144 weeks 
 
primary outcome: proportion of 
patients with HIV RNA levels <400 
copies/mL at week 48 using 
Roche Amplicor HIV-1 Monitor 
viral load assay (version 1.0 and 
version 1.5 [depending on the 
study site], Indianapolis, Ind) 
(lower limit of quantification, 400 
copies/mL); 
antiretroviral 
naïve patients; 
Plasma HIV-1 
RNA levels > 5 
000 copies/ml at 
screening 
A) tenofovir disoproxil 
fumarate 300 mg every 
day + corresponding 
placebo + 150 mg 
twice daily of 
lamivudine and 600 
mg/day of efavirenz 
(400 mg/day nevirapine 
could be substituted for 
efavirenz if intolerable 
neuropsychiatric 
toxicity) 
B) stavudine 40mg 
twice daily (or 30 mg 
twice daily if weight <60 
kg) + corresponding 
placebo + 150 mg 
twice daily of 
lamivudine and 600 
mg/day of efavirenz 
(400 mg/day nevirapine 
could be substituted for 
efavirenz if intolerable 
neuropsychiatric 
toxicity) 
samples: blood plasma (details 
NR) 
 
method: "Genotypic analyses 
(Virtual Phenotype26: Virco, 
Mechelen, Belgium) included 
the first 400 amino acids of the 
reverse transcriptase coding 
sequence and phenotypic 
analyses (PhenoSense HIV27: 
Virologic, South San Francisco, 
Calif) included susceptibility to 
tenofovir and all other licensed 
NRTIs and NNRTIs. All resistance 
assays were performed and 
analyzed in a blinded fashion"228 
 
threshold: N/A 
 
group N BM+ BM- 
A 299 17 5 
B 301 11 4 
 
 
Patients with virologic rebound or 
suboptimal therapy - tenofovir (n=22): 
14 Any NNRTI Resistance Mutation†, 9 
K103N, 8 M184V/I, 9 Other NRTI 
Resistance‡, 7 K65R, 5 none detected 
Patients with virologic rebound or 
suboptimal therapy - control (n=15): 
10 Any NNRTI Resistance Mutation, 6 
K103N, 8 M184V/I, 3 Other NRTI 
Resistance, 2 K65R, 4 none detected 
                                                                
* Only 600 patients were analysed 
† L100I, K103N, V106A/M, V108I, Y181C/I, Y188C/L/H, or G190A/S/E/Q in RT 
‡ M41L, A62V, K65R, D67N, T69D/N, K70R, L74V/I, V75T, F77L, Y115F, F116Y, Q151M, M184V, L210W, T215Y/F, or K219Q/E/N in RT 
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907224,226 
 
EMA 
status: 
main 
 
Phase III 
 
N= 552* 
 
Status: 
complete
d 
Biomarker evaluation: subgroup 
analysis (prospective) 
 
design: randomised 2:1; 24 
weeks as double blind and 24 
weeks as open-label 
 
follow-up: 48 weeks 
 
primary outcome: time-
weighted average change in 
HIV-1 RNA level from baseline to 
week 24 (DAVG24) (details NR) 
patients on a 
stable 
antiretroviral 
regimen (no 
more than 4 
antiretroviral 
agents) for 8 
weeks prior to 
enrolment; 
Antiretroviral 
experienced 
patients (> 4 
years) HIV RNA ≥ 
400 and ≤ 
100,000 
copies/ml 
A) tenofovir disoproxil 
fumarate 300 mg every 
day + stable 
antiretroviral therapy 
B) placebo + stable 
antiretroviral therapy 
samples: blood plasma 
 
method: reverse transcriptase 
PCR from plasma HIV-1 RNA 
(Vircogen, Virco, Mechelen, 
Belgium) 
 
threshold: N/A 
 
group N BM+ BM- 
A 368 NR NR 
B 184 NR NR 
 
 
virological substudy: “The highest 
reduction in viral load was observed 
in patients without zidovudine 
resistance but with the M184V 
mutation among all genotypic 
groups at week 24 (-0.97 log10 
DAVG24, p <0.0001) and at week 48 
(-0.90 log10 DAVG48, p <0.0001). The 
difference with other groups was not 
statistically relevant. Patients with 
K65R mutation at baseline did not 
respond to tenofovir DF (+ 0.12 log10 
mean DAVG24). Treatment with 
tenofovir DF resulted in infrequent 
development of resistance to 
tenofovir, as only 8/274 patients (3%) 
developed the K65R mutation by 
week 48." 5 patients developed K65R 
mutation (resistance to tenofovir) 
after treatment with tenofovir” 
                                                                
* one pateint had no post-baseline data and was excluded from analysis 
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Viral resistance – HIV infection - tipranavir 
Study Design Population Interventions  Biomarker measurement Results  
RESIST 1229-231 
 
EMA status: 
main 
 
Phase III 
 
N=630 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label;  
 
follow-up: 48 weeks 
 
primary outcome: virologic 
response (proportion of 
patients with a reduction in 
the HIV-1 load of at least 1 
log after 24 weeks) 
HIV-positive, 
multiple antiviral 
drug experienced 
patients 
A) tipranavir 500 mg + ritonavir 
200 mg twice daily with 
optimised background therapy 
B) investigator-selected, 
ritonavir-boosted standard of 
care PI with optimised 
background therapy 
 
samples: NR 
 
method: TruGene method, 
version 1.0; less than 3 mutations 
at codons 33, 82, 84 or 90 
 
threshold: N/A 
 
group N BM+ BM- 
A 313 313 0 
B 317 317 0 
 
 
virologic response at week 
48: tipranavir (n=311) 103 
patients achieved, 
standard care (n=309) 49 
achieved; weighted 
difference 16.8% (95% CI: 
10.3, 23.2%, p<0.0001) 
RESIST 
2229,230,232 
 
EMA status: 
main 
 
Phase III 
 
N=863 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; open-label; 
randomised 1:1; stratified by 
preselected PI and the use of 
enfuvirtide 
 
follow-up: 48 weeks 
 
primary outcome: virologic 
response (proportion of 
patients with a reduction in 
the HIV-1 load of at least 1 
log after 24 weeks) 
HIV-positive, 
multiple antiviral 
drug experienced 
patients 
A) tipranavir 500 mg + ritonavir 
200 mg twice daily with 
optimised background therapy 
B) investigator-selected, 
ritonavir-boosted standard of 
care PI with optimised 
background therapy 
 
samples: NR 
 
method: Virtual Phenotype, 
version 3.6 (Virco), for European 
countries and the HIV-1 
genotyping method, version 1.0 
(TruGene), for Latin America 
version 1.0; less than 3 mutations 
at codons 33, 82, 84 or 90 
 
threshold: N/A 
 
group N BM+ BM- 
A 435 435 0 
B 428 428 0 
 
 
virologic response at week 
24 (NR for week 48): 
tipranavir (n=435) 177 
patients achieved, 
standard care (n=428) 76 
achieved; weighted 
difference 22.3% (95% CI: 
16.4, 28.1%, p<0.0001) 
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Study Design Population Interventions  Biomarker measurement Results  
1182.4229,233 
 
EMA status: 
supportive 
 
Phase II 
 
N=81 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: RCT; open-label; 
randomised 1:1:1 
 
follow-up: 96 weeks 
 
primary outcome: NR 
single PI-
experienced HIV-1 
patients 
A) tipranavir 500 mg + ritonavir 
100 mg twice daily with 
background therapy 
B) tipranavir 1250 mg + ritonavir 
100 mg twice daily with 
background therapy 
C) saquinavir 400 mg + ritonavir 
400 mg twice daily with 
background therapy 
 
samples: blood (details NR) 
 
method: TruGene 6.0 and 7.0 
[Bayer] or Virtual Phenotype 
assays (version 3.6; [VIRCO]) 
 
threshold: N/A 
 
group N BM+ BM- 
A NR NR NR 
B NR NR NR 
C NR NR NR 
 
 
NR 
1182.51229,234 
 
EMA status: 
supportive 
 
Phase II 
 
N=315 
 
Status: 
completed 
Biomarker evaluation:  
 
design: RCT; open-label; 
included patietns excluded 
from RESIST 1 and 2 
 
follow-up: 24 weeks 
 
primary outcome: 
pharmacokinetics 
HIV-positive, 
multiple antiviral 
drug experienced 
patients 
A) tipranavir 500mg and ritonavir 
200 mg twice daily and 
optimised non-PI background 
B) lopinavir 400 mg + ritonavir 
100 mg+ optimised non-PI 
background + from week 2 
tipranavir 500mg and ritonavir 
100mg twice daily 
C) amprenavir 600 mg + ritonavir 
100 mg+ optimised non-PI 
background + from week 2 
tipranavir 500mg and ritonavir 
100mg twice daily 
D) saquinavir 1000 mg + ritonavir 
100 mg+ optimised non-PI 
background + from week 2 
tipranavir 500mg and ritonavir 
100mg twice daily 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A NR NR NR 
B NR NR NR 
C NR NR NR 
D NR NR NR 
 
 
72 patients were included 
in resistance testing, results 
NR 
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Study Design Population Interventions  Biomarker measurement Results  
1182.52229,235 
 
EMA status: 
supportive 
 
Phase II 
 
N=216 
 
Status: 
completed 
Biomarker evaluation: 
enrichment 
 
design: RCT; double-blind; 
dose-optimisation study 
 
follow-up: up to 32 weeks 
 
primary outcome: viral load 
reduction after 2 weeks 
similar: HIV-
positive, multiple 
antiviral drug 
experienced 
patients 
A) tipranavir 500 mg + ritonavir 
100 mg twice daily 
B) tipranavir 500 mg + ritonavir 
200 mg twice daily 
C) tipranavir 750 mg + ritonavir 
200 mg twice daily 
 
samples: NR 
 
method: NR 
 
threshold: N/A 
 
group N BM+ BM- 
A 73 NR NR 
B 72 NR NR 
C 71 NR NR 
 
 
viral load reduction after 2 
weeks - the difference  
"was not statistically 
significant between the 
three treatment arms, a 
trend towards a dose-
effect could be observed" 
Markowitz 
2007229,236 
 
EMA status: 
supportive 
 
Phase II 
 
N=41 
 
Status: 
completed 
Biomarker evaluation: 
subgroup (cross-sectional) 
 
design: RCT; open-label; 
details NR 
 
follow-up: 80 weeks 
 
primary outcome: viral load 
change from baseline and 
the proportion of patients 
with a viral load,400 and ,50 
copies/mL 
HIV-positive, 
multiple antiviral 
drug experienced 
patients 
A) tipranavir 1200mg + 100 mg 
ritonavir twice daily + 
background therapy 
B) tipranavir 2400mg + 200 mg 
ritonavir twice daily + 
background therapy 
samples: NR 
 
method: initially Visible Genetics 
Trugene Assay (samples up to 
week 48), and then by VIRCO 
NV. The Affymetrix Gene Chip 
Method (Affymetrix, Santa Clara, 
CA) was used for measurement 
before study initiation 
 
threshold: N/A 
 
group N BM+ BM- 
A 19 NR NR 
B 22 NR NR 
 
 
NR 
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13.1. EFFECTIVENESS BIOMARKERS (NON-ORPHAN DRUGS)  
Biomarker: ALK gene rearrangement 
Indication: NSCLC (previously treated, advanced) 
Drug: crizotinib 
Status: authorised 
B-I-D: ALKNC 
Main study 
 
Supportive studies  
  
Both ongoing at time of inclusion 
Biomarker: BRAF V600 mutation 
Indication: unresectable or metastatic melanoma 
Drug: vemurafenib 
Status: authorised 
B-I-D: BRMV 
Main study 
 
ongoing at time of inclusion 
Supportive study 
  
Biomarker: CCR5 tropism 
Indication: HIV (treatment-experienced) 
Drug: maraviroc 
Status: authorised 
B-I-D: CCR5HM 
Main studies   
   
Only combined results of both MOTIVATE studies 
available for F 
Supportive study  
 
Study in biomarker negative patients 
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Biomarker: EGFR expression 
Indication: colorectal neoplasms 
Drug: cetuximab 
Status: authorised 
B-I-D: EGFR(E)CC 
Main study 
  
Study compares monotherapy with 
combination therapy 
 
Supportive studies 
 
Biomarker: EGFR expression 
Indication: NSCLC 
Drug: cetuximab 
Status: refused 
B-I-D: EGFR(E)NC 
Main studies  
 
Supportive study 
 
Biomarker: EGFR expression 
Indication: NSCLC 
Drug: erlotinib 
Status: authorised 
B-I-D: EGFR(E)NE 
Main study 
 
Supportive study 
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Biomarker: EGFR  mutation 
Indication: NSCLC 
Drug: erlotinib 
Status: authorised 
B-I-D: EGFR(M)NE 
Main study 
 
 
Supportive studies 
 
 
 
Paz-Ares 2010 was a literature review comparing erlotinib with gefitinib 
 
Biomarker: EGFR  mutation 
Indication: NSCLC 
Drug: geftinib 
Status: authorised 
B-I-D: EGFR(M)NG 
Main studies 
 
 
Supportive studies 
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Biomarker: EpCAM expression 
Indication: cancer ascites 
Drug: catumaxomab 
Status: authorised 
B-I-D: EpCAMAC 
Main study 
 
Supportive studies 
 
Biomarker: oestrogen receptor expression 
Indication: breast neoplasms 
Drug: fulvestrant 
Status: authorised 
B-I-D: ERBF 
Main studies 
 
Supportive studies 
 
 
Biomarker: oestrogen receptor expression 
Indication: breast neoplasms 
Drug: toremifene 
Status: authorised 
B-I-D: ERBT 
Main studies 
Only combined data from three main studies available for biomarker 
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Biomarker: genotype 1 
Indication: chronic hepatitis C 
Drug: bocepravir 
Status: authorised 
B-I-D: G1CB 
Main studies 
 
Supportive study 
 
Biomarker: genotype 1 
Indication: chronic hepatitis C 
Drug: telaprevir 
Status: authorised 
B-I-D: G1CT 
Main studies 
 
 
Supportive study 
 
 
Biomarker: hormone dependency 
Indication: prostatic neoplasms 
Drug: degarelix 
Status: authorised 
B-I-D: HDDP 
Main study 
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Biomarker: HER2 expression 
Indication: breast neoplasms 
Drug: everolimus 
Status: authorised 
B-I-D: HER2BE 
Main study 
 
 
Supportive study 
 
 
  
Biomarker: HER2 expression 
Indication: breast neoplasms 
Drug: lapatinib 
Status: authorised 
B-I-D: HER2BL 
Main study 
 
 
Supportive studies 
   
 
EGF103659 and French ATU were ongoing 
 
Biomarker: HER2 expression 
Indication: breast neoplasms 
Drug: pertuzumab 
Status: authorised 
B-I-D: HER2BP 
Main study 
 
 
Supportive studies 
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Biomarker: HER2 expression 
Indication: breast neoplasms 
Drug: trastuzumab 
Status: authorised 
B-I-D: HER2BT 
Unclear studies 
  
 
 
Biomarker: HER2 expression 
Indication: stomach neoplasms 
Drug: trastuzumab 
Status: authorised 
B-I-D: HER2ST 
Main study 
 
 
 
Biomarker: Hormone receptor expression 
Indication: breast neoplasms 
Drug: everolimus 
Status: authorised 
B-I-D: HRBE 
Main study 
 
 
Supportive study 
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Biomarker: Hormone receptor expression 
Indication: breast neoplasms 
Drug: zoledronic acid 
Status: pending => withdrawn (prior to refusal) 
B-I-D: HRBZ 
Main study 
 
 
Supportive studies 
 
 
Biomarker: KRAS mutation 
Indication: colorectal cancer (metastatic) 
Drug: cetuximab 
Status: authorised 
B-I-D: KRASCC 
Unclear studies 
 
 
Biomarker: KRAS mutation 
Indication: colorectal cancer (metastatic) 
Drug: panitumumab 
Status: authorised 
B-I-D: KRASCP 
Main study 
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Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: amprenavir 
Status: withdrawn 
B-I-D: VRHAm 
Main studies 
  
 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: atazanavir 
Status: authorised 
B-I-D: VRHAt 
Main studies 
 
 
retrospective analysis in AI424045, as administration of treatment in many cases did not result in undetectable 
virus 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: darunavir 
Status: authorised 
B-I-D: VRHD 
Unclear studies 
 
 
Information relevant to biomarker assessment was only provided for all three POWER studies together 
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Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: efavirenz / emtricitabine / tenofovir disoproxil 
Status: authorised 
B-I-D: VRHEET 
Main study 
 
 
 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: emtricitabine 
Status: authorised 
B-I-D: VRHEm 
Main study 
 
 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: enfuvirtide 
Status: authorised 
B-I-D: VRHEn 
Main studies 
 
 
Information relevant to biomarker assessment was only provided for two TORO studies together 
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Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: emticitabine/ rilpivirine/ tenofovir 
Status: authorised 
B-I-D: VRHERT 
Main studies 
 
 
 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: fosamprenavir 
Status: authorised 
B-I-D: VRHF 
Main studies 
  
Supportive study 
 
retrospective analysis in APV 30003, as administration of treatment in many cases did not result in undetectable 
virus 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: lopinavir/ ritonavir 
Status: authorised 
B-I-D: VRHAmL 
Main study 
 
 
Supportive study 
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Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: nelfinavir 
Status: withdrawn  
B-I-D: VRHNel 
Main studies 
 
 
Information relevant to biomarker assessment was only provided for two studies together; retrospective 
analysis, as administration of nelfinavir in most cases did not result in undetectable virus 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: rilpivirine 
Status: authorised 
B-I-D: VRHR 
Main studies 
 
 
Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: tenofovir 
Status: authorised 
B-I-D: VRHTe 
Main studies 
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Biomarker: viral resistance mutations 
Indication: HIV-1 infection 
Drug: tipranavir 
Status: authorised 
B-I-D: VRHTr 
Main studies 
 
RESIST studies were ongoing 
 
Supportive studies 
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13.2. EFFECTIVENESS BIOMARKERS (ORPHAN DRUGS) 
Biomarker: CD-33 
Indication: AML (first relapse, not candidates for other intensive re-induction chemotherapy) 
Drug: gemtuzumab ozogamicin 
Status: refused 
B-I-D: CD33AG 
Main studies  
 
Biomarker: D816V mutation in c-Kit 
Indication: systemic mastocytosis (adults) 
Drug: imatinib 
Status: withdrawn prior to refusal 
B-I-D: D816VSI 
Unclear studies 
   
 
Biomarker: FIP1L1-PDGFRα rearrangement 
Indication: HES/CEL 
Drug: imatinib 
Status: authorized 
B-I-D: FIP1L1HI 
Unclear studies 
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 526 
 
Biomarker: G551D mutation 
Indication: cystic fibrosis 
Drug: ivacaftor 
Status: authorised 
B-I-D: G55CI 
Main studies 
  
 
 
Supportive studies 
 
  
VX08-770-105 was ongoing 
Biomarker: Kit (CD 117) mutation positive 
Indication: gastrointestinal stromal tumors 
Drug: imatinib  
Status: authorised 
B-I-D: KitGI 
Unclear studies 
 
 
 
 
 
Biomarker: LPL protein expression 
Indication: hyperlipoproteinemia type I 
Drug: alipogene tiparvovec 
Status: authorized 
B-I-D: LPLNH 
N/A 
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Biomarker: PDGFR gene re-arrangements 
Indication: myelodysplastic-myeloproliferative disease 
Drug: imatinib  
Status: authorised 
B-I-D: PDGFRMI 
Main study 
 
 
Supportive studies 
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Biomarker: Philadelphia chromosome 
Indication: precursor cell lymphoblastic leukemia-
lymphoma 
Drug: dasatinib 
Status: authorised 
B-I-D: PHPD 
Main study 
 
 
Supportive study 
 
 
Biomarker: Philadelphia chromosome 
Indication: precursor cell lymphoblastic leukemia-lymphoma 
Drug: imatinib  
Status: authorised 
B-I-D: PHPI 
Unclear studies 
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Biomarker: t(15;17) translocation and/or PML/RAR-α 
gene 
Indication: acute promyelocytic leukemia 
Drug: arsenic trioxide 
Status: authorised 
B-I-D: t(15;19)AA 
Main studies 
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13.3. SAFETY BIOMARKERS 
Biomarker: DPD deficiency 
Indication: colorectal, colonic, stomach, breast 
neoplasms 
Drug: capecitabine 
Status: authorised 
B-I-D: DPDCC 
N/A 
Biomarker: DPD deficiency 
Indication: stomach neoplasms 
Drug: tegafur/ gimeracil/ oteracil 
Status: authorized 
B-I-D: DPDST 
N/A 
Biomarker: HLA-B*5701 allele 
Indication: HIV-1 infection 
Drug: abacavir 
Status: authorized 
B-I-D: HLAHA 
Unclear study 
 
 
Biomarker: NADPH reductase deficiency 
Indication: Methaemoglobinaemia 
Drug: methylthioninum chloride 
Status: authorised 
B-I-D: NMMc 
N/A  
 
  
 
APPENDIX 14. CRITICAL APPRAISAL OF TAJIK 2013 SYSTEMATIC 
REVIEW 
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It was reported in the Introduction of this review that it is a “systematic review of literature 
on trial designs for evaluating biomarkers for treatment selection.”237 This scope, however, 
seemed to be inconsistent with the inclusion criteria in the Materials and Methods, which 
were looking at identification and validation of biomarkers: “methodologic articles that 
described one or more trial designs for identification and/or validation of prognostic or 
predictive biomarkers for treatment selection”237. It was not clear whether this paper used 
the terms “validation” and “evaluation” interchangeably. It was however judged that the 
findings of the review would be directly applicable to the questions addressed by this 
chapter. 
1. Was an ‘a priori’ design provided? 
It was not reported whether this review followed a pre-defined protocol. Elements of 
methodology used were reported. 
2. Was there duplicate paper selection and data extraction? 
Abstracts were screened by one reviewer, with a second reviewer checking 400 out of 
2056 references (19.5%). This checking gave a 99% agreement. There was no information 
on how many of these were references missed by the reviewer assessing all abstracts. 
There was no information on whether full texts were assessed for inclusion by one or two 
reviewers. There was also no information on whether data extraction was carried out by 
one or two reviewers.  
3. Was a comprehensive literature search performed? 
Given the topic, the search strategy in MEDLINE/PubMed (reporting of database 
searched inconsistent) and EMBASE was relatively narrow. Although the paper states that 
the review question included both prognostic and predictive biomarkers, the search 
strategy does not include terms specific for prognostic biomarkers. It was also focused on 
genomic and genetic biomarkers and there are no terms for, as an example, proteomic 
or imaging biomarkers, although these would also be relevant.  
It is not clear whether MEDLINE or PubMed was searched. The text of the paper and 
supplemental methods state that MEDLINE was searched (via PubMed), while Figure 1 in 
the paper reports that PubMed was searched.  
In the MEDLINE/PubMed (?) search strategy, restriction of the MeSH term “Clinical Trials as 
Topic” to major headings can potentially lead to missing relevant papers. For example a 
paper describing a number of relevant trial designs238 would have been identified if the 
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MEDLINE/PubMed searches using the term “Clinical Trials as Topic” were not limited to 
major headings. There are also other MeSH terms which could have been used in the 
searches, such as “Individualized Medicine” or “Tumour Markers, Biological”. 
Similar concerns apply to EMBASE. For example the index terms “clinical trial (topic)” or 
“personalized medicine” could have been used.  
Searches in Cochrane Methodology Register and MathSciNet were relatively wide. 
The searches were supplemented by checking citations in included papers. 
It is therefore possible that some relevant papers that could have contributed additional 
information were missed.  
4. Was the status of the publication used as an inclusion criterion? 
The publication status was not an inclusion criterion. The searches were not limited to 
oncology and no language restrictions were applied. However the limitation of included 
papers to methodological papers potentially missed some methodology developed and 
published alongside a study, as for example relating to development of continuous 
signatures in clinical trials.239  
5. Was a list of papers (included and excluded) provided? 
Included papers were reported in Supplementary Table 1. A list of excluded papers was 
not provided, neither were detailed reasons for exclusion of papers. 
6. Were the characteristics of the included papers provided? 
The authors only provided the citations of the included papers. Some additional 
information could, for example, include what study designs were described within each 
paper. 
7. Was the scientific quality of the included papers assessed and documented? 
The assessment of scientific quality is not applicable here, as the papers describe different 
study methodologies.  
8. Was the scientific quality of the included papers used appropriately in formulating 
conclusions? 
Not applicable in this context.  
9. Were the methods used to combine the information in the papers appropriate? 
The framework used for summarising the different study designs was based on the 
“patient-intervention-comparator components of patient flow”. As this review is looking at 
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trial designs for evaluation (and possibly identification) of biomarkers, it seems 
inappropriate that whether the biomarker was part of study hypothesis was not part of the 
framework. This is particularly evident in the category of “randomise-all” designs where 
trials designed to prospectively test a biomarker hypothesis (with randomisation stratified 
by the biomarker and testing for biomarker by treatment interaction) have been grouped 
together with post hoc subgroup analysis or an adaptive signature design.  
Another issue here is that although according to the methods of this review study designs 
for different stages of biomarker development were included, there was no recognition of 
this fact in the framework proposed. There was no indication of whether the identified 
designs are suitable for biomarker identification, evaluation/validation, or both. 
Also, since the searches were narrow and did not identify all relevant papers, selecting 
the label used for each category based on vote-counting may not be representative of 
the most frequent practice. 
There is no information on what the authors planned to do in cases of disagreement on a 
certain issue between different methodological papers.   
10. Was the likelihood of publication bias assessed? 
No, however this issue is probably not applicable here, unless it is considered that for 
example certain arguments or opinions are less likely to be published.  
11. Was the conflict of interest stated? 
It was stated that “no potential conflicts of interests were disclosed”. 
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APPENDIX 15. STUDY DATA FROM EMA REVIEW MATCHED TO 
THE TAJIK 2013 FRAMEWORK 
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
ALK mutation – NSCLC – crizotinib                 
A8081001 Crizotinib is well tolerated with rapid, 
durable responses in patients with 
ALK-positive NSCLC. There seems to 
be potential for ongoing benefit 
after initial disease progression in this 
population, but a more formal 
definition of ongoing benefit in this 
context is needed.46 
Q1 single-arm 
study 
single-arm 
(only positive)
             
A8081005 NA NA NA single-arm 
(only positive) 
             
A8081007 NA NA NA enrichment              
BRAF V600 mutation – melanoma - vemurafenib                 
BRIM 3 Vemurafenib produced improved 
rates of overall and progression-free 
survival in patients with previously 
untreated melanoma with the BRAF 
V600E mutation.52 
Q1 randomized 
clinical trial 
enrichment              
NP22657 NA NA NA single-arm 
(only positive)
             
CCR5 tropism – HIV – maraviroc                 
MOTIVATE 
1 
Maraviroc, as compared with 
placebo, resulted in significantly 
greater suppression of HIV-1 and 
greater increases in CD4 cell counts 
at 48 weeks in previously treated 
patients with R5 HIV-1 who were 
receiving OBT [optimised 
background therapy].56§§§§§§§§§§§§§§§ 
Q1 
randomized, 
double-
blind, 
placebo-
controlled 
study 
enrichment              
MOTIVATE 
2 
randomized, 
double-
blind, 
placebo-
controlled 
study 
enrichment              
                                                                
§§§§§§§§§§§§§§§ Both studies reported in one paper 
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
Saag 
2009 
In this exploratory study involving 
extensively treatment-experienced 
patients with advanced, non-R5 
HIV-1 infection, neither superiority 
nor noninferiority was statistically 
demonstrated for either maraviroc 
dosage compared with placebo at 
24 weeks of treatment.57 
Q2 randomized, 
placebo-
controlled, 
double-
blind trial 
enrichment 
(biomarker 
negative)
             
CD-33 expression – AML – gemtuzumab 
ozogamicin 
                
0903B1-
201-
US/CA 
In conclusion, GO [gemtuzumab 
ozogamicin], which is an antibody-
targeted chemotherapy, provides 
an effective and relatively well 
tolerated treatment option for 
patients with CD33-positive AML in 
recurrence.58**************** 
A1 
open-label, 
single-arm 
study 
single-arm 
(only positive)
             
0903B1-
202-EU 
open-label, 
single-arm 
study 
single-arm 
(only positive)
             
0903B1-
203-US/EU 
open-label, 
single-arm 
study 
single-arm 
(only positive)
             
DPD deficiency – Colorectal, colonic, stomach and breast neoplasms – 
capecitabine 
               
None  N/A N/A N/A N/A              
DPD deficiency – stomach neoplasms - 
tegafur / gimeracil / oteracil 
                 
None N/A N/A N/A N/A              
                                                                
**************** All three studies reported in one paper 
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
EGFR expression - Colorectal Neoplasms – cetuximab                
BOND there was no apparent relationship 
between the efficacy of cetuximab 
and the level of EGFR in the tumor 
(…) Only patients with 
immunohistochemical evidence of 
EGFR expression were included in 
our study, and therefore whether 
patients without EGFR expression 
would benefit from cetuximab is 
unknown240 
Q1 open-label, 
randomized 
trial 
enrichment              
IMCL 
CP02-
0141 
NA NA NA single-arm 
(only positive)
             
IMCL 
CP02-
9923 
NA NA NA single-arm 
(only positive)
             
EGFR expression – NSCLC – cetuximab               
CA225099 "This trial did not show a significant 
difference in PFS"69 
"In conclusion, the results of this 
correlative  study of cetuximab plus 
chemotherapy in NSCLC do not 
show that any of the biomarkers 
analyzed have a statistically 
significant effect on cetuximab 
benefit" 70 
Q3, Q6 open-label  
trial that 
enrolled 
patients 
regardless 
of EGFR 
expression 
(correlative 
analysis) 
randomise-all 
(retrospective 
subgroup)
             
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
FLEX The FLEX trial showed that overall 
survival is prolonged with the EGFR 
targeted antibody cetuximab 
added to chemotherapy in patients 
with advanced non-small-cell lung 
cancer (…) In conclusion, 
cetuximab added to platinum-
based chemotherapy can be 
regarded as a new standard first-
line treatment option for patients 
with EGFR-expressing advanced 
non-small-cell lung cancer."71 
Q1 open-label 
trial 
enrichment              
Rosell 
2007 
to our knowledge, this is the first 
randomized trial demonstrating that 
combination treatment with 
cetuximab plus cisplatin/vinorelbine 
enhances the response rate and 
improves PFS and survival time with 
an acceptable safety profile 
compared with cisplatin/vinorelbine 
alone. To validate these results a 
large, randomized phase III trial of 
first-line Erbitux in lung cancer (FLEX) 
(…) is underway in patients with 
EGFR-expressing stage IIIB or IV 
NSCLC.72 
Q1 open-label, 
randomized 
pilot study 
enrichment              
EGFR expression – NSCLC – erlotinib               
BR.21 In summary, multivariate analysis 
revealed that expression of EGFR 
and an increased number of copies 
of EGFR [measured by FISH], but not 
mutations in EGFR, were associated 
with responsiveness to erlotinib but 
not with increased survival. Our 
results suggest that mutational 
analysis is not necessary to identify 
patients in whom treatment with 
EGFR inhibitors is appropriate.76 
Q6 clinical trial 
(correlative 
studies) 
randomise-all 
(prospective 
subgroup)
             
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
Perez-
Soler 2004 
In conclusion, this study indicates 
that erlotinib is an active and well-
tolerated agent for the treatment of 
relapsing NSCLC and supports the 
continued clinical development of 
this promising agent241 
A1 single-arm, 
open-label 
study 
(Gehan 
two-stage 
design) 
single-arm 
(only positive)
             
EGFR mutation – NSCLC – erlotinib                
EURTAC The EURTAC results reinforce the 
feasibility of upfront genotyping of 
patients and the improved 
outcomes attained with therapy 
directed against a known target. 
Taken together with the findings of 
the OPTIMAL study, our results 
suggest a benefit in PFS with first-line 
erlotinib in a European population 
and confirm those improvements 
attained with EGFR targeted agents 
in Asian patients, thus strengthening 
the rationale for routine baseline 
tissue-based assessment of EGFR 
mutations in patients with NSCLC.83 
Q1 open-label 
randomised 
trial 
enrichment              
CALGB30
406
†††††††††††††††† 
Patients with NSCLC whose tumors 
harbour EGFR mutations derive the 
greatest degree of benefit from first-
line EGFR TKI therapy (…). Improving 
PFS of patients with EGFR-mutant 
NSCLC treated with erlotinib remains 
a critical therapeutic challenge.80 
Q5 randomized 
trial 
single arm              
Laskin 
2009 
Clinical selection of pts enriches the 
EGFR mutation positive and KRAS 
mutation negative population and 
leads to high rates of non-
progression82 
A1 clinical trial single-arm 
(only positive)
             
                                                                
†††††††††††††††† Patients randomised to erlotinib monotherapy or erlotinib + chemotherapy 
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
OPTIMAL The OPTIMAL study provides the first 
conclusive evidence that erlotinib 
provides superior overall response 
rate and progression-free survival 
versus platinum doublet 
chemotherapy as first-line treatment 
in Asian patients whose tumours 
harbour activating mutations of 
EGFR. The results of this study have 
practice-changing implications and 
provide justification for widespread 
implementation of routine EGFR 
mutation testing in advanced 
NSCLC.242 
Q1 open-label, 
randomised 
trial 
enrichment              
Paz-Ares 
2010 
This extensive review of the literature 
has shown that NSCLC associated 
with EGFR mutations presents as a 
distinct disease that is dependent 
on hyperactivated EGFR for survival. 
Because of this, it is not surprising 
that blockade of EGFR TK activity 
appears to be the most effective 
treatment for this subgroup of 
NSCLC.243 
Q1 in-depth 
review of 
the 
published 
literature/ 
pooled 
analysis 
literature 
review
             
Rosell 
2009 
We evaluated the feasibility of 
large-scale screening for EGFR 
mutations in such patients and 
analyzed the association between 
the mutations and the outcome of 
erlotinib treatment… 
In conclusion, screening for EGFR 
mutations is warranted in women 
with lung cancer, in those who have 
never smoked, and in those with 
nonsquamous tumors. Large-scale 
screening of patients for EGFR 
mutations, with subsequent 
customization of erlotinib, is feasible 
and improves the outcome79 
Q5 prospective 
study 
single-arm 
(only positive) 
             
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
SATURN PFS benefit with erlotinib was noted 
in both EGFR mutation-positive and 
EGFR wild-type subgroups, with 
those with EGFR mutation-positive 
tumours obtaining the greatest 
benefit from erlotinib. Overall 
survival was also significantly longer 
with erlotinib than with placebo in 
the intention to treat population. 
The PFS benefit seen for patients 
with EGFR mutation-positive tumours 
did not translate into an equally 
impressive overall survival benefit, 
probably due to the high degree of 
censoring and the 67% cross-over 
rate to second-line EGFR TKI therapy 
in the placebo group for this 
population78 
Q1, Q2, 
Q3 
randomised, 
placebo-
controlled 
study (pre-
planned 
analyses 
according 
to 
predefined 
candidate 
biomarkers) 
randomise-all 
(prospective 
subgroup)
             
EGFR mutation – NSCLC – gefitinib                
INTEREST We detected no difference in 
overall survival between gefitinib 
and docetaxel irrespective of a 
patient’s EGFR protein expression, 
EGFR gene mutation, or K-Ras gene 
mutation status (treatment by 
biomarker interaction test was not 
significant for any biomarker86 
Q6 open-label, 
phase III trial 
(exploratory 
analyses in 
patient 
subgroups) 
randomise-all 
(prospective 
subgroup) 
             
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IPASS Our findings suggest that, whenever 
possible, EGFR-mutation status 
should be determined before the 
initial treatment of pulmonary 
adenocarcinoma (…) The presence 
of an EGFR mutation was a robust 
predictor of improved progression-
free survival with gefitinib, as 
compared with carboplatin–
paclitaxel, and of the benefit of 
gefitinib with respect to the 
objective response rate, indicating 
that patients in whom an EGFR 
mutation has been identified will 
benefit most from first-line therapy 
with gefitinib.89 
Q1, Q6 randomized, 
open-label, 
parallel-
group study 
(planned 
subgroup 
analyses) 
randomise-all 
(prospective 
subgroup) 
             
ISEL In agreement with previously 
published reports, patients with 
EGFR mutations had higher 
response rates with gefitinib, 
compared with patients without 
EGFR mutations.85 
Q5 placebo-
controlled 
study 
(biomarker 
analysis) 
randomise-all 
(retrospective 
subgroup) 
             
V-15-32 Although the patient numbers were 
too small for firm conclusions, the 
biomarker data from this study 
suggest that EGFR mutation–positive 
or EGFR FISH–positive patients have 
a greater response to both gefitinib 
and docetaxel compared with 
EGFR mutation– or FISH–negative 
patients244 
Q4, Q5 randomized, 
open-label, 
postmarketi
ng clinical 
study 
(preplanned 
subgroup 
analyses) 
randomise-all 
(prospective 
subgroup) 
             
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EpCAM expression – CancerAscites - 
Catumaxomab 
                
Heiss 2010 In conclusion, treatment with four 
i.p. [intraperitoneal] doses of C + P 
[catumaxomab + paracentesis] 
demonstrated clinically relevant 
benefits in patients with recurrent 
malignant ascites due to 
carcinomas of different origin. 
Positive trends in OS together with its 
demonstrated efficacy against 
tumor cells in the peritoneal cavity 
support the antitumor activity of 
catumaxomab and suggest that it 
could be even more effective if 
used at an earlier stage in the 
treatment of epithelial cancers. 91 
Q1 two-arm, 
randomized, 
open-label, 
study 
enrichment              
Baumann 
2011 
NR N/A N/A none
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡
             
Burges 
2007 
In conclusion, the i.p. 
[intraperitoneal] application of 
catumaxomab induced effective 
tumor cell destruction in malignant 
ascites, substantially decreased 
ascites accumulation, and reduced 
the necessity for paracentesis. Thus, 
i.p. infusion of catumaxomab 
represents a targeted tumor 
therapy within the peritoneal cavity 
associated with a substantial 
improvement of symptoms related 
to malignant ascites.92 
Q1 dose-
escalating 
study 
single-arm 
(only positive) 
             
                                                                
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡ Biomarker measurement not reported; partly based on the fact that a high proportion of ovarian tumours are EpCAM+ (prevalence of biomarker positive patients 
in patient population) 
 548 
 
Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
Oestrogen receptor expression – breast neoplasms – fulversant              
0020 Fulvestrant was tolerated well and 
was at least as effective as 
anastrozole in the second-line 
treatment of patients with ABC. This 
new hormonaltherapy may provide 
a valuable treatment option for 
ABC in postmenopausal 
women.96§§§§§§§§§§§§§§§§ 
Q1 open-label, 
randomized, 
parallel-
group trial 
enrichment              
0021 double 
blind, 
double-
dummy, 
randomized, 
parallel- 
group trial 
enrichment              
0004 NA NA NA single-arm 
(only positive)
             
O-15-22 NA NA NA single-arm 
(only positive)
             
SAKK In conclusion, by inducing a CB 
[clinical benefit] in 30% of patients 
with hormone receptor-positive 
tumors having received prior 
steroidal and nonsteroidal AI 
[aromatase inhibitor] and most of 
them having also been exposed to 
tamoxifen, fulvestrant emerges as 
an interesting and potentially 
important player in the sequential 
endocrine treatment of ABC 
[advanced breast cancer].98 
A1 open 
noncompar
ative study 
single-arm 
(only positive)
             
                                                                
§§§§§§§§§§§§§§§§ Both studies reported in one paper 
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Oestrogen receptor expression – breast neoplasms 
– toremifene 
               
Gershano
vich 1997 
Toremifene 60 mg daily is safe and 
effective treatment for 
postmenopausal women with 
advanced ER [oestrogen receptor] 
positive or ER unknown breast 
cancer.100 
Q1, A5 randomized, 
open label 
study 
(NR) 
randomise-all 
(prospective 
subgroup) 
             
Hayes 
1995 
response rates, times to progression, 
and overall survival for patients on 
each arm were superior for ER 
[oestrogen receptor] -positive 
patients when compared with those 
whose tumors were ER-negative (…) 
In this study, we have demonstrated 
that TOR [toremifene] has similar 
efficacy and toxicities as those of its 
parent compound in 
postmenopausal patients with 
metastatic, hormone receptor-
positive (or -unknown) breast 
cancer.245 
Q1, Q2,  
A5 
randomized 
three-arm 
comparison 
of tamoxifen 
and two  
doses of 
toremifene 
(NR) 
randomise-all 
(prospective 
subgroup) 
             
Pyrhonen 
1997 
the results of this double blind trial 
suggest that TOR [toremifene] (60 
mg day) and TAM [tamoxifen] (40 
mg day) are equally effective in the 
treatment of advanced ER 
[oestrogen receptor] -positive or ER-
unknown breast cancer in post-
menopausal patients102 
Q1, A5 double-
blind, 
parallel 
group, 
randomized 
clinical 
study (NR) 
randomise-all 
(prospective 
subgroup) 
             
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FIP1L1-PDGFRα rearrangement – HES/CEL - imatinib                
Cervetti 
2005 
This experience sustains not only the 
clinical role of imatinib in HES 
patients, but also its molecular 
activity. Indeed, notwithstanding 
clinical beneficial activity of IFN-
alpha in HES, any molecular 
remission has been reported with 
this treatment. The molecular 
response achieved by the second 
patient with imatinib would support 
the usefulness of a molecular target-
tailored therapy even in this 
haematological disorder.104 
Q1, A1 a case case report 
(biomarker 
positive) 
             
Chung 
2006 
Imatinib selectively inhibits ABL, 
PDGFR and KIT tyrosine kinases. 
FIP1L1-PDGFRA is particularly 
sensitive to imatinib and a low initial 
dose is therefore appropriate. The 
FIP1L1-PDGFRA syndrome may lead 
to death, either from end-organ 
(particularly cardiac) damage or 
from transformation to acute 
leukaemia. The striking response to 
imatinib therapy means that its 
correct identification and treatment 
is of critical importance to the 
patient.105 
Q1, A1 case report case report 
(biomarker 
positive) 
             
Cools 
2003 
demonstrates that FIP1L1-PDGFRA is 
the therapeutic target of imatinib in 
the hypereosinophilic syndrome246 
A1 study non-RCT 
(positive and 
negative; two 
different 
treatments 
each) 
             
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Frickhofen 
2004 
In summary, these findings 
demonstrate that all patients with 
persistent eosinophilia and a 
diagnosis of HES or CEL should be 
tested for fusion genes involving 
PDGFR and FGFR1. Imatinib will 
control most diseases with 
rearranged PDGFR-A or PDGFR-B 
genes106 
Q1 case report case report 
(biomarker 
positive) 
             
Imashuku 
2005 
Here we have described the case 
of an HES patient with increased 
numbers of mast cells in his bone 
marrow and CSS-like features who 
responded well to imatinib therapy, 
regardless of the negative 
molecular and cytogenetic findings. 
The molecular mechanisms 
involving genes such as PDGFRA, 
PDGFRB, c-KIT, and perhaps even 
unidentified kinases involved in the 
development of HES should be 
systematically characterized in 
order to further clarify the 
heterogeneity of HES and to identify 
imatinib-sensitive cases.107 
A2 case report case report 
(biomarker 
negative) 
             
Klion 2004 The FIP1L1-PDGFRA fusion tyrosine 
kinase is over 100 times more 
sensitive to imatinib mesylate than is 
bcr-abl (...), explaining the dramatic 
clinical and hematologic response 
in HES to imatinib mesylate doses as 
low as 100 mg weekly.108 
Q1, A1 cohort of 
patients 
case series 
(all positive) 
             
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La Starza 
2005 
Finally, five of 16 patients with HES 
who were FIP1L1/PDGFRA-negative 
underwent imatinib mesylate 
treatment. Two patients (...) 
achieved hematologic remission 
with peripheral eosinophil count 
normalization, confirming previous 
observations of succesful imatinib 
therapy in a subgroup of 
FIP1L1/PDGFRA-negative CEL.109 
Q1 study on 
retrospectiv
e cases 
non-RCT 
(positive and 
negative; two 
different 
treatments) 
             
Malagola 
2004 
This case report confirms that 
imatinib is highly effective in cases 
of CEL, carrying the rearrangements 
of FIP1L1-PDGFR-alpha. Assessing 
the long term benefit of the 
treatment and the possibility of 
eradicating the mutated clone will 
require a much longer follow up.110 
Q1 case report case report 
(biomarker 
positive) 
             
Martinelli 
2004 
we believe that imatinib treatment 
might be curative111 
A1 case report case report 
(biomarker 
positive)
             
Martinelli 
2006 
In conclusion, we have confirmed 
that imatinib is the treatment of 
choice for patients with FIP1L1-
PDGFRα-rearranged HES/CEL, since 
almost all patients achieve and 
maintain complete hematologic, 
clinical and molecular remissions, 
chronic treatment is well tolerated, 
and responses are stable over time 
at doses as low as 100 mg daily.247 
Q1 prospective 
study 
single-arm              
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Muller 
2006 
Particularly exceptional is the 
activity of FIP1L1–PDGFRA as the first 
gain-of-function gene. Its tyrosine 
kinase receptor activity displays the 
molecular basis for efficiency of 
treatment with the inhibitor of this 
receptor family, imatinib mesylate. 
Approximately two thirds (in our 
cumulative data, 31/48 [65%]) of 
patients with HES express the fusion 
gene, with mostly very good 
responses to the specific therapy. 
However, also FIP1L1–PDGFRA 
negative patients have often been 
reported to respond favourably to 
treatment with imatinib mesylate."113 
A1, A2 case report case report 
(biomarker 
positive and 
negative) 
             
Musial 
2005 
In HES with FIP1L1-PDGFRA fusion 
gene, imatinib offers an advantage 
beyond symptomatic, molecular 
and laboratory improvement. Our 
observation provides evidence for 
the postulated organ function 
improvement with imatinib 
therapy114 
Q1 NR case report 
(biomarker 
positive) 
             
Musto 
2004 
NA NA NA case report 
(biomarker 
positive and 
unknown) 
             
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Roche-
Lestienne 
2005 
In the present study, clinical 
improvement and complete 
hematological remission under 
imatinib was observed in all six F/P 
[FIP1L1-PDGFRA] patients, 
confirming previous results. By 
contrast, only one of the five 
treated F/P-negative patients (no. 
16) responded to imatinib, which 
may be indicative of a deregulated 
TK activity in this patient, although 
this remains putative.115 
Q1 molecular 
characteriz
ation 
non-RCT 
(positive and 
negative; two 
different 
treatments) 
             
Rose 2004 Analysis of the FIP1L1-PDGFRA fusion 
transcript appears very helpful in 
HES, in order to identify patients with 
FIP1L1-PDGFRA fusion transcripts 
with a high probability of 
responding to Imatinib. Although 
some HES patients without 
FIP1LPDGFRA transcript may 
respond to imatinib.248 
A1 case report case report 
(biomarker 
positive) 
             
Rotoli 
2004 
NA NA NA case report 
(biomarker 
positive) 
             
Smith 
2004 
In conclusion, cytogenetic and 
molecular genetic analyses are 
probably indicated in all patients 
who meet the criteria for idiopathic 
HES, especially since they may 
define defects that result in 
activation of molecular pathways 
for which we now have inhibitors.116 
A1 case report case report 
(biomarker 
positive and 
negative) 
             
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Vanderbe
rghe 2004 
[in patients with FIP1L1-PDGFRα 
rearrangement] The gratifying 
clinical, hematological and 
molecular responses with imatinib in 
this setting are unprecedented, but 
more cases and longer follow-up will 
be required to resolve definitively 
whether imatinib can induce long-
term molecular remission in this 
disease."117 
A1 case series case series 
(positive and 
negative; two 
different 
treatments)
             
Wolf 2004 NA NA NA case report 
(biomarker 
negative) 
             
genotype 1 - HCV – boceprevir               
RESPOND-
2 
Our data show that the addition of 
boceprevir to peginterferon–
ribavirin therapy leads to high rates 
of sustained virologic response 
among patients in whom prior 
treatment had failed.119 
Q1 NA enrichment              
SPRINT-2 As compared with peginterferon 
alfa-2b–ribavirin therapy alone, the 
addition of boceprevir significantly 
increased the rate of a sustained 
virologic response among previously 
untreated black and nonblack 
patients infected with HCV 
genotype 1, including those with a 
decrease of less than 1 log10 IU per 
milliliter in the HCV RNA level at 
week 4. Among nonblack patients, 
the combination therapy with 
boceprevir was associated with a 
relative increase of approximately 
70% in the rates of sustained 
virologic response over standard 
therapy.120 
Q1 randomized, 
placebo-
controlled 
study  
enrichment              
P05685 NA NA NA enrichment              
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genotype 1 - HCV – telaprevir               
ADVANCE These results confirm earlier studies 
and showed a significant increase in 
the rate of sustained virologic 
response among patients with HCV 
genotype 1 infection who are 
treated with a regimen combining 
peginterferon alfa-2a and ribavirin 
with telaprevir for 12 or 8 weeks, 
followed by peginterferon–ribavirin 
alone, for a total of 24 or 48 weeks 
of therapy, as compared with a 
standard regimen of peginterferon – 
ribavirin alone for 48 weeks.123 
Q1 randomized, 
double-
blind, 
placebo-
controlled 
trial  
enrichment              
ILLUMINAT
E 
We found that a 24-week treatment 
regimen of peginterferon–ribavirin, 
with telaprevir added for the first 12 
weeks, was noninferior to a 48-week 
regimen of peginterferon–ribavirin, 
with telaprevir added for the first 12 
weeks in patients with chronic 
infection with HCV genotype 1 who 
have not received treatment 
previously and who had an 
extended rapid virologic 
response.124 
Q1 randomized 
study 
enrichment              
REALIZE Telaprevir in combination with 
peginterferon alfa-2a plus ribavirin 
significantly improved the rates of 
sustained virologic response for 
patients who had received previous 
therapy for HCV infection.125 
Q1 randomized, 
double-
blind, 
placebo-
controlled 
study 
enrichment              
EXTEND NA NA NA single-arm 
(only positive)
             
G551D mutation – cystic fibrosis – ivacaftor               
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VX08-770-
102 
In this randomized, placebo-
controlled trial, administration of 
ivacaftor, an oral CFTR potentiator, 
was associated with significant 
improvements in primary and 
secondary end points in persons 
with cystic fibrosis who had at least 
one copy of the G551D-CFTR 
mutation249 
Q1 randomized, 
double-
blind, 
placebo-
controlled 
trial 
enrichment              
VX08-770-
103 
NA NA NA enrichment              
VX08-770-
104 
NA NA NA enrichment              
VX08-770-
105 
NA NA NA single-arm 
(only positive)
             
HER2 expression*****************  – breast cancer - everolimus               
BOLERO-2 Everolimus combined with an 
aromatase inhibitor improved 
progression-free survival in patients 
with hormone-receptor–positive 
advanced breast cancer previously 
treated with nonsteroidal 
aromatase inhibitors.133 
Q1 randomized 
trial 
enrichment              
Baselga 
2009 
NR250 N/A randomized, 
double-
blind, 
placebo-
controlled 
trial (NR) 
randomise-all 
(retrospective 
subgroup)
             
HER2 expression  – breast cancer - lapatinib               
EGF10015
1 
Overall, these updated analyses 
continue to support the clinical 
benefit and safety of lapatinib in 
patients with HER-2+ MBC 
[metastatic breast cancer].136 
Q1 randomized 
trial 
enrichment              
                                                                
***************** HER2 expression negative is the target population – for consistency reported as positive in table 
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EGF10365
9 and 
French 
ATU 
NA NA NA single-arm 
(only positive)
             
EGF10508
4 
lapatinib is associated with 
regressions of CNS metastases in 
patients who have progressed 
despite trastuzumab and 
radiotherapy. Additional activity 
was seen when capecitabine was 
added to lapatinib.137 
A1 open-label 
study 
single-arm 
(only positive)
             
EGF30001 This study demonstrated that the 
primary activity of lapatinib in breast 
cancer patients is mediated 
through HER-2 inhibition. Other than 
a higher response rate (influenced 
by the HER-2–positive subset), no 
clinically relevant antitumor activity 
was demonstrated when lapatinib 
was used in the heterogeneous 
population of patients with 
advanced breast cancer with 
locally defined HER-2–negative or 
HER-2–untested tumors. Conversely, 
in a preplanned, blinded, subset 
analysis of patients with centrally 
defined HER-2–positive tumors, 
lapatinib plus paclitaxel resulted in a 
clinically significant 11-week 
increase in median TTP as well as 
significant increases in ORR, CBR, 
and EFS. Although the data are not 
yet mature and differences did not 
achieve statistical significance, 
median OS was longer in patients 
receiving lapatinib. Therefore, this 
combination seems to be active as 
first-line therapy for HER-2–positive 
breast cancer.138 
Q1, Q2, 
A5 
randomized, 
double-
blind, 
placebo-
controlled 
trial 
(preplanned
, blinded, 
subset 
analysis) 
randomise-all 
(prospective 
subgroup)
             
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HER2 expression  – breast cancer – pertuzumab               
CLEOPATR
A 
We found that the combination of 
the anti-HER2 monoclonal 
antibodies pertuzumab and 
trastuzumab with docetaxel as first-
line therapy prolonged progression-
free survival in patients with HER2-
positive metastatic breast cancer.141 
Q1 randomized, 
double-
blind, 
placebo 
controlled 
trial 
enrichment              
Baselga 
2010 
The combination of pertuzumab 
and trastuzumab is well tolerated 
and shows encouraging results in 
patients with HER2-positive breast 
cancer with documented 
progression on trastuzumab as prior 
therapy. The observed AEs [adverse 
events] were generally mild or 
moderate149 
A1 open-label, 
single-arm, 
Simon two-
stage study 
single-arm 
(only positive)
             
NeoSpher
e 
Data obtained from NeoSphere 
supported the conduct and 
informed the design of an ongoing 
adjuvant trial with pertuzumab 
(NCT01358877), and illustrated the 
potential of the neoadjuvant 
approach in new drug 
development.251 
Q1 randomised, 
multicentre, 
open-label 
study 
enrichment              
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HER2 expression  – breast cancer – trastuzumab               
H0648g The results of this phase 3 clinical trial 
indicate that trastuzumab, when 
added to conventional 
chemotherapy, can benefit patients 
with metastatic breast cancer that 
overexpresses HER2. As compared 
with the best available standard 
chemotherapy, concurrent 
treatment with trastuzumab and 
first-line chemotherapy was 
associated with a significantly 
longer time to disease progression, 
a higher rate of response, a longer 
duration of response, and improved 
overall survival. If confirmed in 
additional studies of patients with 
HER2-positive metastatic breast 
cancer, our results may affect 
treatment of this disease.27 
Q1 clinical trial enrichment              
H0649g In summary, this study supports the 
use of rhuMAb HER2 [trastuzumab] 
for women with HER2-overexpressing 
metastatic breast cancer. The 
benefits of this therapy, durable 
objective responses, and favorable 
toxicity profile indicate that rhuMAb 
HER2 is an important new treatment 
option for women who have tumors 
that overexpress HER2.252 
Q1 NA single-arm 
(only positive)
             
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HER2 expression  – stomach cancer – trastuzumab               
ToGA In patients with advanced gastric or 
gastro-oesophageal junction 
cancer, addition of trastuzumab to 
chemotherapy significantly 
improved overall survival compared 
with chemotherapy alone. 
Furthermore, an exploratory, post-
hoc analysis showed that 
trastuzumab plus chemotherapy 
substantially improved overall 
survival in patients with high 
expression of HER2 protein 
(immunohistochemistry 2+ and FISH 
positive or immunohistochemistry 
3+) compared with patients with low 
expression of HER2 protein 
(immunohistochemistry 0 or 1+ and 
FISH positive).253 
Q1, Q5 open-label, 
randomised 
controlled 
trial 
enrichment              
HLA-B*5701 allele – HIV - abacavir†††††††††††††††††               
PREDICT-1 The results of the PREDICT-1 study 
show that prospective HLA-B*5701 
screening can reduce the 
incidence of hypersensitivity 
reaction to abacavir. (…) 
Prospective HLA-B*5701 screening, 
as shown in the PREDICT-1 study, 
may therefore be broadly useful, 
although the cost-effectiveness of 
the test will depend on several 
estimates that vary among 
populations and health care 
settings as well as the availability of 
appropriate laboratory assays.148 
Q7 double-
blind, 
prospective, 
randomized 
study 
biomarker-
strategy with 
biomarker 
measurement 
in the control 
arm 
(modified)
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡
    
§§§§§§§§§§§§§§§§§
        
                                                                
††††††††††††††††† Prediction of adverse events 
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡ Biomarker negative patients (carriers of HLA-B*5701 allele) were excluded from the strategy arm 
§§§§§§§§§§§§§§§§§  indicates the study did not address this question due to design modification from that in the framework 
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hormone dependent – prostate cancer - degarelix               
FE 200486 
CS21 
NA NA NA unclear              
hormone receptor expression  – breast cancer – everolimus               
BOLERO-2 we report a phase 3 trial in patients 
with HR [hormone receptor]-positive 
advanced breast cancer showing 
that the addition of everolimus to 
endocrine therapy results in an 
improved clinical outcome133 
Q1 randomized 
trial 
enrichment              
Baselga 
2009 
this study showed that everolimus 
significantly increased the efficacy 
of letrozole in the treatment of 
newly diagnosed, ER [oestrogen 
receptor]-positive breast cancer in 
terms of both clinical and 
antiproliferative response.250 
Q1 randomized, 
double-
blind, 
placebo-
controlled 
trial 
enrichment              
hormone receptor expression  – breast cancer – zoledronic acid               
ABCSG-12 On the basis of the results of this 
study, combination of zoledronic 
acid with adjuvant endocrine 
therapy (ovarian suppression plus 
tamoxifen) should be considered for 
premenopausal women with low-or-
moderate-risk, early-stage, 
hormone-receptor positive breast 
cancer254 
Q1 randomised, 
controlled, 
open-label, 
two-by-two 
factorial, 
trial  
enrichment              
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E-ZO-FAST These 12-month E-ZO-FAST results 
add to the considerable clinical 
experience of letrozole-ZOL 
combination therapy in the 
adjuvant BC setting. Administering 
ZOL immediately with adjuvant 
letrozole in postmenopausal women 
with BC protects and maintains BMD 
with an acceptable safety profile. 
Further insight on the role of ZOL in 
treating AIBL is expected from 
longer follow-up of patients from this 
(E-ZO-FAST) and its companion 
studies (Z-FAST and ZO-FAST).152 
Q1 open-label 
randomized 
study 
enrichment              
Z-FAST Zoledronic acid initiated with the 
beginning of aromatase inhibitor 
therapy substantially prevents bone 
loss at 36 months of therapy255 
Q1 open-label 
study, 
randomized 
enrichment              
ZO-
FAST
****************** 
Longer follow-up is needed to 
determine whether the bone loss 
observed in the delayed group can 
be stabilized or restored to baseline 
values with the subsequent 
administration of zoledronic acid. 
The 2-year, 3-year, and 5-year results 
of this trial and other ongoing 
clinical trials are necessary to further 
assess the impact on BMD loss and 
fracture rates in patients with early 
stage breast cancer who are 
receiving long-term adjuvant AIs.151 
Q1 open-label, 
randomized 
study 
Single-arm              
                                                                
****************** RCT comparing two different strategies using the same drug 
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Kit (CD 117) mutation – gastrointestinal stromal tumours – imatinib               
Blanke 
2008b
†††††††††††††††††† 
This trial confirms the effectiveness 
of imatinib as primary systemic 
therapy for patients with incurable 
GIST but did not show any 
advantage to higher dose 
treatment. It appears reasonable to 
initiate therapy with 400 mg daily 
and to consider dose escalation on 
progression of disease.155 
Q1 Randomize
d open-
label clinical 
trial  
Single-arm              
Demetri 
2002
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡ 
Imatinib induced a sustained 
objective response in more than half 
of patients with an advanced 
unresectable or metastatic 
gastrointestinal stromal tumor. 
Inhibition of the KIT signal-
transduction pathway is a promising 
treatment for advanced 
gastrointestinal stromal tumors, 
which resist conventional 
chemotherapy.256 
A1 open-label, 
randomized 
trial 
Single-arm              
                                                                
†††††††††††††††††† RCT comparing two different strategies using the same drug 
‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡‡ RCT comparing two different strategies using the same drug 
 565 
 
Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
Kit (D816V) mutation – systemic mastocytosis – imatinib               
Heinrich 
2008 
In this study, one patient with 
systemic mastocytosis had a 
favorable response to imatinib and 
was found to have a novel imatinib-
sensitive KIT mutation (D816T). This 
result is consistent with other reports 
of favorable responses of systemic 
mastocytosis patients with imatinib-
sensitive kinase mutations to 
imatinib treatment. Therefore, 
molecular characterization of 
systemic mastocytosis cases may be 
useful in identifying patients for 
treatment with imatinib or other KIT 
kinase inhibitors.61 
A1 single-arm/ 
open-label 
exploratory 
study 
single-arm              
other 
studies 
NA NA NA collection of 
patient data
             
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KRAS mutation§§§§§§§§§§§§§§§§§§ - colorectal cancer - cetuximab               
CO.17 Our findings show that the mutation 
status of the K-ras gene is 
associated with overall survival 
among patients with advanced 
colorectal cancer who are being 
treated with cetuximab after 
previous chemotherapy has failed. 
Treatment with cetuximab as 
compared with supportive care 
alone was associated with almost a 
doubling of the median overall and 
progression-free survival among 
patients with wild-type K-ras tumors. 
There was no significant survival 
benefit from cetuximab, however, 
among patients with tumors that 
had K-ras mutations. (…) Our 
analysis identified a biomarker that 
would effectively exclude a 
clinically significant proportion of 
patients with colorectal cancer — 
those with tumors bearing K-ras 
mutations (42%) — from receipt of a 
therapy offering little prospect of a 
benefit. Nevertheless, there were 
also patients with wild-type K-ras 
tumors who did not have a response 
to cetuximab and in whom the 
tumor rapidly progressed. Additional 
reliable and easily measured 
biomarkers are clearly needed to 
improve the identification of 
patients who will benefit from 
treatment with cetuximab.158 
Q1, Q2, 
Q5, Q6 
randomized 
trial 
(correlative 
analyses) 
randomise-all 
(retrospective 
subgroup)
             
                                                                
§§§§§§§§§§§§§§§§§§ KRAS wild type as biomarker positive 
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CRYSTAL This trial provides confirmation that, 
as compared with FOLFIRI alone, 
cetuximab plus FOLFIRI reduces the 
risk of progression of metastatic 
colorectal cancer when used as the 
first-line treatment and that this 
benefit is seen mainly in patients 
with wild-type–KRAS tumors.161 
Q1 randomized, 
open-label, 
multicentre 
study 
(retrospectiv
e subgroup 
analysis) 
randomise-all 
(retrospective 
subgroup)
             
EPIC NA NA NA randomise-all 
(retrospective 
subgroup)
             
OPUS These results confirm the efficacy of 
cetuximab plus FOLFOX-4 in the first-
line treatment of patients with KRAS 
wild-type mCRC and confirm KRAS 
mutation status as an effective 
predictive biomarker.163 
Q1, Q6 randomized 
study 
(biomarker 
analysis) 
randomise-all 
(retrospective 
subgroup)
             
KRAS mutation******************* - colorectal cancer - panitumumab               
20020408 Panitumumab monotherapy 
efficacy in mCRC is confined to 
patients with WT KRAS tumors. KRAS 
status should be considered in 
selecting patients with mCRC as 
candidates for panitumumab 
monotherapy.257 
Q1, Q6 randomized 
trial 
(biomarker 
analyses) 
randomise-all 
(retrospective 
subgroup)
             
LPL protein expression - familial lipoprotein lipase deficiency - alipogene 
tiparvovec 
              
None                  
NADPH reductase deficiency - acquired methaemoglobinaemia – 
methylthionium chloride 
              
None                  
                                                                
******************* KRAS wild type as biomarker positive 
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PDGFR gene re-arrangements               
Heinrich 
2008 
imatinib treatment in this study was 
associated with favourable 
outcomes in patients with (…) 
myeloproliferative disorders, (…) 
adding to data showing the 
therapeutic efficacy of imatinib in 
tumour types with genomic 
mechanisms of activating imatinib 
sensitive tyrosine kinases61 
Q1 single-arm/ 
open-label 
exploratory 
study 
single-arm              
Apperley 
2002 
Imatinib mesylate induces durable 
responses in patients with chronic 
myeloproliferative diseases 
associated with activation of 
PDGFRB171 
A1 NA single-arm 
(only positive)
             
Cortes 
2003 
imatinib did not achieve a 
significant clinical response among 
patients with (…) atypical CML, or 
CMML without PDGFR fusion 
genes.172 
A2 study single-arm 
(only 
negative)
             
Garcia 
2003 
Our results demonstrate the 
efficiency of imatinib in the 
treatment of patients displaying the 
translocation involving H4 and 
PDGFBR genes. (…) Hence, the 
observed positive response strongly 
suggests that inhibition of PDGFBR 
activity may also be effective in 
other myeloproliferative diseases 
involving this tyrosine kinase 
receptor.173 
Q1 NR case report 
(positive)
             
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Grand 
2004 
Imatinib, a known inhibitor of 
PDGFRB, blocked the growth of 
patient colony-forming unit, 
granulocyte macrophage in vitro 
and produced a clinically significant 
response before relapse and 
subsequent death with imatinib-
resistant disease.174 
A1 NR case report 
(positive)
             
Levine 
2005 
Treatment with imatinib resulted in 
rapid, complete and sustained 
hematologic and cytogenetic 
response.175 
A1 case report case report 
(positive)
             
Magnusso
n 2002 
These results clearly demonstrate 
(…) inhibitory effect of STI571 
[imatinib] against leukemic cells 
harbouring a PDGFBR fusion 
oncogene, in a clinically relevant 
situation176 
A1 NR case report 
(positive)
             
Pardanan
i 2002 
imatinib is clearly an active agent in 
HES and, as demonstrated in this 
report.177 
A1 case case report 
(negative)
             
Pitini 2007 Our case demonstrates many 
typical forms of myeloproliferative 
disorders with translocation 
t(5;12)(q33;p13), involvement of 
PDGFRB and response to STI571 
[imatinib] treatment. (…) there is 
clearly a need for further studies of 
STI571 in this setting to confirm these 
promising initial results.178 
A1 case report case report 
(positive)
             
Safley 
2004 
Continuing observation and future 
cytogenetic and molecular analysis 
of the patient's bone marrow will be 
required to determine whether 
treatment has truly resulted in a 
durable hematologic and 
cytogenetic response.179 
A1 case case report 
(positive)
             
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Trempat 
2003 
The results of the present study 
expand the list of Glivec targets and 
have direct clinical implication. In 
addition to myeloproliferative 
diseases bearing ABL or PDGFRB 
rearrangements, this molecule is 
also effective in CML-like disorders 
with fusion genes involving PDGFRA 
as demonstrated in the present 
study. 180 
Q1 case case report 
(positive)
             
Vizmanos 
2004 
After treatment with imatinib, the 
patient achieved hematological 
and cytogenetical remission, but 
NIN-PDGFRB mRNA remained 
detectable by reverse-transcription-
PCR.181 
A1 NR case report 
(positive)
             
Wilkinson 
2003 
we have shown that the 
t(1;5)(q23;q33) targets PDGFRB and 
that complete remission can be 
achieved with imatinib in a heavily 
pretreated patient with progressive 
disease182 
A1 case case report 
(positive)
             
Wittman 
2004 
Imatinib mesylate proved to be 
highly effective in treating our 
patient's leukemia. (…) More 
experience is needed to know 
whether the efficacy of this agent 
for t(5;12)(q33;p13) disorders will 
similarly be affected by stage of 
disease and type of leukemia [as 
with CML].183 
A1 case report case report 
(positive)
             
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Philadelphia chromosome – ALL - dasatinib               
START-L Dasatinib is highly active and 
produces hematologic and 
cytogenetic responses186 
(conclusions from the START 
programme including studies in 
mainly CML and some AML 
patients) 
A1 open-label, 
single-arm, 
study 
single-arm 
(only positive)
             
CA180002 Our results demonstrate that 
dasatinib has clinical activity in all 
stages of imatinib-resistant CML and 
Ph-positive ALL, including resistance 
caused by BCR-ABL gene 
mutation185 
A1 open-label, 
dose-
escalation 
study 
single-arm 
(only positive)
             
Philadelphia chromosome – ALL - imatinib               
0109 Our current study provides the basis 
for investigations aimed at 
identifying combination therapies 
most appropriate in the various 
clinical settings of Ph+ acute 
leukemias192 
A1 open-label, 
nonrandomi
zed trial 
single-arm 
(only positive)
             
0114 The interpretation of the results of 
the EAP should take into account 
that only limited efficacy and safety 
data were collected, and that the 
length of follow-up was directly 
related to, and limited by, the date 
when imatinib became 
commercially available. Despite 
these limitations, it is encouraging 
that TTP and OS were similar to the 
previously published results of the 
phase II studies which led to the 
worldwide regulatory approval of 
the drug258 
A1 open-label, 
nonrandomi
zed trials 
single-arm 
(only positive)
             
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03001 This study demonstrates that STI571 
as a single agent is well tolerated 
and has substantial activity against 
acute leukemias characterized by 
the BCRABL fusion protein191 
A1 dose-
escalating 
pilot study 
single-arm 
(only positive)
             
AAU02 NA NA NA single-arm 
(only positive)
             
ADE04 our study strongly suggests that 
schedules based on the 
simultaneous administration of 
imatinib and cytotoxic agents 
should form the basis for 
prospective, comparative studies 
aimed at improving the 
pretransplantation molecular 
response during firstline treatment of 
Ph+ ALL197 
A1 prospective 
clinical trial 
Single-arm 
(only positive)
             
ADE10 This randomized trial demonstrates a 
strikingly superior response to 
remission induction with single agent 
imatinib compared with multiagent 
chemotherapy in newly diagnosed 
Ph+ALL, as well as markedly more 
rapid hematopoietic recovery, a 
significantly lower frequency of 
SAEs, fewer early deaths, and better 
adherence to subsequent 
consolidation therapy196 
Q1 prospective, 
randomized 
trial 
enrichment              
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AFR09 Although this study is encouraging, 
the long-term fate of patients 
treated according to this protocol is 
unknown. Clearly, there is room for 
substantial improvement in the field 
of Ph+ ALL in the elderly. The optimal 
dose of imatinib, the proper 
duration of treatment, the value of 
chemotherapy given in addition to 
imatinib, the contribution of new 
tyrosine kinase inhibitors and the 
place, if any, of stem cell 
transplantation still remain to be 
determined194 
A1 non-
randomized 
study 
single-arm 
(only positive)
             
AIT04 NA NA NA single-arm 
(only positive)
             
AJP01 NR; the main objective of this study 
was to identify associated with 
resistance to imatinib193 
N/A NR single-arm 
(only positive)
             
AUS01 NA NA NA single-arm 
(only positive)
             
t(15;17) translocation and/or PML/RAR-α gene - acute promyelocytic leukaemia - arsenic 
trioxide
             
97-66 In summary, arsenic trioxide can 
induce a complete remission in 
patients with APL who have 
relapsed after extensive prior 
therapy. This drug causes partial but 
incomplete cytodifferentiation of 
leukemic cells, followed by caspase 
activation and induction of 
apoptosis. The striking degree of 
activity of arsenicals in this disease, 
plus their lack of specificity for APL-
specific proteins, suggests that they 
may warrant further study as 
therapy for other neoplastic 
diseases200 
A1 NR single-arm 
(only positive)
             
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PLRXAS01 In summary, the results of this study 
establish ATO as a highly effective 
therapy for patients with APL 
despite prior therapy with retinoids 
and chemotherapy. Moreover, 
responses have proven to be 
durable for at least 18 months in 
over half the patients who achieved 
CR.259 
Q1 expanded 
study 
single-arm 
(only positive)
             
viral resistance mutations – HIV - amprenavir               
PROAB300
4 
NA NA NA unclear              
PROAB300
6 
In summary, the role of the I50V 
mutation in conferring resistance to 
APV has been confirmed in a large 
phase III study. Three additional viral 
protease genotypes characterized 
by the development of substitutions 
I54L, I54M, V32I + I47V, and I84V, 
which may occur with concomitant 
accessory mutations (e.g., M46I/L, 
L33F, L10F), evolved in response to 
APV and generally conferred lower 
levels of APV resistance. Each of 
these four genotypes conferred little 
or no cross-resistance to other PIs. 
Finally, the significant association 
between preexisting viral resistance 
to NRTIs subsequently administered 
in the PI/NRTI combination regimen 
and the emergence of protease 
mutations, emphasizes the 
importance of optimising treatment 
regimens to ensure that the virus is 
susceptible to as many components 
as possible.203 
Q5, Q6 clinical trial 
(retrospectiv
e genotypic 
and 
phenotypic 
analyses) 
randomise-all 
(cross-
sectional)
             
viral resistance mutations – HIV – atazanavir               
AI424009 NA NA NA unclear              
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AI424043 NA NA NA unclear              
AI424045 NA NA NA randomise-all 
(retrospective 
subgroup) 
             
viral resistance mutations – HIV – darunavir               
POWER 1 NA NA NA randomise-all 
(cross-
sectional) 
             
POWER 2 NA NA NA randomise-all 
(cross-
sectional) 
             
POWER 3 NA NA NA randomise-all 
(cross-
sectional) 
             
viral resistance mutations – HIV – efavirenz / emtricitabine / tenofovir 
disoproxil 
              
Gallant 
2006 
Consistent with other studies in ARV-
naïve subjects, NNRTI-R was found 
to be the most clinically relevant 
form of transmitted resistance with 
regard to risk of virologic failure on 
an EFV-containing regimen. This 
finding highlights the importance of 
baseline genotyping when initiation 
of ARV therapy is being considered, 
especially when considering an 
NNRTI-containing regimen. 
Nevertheless, it was notable that a 
small proportion of patients enrolled 
in Study 934 (approximately 2%) 
entered the study with evidence of 
genotypic and phenotypic 
resistance to PIs. Therefore, 
resistance testing is warranted for all 
ARV-naïve subjects.101 
Q6 prospective, 
randomized, 
noninferiorit
y study 
(genotypic 
and 
phenotypic 
resistance 
analyses) 
randomise-all 
(cross-
sectional)
             
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viral resistance mutations – HIV – emtricitabine               
Benson 
2004 
NR97 N/A randomized, 
open-label 
equivalenc
e trial 
(genotypic 
analysis) 
randomise-all 
(cross-
sectional)
             
viral resistance mutations – HIV – enfuvirtide               
TORO 1 NA NA NA randomise-all 
(cross-
sectional)
             
TORO 2 NA NA NA randomise-all 
(cross-
sectional)
             
viral resistance mutations – HIV – emtricitabine / rilpivirine / tenofovir 
disoproxil 
              
ECHO The most prevalent treatment-
emergent NNRTI RAMs [resistance 
associated mutations] were 
consistent with data from TMC278-
C204  and THRIVE217 
A6 randomised, 
double-
blind, 
double-
dummy, 
active-
controlled 
trial 
enrichment              
THRIVE Consistent with reports from the 
phase 2b TMC278-C204 trial, E138K 
was the most prevalent NNRTI [non-
nucleoside reverse transcriptase 
inhibitor] RAM [resistance-
associated mutation] in the rilpivirine 
group and K103N was in the 
efavirenz group, whereas M184I/V 
were the most prevalent N(t)RTI 
[nucleoside/nucleotide reverse 
transcriptase inhibitor] RAMs in both 
groups260 
A6 randomised, 
double-
blind, 
double-
dummy, 
non-
inferiority 
trial 
enrichment              
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viral resistance mutations – HIV – fosamprenavir                
APV 
30003 
NA NA NA randomise-all 
(retrospective 
subgroup)
             
SOLO NR220 N/A randomized, 
open-label 
study (NR) 
randomise-all 
(cross-
sectional)
             
NEAT The spectrum of mutations selected 
by 908 is consistent with that 
observed with the active moiety, 
APV, and is distinct from that 
observed with most other PIs. 
Subjects experiencing virologic 
failure on NFV developed protease 
mutations, selecting the common 
NFV resistance–associated 
mutations including D30N and 
L90M.261 
A6 randomized, 
open-label 
2-arm study 
(NR) 
randomise-all 
(cross-
sectional)
             
viral resistance mutations – HIV – lopinavir / ritonavir               
M98-863 NA NA NA randomise-all 
(cross-
sectional) 
             
M97-720 NA NA NA randomise-all 
(cross-
sectional) 
             
viral resistance mutations – HIV – nelfinavir               
505 NA NA NA randomise-all 
(retrospective 
subgroup) 
             
511 NA NA NA unclear              
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Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
viral resistance mutations – HIV – rilpivirine               
ECHO The most prevalent treatment-
emergent NNRTI RAMs [resistance 
associated mutations] were 
consistent with data from TMC278-
C204  and THRIVE217 
A6 randomised, 
double-
blind, 
double-
dummy, 
active-
controlled 
trial 
enrichment              
THRIVE Consistent with reports from the 
phase 2b TMC278-C204 trial, E138K 
was the most prevalent NNRTI [non-
nucleoside reverse transcriptase 
inhibitor] RAM [resistance-
associated mutation] in the rilpivirine 
group and K103N was in the 
efavirenz group, whereas M184I/V 
were the most prevalent N(t)RTI 
[nucleoside/nucleotide reverse 
transcriptase inhibitor] RAMs in both 
groups260 
A6 randomised, 
double-
blind, 
double-
dummy, 
non-
inferiority 
trial 
enrichment              
viral resistance mutations – HIV – tenofovir               
902 NA NA NA randomise-all 
(prospective 
subgroup)
             
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
903 treatment failure was uncommon. 
The development of the K65R 
mutation was less common than 
resistance to efavirenz or 
lamivudine. This mutation appears 
to be the only pathway to tenofovir 
resistance among treatment-naive 
patients, analogous to observations 
in treatment-experienced patients. 
The K65R mutation was observed in 
8 patients (1 patient after week 48) 
failing therapy in the tenofovir DF 
group through 144 weeks, which 
represents less than 3% of the total 
number of patients treated or 17% 
of those experiencing virologic 
failure in the tenofovir DF group.228 
Q6 prospective, 
randomized, 
double-
blind study 
(resistance 
analysis) 
randomise-all 
(cross-
sectional)
             
907 Given the low percentage of 
patients who achieved 
undetectable HIV-1 RNA levels in 
both the tenofovir DF and placebo 
groups, resistance mutations 
continued to develop. After 24 
weeks, there was a trend toward 
development of fewer additional 
nucleoside resistance mutations in 
the tenofovir DF group compared 
with the placebo-treated group, but 
it did not achieve statistical 
significance. Despite ongoing viral 
replication in nearly 80% of patients 
receiving tenofovir DF, the K65R 
mutation, selected by tenofovir in 
vitro, was seen in only 3% of patients 
through week 48.227 
A6 randomized, 
double-
blind, 
placebo-
controlled 
study 
(virologic 
genotyping 
substudy) 
randomise-all 
(prospective 
subgroup)
             
viral resistance mutations – HIV – tipranavir               
RESIST 1 NR230,231 N/A randomised, 
open-label 
trial 
enrichment              
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Studyi Authors’ conclusions Study 
design label 
(paper) 
Study design 
label 
Questions addressed with study designsii 
Quote Summar
y 
A1 A2 A3 A4 Q
1 
Q
2 
A5 Q
3 
Q
4 
Q
5 
Q
6 
Q
7 
Q
8 
A6 
RESIST 2 NR230,232 N/A randomised, 
open-label 
trial 
enrichment              
1182.4 NR233 N/A dose-
ranging trial 
(NR) 
randomise-all 
(cross-
sectional)
             
1182.51 NA NA NA enrichment              
1182.52 NA NA NA enrichment              
Markowitz 
2007 
Furthermore, patient viral isolates 
with reduced susceptibility had the 
emergence of the V82T mutation 
combined with an L33 (I for V) 
codon mutation on treatment with 
TPV. This suggests that reduced 
susceptibility to TPV may occur 
when these 2 mutations are present 
along with at least 10 other 
mutations. The presence of single PI 
mutations at codon 46, 82, 84, or 90 
did not seem to influence the 
virologic response to TPV.236 
Q6 open-label, 
randomized 
study (NR) 
randomise-all 
(2 different 
doses) (cross-
sectional)
             
 
 
i Names of main studies are in bold 
ii For B-I-D combinations the questions addressed by main studies are underlined 
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16.1. IMMUNOHISTOCHEMISTRY 
IHC measures ERCC1 expression at protein level. In this method an antibody is used that 
binds to the ERCC1 protein. The part of the protein to which the antibody binds is known 
as an epitope. Antibody-epitope binding results in formation of an antibody-ERCC1 
complex. Further steps are then undertaken to visualise the complex.  
The main antibody in use appears to be 8F1 (Neomarkers, Fremont, California, USA), 
however others are commercially available.262 A number of systems exist for quantification 
of results of IHC experiments, and some of these are described here.  
In quantifying the results of IHC assessments are usually undertaken of: 
 staining (or reactivity) - aiming to measure the proportion of cells which stain 
positive using a given antibody,263 
 intensity - usually based on a microscopic examination of the stained tissue in 
comparison with positive controls with a known range of expression levels.263-265 
It is often expressed on a scale from 0 to 3 corresponding to no, weak, moderate and 
strong expression respectively.266,267 A number of scoring systems have been introduced 
that take into account both the proportion of cells staining and intensity. Two of these will 
be discussed here: the H-score and the Quick Score.  
The H-score, which was originally introduced in the context of oestrogen receptor 
expression, but was adapted to a wider range of biomarkers. This score can be 
summarised as:263,268 
𝐻 − 𝑠𝑐𝑜𝑟𝑒 =  ∑ 𝑝𝑖 × 𝑖
3
𝑖=0
 
Where: i – intensity score, pi – percentage of cells with a given intensity 
The H-score has a value between 0 and 300, where 0 indicates no cell staining and 300 
indicates 100% of tumour cells staining at strong intensity (intensity score of 3).263,268 
The Quick Score was introduced partly to overcome some of the complexities in 
calculating the H-score. It involves the addition of a score obtained based on the 
percentage of cells staining positive (proportion score) and an overall intensity score:263  
𝑄𝑢𝑖𝑐𝑘 𝑆𝑐𝑜𝑟𝑒 = 𝐴 + 𝐵 
Where: A – proportion score (assigned based on proportion of cells staining positive); B – intensity 
score (assigned based on overall staining intensity) 
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A number of modifications of the Quick Score were suggested, which assign different 
possible values to the proportion score and the intensity score. One of the more popular 
versions is the Allred Quick Score, where the possible values for the proportion score range 
from 0 to 5 and for the intensity score from 0 to 3 (as shown in Table 61), giving a total 
score ranging from 0 to 8.263,269 
Table 61 Values of proportion score and intensity score used for calculation of the Allred Quick Score for IHC 
proportion 
score 
proportion of cells 
staining positive 
 intensity 
score 
overall staining 
intensity 
0 0  0 none 
1 <
1
100
   1 weak 
2 1
100
 to 
1
10
   2 intermediate 
3 1
10
 to 
1
3
    3 strong 
4 1
3
 to 
2
3
      
5 >  
2
3
     
     
16.2. REVERSE TRANSCRIPTASE QUANTITATIVE POLYMERASE CHAIN REACTION 
RTqPCR measures ERCC1 expression at RNA level.270 As RNA cannot be directly used in a 
PCR reaction, reverse transcriptase is first used to obtain a complementary DNA (cDNA) 
copy of the RNA molecules extracted from tumour tissue.271 The quantity of cDNA 
obtained in this step may vary depending on reaction conditions. As the quantity of cDNA 
needs to reflect the quantity of RNA present in the sample, this point is of extreme 
importance.272  
Afterwards, primers are used to generate new DNA strands containing the target 
sequence. These primers are short DNA sequences designed to match regions bordering 
on the target sequence.271 The main points of the laboratory procedure can be 
summarised in the following (normally automated) steps, which constitute one cycle of 
PCR: 
1) Separation of DNA strands by heating the solution, 
2) Binding of primers to DNA strands enabled by cooling the solution, 
3) Synthesis of new DNA starting from the bound primer enabled by increasing 
temperature (to a level below that in step 1).271,272 
The procedure is then repeated for a number of cycles by changing the temperature. In 
a 100% efficient PCR reaction the quantity of copies of the sequence of interest is 
increased 2n fold, where n is the number of cycles.271 In a less efficient experiment this 
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increase is somewhat lower, but still progresses exponentially until one of the critical 
components of the reaction is used up or largely depleted, leading to below-exponential 
increase and eventually the reaction stops.272 
In quantitative PCR the reaction mix contains a dye which becomes fluorescent when it is 
either bond to double stranded DNA or a target sequence.271 Based on the fluorescence 
level, the quantity of product is continuously monitored.270,273 In the initial cycles, this 
quantity is below a pre-determined threshold of detection. The cycle (often labelled CT) 
at which the product first reaches the detection threshold is proportional to the quantity 
of original cDNA copies.271,272  
As the threshold level is influenced by the instrument settings, each quantitative PCR 
experiment needs to include a control (or a reference standard) relative to which the 
expression level of the target protein can be established.272 The expression level is 
therefore normalised to the reference standard, which also enables comparisons 
between different tissue samples. The choice of a reference standard is not 
straightforward, as ideally it should be expressed at constant levels in all tissues and at all 
developmental stages.274 For this reason, housekeeping genes275,276 (which need to be 
expressed in all cells270), such as glyceraldehyde 3-phosphate dehydrogenase and β-
actin have been widely used in practice.274 
When multiple PCR reactions are run at the same time in the same reaction either 
labelling of primers or sequence-specific probes are utilised. These labels become 
fluorescent when incorporated into a copy of the target DNA sequence. As probes or 
labelled primers directed at different DNA sequences emit different coloured 
fluorescence, the quantity of multiple DNA sequences can be measured at the same 
time.272 
This relative expression of a gene compared to a reference standard can be calculated: 
𝑁𝐴
𝑁𝐵
=  𝐾𝑅𝑆  
𝜂𝐵 (1 + 𝐸𝐵)
𝐶𝑇𝐵−1
𝜂𝐴 (1 + 𝐸𝐴)𝐶𝑇𝐴−1
 
Where: A – target gene, B – reference gene, NA, NB – numbers of mRNA molecules of gene A or B 
present in the sample, KRS – relative sensitivity of detection of the genes, ηA, ηB – yields of cDNA 
synthesis from mRNA for gene A and B, EA, EB – efficiencies of PCR, CTA, CTB – cycle at which product 
reaches threshold of detection (CT-1 used to account for single cDNA strand in first cycle) 
In most cases more than one sample is used and for two samples and under the 
assumption that KRS, ηA, ηB, EA and EB values are constant, this leads to a much simpler 
formula:272 
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𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 =  
(1 + 𝐸𝐵)
𝐶𝑇𝐵1−𝐶𝑇𝐵2
(1 + 𝐸𝐴)𝐶𝑇𝐴1−𝐶𝑇𝐴2
 
Where CTA1, CTA2, CTB1, CTB2 ate the CT values obtained for samples 1 and 2 
With a further assumption that PCR efficiency is 100% this simplifies to the ΔΔCT method: 
272,277290,295 
𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 =  
2𝐶𝑇𝐵1−𝐶𝑇𝐵2
2𝐶𝑇𝐴1−𝐶𝑇𝐴2
= 2(𝐶𝑇𝐵1−𝐶𝑇𝐵2)−(𝐶𝑇𝐴1−𝐶𝑇𝐴2) = 2ΔΔCT 
Which has been relatively frequently used in practice.22,27 
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APPENDIX 17. SEARCH STRATEGIES FOR ERCC1 SYSTEMATIC 
REVIEW 
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Search strategies used in ongoing trials databases to identify studies assessing ERCC1 
expression are shown below for each database separately. 
 
ClinicalTrials.gov (317 hits): 
(lung OR NSCLC) AND (customized OR individualized OR tailored OR personalized OR 
biomarker OR ERCC1OR ERCC OR ERCC-1 OR (excision AND repair) OR 
pharmacogenomic OR pharmacogenetic) AND (cisplatin OR carboplatin OR platinum 
OR platin OR chemotherapy) 
 
WHO (303 hits): 
Lung AND customized OR Lung AND individualized OR Lung AND tailored OR Lung AND 
personalized OR Lung AND biomarker OR Lung AND ERCC1 OR Lung AND ERCC-1 OR 
Lung AND ERCC OR Lung AND excision AND repair OR Lung AND pharmacogenomic OR 
Lung AND pharmacogenetic OR NSCLC AND customized OR NSCLC AND individualized 
OR NSCLC AND tailored OR NSCLC AND personalized OR NSCLC AND biomarker OR 
NSCLC AND ERCC1 OR NSCLC AND ERCC-1 OR NSCLC AND ERCC OR NSCLC AND 
excision AND repair OR NSCLC AND pharmacogenomic OR NSCLC AND 
pharmacogenetic 
(WHO portal does not recognise brackets; operator priority: NOT, AND, OR) 
 
Controlled-Trials (301 hits): 
(lung OR NSCLC) AND (customized OR individualized OR tailored OR personalized OR 
biomarker OR ERCC1 OR ERCC OR ERCC-1 OR (excision AND repair) OR 
pharmacogenomic OR pharmacogenetic) 
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APPENDIX 18. QUESTIONNAIRE ON TRIALS EVALUATING ERCC1  
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ERCC1 Trial Review 
Trial Name: 
Trial Co-ordinator or Name and email address of person responding to questionnaire: 
Laboratory Lead: 
Chief Investigator: 
 
 
 
Is the ERCC1 Assessment carried out prospectively-ie prior to patients receiving 
treatment? 
        
 Yes     
 No    
If no - please describe 
 
 
If not prospective, is the ERCC1 assessment carried out by staff blind to the 
patient’s outcome? 
   
Yes      
No      
What type(s) of specimen are you using?-Please tick the appropriate box(es) and 
provide the approximate percentage of different specimen types (if known). 
 Percentage  
Surgical resection   ____________ 
Biopsy   ____________ 
Cytology   ____________ 
 
Please give details of the procedure for collection and storage of the 
specimen
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 
Where is the ERCC1 testing done? Please tick the appropriate box(es) 
        
Individual hospital       
Central laboratory      
Other      
If other please specify? 
How long does it take to get the ERCC1 results back to the treating physician? 
 ___________________________________________________________________________________________ 
 
What method are you using for measuring ERCC1 expression? Please tick the 
appropriate box(es) 
        
IHC      
RTqPCR      
Other      
If other please specify? 
 
Please give full details of the scoring system used to measure ERCC1  
Staining score ________________________________________________  
Intensity score _______________________________________________  
H-score _____________________________________________________  
If possible, please provide an estimate of the proportion of patients classified as ERCC1 positive in your study 
 ___________________________________________________________________________________________  
PLEASE TURN OVER  
  
 
 
 
If using immunohistochemistry 
Which antibody are you using (i.e. name of company/clone)? 
In what dilution? 
Are you using any ancillary techniques? (e.g. microwave pretreatment)  
What threshold are you using to categorise a patient as ERCC1 high vs low? 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 
If using RTqPCR  
What strategy are you using (i.e. primers, exons covered, endogenous control? e.g. primers spanning exons 8-10 
of the ENST00000300853 ERCC1 transcript: 5’ CTGACCACCGTGAAGTCA 3’ and 5’ AAGGGCTCGTGCAGGAC 3’; B2M 
as endogenous control)  
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 
What threshold are you using to categorise a patient as ERCC1 high vs low? (e.g. patients with dCt values between 
B2M and ERRC1 >7 are considered ERCC1 low, while patients with dCT values <4 are considered ERCC1 high; 
Patients wich dCT values between 4-7 are considered uncertain or unclassified. This latter group represents 20% 
of our population). 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 
 
 
Please state the rationale for the choice of ERCC1 assessment method 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 ___________________________________________________________________________________________ 
 
 
 
 
 
 
 
 
From Professor Lucinda Billingham, (l.j.billingham@bham.ac.uk) University of Birmingham, UK  
Dr Sanjay Popat, Imperial College and Royal Marsden Hospital, London, UK  
 
 Thank you very much 
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